

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 48/00, C07H 21/04, C07K 14/00, 16/00, C12N 15/63, 15/85, 15/86	A1	(11) International Publication Number: WO 00/66178 (43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/US00/11664 (22) International Filing Date: 28 April 2000 (28.04.00) (30) Priority Data: 60/132,021 30 April 1999 (30.04.99) US (71) Applicant (for all designated States except US): EMORY UNIVERSITY [US/US]; 1380 South Oxford Road, Atlanta, GA 30322 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BODEN, Scott, D. [US/US]; 2842 Cravey Drive, N.E., Atlanta, GA 30345 (US). HAIR, Gregory, A. [US/US]; 1887 Chrysler Drive, N.E., Atlanta, GA 30345 (US). (74) Agents: GARRETT, Arthur, S. et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC 20005-3315 (US).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <i>With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.</i>
(54) Title: LIM MINERALIZATION PROTEIN SPLICE VARIANTS		
(57) Abstract <p>The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising splice variants of nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation by transfecting osteogenic precursor cells with an isolated nucleic acid molecule comprising a nucleotide sequence encoding splice variants of LIM mineralization protein. The transfection may occur <i>ex vivo</i> or <i>in vivo</i> by direct injection of virus or naked plasmid DNA. In a particular embodiment, the invention provides a method of fusing a spine by transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected osteogenic precursor cells with a matrix and contacting the matrix with the spine. Finally, the invention relates to methods for inducing systemic bone formation by stable transfection of host cells with the vectors of the invention.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

LIM Mineralization Protein Splice Variants

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

The field of the invention relates generally to osteogenic cells and the formation of bone and boney tissue in mammalian species. Specifically, the invention concerns a novel family of proteins, and nucleic acids encoding those proteins, that enhances the efficacy of bone mineralization *in vitro* and *in vivo*.

10 The invention provides methods for treating a variety of pathological conditions associated with bone and boney tissue, such as, for example, spine fusion, fracture repair and osteoporosis.

2. Description of the Related Art

15 Osteoblasts are thought to differentiate from pluripotent mesenchymal stem cells. The maturation of an osteoblast results in the secretion of an extracellular matrix which can mineralize and form bone. The regulation of this complex process is not well understood but is thought to involve a group of signaling glycoproteins known as bone morphogenetic proteins (BMPs). These
20 proteins have been shown to be involved with embryonic dorsal-ventral patterning, limb bud development, and fracture repair in adult animals. B. L. Hogan, Genes & Develop., 10:1580 (1996). This group of transforming growth factor-beta superfamily secreted proteins has a spectrum of activities in a variety of cell types at different stages of differentiation; differences in
25 physiological activity between these closely related molecules have not been clarified. D. M. Kingsley, Trends Genet., 10:16 (1994).

To better discern the unique physiological role of different BMP signaling proteins, we recently compared the potency of BMP-6 with that of BMP-2 and BMP-4, for inducing rat calvarial osteoblast differentiation. Boden *et al.*,
30 Endocrinology, 137:3401 (1996). We studied this process in first passage (secondary) cultures of fetal rat calvaria that require BMP or glucocorticoid for

initiation of differentiation. In this model of membranous bone formation, glucocorticoid (GC) or a BMP will initiate differentiation to mineralized bone nodules capable of secreting osteocalcin, the osteoblast-specific protein. This secondary culture system is distinct from primary rat osteoblast cultures which
5 undergo spontaneous differentiation. In this secondary system, glucocorticoid resulted in a ten-fold induction of BMP-6 mRNA and protein expression which was responsible for the enhancement of osteoblast differentiation. Boden *et al.*, Endocrinology, 138:2920 (1997).

In addition to extracellular signals, such as the BMPs, intracellular
10 signals or regulatory molecules may also play a role in the cascade of events leading to formation of new bone. One broad class of intracellular regulatory molecules are the LIM proteins, which are so named because they possess a characteristic structural motif known as the LIM domain. The LIM domain is a cysteine-rich structural motif composed of two special zinc fingers that are
15 joined by a 2-amino acid spacer. Some proteins have only LIM domains, while others contain a variety of additional functional domains. LIM proteins form a diverse group, which includes transcription factors and cytoskeletal proteins. The primary role of LIM domains appears to be in mediating protein-protein interactions, through the formation of dimers with identical or different LIM
20 domains, or by binding distinct proteins.

In LIM homeodomain proteins, that is, proteins having both LIM domains and a homeodomain sequence, the LIM domains function as negative regulatory elements. LIM homeodomain proteins are involved in the control of cell lineage determination and the regulation of differentiation, although LIM-
25 only proteins may have similar roles. LIM-only proteins are also implicated in the control of cell proliferation since several genes encoding such proteins are associated with oncogenic chromosome translocations.

Humans and other mammalian species are prone to diseases or injuries that require the processes of bone repair and/or regeneration. For example,
30 treatment of fractures would be improved by new treatment regimens that could stimulate the natural bone repair mechanisms, thereby reducing the time

required for the fractured bone to heal. In another example, individuals afflicted with systemic bone disorders, such as osteoporosis, would benefit from treatment regimens that would results in systemic formation of new bone. Such treatment regimens would reduce the incidence of fractures arising from the loss of bone mass that is a characteristic of this disease.

For at least these reasons, extracellular factors, such as the BMPs, have been investigated for the purpose of using them to stimulate formation of new bone *in vivo*. Despite the early successes achieved with BMPs and other extracellular signalling molecules, their use entails a number of disadvantages. For example, relatively large doses of purified BMPs are required to enhance the production of new bone, thereby increasing the expense of such treatment methods. Furthermore, extracellular proteins are susceptible to degradation following their introduction into a host animal. In addition, because they are typically immunogenic, the possibility of stimulating an immune response to the administered proteins is ever present.

Due to such concerns, it would be desirable to have available treatment regimens that use an intracellular signalling molecule to induce new bone formation. Advances in the field of gene therapy now make it possible to introduce into osteogenic precursor cells, that is, cells involved in bone formation, or peripheral blood leukocytes, nucleotide fragments encoding intracellular signals that form part of the bone formation process. Gene therapy for bone formation offers a number of potential advantages: (1) lower production costs; (2) greater efficacy, compared to extracellular treatment regimens, due to the ability to achieve prolonged expression of the intracellular signal; (3) it would by-pass the possibility that treatment with extracellular signals might be hampered due to the presence of limiting numbers of receptors for those signals; (4) it permits the delivery of transfected potential osteoprogenitor cells directly to the site where localized bone formation is required; and (5) it would permit systemic bone formation, thereby providing a treatment regimen for osteoporosis and other metabolic bone diseases.

SUMMARY OF THE INVENTION

The present invention seeks to overcome the drawbacks in the prior art
5 by providing novel compositions and methods for inducing bone formation
using an intracellular signalling molecule that participates early in the cascade
of events that leads to bone formation. Applicants have discovered 10-
4/RLMP (SEQ ID NO: 1, SEQ ID NO: 2), a novel LIM gene with a sequence
originally isolated from stimulated rat calvarial osteoblast cultures. The gene
10 has been cloned, sequenced and assayed for its ability to enhance the efficacy
of bone mineralization *in vitro*. The protein RLMP affects mineralization of
bone matrix as well as differentiation of cells into the osteoblast lineage. Unlike
other known cytokines, for example, BMPs, RLMP is not a secreted protein,
but is instead an intracellular signaling molecule. This feature has the
15 advantage of providing intracellular signaling amplification as well as easier
assessment of transfected cells. It is also suitable for more efficient and
specific *in vivo* applications. Suitable clinical applications include enhancement
of bone repair in fractures, bone defects, bone grafting, and normal
homeostasis in patients presenting with osteoporosis.

20 Applicants have also cloned, sequenced and deduced the amino acid
sequence of a corresponding human protein, named human LMP-1. The
human protein demonstrates enhanced efficacy of bone mineralization *in vitro*
and *in vivo*.

In addition, the applicants have characterized a truncated (short) version
25 of LMP-1, termed HLMP-1s. This short version resulted from a point mutation
in one source of a cDNA clone, providing a stop codon which truncated the
protein. The short version (LMP-1s) is fully functional when expressed in cell
culture and *in vivo*.

Using PCR analysis of human heart cDNA library, Applicants have
30 identified two alternative splice variants (referred to as HLMP-2 and HLMP-3)
that differ from HLMP-1 in a region between base pairs 325 and 444 in the

nucleotide sequence encoding HLMP-1. The HLMP-2 sequence has a 119 base pair deletion and an insertion of 17 base pairs in this region. Compared to HLMP-1, the nucleotide sequence encoding HLMP-3 has no deletions, but it does have the same 17 base pairs as HLMP-2, which are inserted at position
5 444 in the HLMP-1 sequence.

Additional features and advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by practice of the invention. The objectives and other advantages of the invention will be realized and attained by the methods and
10 compositions of matter particularly pointed out in the written description and claims hereof.

In one broad aspect, the invention relates to an isolated nucleic acid molecule comprising a nucleic acid sequence encoding any LIM mineralization protein, wherein the nucleic acid molecule hybridizes under standard
15 conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 25, and wherein the molecule hybridizes under highly stringent conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 26. In a specific aspect, the isolated nucleic acid molecule encodes HLMP-1, HLMP-1s, RLMP, HLMP-2, or HLMP-3. In addition, the invention is
20 directed to vectors comprising these nucleic acid molecules, as well as host cells comprising the vectors. In another specific aspect, the invention relates to the proteins themselves.

In a second broad aspect, the invention relates to antibody that is specific for LIM mineralization protein, including HLMP-1, HLMP-1s, RLMP,
25 HLMP-2, and HLMP-3. In one specific aspect, the antibody is a polyclonal antibody. In another specific aspect, the antibody is a monoclonal antibody.

In a third broad aspect, the invention relates to method of inducing bone formation wherein osteogenic precursor cells are transfected with an isolated nucleic acid molecule comprising a nucleotide sequence encoding LIM
30 mineralization protein. In one specific aspect, the isolated nucleic acid molecule is in a vector, which may be a plasmid or a virus, such as adenovirus

or retrovirus. The transfection may occur *ex vivo* or *in vivo* by direct injection of the isolated nucleic acid molecule. The transfected isolated nucleic acid molecule may encode HLMP-1, HLMP-1s, RLMP, HLMP-2, or HLMP-3.

In a further aspect, the invention relates to methods of fusing a spine by
 5 transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected osteogenic precursor cells with a matrix and contacting the matrix with the spine.

In yet another aspect, the invention relates to methods for inducing
 10 systemic bone formation by stable transfection of host cells with the vectors of the invention.

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed.

15

ABBREVIATIONS AND DEFINITIONS

	BMP	Bone Morphogenetic Protein
	HLMP-1	Human LMP-1, also
20		designated as Human LIM
		Protein or HLMP
	HLMP-1s	Human LMP-1 Short
		(truncated) protein
	HLMPU	Human LIM Protein Unique
25		Region
	LMP	LIM mineralization protein
	MEM	Minimal essential medium
	Trm	Triamcinolone
	-GlyP	Beta-glycerolphosphate
30	RACE	Rapid Amplification of cDNA
		Ends

	RLMP	Rat LIM mineralization protein, also designated as RLMP-1
	RLMPU	Rat LIM Protein Unique Region
5	RNasin	RNase inhibitor
	ROB	Rat Osteoblast
	10-4	Clone containing cDNA sequence for RLMP (SEQ ID NO: 2)
10	UTR	Untranslated Region
	HLMP-2	Human LMP Splice Variant 2
	HLMP-3	Human LMP Splice Variant 3
15		

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to novel mammalian LIM proteins, herein
 20 designated LIM mineralization proteins, or LMP. The invention relates more
 particularly to human LMP, known as HLMP or HLMP-1, or alternative splice
 variants of human LMP, which are known as HLMP-2 or HLMP-3. The
 applicants have discovered that these proteins enhance bone mineralization in
 mammalian cells grown *in vitro*. When produced in mammals, LMP also
 25 induces bone formation *in vivo*.

Ex vivo transfection of bone marrow cells, osteogenic precursor cells,
 peripheral blood leukocytes, or mesenchymal stem cells with nucleic acid that
 encodes LMP or HLMP, followed by reimplantation of the transfected cells in
 the donor, is suitable for treating a variety of bone-related disorders or injuries.
 30 For example, one can use this method to: augment long bone fracture repair;
 generate bone in segmental defects; provide a bone graft substitute for

fractures; facilitate tumor reconstruction or spine fusion; and provide a local treatment (by injection) for weak or osteoporotic bone, such as in osteoporosis of the hip, vertebrae, or wrist. Transfection with LMP or HLMP-encoding nucleic acid is also useful in: the percutaneous injection of transfected marrow
5 cells to accelerate the repair of fractured long bones; treatment of delayed union or non-unions of long bone fractures or pseudoarthrosis of spine fusions; and for inducing new bone formation in avascular necrosis of the hip or knee.

In addition to *ex vivo*-based methods of gene therapy, transfection of a recombinant DNA vector comprising a nucleic acid sequence that encodes
10 LMP or HLMP can be accomplished *in vivo*. When a DNA fragment that encodes LMP or HLMP is inserted into an appropriate viral vector, for example, an adenovirus vector, the viral construct can be injected directly into a body site where endochondral bone formation is desired. By using a direct, percutaneous injection to introduce the LMP or HLMP sequence stimulation of
15 bone formation can be accomplished without the need for surgical intervention either to obtain bone marrow cells (to transfect *ex vivo*) or to reimplant them into the patient at the site where new bone is required. Alden *et al.*, Neurosurgical Focus (1998), have demonstrated the utility of a direct injection method of gene therapy using a cDNA that encodes BMP-2, which was cloned
20 into an adenovirus vector.

It is also possible to carry out *in vivo* gene therapy by directly injecting into an appropriate body site, a naked, that is, unencapsulated, recombinant plasmid comprising a nucleic acid sequence that encodes HLMP. In this embodiment of the invention, transfection occurs when the naked plasmid DNA
25 is taken up, or internalized, by the appropriate target cells, which have been described. As in the case of *in vivo* gene therapy using a viral construct, direct injection of naked plasmid DNA offers the advantage that little or no surgical intervention is required. Direct gene therapy, using naked plasmid DNA that encodes the endothelial cell mitogen VEGF (vascular endothelial growth
30 factor), has been successfully demonstrated in human patients. Baumgartner *et al.*, Circulation, 97(12):1114-23 (1998).

By using an adenovirus vector to deliver LMP into osteogenic cells, transient expression of LMP is achieved. This occurs because adenovirus does not incorporate into the genome of target cells that are transfected. Transient expression of LMP, that is, expression that occurs during the lifetime
5 of the transfected target cells, is sufficient to achieve the objects of the invention. Stable expression of LMP, however, can occur when a vector that incorporates into the genome of the target cell is used as a delivery vehicle. Retrovirus-based vectors, for example, are suitable for this purpose.

Stable expression of LMP is particularly useful for treating various
10 systemic bone-related disorders, such as osteoporosis and osteogenesis imperfecta. For this embodiment of the invention, in addition to using a vector that integrates into the genome of the target cell to deliver an LMP-encoding nucleotide sequence into target cells, LMP expression is placed under the control of a regulatable promoter. For example, a promoter that is turned on by
15 exposure to an exogenous inducing agent, such as tetracycline, is suitable. Using this approach, one can stimulate formation of new bone on a systemic basis by administering an effective amount of the exogenous inducing agent. Once a sufficient quantity of bone mass is achieved, administration of the exogenous inducing agent is discontinued. This process may be repeated as
20 needed to replace bone mass lost, for example, as a consequence of osteoporosis.

Antibodies specific for HLMP are particularly suitable for use in methods for assaying the osteoinductive, that is, bone-forming, potential of patient cells. In this way one can identify patients at risk for slow or poor healing of bone
25 repair. Also, HLMP-specific antibodies are suitable for use in marker assays to identify risk factors in bone degenerative diseases, such as, for example, osteoporosis.

Following well known and conventional methods, the genes of the present invention are prepared by ligation of nucleic acid segments that
30 encode LMP to other nucleic acid sequences, such as cloning and/or expression vectors. Methods needed to construct and analyze these

recombinant vectors, for example, restriction endonuclease digests, cloning protocols, mutagenesis, organic synthesis of oligonucleotides and DNA sequencing, have been described. For DNA sequencing DNA, the dieoxyterminator method is the preferred.

5 Many treatises on recombinant DNA methods have been published, including Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, 2nd edition (1988), Davis *et al.*, Basic Methods in Molecular Biology, Elsevier (1986), and Ausubel *et al.*, Current Protocols in Molecular Biology, Wiley Interscience (1988). These reference manuals are
10 specifically incorporated by reference herein.

Primer-directed amplification of DNA or cDNA is a common step in the expression of the genes of this invention. It is typically performed by the polymerase chain reaction (PCR). PCR is described in U.S. Patent No. 4,800,159 to Mullis *et al.* and other published sources. The basic principle of
15 PCR is the exponential replication of a DNA sequence by successive cycles of primer extension. The extension products of one primer, when hybridized to another primer, becomes a template for the synthesis of another nucleic acid molecule. The primer-template complexes act as substrate for DNA polymerase, which in performing its replication function, extends the primers.
20 The conventional enzyme for PCR applications is the thermostable DNA polymerase isolated from *Thermus aquaticus*, or Taq DNA polymerase.

Numerous variations of the basic PCR method exist, and a particular procedure of choice in any given step needed to construct the recombinant vectors of this invention is readily performed by a skilled artisan. For example,
25 to measure cellular expression of 10-4/RLMP, RNA is extracted and reverse transcribed under standard and well known procedures. The resulting cDNA is then analyzed for the appropriate mRNA sequence by PCR.

The gene encoding the LIM mineralization protein is expressed in an expression vector in a recombinant expression system. Of course, the
30 constructed sequence need not be the same as the original, or its complimentary sequence, but instead may be any sequence determined by the

degeneracy of the DNA code that nonetheless expresses an LMP having bone forming activity. Conservative amino acid substitutions, or other modifications, such as the occurrence of an amino-terminal methionine residue, may also be employed.

- 5 A ribosome binding site active in the host expression system of choice is ligated to the 5' end of the chimeric LMP coding sequence, forming a synthetic gene. The synthetic gene can be inserted into any one of a large variety of vectors for expression by ligating to an appropriately linearized plasmid. A regulatable promoter, for example, the *E. coli* lac promoter, is also suitable for
10 the expression of the chimeric coding sequences. Other suitable regulatable promoters include trp, tac, recA, T7 and lambda promoters.

DNA encoding LMP is transfected into recipient cells by one of several standard published procedures, for example, calcium phosphate precipitation, DEAE-Dextran, electroporation or protoplast fusion, to form stable
15 transformants. Calcium phosphate precipitation is preferred, particularly when performed as follows.

DNAs are coprecipitated with calcium phosphate according to the method of Graham and Van Der, Virology, 52:456 (1973), before transfer into cells. An aliquot of 40-50 μ g of DNA, with salmon sperm or calf thymus DNA as
20 a carrier, is used for 0.5×10^6 cells plated on a 100 mm dish. The DNA is mixed with 0.5 ml of 2X Hepes solution (280 mM NaCl, 50 mM Hepes and 1.5 mM Na_2HPO_4 , pH 7.0), to which an equal volume of 2x CaCl_2 (250 mM CaCl_2 and 10 mM Hepes, pH 7.0) is added. A white granular precipitate, appearing after 30-40 minutes, is evenly distributed dropwise on the cells, which are allowed to
25 incubate for 4-16 hours at 37°C. The medium is removed and the cells shocked with 15% glycerol in PBS for 3 minutes. After removing the glycerol, the cells are fed with Dulbecco's Minimal Essential Medium (DMEM) containing 10% fetal bovine serum.

DNA can also be transfected using: the DEAE-Dextran methods of
30 Kimura *et al.*, Virology, 49:394 (1972) and Sompayrac *et al.*, Proc. Natl. Acad. Sci. USA, 78:7575 (1981); the electroporation method of Potter, Proc. Natl.

Acad. Sci. USA, 81:7161 (1984); and the protoplast fusion method of Sandri-Goddin *et al.*, Molec. Cell. Biol., 1:743 (1981).

Phosphoramidite chemistry in solid phase is the preferred method for the organic synthesis of oligodeoxynucleotides and polydeoxynucleotides. In addition, many other organic synthesis methods are available. Those methods are readily adapted by those skilled in the art to the particular sequences of the invention.

The present invention also includes nucleic acid molecules that hybridize under standard conditions to any of the nucleic acid sequences encoding the LIM mineralization proteins of the invention. "Standard hybridization conditions" will vary with the size of the probe, the background and the concentration of the nucleic acid reagents, as well as the type of hybridization, for example, *in situ*, Southern blot, or hybridization of DNA-RNA hybrids (Northern blot). The determination of "standard hybridization conditions" is within the level of skill in the art. For example, see U.S. Patent 5,580,775 to Fremeau *et al.*, herein incorporated by reference for this purpose. See also, Southern, E. M., J. Mol. Biol., 98:503 (1975), Alwine *et al.*, Meth. Enzymol., 68:220 (1979), and Sambrook *et al.*, Molecular Cloning: A laboratory Manual, 2nd edition, pp. 7.19-7.50, Cold Spring Harbor Press (1989).

One preferred set of standard hybridization conditions involves a blot that is prehybridized at 42°C for 2 hours in 50% formamide, 5X SSPE (150 mM NaCl, 10 mM Na H₂PO₄ [pH 7.4], 1 mM EDTA [pH 8.0]), 5X Denhardt's solution (20 mg Ficoll, 20 mg polyvinylpyrrolidone and 20 mg BSA per 100 ml water), 10% dextran sulphate, 1% SDS and 100 g/ml salmon sperm DNA. A ³²P-labelled cDNA probe is added, and hybridization is continued for 14 hours. Afterward, the blot is washed twice with 2X SSPE, 0.1% SDS for 20 minutes at 22°C, followed by a 1 hour wash at 65°C in 0.1X SSPE, 0.1 %SDS. The blot is then dried and exposed to x-ray film for 5 days in the presence of an intensifying screen.

Under "highly stringent conditions," a probe will hybridize to its target sequence if those two sequences are substantially identical. As in the case of standard hybridization conditions, one of skill in the art can, given the level of skill in the art and the nature of the particular experiment, determine the conditions under which only substantially identical sequences will hybridize.

Another aspect of the invention includes the proteins encoded by the nucleic acid sequences. In still another embodiment, the invention relates to the identification of such proteins based on anti-LMP antibodies. In this embodiment, protein samples are prepared for Western blot analysis by lysing cells and separating the proteins by SDS-PAGE. The proteins are transferred to nitrocellulose by electroblotting as described by Ausubel *et al.*, Current Protocols in Molecular Biology, John Wiley and Sons (1987). After blocking the filter with instant nonfat dry milk (1 gm in 100 ml PBS), anti-LMP antibody is added to the filter and incubated for 1 hour at room temperature. The filter is washed thoroughly with phosphate buffered saline (PBS) and incubated with horseradish peroxidase (HRPO)-antibody conjugate for 1 hour at room temperature. The filter is again washed thoroughly with PBS and the antigen bands are identified by adding diaminobenzidine (DAB).

Monospecific antibodies are the reagent of choice in the present invention, and are specifically used to analyze patient cells for specific characteristics associated with the expression of LMP. "Monospecific antibody" as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for LMP. "Homogeneous binding" as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with LMP, as described above. Monospecific antibodies to LMP are purified from mammalian antisera containing antibodies reactive against LMP or are prepared as monoclonal antibodies reactive with LMP using the technique of Kohler and Milstein, Nature, 256:495-97 (1975). The LMP specific antibodies are raised by immunizing animals such as, for example, mice, rats, guinea

pigs, rabbits, goats or horses, with an appropriate concentration of LMP either with or without an immune adjuvant.

In this process, preimmune serum is collected prior to the first immunization. Each animal receives between about 0.1 mg and about 1000 mg of LMP associated with an acceptable immune adjuvant, if desired. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing *Corynebacterium parvum* and tRNA adjuvants. The initial immunization consists of LMP in, preferably, Freund's complete adjuvant injected at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. Those animals receiving booster injections are generally given an equal amount of the antigen in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20° C.

Monoclonal antibodies (mAb) reactive with LMP are prepared by immunizing inbred mice, preferably Balb/c mice, with LMP. The mice are immunized by the IP or SC route with about 0.1 mg to about 10 mg, preferably about 1 mg, of LMP in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3-30 weeks. Immunized mice are given one or more booster immunizations of about 0.1 to about 10 mg of LMP in a buffer solution such as phosphate buffered saline by the intravenous (IV) route. Lymphocytes from antibody-positive mice, preferably splenic lymphocytes, are obtained by removing the spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions

which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NS1/Ag 4-1; MPC-11; S-194 and Sp 2/0, with Sp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin in supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21, and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using LMP as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, "Soft Agar Techniques", in Tissue Culture Methods and Applications, Kruse and Paterson (eds.), Academic Press (1973). See, also, Harlow *et al.*, Antibodies: A Laboratory Manual, Cold Spring Laboratory (1988).

Monoclonal antibodies may also be produced *in vivo* by injection of pristane- primed Balb/c mice, approximately 0.5 ml per mouse, with about 2×10^6 to about 6×10^6 hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.

In vitro production in anti-LMP mAb is carried out by growing the hybridoma cell line in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.

Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays, which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays

are used to detect the presence of the LMP in body fluids or tissue and cell extracts.

It is readily apparent to those skilled in the art that the above described methods for producing monospecific antibodies may be utilized to produce
5 antibodies specific for polypeptide fragments of LMP, full-length nascent LMP polypeptide, or variants or alleles thereof.

In another embodiment, the invention is directed to alternative splice variants of HLMP-1. PCR analysis of human heart cDNA revealed mRNA for two HLMP alternative splice variants, named HLMP-2 and HLMP-3, that differ
10 from HLMP-1 in a region between base pairs 325 and 444 in the hLMP-1 sequence. The HLMP-2 sequence has a 119 base pair deletion and an insertion of 17 base pairs in this region. These changes preserve the reading frame, resulting in a 423 amino acid protein, which compared to HLMP-1, has a net loss of 34 amino acids (40 amino acids deleted plus 6 inserted amino
15 acids). HLMP-2 contains the c-terminal LIM domains that are present in HLMP-1.

Compared to HLMP-1, HLMP-3 has no deletions, but it does have the same 17 base pair insertion at position 444. This insertion shifts the reading frame, causing a stop codon at base pairs 459-461. As a result, HLMP-3
20 encodes a protein of 153 amino acids. This protein lacks the c-terminal LIM domains that are present in HLMP-1 and HLMP-2. The predicted size of the proteins encoded by HLMP-2 and HLMP-3 was confirmed by western blot analysis.

PCR analysis of the tissue distribution of the three splice variants
25 revealed that they are differentially expressed, with specific isoforms predominating in different tissues. HLMP-1 is apparently the predominant form expressed in leukocytes, spleen, lung, placenta, and fetal liver. HLMP-2 appears to be the predominant isoform in skeletal muscle, bone marrow, and heart tissue. HLMP-3, however, was not the predominant isoform in any tissue
30 examined.

Overexpression of HLMP-3 in secondary rat osteoblast cultures induced bone nodule formation (287 ± 56) similar to the effect seen for glucocorticoid (272 ± 7) and HLMP-1 (232 ± 200). Since HLMP-3 lacks the C-terminal LIM domains, these regions are not required for osteoinductive activity.

5 Overexpression of HLMP-2, however, did not induce nodule formation (11 ± 3). These data suggest that the amino acids encoded by the deleted 119 base pairs are necessary for osteoinduction. The data also suggest that the distribution of HLMP splice variants may be important for tissue-specific function. Surprisingly, we have shown that HLMP-2 inhibits steroid-induced

10 osteoblast formation in secondary rat osteoblast cultures. Therefore, HLMP-2 will have therapeutic utility in clinical situations where bone formation is not desirable.

On July 22, 1997, a sample of 10-4/RLMP in a vector designated pCMV2/RLMP (which is vector pRc/CMV2 with insert 10-4 clone/RLMP) was

15 deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852. The culture accession number for that deposit is 209153. On March 19, 1998, a sample of the vector pHis-A with insert HLMP-1s was deposited at the American Type Culture Collection ("ATCC"). The culture accession number for that deposit is 209698. On April 14, 2000,

20 samples of plasmids pHAhLMP-2 (vector pHisA with cDNA insert derived from human heart muscle cDNA with HLMP-2) and pHAhLMP-3 (vector pHisA with cDNA insert derived from human heart muscle cDNA with HLMP-3) were deposited with the ATCC, 10801 University Blvd., Manassas, VA, 20110-2209, USA, under the conditions of the Budapest treaty. The accession numbers for

25 these deposits are _____ and _____, respectively. These deposits, as required by the Budapest Treaty, will be maintained in the ATCC for at least 30 years and will be made available to the public upon the grant of a patent disclosing them. It should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent

30 rights granted by government action.

In assessing the nucleic acids, proteins, or antibodies of the invention, enzyme assays, protein purification, and other conventional biochemical methods are employed. DNA and RNA are analyzed by Southern blotting and Northern blotting techniques, respectively. Typically, the samples analyzed are size fractionated by gel electrophoresis. The DNA or RNA in the gels are then transferred to nitrocellulose or nylon membranes. The blots, which are replicas of sample patterns in the gels, were then hybridized with probes. Typically, the probes are radiolabelled, preferably with ^{32}P , although one could label the probes with other signal-generating molecules known to those in the art. Specific bands of interest can then be visualized by detection systems, such as autoradiography.

For purposes of illustrating preferred embodiments of the present invention, the following, non-limiting examples are included. These results demonstrate the feasibility of inducing or enhancing the formation of bone using the LIM mineralization proteins of the invention, and the isolated nucleic acid molecules encoding those proteins.

Example 1: Calvarial Cell Culture

Rat calvarial cells, also known as rat osteoblasts ("ROB"), were obtained from 20-day pre-parturition rats as previously described. Boden *et al.*, Endocrinology, 137(8):3401-07 (1996). Primary cultures were grown to confluence (7 days), trypsinized, and passed into 6-well plates (1×10^5 cells/35 mm well) as first subculture cells. The subculture cells, which were confluent at day 0, were grown for an additional 7 days. Beginning on day 0, media were changed and treatments (Tm and/or BMPs) were applied, under a laminar flow hood, every 3 or 4 days. The standard culture protocol was as follows: days 1-7, MEM, 10% FBS, 50 g/ml ascorbic acid, \pm stimulus; days 8-14, BGJb medium, 10% FBS, 5mM -GlyP (as a source of inorganic phosphate to permit mineralization). Endpoint analysis of bone nodule formation and osteocalcin secretion was performed at day 14. The dose of BMP was chosen as 50 ng/ml

based on pilot experiments in this system that demonstrated a mid-range effect on the dose-response curve for all BMPs studied.

EXAMPLE 2: Antisense Treatment and Cell Culture

5

To explore the potential functional role of LMP-1 during membranous bone formation, we synthesized an antisense oligonucleotide to block LMP-1 mRNA translation and treated secondary osteoblast cultures that were undergoing differentiation initiated by glucocorticoid. Inhibition of RLMP
10 expression was accomplished with a highly specific antisense oligonucleotide (having no significant homologies to known rat sequences) corresponding to a 25 bp sequence spanning the putative translational start site (SEQ ID NO: 42). Control cultures either did not receive oligonucleotide or they received sense oligonucleotide. Experiments were performed in the presence (preincubation)
15 and absence of lipofectamine. Briefly, 22 g of sense or antisense RLMP oligonucleotide was incubated in MEM for 45 minutes at room temperature. Following that incubation, either more MEM or pre-incubated lipofectamine/MEM (7% v/v; incubated 45 minutes at room temperature) was added to achieve an oligonucleotide concentration of 0.2 M. The resulting
20 mixture was incubated for 15 minutes at room temperature. Oligonucleotide mixtures were then mixed with the appropriate medium, that is, MEM/Ascorbate/ \pm Trm, to achieve a final oligonucleotide concentration of 0.1 M.

Cells were incubated with the appropriate medium (\pm stimulus) in the
25 presence or absence of the appropriate oligonucleotides. Cultures originally incubated with lipofectamine were re-fed after 4 hours of incubation (37°C; 5% CO₂) with media containing neither lipofectamine nor oligonucleotide. All cultures, especially cultures receiving oligonucleotide, were re-fed every 24 hours to maintain oligonucleotide levels.

30 LMP-1 antisense oligonucleotide inhibited mineralized nodule formation and osteocalcin secretion in a dose-dependent manner, similar to the effect of

BMP-6 oligonucleotide. The LMP-1 antisense block in osteoblast differentiation could not be rescued by addition of exogenous BMP-6, while the BMP-6 antisense oligonucleotide inhibition was reversed with addition of BMP-6. This experiment further confirmed the upstream position of LMP-1 relative to BMP-6 in the osteoblast differentiation pathway. LMP-1 antisense oligonucleotide also inhibited spontaneous osteoblast differentiation in primary rat osteoblast cultures.

EXAMPLE 3: Quantitation of Mineralized Bone Nodule Formation

10

Cultures of ROB's prepared according to Examples 1 and 2 were fixed overnight in 70% ethanol and stained with von Kossa silver stain. A semi-automated computerized video image analysis system was used to quantitate nodule count and nodule area in each well. Boden *et al.*, Endocrinology, 137(8):3401-07 (1996). These values were then divided to calculate the area per nodule values. This automated process was validated against a manual counting technique and demonstrated a correlation coefficient of 0.92 ($p < 0.000001$). All data are expressed as the mean \pm standard error of the mean (S.E.M.) calculated from 5 or 6 wells at each condition. Each experiment was confirmed at least twice using cells from different calvarial preparations.

15
20

EXAMPLE 4: Quantitation of Osteocalcin Secretion

Osteocalcin levels in the culture media were measured using a competitive radioimmunoassay with a monospecific polyclonal antibody (Pab) raised in our laboratory against the C-terminal nonapeptide of rat osteocalcin as described in Nanes *et al.*, Endocrinology, 127:588 (1990). Briefly, 1 g of nonapeptide was iodinated with 1 mCi ^{125}I -Na by the lactoperoxidase method. Tubes containing 200 μ l of assay buffer (0.02 M sodium phosphate, 1 mM EDTA, 0.001% thimerosal, 0.025% BSA) received media taken from cell cultures or osteocalcin standards (0 - 12,000 fmole) at 100 μ l/tube in assay

25
30

buffer. The Pab (1:40,000; 100 l) was then added, followed by the iodinated peptide (12,000 cpm; 100 l). Samples tested for non-specific binding were prepared similarly but contained no antibody.

Bound and free PABs were separated by the addition of 700 l goat anti-rabbit IgG, followed by incubation for 18 hours at 4°C. After samples were centrifuged at 1200 rpm for 45 minutes, the supernatants were decanted and the precipitates counted in a gamma counter. Osteocalcin values were reported in fmole/100 l, which was then converted to pmole/ml medium (3-day production) by dividing those values by 100. Values were expressed as the mean \pm S.E.M. of triplicate determinations for 5-6 wells for each condition. Each experiment was confirmed at least two times using cells from different calvarial preparations.

EXAMPLE 5: Effect of Trm and RLMP on Mineralization *In Vitro*

15

There was little apparent effect of either the sense or antisense oligonucleotides on the overall production of bone nodules in the non-stimulated cell culture system. When ROB's were stimulated with Trm, however, the antisense oligonucleotide to RLMP inhibited mineralization of nodules by > 95%. The addition of exogenous BMP-6 to the oligonucleotide-treated cultures did not rescue the mineralization of RLMP-antisense-treated nodules.

Osteocalcin has long been synonymous with bone mineralization, and osteocalcin levels have been correlated with nodule production and mineralization. The RLMP-antisense oligonucleotide significantly decreases osteocalcin production, but the nodule count in antisense-treated cultures does not change significantly. In this case, the addition of exogenous BMP-6 only rescued the production of osteocalcin in RLMP-antisense-treated cultures by 10-15%. This suggests that the action of RLMP is downstream of, and more specific than, BMP-6.

EXAMPLE 6: Harvest and Purification of RNA

- Cellular RNA from duplicate wells of ROBs (prepared according to
- 5 Examples 1 and 2 in 6-well culture dishes) was harvested using 4M guanidine isothiocyanate (GIT) solution to yield statistical triplicates. Briefly, culture supernatant was aspirated from the wells, which were then overlaid with 0.6 ml of GIT solution per duplicate well harvest. After adding the GIT solution, the plates were swirled for 5-10 seconds (being as consistent as possible).
- 10 Samples were saved at -70°C for up to 7 days before further processing.

- RNA was purified by a slight modification of standard methods according to Sambrook *et al.*, Molecular Cloning: a Laboratory Manual, 2nd Ed., chapter 7.19, Cold Spring Harbor Press (1989). Briefly, thawed samples received 60 l 2.0 M sodium acetate (pH 4.0), 550 l phenol (water saturated)
- 15 and 150 l chloroform:isoamyl alcohol (49:1). After vortexing, the samples were centrifuged (10000 x g; 20 minutes; 4°C), the aqueous phase transferred to a fresh tube, 600 l isopropanol was added and the RNA precipitated overnight at -20°C.

- Following the overnight incubation, the samples were centrifuged
- 20 (10000 x g; 20 minutes) and the supernatant was aspirated gently. The pellets were resuspended in 400 l DEPC-treated water, extracted once with phenol:chloroform (1:1), extracted with chloroform:isoamyl alcohol (24:1) and precipitated overnight at -20°C after addition of 40 l sodium acetate (3.0 M; pH 5.2) and 1.0 ml absolute ethanol. To recover the cellular RNA, the samples
- 25 were centrifuged (10000 x g; 20 min), washed once with 70% ethanol, air dried for 5-10 minutes and resuspended in 20 l of DEPC-treated water. RNA concentrations were calculated from optical densities that were determined with a spectrophotometer.

EXAMPLE 7: Reverse Transcription-Polymerase Chain Reaction

Heated total RNA (5 μ g in 10.5 μ l total volume DEPC-H₂O at 65°C for 5 minutes) was added to tubes containing 4 μ l 5X MMLV-RT buffer, 2 μ l dNTPs, 2 μ l dT17 primer (10 pmol/ml), 0.5 μ l RNAsin (40U/ml) and 1 μ l MMLV-RT (200 units/ μ l). The samples were incubated at 37°C for 1 hour, then at 95°C for 5 minutes to inactivate the MMLV-RT. The samples were diluted by addition of 80 μ l of water.

Reverse-transcribed samples (5 μ l) were subjected to polymerase-chain reaction using standard methodologies (50 μ l total volume). Briefly, samples were added to tubes containing water and appropriate amounts of PCR buffer, 25 mM MgCl₂, dNTPs, forward and reverse primers for glyceraldehyde 3-phosphate dehydrogenase (GAP, a housekeeping gene) and/or BMP-6, ³²P-dCTP, and Taq polymerase. Unless otherwise noted, primers were standardized to run consistently at 22 cycles (94°C, 30"; 58°C, 30"; 72°C, 20").

EXAMPLE 8: Quantitation of RT-PCR Products by Polyacrylamide Gel Electrophoresis (PAGE) and PhosphorImager Analysis

RT-PCR products received 5 μ l/tube loading dye, were mixed, heated at 65°C for 10 min and centrifuged. Ten μ l of each reaction was subjected to PAGE (12% polyacrylamide:bis; 15 V/well; constant current) under standard conditions. Gels were then incubated in gel preserving buffer (10% v/v glycerol, 7% v/v acetic acid, 40% v/v methanol, 43% deionized water) for 30 minutes, dried (80°C) *in vacuo* for 1-2 hours and developed with an electronically-enhanced phosphorescence imaging system for 6-24 hours. Visualized bands were analyzed. Counts per band were plotted graphically.

EXAMPLE 9: Differential Display PCR

RNA was extracted from cells stimulated with glucocorticoid (Trm, 1 nM). Heated, DNase-treated total RNA (5 g in 10.5 l total volume in DEPC-H₂O at 65°C for 5 minutes) was reverse transcribed as described in Example 7, but H-T₁₁M (SEQ ID. NO: 4) was used as the MMLV-RT primer. The resulting cDNAs were PCR-amplified as described above, but with various commercial primer sets (for example, H-T₁₁G (SEQ ID NO: 4) and H-AP-10 (SEQ ID. NO: 5); GenHunter Corp, Nashville, TN). Radiolabelled PCR products were fractionated by gel electrophoresis on a DNA sequencing gel. After electrophoresis, the resulting gels were dried *in vacuo* and autoradiographs were exposed overnight. Bands representing differentially-expressed cDNAs were excised from the gel and reamplified by PCR using the method of Conner *et al.*, Proc. Natl. Acad. Sci. USA, 88:278 (1983). The products of PCR reamplification were cloned into the vector PCR-II (TA cloning kit; InVitrogen, Carlsbad, CA).

EXAMPLE 10: Screening of a UMR 106 Rat Osteosarcoma Cell cDNA Library

A UMR 106 library (2.5 x 10¹⁰ pfu/ml) was plated at 5 x 10⁴ pfu/ml onto agar plates (LB bottom agar) and the plates were incubated overnight at 37°C. Filter membranes were overlaid onto plates for two minutes. Once removed, the filters were denatured, rinsed, dried and UV cross-linked. The filters were then incubated in pre-hybridization buffer (2X PIPES [pH 6.5], 5% formamide, 1% SDS and 100 g/ml denatured salmon sperm DNA) for 2 h at 42°C. A 260 base-pair radiolabelled probe (SEQ ID NO: 3; ³²P labelled by random priming) was added to the entire hybridization mix/filters, followed by hybridization for 18 hours at 42°C. The membranes were washed once at room temperature (10 min, 1 x SSC, 0.1% SDS) and three times at 55°C (15 min, 0.1 x SSC, 0.1% SDS).

After they were washed, the membranes were analyzed by autoradiography as described above. Positive clones were plaque purified. The procedure was repeated with a second filter for four minutes to minimize spurious positives. Plaque-purified clones were rescued as lambda SK(-) phagemids. Cloned cDNAs were sequenced as described below.

EXAMPLE 11: Sequencing of Clones

Cloned cDNA inserts were sequenced by standard methods. Ausubel *et al.*, Current Protocols in Molecular Biology, Wiley Interscience (1988). Briefly, appropriate concentrations of termination mixture, template and reaction mixture were subjected to an appropriate cycling protocol (95°C,30s; 68°C,30s; 72°C,60s; x 25). Stop mixture was added to terminate the sequencing reactions. After heating at 92°C for 3 minutes, the samples were loaded onto a denaturing 6% polyacrylamide sequencing gel (29:1 acrylamide:bis-acrylamide). Samples were electrophoresed for about 4 hours at 60 volts, constant current. After electrophoresis, the gels were dried *in vacuo* and autoradiographed.

The autoradiographs were analyzed manually. The resulting sequences were screened against the databases maintained by the National Center for Biotechnology Information (NIH, Bethesda, MD; <http://www.ncbi.nlm.nih.gov/>) using the BLASTn program set with default parameters. Based on the sequence data, new sequencing primers were prepared and the process was repeated until the entire gene had been sequenced. All sequences were confirmed a minimum of three times in both orientations.

Nucleotide and amino acid sequences were also analyzed using the PCGENE software package (version 16.0). Per cent homology values for nucleotide sequences were calculated by the program NALIGN, using the following parameters: weight of non-matching nucleotides, 10; weight of non-matching gaps, 10; maximum number of nucleotides considered, 50; and minimum number of nucleotides considered, 50.

For amino acid sequences, per cent homology values were calculated using PALIGN. A value of 10 was selected for both the open gap cost and the unit gap cost.

5 EXAMPLE 12: Cloning of RLMP cDNA

The differential display PCR amplification products described in Example 9 contained a major band of approximately 260 base pairs. This sequence was used to screen a rat osteosarcoma (UMR 106) cDNA library.

- 10 Positive clones were subjected to nested primer analysis to obtain the primer sequences necessary for amplifying the full length cDNA: (SEQ. ID NOs: 11, 12, 29, 30 and 31) One of those positive clones selected for further study was designated clone 10-4.

- Sequence analysis of the full-length cDNA in clone 10-4, determined by
15 nested primer analysis, showed that clone 10-4 contained the original 260 base-pair fragment identified by differential display PCR. Clone 10-4 (1696 base pairs; SEQ ID NO: 2) contains an open reading frame of 1371 base pairs encoding a protein having 457 amino acids (SEQ ID NO: 1). The termination codon, TGA, occurs at nucleotides 1444-1446. The polyadenylation signal at
20 nucleotides 1675-1680, and adjacent poly(A)⁺ tail, was present in the 3' noncoding region. There were two potential N-glycosylation sites, Asn-Lys-Thr and Asn-Arg-Thr, at amino acid positions 113-116 and 257-259 in SEQ ID NO: 1, respectively. Two potential cAMP- and cGMP-dependent protein kinase phosphorylation sites, Ser and Thr, were found at amino acid positions 191
25 and 349, respectively. There were five potential protein kinase C phosphorylation sites, Ser or Thr, at amino acid positions 3, 115, 166, 219, 442. One potential ATP/GTP binding site motif A (P-loop), Gly-Gly-Ser-Asn-Asn-Gly-Lys-Thr, was determined at amino acid positions 272-279.

- In addition, two highly conserved putative LIM domains were found at
30 amino acid positions 341-391 and 400-451. The putative LIM domains in this newly identified rat cDNA clone showed considerable homology with the LIM

domains of other known LIM proteins. However, the overall homology with other rat LIM proteins was less than 25%. RLMP (also designated 10-4) has 78.5% amino acid homology to the human enigma protein (see U.S. Patent No. 5,504,192), but only 24.5% and 22.7% amino acid homology to its closest rat homologs, CLP-36 and RIT-18, respectively.

EXAMPLE 13: Northern Blot Analysis of RLMP Expression

Thirty g of total RNA from ROB's, prepared according to Examples 1 and 2, was size fractionated by formaldehyde gel electrophoresis in 1% agarose flatbed gels and osmotically transblotted to nylon membranes. The blot was probed with a 600 base pair EcoR1 fragment of full-length 10-4 cDNA labeled with ³²P-dCTP by random priming.

Northern blot analysis showed a 1.7 kb mRNA species that hybridized with the RLMP probe. RLMP mRNA was up-regulated approximately 3.7-fold in ROB's after 24 hours exposure to BMP-6. No up-regulation of RMLP expression was seen in BMP-2 or BMP-4-stimulated ROB's at 24 hours.

EXAMPLE 14: Statistical Methods

For each reported nodule/osteocalcin result, data from 5-6 wells from a representative experiment were used to calculate the mean \pm S.E.M. Graphs may be shown with data normalized to the maximum value for each parameter to allow simultaneous graphing of nodule counts, mineralized areas and osteocalcin.

For each reported RT-PCR, RNase protection assay or Western blot analysis, data from triplicate samples of representative experiments, were used to determine the mean \pm S.E.M. Graphs may be shown normalized to either day 0 or negative controls and expressed as fold-increase above control values.

Statistical significance was evaluated using a one-way analysis of variance with post-hoc multiple comparison corrections of Bonferroni as appropriate. D. V. Huntsberger, "The Analysis of Variance," in Elements of Statistical Variance, P. Billingsley (ed.), pp. 298-330, Allyn & Bacon Inc.,
5 Boston, MA (1977) and Sigmapstat, Jandel Scientific, Corte Madera, CA. Alpha levels for significance were defined as $p < 0.05$.

EXAMPLE 15: Detection of Rat LIM Mineralization Protein by Western Blot Analysis

10

Polyclonal antibodies were prepared according to the methods of England *et al.*, Biochim.Biophys. Acta, 623:171 (1980) and Timmer *et al.*, J. Biol. Chem., 268:24863 (1993).

HeLa cells were transfected with pCMV2/RLMP. Protein was harvested
15 from the transfected cells according to the method of Hair *et al.*, Leukemia Research, 20:1 (1996). Western Blot Analysis of native RLMP was performed as described by Towbin *et al.*, Proc. Natl. Acad. Sci. USA, 76:4350 (1979).

EXAMPLE 16: Synthesis of the Rat LMP-Unique (RLMPU) derived Human
20 PCR product

Based on the sequence of the rat LMP-1 cDNA, forward and reverse PCR primers (SEQ ID NOs: 15 and 16) were synthesized and a unique 223 base-pair sequence was PCR amplified from the rat LMP-1 cDNA. A similar
25 PCR product was isolated from human MG63 osteosarcoma cell cDNA with the same PCR primers.

RNA was harvested from MG63 osteosarcoma cells grown in T-75 flasks. Culture supernatant was removed by aspiration and the flasks were overlayed with 3.0 ml of GIT solution per duplicate, swirled for 5-10 seconds,
30 and the resulting solution was transferred to 1.5 ml eppendorf tubes (5 tubes with 0.6 ml/tube). RNA was purified by a slight modification of standard

methods, for example, see Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, chapter 7, page 19, Cold Spring Harbor Laboratory Press (1989) and Boden *et al.*, Endocrinology, 138:2820-28 (1997). Briefly, the 0.6 ml samples received 60 μ l 2.0 M sodium acetate (pH 4.0), 550 μ l water saturated phenol and 5 150 μ l chloroform:isoamyl alcohol (49:1). After addition of those reagents, the samples were vortexed, centrifuged (10000 x g; 20 min; 4°C) and the aqueous phase transferred to a fresh tube. Isopropanol (600 μ l) was added and the RNA was precipitated overnight at -20°C. The samples were centrifuged (10000 x g; 20 minutes) and the supernatant was aspirated gently. The pellets were 10 resuspended in 400 μ l of DEPC-treated water, extracted once with phenol:chloroform (1:1), extracted with chloroform:isoamyl alcohol (24:1) and precipitated overnight at -20°C in 40 μ l sodium acetate (3.0 M; pH 5.2) and 1.0 ml absolute ethanol. After precipitation, the samples were centrifuged (10000 x g; 20 min), washed once with 70% ethanol, air dried for 5-10 minutes and 15 resuspended in 20 μ l of DEPC-treated water. RNA concentrations were derived from optical densities.

Total RNA (5 μ g in 10.5 μ l total volume in DEPC-H₂O) was heated at 65°C for 5 minutes, and then added to tubes containing 4 μ l 5X MMLV-RT buffer, 2 μ l dNTPs, 2 μ l dT17 primer (10 pmol/ml), 0.5 μ l RNAsin (40 U/ml) and 1 μ l MMLV-RT 20 (200 units/ μ l). The reactions were incubated at 37°C for 1 hour. Afterward, the MMLV-RT was inactivated by heating at 95°C for 5 minutes. The samples were diluted by addition of 80 μ l water.

Transcribed samples (5 μ l) were subjected to polymerase-chain reaction using standard methodologies (50 μ l total volume). Boden *et al.*, Endocrinology, 25 138:2820-28 (1997); Ausubel *et al.*, "Quantitation of rare DNAs by the polymerase chain reaction", in Current Protocols in Molecular Biology, chapter 15.31-1, Wiley & Sons, Trenton, NJ (1990). Briefly, samples were added to tubes containing water and appropriate amounts of PCR buffer (25 mM MgCl₂, dNTPs, forward and reverse primers (for RLMPU; SEQ ID NOs: 15 and 16), 30 ³²P-dCTP, and DNA polymerase. Primers were designed to run consistently at

22 cycles for radioactive band detection and 33 cycles for amplification of PCR product for use as a screening probe (94°C, 30 sec, 58°C, 30 sec; 72°C, 20 sec).

Sequencing of the agarose gel-purified MG63 osteosarcoma-derived
5 PCR product gave a sequence more than 95% homologous to the RLMPU PCR product. That sequence is designated HLMP unique region (HLMPU; SEQ ID NO: 6).

EXAMPLE 17: Screening of reverse-transcriptase-derived MG63 cDNA

10

Screening was performed with PCR using specific primers (SEQ ID NOs: 16 and 17) as described in Example 7. A 717 base-pair MG63 PCR product was agarose gel purified and sequenced with the given primers (SEQ. ID NOs: 12, 15, 16, 17, 18, 27 and 28). Sequences were confirmed a
15 minimum of two times in both directions. The MG63 sequences were aligned against each other and then against the full-length rat LMP cDNA sequence to obtain a partial human LMP cDNA sequence (SEQ ID NO: 7).

EXAMPLE 18: Screening of a Human Heart cDNA Library

20

Based on Northern blot experiments, it was determined that LMP-1 is expressed at different levels by several different tissues, including human heart muscle. A human heart cDNA library was therefore examined. The library was plated at 5×10^4 pfu/ml onto agar plates (LB bottom agar) and plates were
25 grown overnight at 37° C. Filter membranes were overlaid onto the plates for two minutes. Afterward, the filters denatured, rinsed, dried, UV cross-linked and incubated in pre-hybridization buffer (2X PIPES [pH 6.5]; 5% formamide, 1% SDS, 100 g/ml denatured salmon sperm DNA) for 2 h at 42°C. A radiolabelled, LMP-unique, 223 base-pair probe (^{32}P , random primer labelling;
30 SEQ ID NO: 6) was added and hybridized for 18 h at 42°C. Following hybridization, the membranes were washed once at room temperature (10 min,

1 x SSC, 0.1% SDS) and three times at 55°C (15 min, 0.1 x SSC, 0.1% SDS). Double-positive plaque-purified heart library clones, identified by autoradiography, were rescued as lambda phagemids according to the manufacturers' protocols (Stratagene, La Jolla, CA).

5 Restriction digests of positive clones yielded cDNA inserts of varying sizes. Inserts greater than 600 base-pairs in length were selected for initial screening by sequencing. Those inserts were sequenced by standard methods as described in Example 11.

 One clone, number 7, was also subjected to automated sequence
10 analysis using primers corresponding to SEQ ID NOs: 11-14, 16 and 27. The sequences obtained by these methods were routinely 97-100% homologous. Clone 7 (Partial Human LMP-1 cDNA from a heart library; SEQ. ID NO: 8) contained sequence that was more than 87% homologous to the rat LMP cDNA sequence in the translated region.

15

EXAMPLE 19: Determination of Full-Length Human LMP-1 cDNA

 Overlapping regions of the MG63 human osteosarcoma cell cDNA sequence and the human heart cDNA clone 7 sequence were used to align
20 those two sequences and derive a complete human cDNA sequence of 1644 base-pairs. NALIGN, a program in the PCGENE software package, was used to align the two sequences. The overlapping regions of the two sequences constituted approximately 360 base-pairs having complete homology except for a single nucleotide substitution at nucleotide 672 in the MG63 cDNA (SEQ ID
25 NO: 7) with clone 7 having an "A" instead of a "G" at the corresponding nucleotide 516 (SEQ ID NO: 8).

 The two aligned sequences were joined using SEQIN, another subprogram of PCGENE, using the "G" substitution of the MG63 osteosarcoma cDNA clone. The resulting sequence is shown in SEQ ID NO: 9. Alignment of
30 the novel human-derived sequence with the rat LMP-1 cDNA was accomplished with NALIGN. The full-length human LMP-1 cDNA sequence

(SEQ. ID NO: 9) is 87.3% homologous to the translated portion of rat LMP-1 cDNA sequence.

EXAMPLE 20: Determination of Amino Acid Sequence of Human LMP-1

5

The putative amino acid sequence of human LMP-1 was determined with the PCGENE subprogram TRANSL. The open reading frame in SEQ ID NO: 9 encodes a protein comprising 457 amino acids (SEQ. ID NO: 10). Using the PCGENE subprogram Palign, the human LMP-1 amino acid sequence was
10 found to be 94.1% homologous to the rat LMP-1 amino acid sequence.

EXAMPLE 21: Determination of the 5 Prime Untranslated Region of the Human LMP cDNA

15

MG63 5' cDNA was amplified by nested RT-PCR of MG63 total RNA using a 5' rapid amplification of cDNA ends (5' RACE) protocol. This method included first strand cDNA synthesis using a lock-docking oligo (dT) primer with two degenerate nucleotide positions at the 3' end (Chenchik *et al.*, CLONTECHniques, X:5 (1995); Borson *et al.*, PC Methods Applic., 2:144
20 (1993)). Second-strand synthesis is performed according to the method of Gubler *et al.*, Gene, 25:263 (1983), with a cocktail of *Escherichia coli* DNA polymerase I, RNase H, and *E. coli* DNA ligase. After creation of blunt ends with T4 DNA polymerase, double-stranded cDNA was ligated to the fragment (5' -CTAATACGACTCACTATAGGGCTCGAGCGGCCGCGCCGGGCAGGT- 3')
25 (SEQ.ID NO: 19). Prior to RACE, the adaptor-ligated cDNA was diluted to a concentration suitable for Marathon RACE reactions (1:50). Adaptor-ligated double-stranded cDNA was then ready to be specifically cloned.

First-round PCR was performed with the adaptor-specific oligonucleotide, 5'-CCATCCTAATACGACTCACTATAGGGC- 3' (AP1) (SEQ.ID
30 NO: 20) as sense primer and a Gene Specific Primer (GSP) from the unique region described in Example 16 (HLMPU). The second round of PCR was

performed using a nested primers GSP1-HLMPU (antisense/reverse primer) (SEQ. ID NO: 23) and GSP2-HLMPUF (SEQ. ID NO: 24) (see Example 16; sense/forward primer). PCR was performed using a commercial kit (Advantage cDNA PCR core kit; CloneTech Laboratories Inc., Palo Alto, CA) that utilizes
5 an antibody-mediated, but otherwise standard, hot-start protocol. PCR conditions for MG63 cDNA included an initial hot-start denaturation (94°C, 60 sec) followed by: 94°C, 30 sec; 60°C, 30 sec; 68°C, 4 min; 30 cycles. The first-round PCR product was approximately 750 base-pairs in length whereas the nested PCR product was approximately 230 base-pairs. The first-round PCR
10 product was cloned into linearized pCR 2.1 vector (3.9 Kb). The inserts were sequenced in both directions using M13 Forward and Reverse primers (SEQ. ID NO: 11; SEQ. ID NO: 12)

EXAMPLE 22: Determination of Full-length Human LMP-1 cDNA with 5 Prime
15 UTR

Overlapping MG63 human osteosarcoma cell cDNA 5'-UTR sequence (SEQ ID NO: 21), MG63 717 base-pair sequence (Example 17; SEQ ID NO: 8) and human heart cDNA clone 7 sequence (Example 18) were aligned to derive
20 a novel human cDNA sequence of 1704 base-pairs (SEQ.ID NO: 22). The alignment was accomplished with NALIGN, (both PCGENE and Omega 1.0; Intelligenetics). Over-lapping sequences constituted nearly the entire 717 base-pair region (Example 17) with 100% homology. Joining of the aligned sequences was accomplished with SEQIN.

25

EXAMPLE 23: Construction of LIM Protein Expression Vector

The construction of pHIS-5ATG LMP-1s expression vector was carried out with the sequences described in Examples 17 and 18. The 717 base-pair
30 clone (Example 17; SEQ ID NO: 7) was digested with ClaI and EcoRV. A small fragment (~250 base-pairs) was gel purified. Clone 7 (Example 18; SEQ

ID NO: 8) was digested with Clal and XbaI and a 1400 base-pair fragment was gel purified. The isolated 250 base-pair and 1400 base-pair restriction fragments were ligated to form a fragment of ~1650 base-pairs.

Due to the single nucleotide substitution in Clone 7 (relative to the 717
5 base-pair PCR sequence and the original rat sequence) a stop codon at translated base-pair 672 resulted. Because of this stop codon, a truncated (short) protein was encoded, hence the name LMP-1s. This was the construct used in the expression vector (SEQ ID NO: 32). The full length cDNA
10 NO: 32 with the 5' RACE sequence (SEQ ID NO: 21). The amino acid sequence of LMP-1s (SEQ ID NO: 34) was then deduced as a 223 amino acid protein and confirmed by Western blot (as in Example 15) to run at the predicted molecular weight of ~23.7 kD.

The pHIS-ATG vector (InVitrogen, Carlsbad, CA) was digested with
15 EcoRV and XbaI. The vector was recovered and the 1650 base-pair restriction fragment was then ligated into the linearized pHIS-ATG. The ligated product was cloned and amplified. The pHIS-ATG-LMP-1s Expression vector, also designated pHIS-A with insert HLMP-1s, was purified by standard methods.

20 EXAMPLE 24: Induction of Bone Nodule Formation and Mineralization *In vitro* with LMP Expression Vector

Rat Calvarial cells were isolated and grown in secondary culture according to Example 1. Cultures were either unstimulated or stimulated with
25 glucocorticoid (GC) as described in Example 1. A modification of the Superfect Reagent (Qiagen, Valencia, CA) transfection protocol was used to transfect 3 g/well of each vector into secondary rat calvarial osteoblast cultures according to Example 25.

Mineralized nodules were visualized by Von Kossa staining, as described in
30 Example 3. Human LMP-1s gene product overexpression alone induced bone nodule formation (~203 nodules/well) *in vitro*. Levels of nodules were

approximately 50% of those induced by the GC positive control (~412 nodules/well). Other positive controls included the pHisA-LMP-Rat expression vector (~152 nodules/well) and the pCMV2/LMP-Rat-Fwd Expression vector (~206 nodules/well), whereas the negative controls included the pCMV2/LMP-Rat-Rev. Expression vector (~2 nodules/well) and untreated (NT) plates (~4 nodules/well). These data demonstrate that the human cDNA was at least as osteoinductive as the rat cDNA. The effect was less than that observed with GC stimulation, most likely due to suboptimal doses of Expression vector.

10

EXAMPLE 25: LMP-Induced Cell Differentiation *In Vitro* and *In Vivo*

The rat LMP cDNA in clone 10-4 (see Example 12) was excised from the vector by double-digesting the clone with NotI and ApaI overnight at 37°C. Vector pCMV2 MCS (InVitrogen, Carlsbad, CA) was digested with the same restriction enzymes. Both the linear cDNA fragment from clone 10-4 and pCMV2 were gel purified, extracted and ligated with T4 ligase. The ligated DNA was gel purified, extracted and used to transform *E. coli* JM109 cells for amplification. Positive agar colonies were picked, digested with NotI and ApaI and the restriction digests were examined by gel electrophoresis. Stock cultures were prepared of positive clones.

A reverse vector was prepared in analogous fashion except that the restriction enzymes used were XbaI and HindIII. Because these restriction enzymes were used, the LMP cDNA fragment from clone 10-4 was inserted into pRc/CMV2 in the reverse (that is, non-translatable) orientation. The recombinant vector produced is designated pCMV2/RLMP.

An appropriate volume of pCMV10-4 (60 nM final concentration is optimal [3 g]; for this experiment a range of 0-600 nM/well [0-30 g/well] final concentration is preferred) was resuspended in Minimal Eagle Media (MEM) to 450 l final volume and vortexed for 10 seconds. Superfect was added (7.5 l/ml final solution), the solution was vortexed for 10 seconds and then incubated at

room temperature for 10 minutes. Following this incubation, MEM supplemented with 10% FBS (1 ml/well; 6 ml/plate) was added and mixed by pipetting.

The resulting solution was then promptly pipetted (1 ml/well) onto washed ROB cultures. The cultures were incubated for 2 hours at 37°C in a humidified atmosphere containing 5% CO₂. Afterward, the cells were gently washed once with sterile PBS and the appropriate normal incubation medium was added.

Results demonstrated significant bone nodule formation in all rat cell cultures which were induced with pCMV10-4. For example, pCMV10-4 transfected cells produced 429 nodules/well. Positive control cultures, which were exposed to Trm, produced 460 nodules/well. In contrast, negative controls, which received no treatment, produced 1 nodule/well. Similarly, when cultures were transfected with pCMV10-4 (reverse), no nodules were observed.

For demonstrating *de novo* bone formation *in vivo*, marrow was aspirated from the hindlimbs of 4-5 week old normal rats (rnu/+; heterozygous for recessive athymic condition). The aspirated marrow cells were washed in alpha MEM, centrifuged, and RBCs were lysed by resuspending the pellet in 0.83% NH₄Cl in 10 mM Tris (pH 7.4). The remaining marrow cells were washed 3x with MEM and transfected for 2 hours with 9 µg of pCMV-LMP-1s (forward or reverse orientation) per 3 x 10⁶ cells. The transfected cells were then washed 2X with MEM and resuspended at a concentration of 3 x 10⁷ cells/ml.

The cell suspension (100 µl) was applied via sterile pipette to a sterile 2 x 5 mm type I bovine collagen disc (Sulzer Orthopaedics, Wheat Ridge, CO). The discs were surgically implanted subcutaneously on the skull, chest, abdomen or dorsal spine of 4-5 week old athymic rats (mu/rnu). The animals were scarified at 3-4 weeks, at which time the discs or surgical areas were excised and fixed in 70% ethanol. The fixed specimens were analyzed by radiography and undecalcified histologic examination was performed on 5 m

thick sections stained with Goldner Trichrome. Experiments were also performed using devitalized (guanidine extracted) demineralized bone matrix (Osteotech, Shrewsbury, NJ) in place of collagen discs.

Radiography revealed a high level of mineralized bone formation that conformed to the form of the original collagen disc containing LMP-1s transfected marrow cells. No mineralized bone formation was observed in the negative control (cells transfected with a reverse-oriented version of the LMP-1s cDNA that did not code for a translated protein), and absorption of the carrier appeared to be well underway.

Histology revealed new bone trabeculae lined with osteoblasts in the LMP-1s transfected implants. No bone was seen along with partial resorption of the carrier in the negative controls.

Radiography of a further experiment in which 18 sets (9 negative control pCMV-LMP-REV & 9 experimental pCMV-LMP-1s) of implants were added to sites alternating between lumbar and thoracic spine in athymic rats demonstrated 0/9 negative control implants exhibiting bone formation (spine fusion) between vertebrae. All nine of the pCMV-LMP-1s treated implants exhibited solid bone fusions between vertebrae.

EXAMPLE 26: The Synthesis of pHIS-5' ATG LMP-1s Expression Vector from the sequences Demonstrated in Examples 2 and 3.

The 717 base-pair clone (Example 17) was digested with ClaI and EcoRV (New England Biologicals, city, MA). A small fragment (~250 base-pairs) was gel purified. Clone No. 7 (Example 18) was digested with ClaI and XbaI. A 1400 base-pair fragment was gel purified from that digest. The isolated 250 base-pair and 1400 base-pair cDNA fragments were ligated by standard methods to form a fragment of ~1650 bp. The pHIS-A vector (InVitrogen) was digested with EcoRV and XbaI. The linearized vector was recovered and ligated to the chimeric 1650 base-pair cDNA fragment. The ligated product was cloned and amplified by standard methods, and the pHIS-

A-5' ATG LMP-1s expression vector, also denominated as the vector pHis-A with insert HLMP-1s, was deposited at the ATCC as previously described.

EXAMPLE 27: The Induction of Bone Nodule Formation and Mineralization *In*

5 *Vitro* With pHis-5' ATG LMP-1s Expression Vector

Rat calvarial cells were isolated and grown in secondary culture according to Example 1. Cultures were either unstimulated or stimulated with glucocorticoid (GC) according to Example 1. The cultures were transfected
10 with 3 µg of recombinant pHis-A vector DNA/well as described in Example 25. Mineralized nodules were visualized by Von Kossa staining according to Example 3.

Human LMP-1s gene product overexpression alone (*i.e.*, without GC stimulation) induced significant bone nodule formation (~203 nodules/well) *in*
15 *vitro*. This is approximately 50% of the amount of nodules produced by cells exposed to the GC positive control (~412 nodules/well). Similar results were obtained with cultures transfected with pHisA-LMP-Rat Expression vector (~152 nodules/well) and pCMV2/LMP-Rat-Fwd (~206 nodules/well). In contrast, the negative control pCMV2/LMP-Rat-Rev yielded (~2 nodules/well),
20 while approximately 4 nodules/well were seen in the untreated plates. These data demonstrate that the human LMP-1 cDNA was at least as osteoinductive as the rat LMP-1 cDNA in this model system. The effect in this experiment was less than that observed with GC stimulation; but in some the effect was comparable.

25

EXAMPLE 28: LMP Induces Secretion of a Soluble Osteoinductive Factor

Overexpression of RLMP-1 or HLMP-1s in rat calvarial osteoblast cultures as described in Example 24 resulted in significantly greater nodule
30 formation than was observed in the negative control. To study the mechanism of action of LIM mineralization protein conditioned medium was harvested at

different time points, concentrated to 10 X, sterile filtered, diluted to its original concentration in medium containing fresh serum, and applied for four days to untransfected cells.

Conditioned media harvested from cells transfected with RLMP-1 or
5 HLMP-1s at day 4 was approximately as effective in inducing nodule formation as direct overexpression of RLMP-1 in transfected cells. Conditioned media from cells transfected with RLMP-1 or HLMP-1 in the reverse orientation had no apparent effect on nodule formation. Nor did conditioned media harvested from LMP-1 transfected cultures before day 4 induce nodule formation. These
10 data suggest that expression of LMP-1 caused the synthesis and/or secretion of a soluble factor, which did not appear in culture medium in effective amounts until 4 days post transfection.

Since overexpression of rLMP-1 resulted in the secretion of an osteoinductive factor into the medium, Western blot analysis was used to
15 determine if LMP-1 protein was present in the medium. The presence of rLMP-1 protein was assessed using antibody specific for LMP-1 (QDPDEE) and detected by conventional means. LMP-1 protein was found only in the cell layer of the culture and not detected in the medium.

Partial purification of the osteoinductive soluble factor was accomplished
20 by standard 25% and 100% ammonium sulfate cuts followed by DE-52 anion exchange batch chromatography (100 mM or 500 mM NaCl). All activity was observed in the high ammonium sulfate, high NaCl fractions. Such localization is consistent with the possibility of a single factor being responsible for conditioning the medium.

25

EXAMPLE 29: Gene Therapy In Lumbar Spine Fusion Mediated by Low Dose Adenovirus

This study determined the optimal dose of adenoviral delivery of the
30 LMP-1 cDNA (SEQ ID NO: 2) to promote spine fusion in normal, that is, immune competent, rabbits.

A replication-deficient human recombinant adenovirus was constructed with the LMP-1 cDNA (SEQ ID NO: 2) driven by a CMV promoter using the Adeno-Quest™ Kit (Quantum Biotechnologies, Inc., Montreal). A commercially available (Quantum Biotechnologies, Inc., Montreal) recombinant adenovirus
 5 containing the beta-galactosidase gene was used as a control.

Initially, an *in vitro* dose response experiment was performed to determine the optimal concentration of adenovirus-delivered LMP-1 ("AdV-LMP-1") to induce bone differentiation in rat calvarial osteoblast cultures using a 60-minute transduction with a multiplicity of infection ("MOI") of 0.025, 0.25,
 10 2.5, or 25 plaque-forming units (pfu) of virus per cell. Positive control cultures were differentiated by a 7-day exposure to 10^{-9} M glucocorticoid ("GC"). Negative control cultures were left untreated. On day 14, the number of mineralized bone nodules was counted after von Kossa staining of the cultures, and the level of osteocalcin secreted into the medium (pmol/mL) was
 15 measured by radioimmunoassay (mean \pm SEM).

The results of this experiment are shown in Table I. Essentially no spontaneous nodules formed in the untreated negative control cultures. The data show that a MOI equal to 0.25 pfu/cell is most effective for osteoinducing bone nodules, achieving a level comparable to the positive control (GC).
 20 Lower and higher doses of adenovirus were less effective.

TABLE I

Outcome	AdV-LMP-1 Dose (MOI)					
	Neg. Ctrl.	GC	0.025	0.25	2.5	25
Bone Nodules	0.5 \pm 0.2	188 \pm 35	79.8 \pm 13	145.1 \pm 13	26.4 \pm 15	87.6 \pm 2
Osteocalcin	1.0 \pm 0.1	57.8 \pm 9	28.6 \pm 11	22.8 \pm 1	18.3 \pm 3	26.0 \pm 2

In vivo experiments were then performed to determine if the optimal *in vitro* dose was capable of promoting intertransverse process spine fusions in skeletally mature New Zealand white rabbits. Nine rabbits were anesthetized and 3 cc of bone marrow was aspirated from the distal femur through the intercondylar notch using an 18 gauge needle. The buffy coat was then isolated, a 10-minute transduction with AdV-LMP-1 was performed, and the cells were returned to the operating room for implantation. Single level posterolateral lumbar spine arthrodesis was performed with decortication of transverse processes and insertion of carrier (either rabbit devitalized bone matrix or a collagen sponge) containing 8-15 million autologous nucleated buffy coat cells transduced with either AdV-LMP-1 (MOI = 0.4) or AdV-BGal (MOI = 0.4). Rabbits were euthanized after 5 weeks and spine fusions were assessed by manual palpation, plain x-rays, CT scans, and undecalcified histology.

The spine fusion sites that received AdV-LMP-1 induced solid, continuous spine fusion masses in all nine rabbits. In contrast, the sites receiving AdV-BGal, or a lower dose of AdV-LMP-1 (MOI = 0.04) made little or no bone and resulted in spine fusion at a rate comparable to the carrier alone (< 40%). These results were consistent as evaluated by manual palpation, CT scan, and histology. Plain radiographs, however, sometimes overestimated the amount of bone that was present, especially in the control sites. LMP-1 cDNA delivery and bone induction was successful with both of the carrier materials tested. There was no evidence of systemic or local immune response to the adenovirus vector.

These data demonstrate consistent bone induction in a previously validated rabbit spine fusion model which is quite challenging. Furthermore, the protocol of using autogenous bone marrow cells with intraoperative *ex vivo* gene transduction (10 minutes) is a more clinically feasible procedure than other methods that call for overnight transduction or cell expansion for weeks in culture. In addition, the most effective dose of recombinant adenovirus (MOI=0.25) was substantially lower than doses reported in other gene therapy

applications (MOI-40-500). We believe this is due to the fact that LMP-1 is an intracellular signaling molecule and may have powerful signal amplification cascades. Moreover, the observation that the same concentration of AdV-LMP-1 that induced bone in cell culture was effective *in vivo* was also surprising given the usual required increase in dose of other growth factors when translating from cell culture to animal experiments. Taken together, these observations indicate that local gene therapy using adenovirus to deliver the LMP-1 cDNA is possible and the low dose required will likely minimize the negative effects of immune response to the adenovirus vector.

10

EXAMPLE 30: Use of Peripheral Venous Blood Nucleated Cells (Buffy Coat) for Gene Therapy With LMP-1 cDNA To Make Bone

In four rabbits we performed spine fusion surgery as above (Example 29) except the transduced cells were the buffy coat from venous blood rather than bone marrow. These cells were transfected with Adeno-LMP or pHIS-LMP plasmid and had equivalent successful results as when bone marrow cells were used. This discovery of using ordinary venous blood cells for gene delivery makes gene therapy more feasible clinically since it avoids painful marrow harvest under general anesthesia and yields two times more cells per mL of starting material.

20

EXAMPLE 31: Isolation of Human LMP-1 Splice Variants

Intron/Exon mRNA transcript splice variants are a relatively common regulatory mechanism in signal transduction and cellular/tissue development. Splice variants of various genes have been shown to alter protein-protein, protein-DNA, protein-RNA, and protein-substrate interactions. Splice variants may also control tissue specificity for gene expression allowing different forms (and therefore functions) to be expressed in various tissues. Splice variants are a common regulatory phenomenon in cells. It is possible that the LMP

25

30

splice variants may result in effects in other tissues such as nerve regeneration, muscle regeneration, or development of other tissues.

To screen a human heart cDNA library for splice variants of the HLMP-1 sequence, a pair of PCR primer corresponding to sections of SEQ ID NO: 22 was prepared. The forward PCR primer, which was synthesized using standard techniques, corresponds to nucleotides 35-54 of SEQ ID NO: 22. It has the following sequence:

5' GAGCCGGCATCATGGATTCC 3' (SEQ ID NO: 35)

10

The reverse PCR primer, which is the reverse complement of nucleotides 820-839 in SEQ ID NO: 22, has the following sequence:

5' GCTGCCTGCACAATGGAGGT 3' (SEQ ID NO: 36)

15

The forward and reverse PCR primers were used to screen human heart cDNA (ClonTech, Cat No. 7404-1) for sequences similar to HLMP-1 by standard techniques, using a cycling protocol of 94°C for 30 seconds, 64°C for 30 seconds, and 72°C for 1 minute, repeated 30 times and followed by a 10 minute incubation at 72°C. The amplification cDNA sequences were gel-purified and submitted to the Emory DNA Sequence Core Facility for sequencing. The clones were sequenced using standard techniques and the sequences were examined with PCGENE (Intelligenetics; Programs SEQUIN and NALIGN) to determine homology to SEQ ID NO: 22. Two homologous nucleotide sequences with putative alternative splice sites compared to SEQ ID NO: 22 were then translated to their respective protein products with Intelligenetic's program TRANSL.

20

25

One of these two novel human cDNA sequences (SEQ ID NO: 37) comprises 1456 bp:

30

10 20 30 40 50 60

CGACGCAGAG CAGCGCCCTG GCCGGGCCAA GCAGGAGCCG GCATCATGGA TTCCTTCAAG
 70 80 90 100 110 120
 GTAGTGCTGG AGGGGCCAGC ACCTTGGGGC TTCCGGCTGC AAGGGGGCAA GGACTTCAAT
 130 140 150 160 170 180
 5 GTGCCCCCTCT CCATTTCCCG GCTCACTCCT GGGGGCAAAG CGGCGCAGGC CGGAGTGGCC
 190 200 210 220 230 240
 GTGGGTGACT GGGTGCTGAG CATCGATGGC GAGAATGCGG GTAGCCTCAC ACACATCGAA
 250 260 270 280 290 300
 GCTCAGAACA AGATCCGGGC CTGCGGGGAG CGCCTCAGCC TGGGCCTCAG CAGGGCCCAG
 10 310 320 * 330 340 * 350 360
 CCGGTTTCTG GCAAACCGCA GAAGGTGCAG ACCCCTGACA AACAGCCGCT CCGACCGCTG
 370 380 390 400 410 420
 GTCCCAGATG CCAGCAAGCA GCGGCTGATG GAGAACACAG AGGACTGGCG GCCGCGGCCG
 430 440 450 460 470 480
 15 GGGACAGGCC AGTCGCGTTC CTTCCGCATC CTTGCCCACC TCACAGGCAC CGAGTTCATG
 490 500 510 520 530 540
 CAAGACCCGG ATGAGGAGCA CCTGAAGAAA TCAAGCCAGG TGCCAGGAC AGAAGCCCCA
 550 560 570 580 590 600
 GCCCCAGCCT CATCTACACC CCAGGAGCCC TGGCCTGGCC CTACCGCCCC CAGCCCTACC
 20 610 620 630 640 650 660
 AGCCGCCCCG CCTGGGCTGT GGACCCTGCG TTTGCCGAGC GCTATGCCCC GGACAAAACG
 670 680 690 700 710 720
 AGCACAGTGC TGACCCGGCA CAGCCAGCCG GCCACGCCCA CGCCGCTGCA GAGCCGCACC
 730 740 750 760 770 780
 25 TCCATTGTGC AGGCAGCTGC CGGAGGGGTG CCAGGAGGGG GCAGCAACAA CGGCAAGACT
 790 800 810 820 830 840
 CCCGTGTGTC ACCAGTGCCA CAAGGTCATC CGGGGCCGCT ACCTGGTGCC GTTGGGCCAC
 850 860 870 880 890 900

```

          GCGTACCACC CGGAGGAGTT TGTGTGTAGC CAGTGTGGGA AGGTCTTGGA AGAGGGTGGC
          910          920          930          940          950          960
          TTCTTTGAGG AGAAGGGCGC CATCTTCTGC CCACCATGCT ATGACGTGCG CTATGCACCC
          970          980          990          1000          1010          1020
5          AGCTGTGCCA AGTGCAAGAA GAAGATTACA GGCGAGATCA TGCACGCCCT GAAGATGACC
          1030          1040          1050          1060          1070          1080
          TGGCACGTGC ACTGCTTTAC CTGTGCTGCC TGCAAGACGC CCATCCGGAA CAGGGCCTTC
          1090          1100          1110          1120          1130          1140
          TACATGGAGG AGGGCGTGCC CTATTGCGAG CGAGACTATG AGAAGATGTT TGGCACGAAA
10          1150          1160          1170          1180          1190          1200
          TGCCATGGCT GTGACTTCAA GATCGACGCT GGGGACCGCT TCCTGGAGGC CCTGGGCTTC
          1210          1220          1230          1240          1250          1260
          AGCTGGCATG ACACCTGCTT CGTCTGTGCG ATATGTCAGA TCAACCTGGA AGGAAAGACC
          1270          1280          1290          1300          1310          1320
15          TTCTACTCCA AGAAGGACAG GCCTCTCTGC AAGAGCCATG CCTTCTCTCA TGTGTGAGCC
          1330          1340          1350          1360          1370          1380
          CCTTCTGCCC ACAGCTGCCG CGGTGGCCCC TAGCCTGAGG GGCCTGGAGT CGTGGCCCTG
          1390          1400          1410          1420          1430          1440
          CATTTCTGGG TAGGGCTGGC AATGGTTGCC TTAACCCTGG CTCCTGGCCC GAGCCTGGGC
20          1450
          TCCCGGGCCC TGCCCA

```

Reading frame shifts caused by the deletion of a 119 bp fragment
(between *) and the addition of a 17 bp fragment (underlined) results in a
truncated gene product having the following derived amino acid sequence
(SEQ ID NO: 38):

```

          10          20          30          40          50          60

```

```

MDSFKVVLEG PAPWGFRLQG GKDFNVPLSI SRLTPGGKAA QAGVAVGDWV LSIDGENAGS
      70      80      90      100      110      120
LTHIEAQNKI RACGERLSLG LSRAQPVQNK POKVOTPDQK PLRPLVPDAS KQRLMENTED
      130      140      150      160      170      180
5  WRPRPGTGQS RSFRILAHLT GTEFMQDPDE EHLKKSSQVP RTEAPAPASS TPQEPWPGPT
      190      200      210      220      230      240
APSPTSPPW AVDPAPAERY APDKTSTVLT RHSQPATPTP LQSRTSIVQA AAGGVPGGGS
      250      260      270      280      290      300
NNGKTPVCHQ CHQVIRARYL VALGHAYHPE EFVCSQCGKV LEEGGFFEEK GAIFCPPCYD
10      310      320      330      340      350      360
VRYAPSCAKC KKKITGEIMH ALKMTWHVLC FTCAACKTPI RNRAFYMEEG VPYCERDYEK
      370      380      390      400      410      420
MFGTKCQWCD FKIDAGDRFL EALGFSWHD TCFVCAICQIN LEGKTFYSKK DRPLCKSHAF
SHV

```

15 This 423 amino acid protein demonstrates 100% homology to the protein shown in Sequence ID No. 10, except for the sequence in the highlighted area (amino acids 94-99), which are due to the nucleotide changes depicted above.

 The second novel human heart cDNA sequence (SEQ ID NO: 39)
20 comprises 1575 bp:

```

      10      20      30      40      50      60
CGACGCAGAG CAGCGCCCTG GCCGGGCCAA GCAGGAGCCG GCATCATGGA TTCCTTCAAG
      70      80      90      100      110      120
25 GTAGTGCTGG AGGGGCCAGC ACCTTGGGGC TTCCGGCTGC AAGGGGGCAA GGACTTCAAT
      130      140      150      160      170      180
GTGCCCCCTCT CCATTTCCCG GCTCACTCCT GGGGGCAAAG CGGCGCAGGC CGGAGTGGCC
      190      200      210      220      230      240

```

GTGGGTGACT GGGTGCTGAG CATCGATGGC GAGAATGCGG GTAGCCTCAC ACACATCGAA
 250 260 270 280 290 300
 GCTCAGAACAA AGATCCGGGC CTGCGGGGAG CGCCTCAGCC TGGGCCTCAG CAGGGCCCCAG
 310 320 330 340 350 360
 5 CCGGTTCAGA GCAAACCGCA GAAGGCCTCC GCGGACCTCC GCGGTACACC
 370 380 390 400 410 420
 TTTGCACCCA GCGTCTCCCT CAACAAGACG GCGGCGCCCT TTGGGGCGCC CCCGCCCCGT
 430 440 450 460 470 480
 GACAGCGCCC CGCAACAGAA TGGGTGCAGA CCCCTGACAA ACAGCCGCTC CGACCGCTGG
 10 490 500 510 520 530 540
 TCCCAGATGC CAGCAAGCAG CGGCTGATGG AGAACACAGA GGAAGTGGCGG CCGCGGCCGG
 550 560 570 580 590 600
 GGACAGGCCA GTCGCGTTCC TTCCGCATCC TTGCCCACCT CACAGGCACC GAGTTCATGC
 610 620 630 640 650 660
 15 AAGACCCGGA TGAGGAGCAC CTGAAGAAAT CAAGCCAGGT GCCCAGGACA GAAGCCCCAG
 670 680 690 700 710 720
 CCCCAGCCTC ATCTACACCC CAGGAGCCCT GGCCTGGCCC TACCGCCCCC AGCCCTACCA
 730 740 750 760 770 780
 GCCGCCCCGCC CTGGGCTGTG GACCCTGCGT TTGCCGAGCG CTATGCCCCG GACAAAACGA
 20 790 800 810 820 830 840
 GCACAGTGCT GACCCGGCAC AGCCAGCCGG CCACGCCAC GCGCTGCAG AGCCGCACCT
 850 860 870 880 890 900
 CCATTGTGCA GGCAGCTGCC GGAGGGGTGC CAGGAGGGGG CAGCAACAAC GGCAAGACTC
 910 920 930 940 950 960
 25 CCGTGTGTCA CCAGTGCCAC AAGGTCATCC GGGGCCGCTA CCTGGTGGCG TTGGGCCACG
 970 980 990 1000 1010 1020
 CGTACCACCC GGAGGAGTTT GTGTGTAGCC AGTGTGGGAA GGTCTTGAA GAGGGTGGCT
 1030 1040 1050 1060 1070 1080

```

TCTTTGAGGA GAAGGGCGCC ATCTTCTGCC CACCATGCTA TGACGTGCGC TATGCACCCA
      1090      1100      1110      1120      1130      1140
GCTGTGCCAA GTGCAAGAAG AAGATTACAG GCGAGATCAT GCACGCCCTG AAGATGACCT
      1150      1160      1170      1180      1190      1200
5  GGCACGTGCA CTGCTTTACC TGTGCTGCCT GCAAGACGCC CATCCGGAAC AGGGCCTTCT
      1210      1220      1230      1240      1250      1260
ACATGGAGGA GGGCGTGCCC TATTGCGAGC GAGACTATGA GAAGATGTTT GGCACGAAAT
      1270      1280      1290      1300      1310      1320
GCCATGGCTG TGACTTCAAG ATCGACGCTG GGGACCGCTT CCTGGAGGCC CTGGGCTTCA
      1330      1340      1350      1360      1370      1380
10 GCTGGCATGA CACCTGCTTC GTCTGTGCGA TATGTCAGAT CAACCTGGAA GGAAAGACCT
      1390      1400      1410      1420      1430      1440
TCTACTCCAA GAAGGACAGG CCTCTCTGCA AGAGCCATGC CTTCTCTCAT GTGTGAGCCC
      1450      1460      1470      1480      1490      1500
15 CTTCTGCCCA CAGCTGCCGC GGTGGCCCTT AGCCTGAGGG GCCTGGAGTC GTGGCCCTGC
      1510      1520      1530      1540      1550      1560
ATTTCTGGGT AGGGCTGGCA ATGGTTGCCT TAACCCTGGC TCCTGGCCCG AGCCTGGGCT
      1570
CCCGGGCCCT GCCCA

```

20 Reading frame shifts caused by the addition of a 17 bp fragment
(bolded, italicized and underlined) results in an early translation stop codon at
position 565-567 (underlined).

The derived amino acid sequence (SEQ ID NO: 40) consists of 153
amino acids:

```

25
      10      20      30      40      50      60
MDSFKVVLEG PAPWGFRLQG GKDFNVPLSI SRLTPGGKAA QAGVAVGDWV LSIDGENAGS
      70      80      90      100     110     120

```

LTHIEAQNKI RACGERLSLG LSRAQPVQSK POKASAPAAD PPRYTFAPSV SLNKTARPFG

130

140

150

APPPADSAPO QNGCRPLTNS RSDRWSOMPA SSG

- 5 This protein demonstrates 100% homology to SEQ ID NO: 10 until amino acid 94, where the addition of the 17 bp fragment depicted in the nucleotide sequence results in a frame shift. Over amino acids 94-153, the protein is not homologous to SEQ ID NO: 10. Amino acids 154-457 in SEQ ID NO: 10 are not present due to the early stop codon depicted in nucleotide sequence.

EXAMPLE 32: Genomic HLMP-1 Nucleotide Sequence

Applicants have identified the genomic DNA sequence encoding HLMP-1, including putative regulatory elements associated with HLMP-1 expression.

- 5 The entire genomic sequence is shown in SEQ ID. NO: 41. This sequence was derived from AC023788 (clone RP11-564G9), Genome Sequencing Center, Washington University School of Medicine, St. Louis, MO.

- The putative promoter region for HLMP-1 spans nucleotides 2,660-8,733 in SEQ ID NO: 41. This region comprises, among other things, at least
 10 ten potential glucocorticoid response elements ("GREs") (nucleotides 6148-6153, 6226-6231, 6247-6252, 6336-6341, 6510-6515, 6552-6557, 6727-6732, 6752-6757, 7738-7743, and 8255-8260), twelve potential Sma-2 homologues to Mothers against Drosophilla decapentaplegic ("SMAD") binding element—sites (nucleotides 3569-3575, 4552-4558, 4582-4588, 5226-5232, 6228-6234,
 15 6649-6655, 6725-6731, 6930-6936, 7379-7384, 7738-7742, 8073-8079, and 8378-8384), and three TATA boxes (nucleotides 5910-5913, 6932-6935, and 7380-7383). The three TATA boxes, all of the GREs, and eight of the SMAD binding elements ("SBEs") are grouped in the region spanning nucleotides 5,841-8,733 in SEQ ID NO: 41. These regulatory elements can be used, for
 20 example, to regulate expression of exogenous nucleotide sequences encoding proteins involved in the process of bone formation. This would permit systemic administration of therapeutic factors or genes relating to bone formation and repair, as well as factors or genes associated with tissue differentiation and development.

- 25 In addition to the putative regulatory elements, 13 exons corresponding to the nucleotide sequence encoding HLMP-1 have been identified. These exons span the following nucleotides in SEQ ID NO: 41:

	Exon 1	8733-8767
30	Exon 2	9790-9895
	Exon 3	13635-13787

	Exon 4	13877-13907
	Exon 5	14387-14502
	Exon 6	15161-15297
	Exon 7	15401-15437
5	Exon 8	16483-16545
	Exon 9	16689-16923
	Exon 10	18068-18248
	Exon 11	22117-22240
	Exon 12	22323-22440
10	Exon 13	22575-22911

In HLMP-2 there is another exon (Exon 5A), which spans nucleotides 14887-14904.

All cited publications and patents are hereby incorporated by reference in their entirety.

15 While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be appreciated by one skilled in the art from reading this disclosure that various changes in form and detail can be made without departing from the true scope of the invention.

We claim:

1. An isolated nucleic acid molecule comprising a SEQ ID NO: 37 or SEQ ID NO: 39.
2. An isolated human LMP protein encoded by SEQ ID NO: 37 or SEQ ID NO: 39.
3. A vector comprising the isolated nucleic acid molecule of claims 1.
4. A host cell comprising the vector of claim 3.
5. The host cell of claim 4, wherein the host cell is selected from the group consisting of prokaryotic cells, yeast cells and mammalian cells
6. The isolated nucleic acid molecule of claim 1, further comprising a label.
7. A human LIM mineralization protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 38 and SEQ ID NO: 40.
8. A monoclonal antibody specific for a HLMP-2 (SEQ ID NO: 38) or HLMP-3 (SEQ ID NO: 40).
9. A method of inducing bone formation comprising transfecting osteogenic precursor cells or peripheral blood leukocytes with an isolated nucleic acid molecule comprising SEQ ID NO: 39.
10. The method of claim 9, wherein the isolated nucleic acid molecule is in a vector.
11. The method of claim 10, wherein the vector is an expression vector.
12. The method of claim 11, wherein the vector is a plasmid.
13. The method of claim 11, wherein the vector is a virus.
14. The method of claim 13, wherein the virus is an adenovirus.
15. The method of claim 13, wherein the virus is a retrovirus.
16. The method of claim 9, wherein the osteogenic precursor cells or peripheral blood leukocytes are transfected *ex vivo*.
17. The method of claim 9, wherein the osteogenic precursor cells are transfected *in vivo* by direct injection of the isolated nucleic acid molecule.

18. The method of claim 9, wherein the LIM mineralization protein is HLMP-3 (SEQ ID NO: 40).

19. A method of fusing a spine, comprising:

- (a) transfecting osteogenic precursor cells or peripheral blood leukocytes with an isolated nucleic acid molecule comprising SEQ ID NO: 39;
 - (b) admixing the transfected osteogenic precursor cells or peripheral blood leukocytes with a matrix; and
 - (c) contacting the matrix with the spine;
- wherein expression of the nucleotide sequence causes mineralized bone formation in the matrix.

20. The method of claim 19, wherein the osteogenic precursor cells or peripheral blood cells are transfected *ex vivo*.

21. A method of inducing systemic bone formation in a mammalian host in need thereof, comprising:

- a) transfecting osteogenic precursor cells or peripheral blood leukocytes with a vector that is stably maintained in the osteogenic precursor cells or peripheral blood leukocytes, the vector comprising SEQ ID NO: 39 operably linked to a regulatable promoter, wherein the regulatable promoter responds to an exogenous control compound; and
- (b) administering to the host, as needed, an amount of the exogenous control substance effective to cause expression of SEQ ID NO: 39.

22. A method of stimulating production of an osteogenic soluble factor by an osteogenic cell, comprising:

(a) transfecting the osteogenic cell or peripheral blood leukocyte with an isolated nucleic acid molecule comprising SEQ ID NO: 39; and

5 (b) overexpressing the isolated nucleic acid molecule.

23. An osteogenic soluble factor produced by the method of claim 22.

24. The osteogenic soluble factor of claim 23, wherein the osteogenic factor is a protein.

25. A method of inhibiting the expression of HLMP-2 or HLMP-3
10 comprising transfecting a cell wherein HLMP-2 or HLMP-3 is expressed with an antisense oligonucleotide.

26. The method of claim of claim 17, wherein the isolated nucleic acid molecule is in a vector selected from the group consisting of a plasmid and a virus.

15 27. The method of claim 26, wherein the vector is a plasmid, which plasmid is directly injected into muscle tissue.

28. A method of inhibiting bone formation comprising transfecting osteogenic precursor cells or peripheral blood leukocytes with an isolated nucleic acid molecule comprising SEQ ID NO: 37.

20 29. The method of claim 28, wherein the isolated nucleic acid molecule is in a vector.

30. The method of claim 29, wherein the vector is an expression vector.

31. The method of claim 30, wherein the vector is a plasmid.

32. The method of claim 30, wherein the vector is a virus.

25 33. The method of claim 32, wherein the virus is an adenovirus

34. The method of claim 32, wherein the virus is a retrovirus.

35. The method of claim 28, wherein the osteogenic precursor cells or peripheral blood leukocytes are transfected *ex vivo*.

30 36. The method of claim 28, wherein the osteogenic precursor cells are transfected *in vivo* by direct injection of the isolated nucleic acid molecule.

37. The method of claim 28, wherein the LIM mineralization protein is HLMP-2 (SEQ ID NO: 38).

SEQUENCE LISTING

<110> Boden M.D., Scott D
Hair Ph.D., Gregory A

<120> LIM Mineralization Protein Splice Variants

<130> splice variant LMP

<140> 6148.0222-00304

<141> 2000-04-28

<150> 60/132,021

<151> 1999-04-30

<160> 42

<170> PatentIn Ver. 2.1

<210> 1

<211> 457

<212> PRT

<213> Rattus norvegicus

<400> 1

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
1 5 10 15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
20 25 30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
35 40 45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
50 55 60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
65 70 75 80

Leu Ser Arg Ala Gln Pro Ala Gln Ser Lys Pro Gln Lys Ala Leu Thr
85 90 95

Pro Pro Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Ala Ser Leu
100 105 110

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Thr Asp Ser Ala
115 120 125

Leu Ser Gln Asn Gly Gln Leu Leu Arg Gln Leu Val Pro Asp Ala Ser
130 135 140

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
145 150 155 160

Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
 165 170 175
 Glu Phe Met Gln Asp Pro Asp Glu Glu Phe Met Lys Lys Ser Ser Gln
 180 185 190
 Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Thr Ile Pro Gln Glu
 195 200 205
 Ser Trp Pro Gly Pro Thr Thr Pro Ser Pro Thr Ser Arg Pro Pro Trp
 210 215 220
 Ala Val Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser
 225 230 235 240
 Thr Val Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln
 245 250 255
 Asn Arg Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Gly Thr Gly Gly
 260 265 270
 Gly Ser Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Lys Ile
 275 280 285
 Ile Arg Gly Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu
 290 295 300
 Glu Phe Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe
 305 310 315 320
 Phe Glu Glu Lys Gly Ala Ile Phe Cys Pro Ser Cys Tyr Asp Val Arg
 325 330 335
 Tyr Ala Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile
 340 345 350
 Met His Ala Leu Lys Met Thr Trp His Val Pro Cys Phe Thr Cys Ala
 355 360 365
 Ala Cys Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly
 370 375 380
 Ala Pro Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys
 385 390 395 400
 Arg Gly Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala
 405 410 415
 Leu Gly Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln
 420 425 430
 Ile Asn Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Lys Pro Leu
 435 440 445
 Cys Lys Ser His Ala Phe Ser His Val
 450 455

<210> 2
 <211> 1696
 <212> DNA
 <213> *Rattus norvegicus*

<400> 2
 gcacgaggat cccagcgagg ctcttgagg ccgcccaggca gccgcccagc cgggcattca 60
 ggagcaggta ccatggattc cttcaaggta gtgctggagg gacctgcccc ttggggcttc 120
 cgtctgcaag ggggcaagga cttcaacgtg cccctctcca tctctcggct cactcctgga 180
 ggcaaggccg cacaggccgg tgtggccgtg ggagactggg tactgagtat cgacggtgag 240
 aacgcccggaa gcctcacaca cattgaagcc cagaacaaga tccgtgcctg tggggagcgc 300
 ctacgcctgg gtcttagcag agcccagcct gctcagagca aaccacagaa ggccctgacc 360
 cctcccgccg acccccgag gtacactttt gcaccaagcg cctccctcaa caagacggcc 420
 cggcccttgc gggcaccccc acctactgac agcgccctgt cgcagaatgg acagctgctc 480
 agacagctgg tccctgatgc cagcaagcag cggctgatgg agaatactga agactggcgc 540
 ccgcgccag ggacaggcca gtcccgcttc ttccgcatcc ttgctcacct caggggcaca 600
 gagttcatgc aagaccggga tgaggaattc atgaagaagt caagccagggt gccagggaca 660
 gaagccccag cccagcctc aaccataccc caggaatcct ggccctggccc caccaccccc 720
 agccccacca gccgcccacc ctgggcccgt gatcctgcat ttgctgagcg ctatgcccc 780
 gacaaaacca gcacagtgt gacccgacac agccagccag ccacacctac gcctctgcag 840
 aaccgcacct ccatagtcca ggctgcagct ggagggggca caggaggagg cagcaacaat 900
 ggcaagacgc ctgtatgcca ccagtgccac aagatcatcc gccggccgata cctggtagca 960
 ctggggccacg cgtaccatcc tgaggaattt gtgtgcagcc agtgtgggaa ggtcctggaa 1020
 gaggggtggct tcttcgagga gaaggagct atcttttgcc cctcctgcta tgatgtgcgc 1080
 tatgcaccca gctgtgcca atgcaagaag aagatcactg gagagatcat gcatgcgctg 1140
 aagatgacct ggcattgtcc ctgcttcacc tgtgcagcct gcaaaacccc tatccgcaac 1200
 agggctttct acatggagga gggggctccc tactgcgagc gagattacga gaagatgttt 1260
 ggcacaaagt gtcgcggtg tgacttcaag atcgatgccg gggaccgttt cctggaagcc 1320
 ctgggtttca gctggcatga tacgtgtttt gtttgcgcaa tatgtcaaat caacttggaa 1380
 ggaaagacct tctactccaa gaaggacaag cccctgtgca agagccatgc ctttccccc 1440
 gtatgagcac ctctcacac tactgccacc ctactctgcc agaagggtga taaaatgaga 1500
 gagctctctc tccctcgacc tttctgggtg gggctggcag ccattgtcct agccttggct 1560
 cctggccaga tcctggggct cctcctcac agtcccctt cccacacttc ctccaccacc 1620
 accacggtca ctacaggtg ctacgctcct agcccagtt cactctggtg tcacaataaa 1680
 cctgtatgta gctgtg 1696

<210> 3
 <211> 260
 <212> DNA
 <213> *Rattus norvegicus*

<400> 3
 ttctacatgg aggagggggc tccctactgc gagcgagatt acgagaagat gtttggcaca 60
 aagtgtcgcg gctgtgactt caagatcgat gccggggacc gtttcctgga agccctgggt 120
 ttcagctggc atgatacgtg ttttgtttgc gcaatatgtc aaatcaactt ggaaggaaaag 180
 acccttctact ccaagaagga caagcccctg tgcaagagcc atgccttttc ccacgtatga 240
 gcacctcctc acactactgc 260

<210> 4
 <211> 16
 <212> DNA
 <213> MMLV

<400> 4
aagctttttt tttttg

16

<210> 5
<211> 13
<212> DNA
<213> MMLV

<400> 5
aagcttggt atg

13

<210> 6
<211> 223
<212> DNA
<213> Homo sapiens

<400> 6
atccttgctc acctcacggg caccgagttc atgcaagacc cggatgagga gcacctgaag 60
aaatcaagcc aggtgcccag gacagaagcc ccagccccag cctcatctac accccaggag 120
ccctggcctg gccctaccgc cccagccct accagccgc cgcctgggc tgtggaccct 180
gcgtttgccc agcgctatgc cccagacaaa accagcacag tgc 223

<210> 7
<211> 717
<212> DNA
<213> Homo sapiens

<400> 7
atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaaggg 60
ggcaaggact tcaatgtgcc cctctccatt tcccggctca ctctggggg caaagcggcg 120
caggccggag tggccgtggg tgactgggtg ctgagcatcg atggcgagaa tgcgggtagc 180
ctcacacaca tcgaagctca gaacaagatc cgggcctgcg gggagcgct cagcctgggc 240
ctcagcaggg cccagccggt tcagagcaaa ccgcagaagg cctccgcccc cgcgcggac 300
cctccgcggt acacctttgc acccagcgtc tccctcaaca agacggcccc gccctttggg 360
gcgccccgc cgcgtgacag cgcgccgcaa cagaatggac agccgctccg accgctggtc 420
ccagatgccg gcaagcagcg gctgatggag aacacagagg actggcggcc gcggccgggg 480
acaggccagt cgcgttcctt ccgcatcctt gccacactca caggcaccga gttcatgcaa 540
gaccgggatg aggagcacct gaagaaatca agccaggtgc ccaggacaga agccccagcc 600
ccagcctcat ctacacccca ggagccctgg cctggcccta ccgccccag ccctaccagc 660
cgccccctt gggctgtgga cctgcgttt gccgagcgt atgccccga caaacg 717

<210> 8
<211> 1488
<212> DNA
<213> Homo sapiens

<400> 8
atcgatggcg agaatgcggg tagcctcaca cacatcgaag ctgagaacaa gatccggggc 60
tgccggggagc gcctcagcct gggcctcagc agggcccagc cggttcagag caaaccgcag 120
aaggcctccg ccccgccgc ggaccctccg cggtagacct ttgcacccag cgtctccctc 180
aacaagacgg cccggccctt tggggcgccc ccgcccgtg acagcgcccc gcaacagaat 240
ggacagccgc tccgaccgct ggtcccagat gccagcaagc agcggtgat ggagaacaca 300

```

gaggactggc ggccgcggcc ggggacaggc cagtcgcgtt ccttcgcgat ccttgcccac 360
ctcacaggca ccgagttcat gcaagaccgc gatgaggagc acctgaagaa atcaagccag 420
gtgcccagga cagaagcccc agccccagcc tcatctacac cccaggagcc ctggcctggc 480
cctaccgccc ccagccctac cagccgcccg ccctgagctg tggaccctgc gtttgccgag 540
cgctatgccc cggacaaaac gagcacagtg ctgaccgggc acagccagcc ggccacgccc 600
acgccgctgc agagccgcac ctccattgtg caggcagctg ccggaggggt gccaggaggg 660
ggcagcaaca acggcaagac tcccgtgtgt caccagtgcc acaaggatcat ccggggccgc 720
tacctggtgg cgttggggcca cgcgtaccac ccggaggagt ttgtgtgtag ccagtgtggg 780
aaggtcctgg aagaggggtg cttctttgag gagaagggcg ccattctctg cccaccatgc 840
tatgacgtgc gctatgcacc cagctgtgcc aagtgcaaga agaagattac aggcgagatc 900
atgcacgccc tgaagatgac ctggcacgtg cactgcttta cctgtgctgc ctgcaagacg 960
cccatccgga acagggcctt ctacatggag gaggggcgtg cctattgcga gcgagactat 1020
gagaagatgt ttggcacgaa atgccatggc tgtgacttca agatcgacgc tggggaccgc 1080
ttctggagg ccctgggctt cagctggcat gacacctgct tcgtctgtgc gatatgtcag 1140
atcaacctgg aaggaaagac cttctactcc aagaaggaca ggccctctctg caagagccat 1200
gccttctctc atgtgtgagc cccttctgcc cacagctgcc gcggtggccc ctacgctgag 1260
gggcccggag tcgtggccct gcatttctgg gtagggtgg caatgggtgc ctaaaccttg 1320
gtcctcgccc cgagcctggg ctcccgggcc cctgccacc caccttatcc tcccaccca 1380
ctccctccac caccacagca caccgggtgt ggccacacca gcccccttc acctccagt 1440
ccacaataaa cctgtaccca gctgaattcc aaaaaatcca aaaaaaaa 1488

```

<210> 9

<211> 1644

<212> DNA

<213> Homo sapiens

<400> 9

```

atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaaggg 60
ggcaaggact tcaatgtgcc cctctccatt tcccggctca ctcttggggg caaagcggcg 120
caggccggag tggccgtggg tgactgggtg ctgagcatcg atggcgagaa tgcgggttagc 180
ctcacacaca tcgaagctca gaacaagatc cgggcttgcg gggagcgctt cagcctgggc 240
ctcagcaggg ccagccgggt tcagagcaaa ccgcagaagg cctccgcccc cgcccgggac 300
cctccgcggt acacctttgc acccagcgct tccctcaaca agacggcccc gccctttggg 360
gcgccccgcg ccgctgacag cgccccgcaa cagaatggac agccgctccg accgctggtc 420
ccagatgcca gcaagcagcg gctgatggag aacacagagg actggcgggc gcggccgggg 480
acaggccagt cgcgttcctt ccgcattcct gccacctca caggcaccga gttcatgcaa 540
gacccggtat aggagcacct gaagaaatca agccaggtgc ccaggacaga agccccagcc 600
ccagcctcat ctacacccca ggagccctgg cctggcccta ccgccccag ccctaccagc 660
cgcccgccct gggctgtgga ccctgcgttt gccgagcgct atgccccgga caaaacgagc 720
acagtgtgta cccggcacag ccagccggcc acgcccacgc cgctgcagag ccgcacctcc 780
attgtgcagg cagctgcggg aggggtgcca ggagggggca gcaacaacgg caagactccc 840
gtgtgtcacc agtgccacaa ggtcatccgg ggccgctacc tggtggcgtt gggccacgcg 900
taccacccgg aggagtttgt gtgtagccag tgtgggaagg tcctggaaga ggggtggcttc 960
tttgaggaga agggcgccat cttctgccc ccatgctatg acgtgcgcta tgcaccagc 1020
tgtgccaaat gcaagaagaa gattacaggc gagatcatgc acgcccagaa gatgacctgg 1080
cacgtgcaat gctttacctg tgctgcctgc aagacgcccc tccggaacag ggccttctac 1140
atggaggagg gcgtgccta ttgcgagcga gactatgaga agatgtttgg cacgaaatgc 1200
catggctgtg acttcaagat cgacgctggg gaccgcttcc tggaggccct gggcttcagc 1260
tggcatgaca cctgcttcgt ctgtgcgata tgctgatca acctggaagg aaagaccttc 1320
tactccaaga aggacaggcc tctctgcaag agccatgcct tctctcatgt gtgagccct 1380
tctgcccaca gctgccggg tggcccttag cctgaggggc ctggagtcgt ggccctgcat 1440
ttctgggtag ggctggcaat ggttgcccta accctggctc ctggcccag cctgggctcc 1500
cgggcccctg cccaccacc ttatectccc accccactcc ctccaccacc acagcacacc 1560
ggtgctggcc acaccagccc cctttcacct ccagtgcac aataaacctg taccagctg 1620
aattccaaaa aatccaaaa aaaa 1644

```

<210> 10

<211> 457

<212> PRT

<213> Homo sapiens

<400> 10

```

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
 1              5              10              15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
              20              25              30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
              35              40              45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
 50              55              60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
 65              70              75              80

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
              85              90              95

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
              100              105              110

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
              115              120              125

Pro Gln Gln Asn Gly Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser
              130              135              140

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
145              150              155              160

Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
              165              170              175

Glu Phe Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln
              180              185              190

Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu
              195              200              205

Pro Trp Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro Trp
              210              215              220

Ala Val Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser
225              230              235              240

Thr Val Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln
              245              250              255

Ser Arg Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Val Pro Gly Gly

```

```
<210> 11
<211> 22
<212> DNA
<213> Rattus norvegicus
```

```
<210> 12
<211> 22
<212> DNA
<213> Rattus norvegicus
```

<400> 12
gccaggggttt tcccagtcac ga 22

<210> 13
<211> 22
<212> DNA
<213> Homo sapiens

<400> 13
tcttagcaga gcccagcctg ct 22

<210> 14
<211> 22
<212> DNA
<213> Homo sapiens

<400> 14
gcatgaactc tgtgcccgtg ag 22

<210> 15
<211> 20
<212> DNA
<213> Rattus norvegicus

<400> 15
atccttgctc acctcacggg 20

<210> 16
<211> 22
<212> DNA
<213> Rattus norvegicus

<400> 16
gcactgtgct gggtttgtct gg 22

<210> 17
<211> 23
<212> DNA
<213> Homo sapiens

<400> 17
catggattcc ttcaaggtag tgc 23

<210> 18
<211> 20
<212> DNA
<213> Homo sapiens

<400> 18
gttttgctctg gggcagagcg 20

<210> 19
<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: adaptor for
Marathon RACE reactions

<400> 19

ctaatacgcac tcactatagg gctcgagcgg ccgcccgggc aggt

44

<210> 20

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer
specific for Marathon RACE adaptor

<400> 20

ccatcctaatac acgactcact atagggc

27

<210> 21

<211> 765

<212> DNA

<213> Homo sapiens

<400> 21

```

ccgttggttg taaaacgcag cagagcagcg ccctggccgg gccaaagcagg agccggcatc 60
atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaaggg 120
ggcaaggact tcaatgtgcc ctctccatt tcccggctca cctctggggg caaggccgtg 180
caggccggag tggccgtaag tgactgggtg ctgagcatcg atggcgagaa tgcgggtagc 240
ctcacacaca tcgaagctca gaacaagatc cgggcctgcg gggagcgcct cagcctgggc 300
ctcaacaggg cccagccggt tcagaacaaa ccgcaaaagg cctccgcccc cgccgcggac 360
cctccgcggt acacctttgc accaagcgtc tccctcaaca agacggcccc gcccttgggg 420
gccccccg cgcctgacag cgcgccgcag cagaatggac agccgctccg accgctggtc 480
ccagatgccg gcaagcagcg gctgatggag aacacagagg actggcgggc gcggccgggg 540
acaggccagt gccgttcctt tcgcatcctt gctcacctta caggcaccca gttcatgcaa 600
gacccgatg aggagcacct gaagaaatca agccagggtc ccaggacaga agccccagcc 660
ccagcctcat ctacacccca ggagccctgg cctggcccta ccgccccag ccctaccagc 720
cgcccccc cggctgtgga ccctgcgttt gccgagcgt atgcc 765

```

<210> 22

<211> 1689

<212> DNA

<213> Homo sapiens

<400> 22

```

cgacgcagag cagcgccctg gccgggcca gacaggagccg gcatcatgga ttccttcaag 60
gtagtgtcgg agggggccagc accttggggg ttccggctgc aagggggcaa ggacttcaat 120
gtgcccctct ccatctccc gctcactcct gggggcaaa cggcgaggc cggagtggcc 180
gtgggtgact ggggtgctgag catcgatggc gagaatgcgg gtagcctcac acacatcgaa 240
gctcagaaca agatccgggc ctgcggggag cgctcagcc tgggcctcag cagggccagc 300

```

```

ccggttcaga gcaaaccgca gaaggcctcc gccccgcgcg cggaccctcc gcggtacacc 360
tttgacccca gcgtctccct caacaagacg gcccggccct ttggggcgcc cccgcccgt 420
gacagcgccc cgcaacagaa tggacagccg ctccgaccgc tgggtcccaga tgccagcaag 480
cagcggtga tggagaacac agaggactgg cggccgcggc cggggacagg ccagtcgct 540
tccttcgcga tccttgccca cctcacaggc accgagttca tgcaagacc ggatgaggag 600
cacctgaaga aatcaagcca ggtgcccagg acagaagccc cagccccagc ctcactaca 660
ccccaggagc cctggcctgg ccctaccgcc cccagcccta ccagccgcc gccctgggct 720
gtggaccctg cgtttgccga gcgctatgcc cgggacaaaa cgagcacagt gctgaccgg 780
cacagccagc cggccacgcc cagccgctg cagagccgca cctccattgt gcaggcagct 840
gccggagggg tgccaggagg gggcagcaac aacggcaaga ctcccgtgtg tcaccagtgc 900
cacaaggtca tccggggccg ctacctggtg gcgttgggccc acgctacca cccgaggag 960
tttgtgtgta gccagtgtgg gaaggtcctg gaagagggtg gcttctttga ggagaagggc 1020
gccatcttct gccaccatg ctatgacgtg cgctatgcac ccagctgtgc caagtgaag 1080
aagaagatta caggcgagat catgcacgcc ctgaagatga cctggcacgt gcactgctt 1140
acctgtgctg cctgcaagac gccatccgg aacagggcct tctacatgga ggagggcgtg 1200
ccctattgag agcgagacta tgagaagatg tttggcacga aatgccatgg ctgtgacttc 1260
aagatcgagc ctggggaccg cttcctggag gccctgggct tcagctggca tgacacctgc 1320
ttcgtctgtg cgatatgtca gatcaacctg gaaggaaaaga ccttctactc caagaaggac 1380
aggcctctct gcaagagcca tgccttctct catgtgtgag ccccttctgc ccacagctgc 1440
cgcggtggcc cctagcctga ggggcctgga gtcgtggccc tgcatctctg ggtagggctg 1500
gcaatggttg ccttaacctt ggctcctggc ccgagcctgg gctcccgggc ccctgcccac 1560
ccaccttacc ctcccccccc actccctcca ccaccacagc acaccggtgc tggccacacc 1620
agcccccttt cacctccagt gccacaataa acctgtacct agctgaattc=caaaaaatcc 1680--
aaaaaaaaa 1689

```

```

<210> 23
<211> 22
<212> DNA
<213> Homo sapiens

```

```

<400> 23
gcactgtgct cgttttgtcc gg 22

```

```

<210> 24
<211> 21
<212> DNA
<213> Homo sapiens

```

```

<400> 24
tccttgcctca cctcacgggc a 21

```

```

<210> 25
<211> 30
<212> DNA
<213> Homo sapiens

```

```

<400> 25
tcctcatccg ggtcttgcac gaactcgggtg 30

```

```

<210> 26
<211> 28
<212> DNA

```

<213> Homo sapiens

<400> 26

gcccccgccc gctgacagcg ccccgcaa

28

<210> 27

<211> 24

<212> DNA

<213> Homo sapiens

<400> 27

tccttgctca cctcacgggc accg

24

<210> 28

<211> 22

<212> DNA

<213> Homo sapiens

<400> 28

gtaatacgac tcactatagg gc

22

<210> 29

<211> 23

<212> DNA

<213> Rattus norvegicus

<400> 29

gcggctgatg gagaatactg aag

23

<210> 30

<211> 23

<212> DNA

<213> Rattus norvegicus

<400> 30

atcttggtggc actggtggca tac

23

<210> 31

<211> 22

<212> DNA

<213> Rattus norvegicus

<400> 31

tgtgtcgggt cagcactgtg ct

22

<210> 32

<211> 1620

<212> DNA

<213> Homo sapiens

<400> 32

```

atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaaggg 60
ggcaaggact tcaatgtgcc cctctccatt tcccggctca ctccctggggg caaagcggcg 120
caggccggag tggccgtggg tgactgggtg ctgagcatcg atggcgagaa tgcgggtagc 180
ctcacacaca tcgaagctca gaacaagatc cgggcctgcg gggagcgcct cagcctgggc 240
ctcagcaggg cccagccggt tcagagcaaa ccgcagaagg cctccgcccc cgccgcggac 300
cctccgcggt acacctttgc acccagcgtc tccctcaaca agacggcccc gccctttggg 360
gcgccccgcg ccgctgacag cgccccgcaa cagaatggac agccgctccg accgctggtc 420
ccagatgcca gcaagcagcg gctgatggag aacacagagg actggcggcc gcggccgggg 480
acaggccagt cgcgttcctt ccgcatcctt gccaccta caggcaccga gttcatgcaa 540
gaccgggatg aggagcacct gaagaaatca agccagggtg ccaggacaga agccccagcc 600
ccagcctcat ctacacccca ggagccctgg cctggcccta ccgccccag ccctaccagc 660
cgccccccct gagctgtgga ccctgcgttt gccgagcgt atgccccga caaacagagc 720
acagtgtga cccggcacag ccagccggcc acgcccacgc cgctgcagag ccgcacctcc 780
attgtgcagg cagctgccgg aggggtgcca ggagggggca gcaacaacgg caagactccc 840
gtgtgtcacc agtgccacaa ggtcatccgg ggccgctacc tgggtggcgtt gggccacgcg 900
taccaccggg aggagtgtgt gtgtagccag tgtgggaagg tcctggaaga ggggtggcttc 960
tttgaggaga agggcgccat cttctgcccc catgctatg acgtgcgcta tgcaccagc 1020
tgtgccaagt gcaagaagaa gattacaggc gagatcatgc acgcccgtga gatgacctgg 1080
cacgtgcact gctttacctg tgctgcctgc aagacgcccc tccggaacag ggccttctac 1140
atggaggagg gcgctgccta ttgcgagcga gactatgaga agatgtttgg caggaatgc 1200
catggctgtg acttcaagat cgacgctggg gaccgcttcc tggaggccct gggcttcagc 1260
tggcatgaca cctgcttcgt ctgtgcgata tgtcagatca acctggaagg aaagaccttc 1320
tactccaaga aggacaggcc tctctgcaag agccatgcct tctctcatgt gtgagccct 1380
tctgccaca gctgccgcgg tggcccctag cctgaggggc ctggagtcgt ggccctgcat 1440
ttctgggtag ggctggcaat ggttgccctt accctggctc ctggcccgag cctgggctcc 1500
cgggccccctg cccaccacc ttatcctccc acccaactcc ctccaccacc acagcacacc 1560
ggtgctggcc acaccagccc cctttcacct ccagtgccac aataaacctg taccagctg 1620

```

<210> 33

<211> 1665

<212> DNA

<213> Homo sapiens

<400> 33

```

cgacgcagag cagcgccctg gccggggcaa gcaggagccg gcatcatgga ttccttcaag 60
gtagtgtctg agggggcagc accttggggc tccggctgc aagggggcaa ggacttcaat 120
gtgccccctc ccatttcccg gctcactcct gggggcaaa cggcgaggc cggagtggcc 180
gtgggtgact ggggtgtgag catcgatggc gagaatgcgg gtacccctac acacatcgaa 240
gctcagaaca agatccgggc ctgcggggag cgcctcagcc tgggcctcag caggggccag 300
ccggttcaga gcaaaccgca gaaggcctcc gccccgcgcg cggaccctcc gcggtacacc 360
tttgacccca gcgtctccct caacaagacg gccgggccct ttggggcgcc ccgcccgt 420
gacagcgccc cgcaacagaa tggacagccg ctccgaccgc tgggtccaga tgccagcaag 480
cagcggctga tggagaacac agaggactgg cggcgcgggc cggggacagg ccagtcgcgt 540
tccttccgca tccttgcccc cctcacaggc accgagttca tgcaagacc ggatgaggag 600
cacctgaaga aatcaagcca ggtgcccagg acagaagccc cagccccagc ctcatctaca 660
ccccaggagc cctggcctgg ccctaccgcc ccagcccta ccagccgcc gccctgagct 720
gtggaccctg cgtttgccga gcgctatgcc ccggacaaaa cgagcacagt gctgaccg 780
cacagccagc cggccacgcc cagcgcgtg cagagccgca cctccattgt gcaggcagct 840
gccggagggg tgccaggagg gggcagcaac aacggcaaga ctcccggtg taccagtg 900
cacaaggtca tccggggccg ctacctggtg gcgttggggc acgcgtacca cccggaggag 960
tttggtgtga gccagtgtg gaaggtcctg gaagagggtg gcttctttga ggagaagggc 1020
gccatcttct gccaccatg ctatgacgtg cgctatgcac ccagctgtgc caagtgcag 1080
aagaagatta caggcgagat catgcacgcc ctgaagatga cctggcacgt gcactgctt 1140
acctgtgctg cctgcaagac gcccatccgg aacagggcct tctacatgga ggagggcg 1200

```

```

ccctattgcg agcgagacta tgagaagatg tttggcacga aatgccatgg ctgtgacttc 1260
aagatcgacg ctggggaccg cttcctggag gccctgggct tcagctggca tgacacctgc 1320
ttcgtctgtg cgatatgtca gatcaacctg gaaggaaaga cttctactc caagaaggac 1380
aggcctctct gcaagagcca tgccttctct catgtgtgag ccccttctgc ccacagctgc 1440
cgcggtggcc cctagcctga ggggcctgga gtcgtggccc tgcatttctg ggtagggctg 1500
gcaatggttg ccttaacctt ggctcctggc ccgagcctgg gctcccgggc ccctgcccac 1560
ccaccttata cttccacccc actccctcca ccaccacagc acaccggtgc tggccacacc 1620
agcccccttt cacctccagt gccacaataa acctgtaccc agctg 1665

```

<210> 34

<211> 223

<212> PRT

<213> Homo sapiens

<400> 34

```

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
  1             5             10             15

```

```

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
          20             25             30

```

```

Leu Thr Pro Gly Gly-Lys Ala Ala Gln Ala-Gly Val Ala Val Gly Asp
  35             40             45

```

```

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
  50             55             60

```

```

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
  65             70             75             80

```

```

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
          85             90             95

```

```

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
          100             105             110

```

```

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
          115             120             125

```

```

Pro Gln Gln Asn Gly Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser
          130             135             140

```

```

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
          145             150             155             160

```

```

Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
          165             170             175

```

```

Glu Phe Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln
          180             185             190

```

```

Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu
          195             200             205

```

```

Pro Trp Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro

```

210

215

220

<210> 35
<211> 20
<212> DNA
<213> Homo sapiens

<400> 35
gagccggcat catggattcc

20

<210> 36
<211> 20
<212> DNA
<213> Homo sapiens

<400> 36
gctgcctgca caatggaggt

20

<210> 37
<211> 1456
<212> DNA
<213> Homo sapiens

<400> 37
cgacgcagag cagcgccctg gccggggccaa gcaggagccg gcatcatgga ttccttcaag 60
gtagtgtctg agggggccagc accttggggc ttccggctgc aagggggcaa ggacttcaat 120
gtgcccctct ccatttcccg gctcactcct gggggcaaa cggcgcaggc cggagtggcc 180
gtgggtgact ggggtctgag catcgatggc gagaatgcgg gtagcctcac acacatcgaa 240
gctcagaaca agatccgggc ctgcggggag cgcctcagcc tgggcctcag cagggcccag 300
ccggttcaga gcaaaccgca gaagggtgag acccctgaca aacagccgct ccgaccgctg 360
gtcccagatg ccagcaagca gcggctgatg gagaacacag aggactggcg gccgcggccg 420
gggacaggcc agtcgcgttc cttccgcatc cttgcccacc tcacaggcac cgagttcatg 480
caagaccgag atgaggagca cctgaagaaa tcaagccagg tgcccaggac agaagcccca 540
gccccagcct catctacacc ccaggagccc tggcctggcc ctaccgcccc cagccctacc 600
agccgcccgc cctgggctgt ggaccctgcg tttgccgagc gctatgcccc ggacaaaacg 660
agcacagtgc tgacccgga cagccagccg gccacgcccc cgcgcgtgca gagccgcacc 720
tccattgtgc aggcagctgc cggaggggtg ccaggagggg gcagcaacaa cggcaagact 780
cccgtgtgtc accagtgcc caaggtcatc cggggccgct acctggtggc gttggggcac 840
gcgtaccacc cggaggagtt tgtgtgtagc cagtgtggga aggtcctgga agaggtggc 900
ttctttgagg agaagggcgc catcttctgc ccaccatgct atgacgtgcg ctatgcaccc 960
agctgtgcca agtgcaagaa gaagattaca ggcgagatca tgcacgccct gaagatgacc 1020
tggcacgtgc actgctttac ctgtgctgcc tgcaagacgc ccatccgga cagggccttc 1080
tacatggagg agggcgtgcc ctattgcgag cgagactatg agaagatgtt tggcacgaaa 1140
tgccatggct gtgacttcaa gategacgct ggggaccgct tcctggaggc cctgggcttc 1200
agctggcatg acacctgctt cgtctgtgcg atatgtcaga tcaacctgga aggaaagacc 1260
ttctactcca agaaggacag gcctctctgc aagagccatg ccttctctca tgtgtgagcc 1320
ccttctgccc acagctgccg cgggtggccc tagcctgagg ggctggagt cgtggccctg 1380
catttctggg tagggctggc aatggttgcc ttaaccctgg ctctggccc gagcctgggc 1440
tcccgggccc tgcca 1456

<210> 38
<211> 423

<212> PRT

<213> Homo sapiens

<400> 38

```

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
 1             5             10             15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
          20             25             30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
          35             40             45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
          50             55             60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
 65             70             75             80

Leu Ser Arg Ala Gln Pro Val Gln Asn Lys Pro Gln Lys Val Gln Thr
          85             90             95

Pro Asp Lys Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser Lys Gln
          100            105            110

Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly Thr Gly
          115            120            125

Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr Glu Phe
          130            135            140

Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln Val Pro
          145            150            155            160

Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu Pro Trp
          165            170            175

Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro Trp Ala Val
          180            185            190

Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser Thr Val
          195            200            205

Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln Ser Arg
          210            215            220

Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Val Pro Gly Gly Gly Ser
          225            230            235            240

Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Gln Val Ile Arg
          245            250            255

Ala Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu Glu Phe
          260            265            270

Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe Phe Glu

```

275 280 285
 Glu Lys Gly Ala Ile Phe Cys Pro Pro Cys Tyr Asp Val Arg Tyr Ala
 290 295 300
 Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile Met His
 305 310 315 320
 Ala Leu Lys Met Thr Trp His Val Leu Cys Phe Thr Cys Ala Ala Cys
 325 330 335
 Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly Val Pro
 340 345 350
 Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys Gln Trp
 355 360 365
 Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala Leu Gly
 370 375 380
 Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln Ile Asn
 385 390 395 400
 Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Arg Pro Leu Cys Lys
 405 410 415
 Ser His Ala Phe Ser His Val
 420

<210> 39

<211> 1575

<212> DNA

<213> Homo sapiens

<400> 39

cgacgcagag cagcgccctg gccgggcca gacagagccg gcatcatgga ttccttcaag 60
 gtagtgctgg aggggcccag accttggggc ttccggctgc aagggggcaa ggacttcaat 120
 gtgcccctct ccatctcccg gctcactcct gggggcaaag cggcgaggc cggagtggcc 180
 gtgggtgact ggggtgctgag catcgatggc gagaatgcgg gtagcctcac acacatcgaa 240
 gtcagaaca agatccgggc ctgcggggag cgcctcagcc tgggcctcag caggggcccag 300
 ccggttcaga gcaaaccgca gaaggcctcc gcccccgccg cggaccctcc gcggtacacc 360
 tttgcaccca gcgtctccct caacaagacg gcccgccct ttggggcgcc cccgcccgt 420
 gacagcggc cgcaacagaa tgggtgcaga cccctgacaa acagccgctc cgaccgctgg 480
 tcccagatgc cagcaagcag cggctgatgg agaacacaga ggactggcgg ccgcgggcgg 540
 ggacaggcca gtcgcttcc ttccgcatcc ttgcccacct cacaggcacc gagttcatgc 600
 aagaccgga tggaggcac ctgaagaaat caagccaggt gccaggaca gaagccccag 660
 cccagcctc atctacacc caggagccct ggctggccc taccgcccc agccctacca 720
 gccgcccgc ctgggtgtg gacctgcgt ttgcccagcg ctatgcccc gacaaaacga 780
 gcacagtgt gaccggcac agccagccgg ccacggccac gccgctgcag agccgcacct 840
 ccattgtgca ggcagctgcc ggaggggtgc caggagggg cagcaacaac ggcaagactc 900
 ccgtgtgtca ccagtccac aaggtcatcc ggggcccgt cctggtggcg ttggggccag 960
 cgtaccacc ggaggagtt gtgtgtagcc agtgtgggaa ggtcctggaa gagggtggct 1020
 tctttgagga gaaggcgcc atcttctgcc caccatgcta tgacgtgcg tatgcacca 1080
 gctgtgcaa gtgcaagaag aagattacag gcgagatcat gcacgcctg aagatgacct 1140
 ggcacgtgca ctgctttacc tgtgctgcct gcaagacgcc catccggaac agggccttct 1200

```

acatggagga gggcgtgccc tattgcgagc gagactatga gaagatgttt ggcacgaaat 1260
gccatggctg tgacttcaag atcgacgctg gggaccgctt cctggaggcc ctgggcttca 1320
gctggcatga cacctgcttc gtctgtgcga tatgtcagat caacctggaa ggaaagacct 1380
tctactccaa gaaggacagg cctctctgca agagccatgc cttctctcat gtgtgagccc 1440
cttctgccc aagctgccc ggtggccct agcctgaggg gcctggagtc gtggccctgc 1500
atttctgggt agggctggca atggttgct taacctggc tcctggccc agcctgggct 1560
cccggccct gccca 1575

```

<210> 40

<211> 153

<212> PRT

<213> Homo sapiens

<400> 40

```

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
  1              5              10              15

```

```

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
              20              25              30

```

```

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
  35              40              45

```

```

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
  50              55              60

```

```

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
  65              70              75              80

```

```

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
              85              90              95

```

```

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
  100              105              110

```

```

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
  115              120              125

```

```

Pro Gln Gln Asn Gly Cys Arg Pro Leu Thr Asn Ser Arg Ser Asp Arg
  130              135              140

```

```

Trp Ser Gln Met Pro Ala Ser Ser Gly
  145              150

```

<210> 41

<211> 24740

<212> DNA

<213> Homo sapiens

<400> 41

```

nnnnntgta ttttatcata ttttaaaaat caaaaaacaa aaggcagttg aggttaggca 60
tgagggttc tgctgtaaat ccagcactt tgggaagccg aagcacgtgg atcacctgag 120
gtcaggagtt cgagaccagc ctgcccaata tggtaaaacc ctgtctctac taaaaatata 180
aaaaattagc caggcatggt ggtgggcacc tgtaatccca gctacttggg agactgaggc 240

```

```

aggagaatca cttaaacccg ggaggcgggc tgggcgcggt ggctcatgcc tgtaatccca 300
gcactttggg aggccgagac aggcggatca tgaggtcagg agatcgagat catcctggct 360
aacatggtga aaccccatct ctactaaaaa tacaaaaaaa attagccagg cctggtggcg 420
ggcacctgta gtcccagcta cttgggagggc tgaggcagga gaatggcggtg aacctgggag 480
gcggcggttc agtgagccaa gatcgcgcca ctgcactcca gcctggggcga caagagttag 540
actccatctt aaagaaaaaa aacaaacccg ggaggcgga attgcagtca gccgagatct 600
cgccattgca ctcaagtatg ggtgacagag caagactcca tgtcaaaaaa aaaggcagtt 660
gacaggagca aggagcctgg tgaggaagct gtggcatttg acccggtgtg gttgctatgg 720
gccagggtgg tgctagtaga ggagctgagt gggaaagagc acaggggaca tgctgaaggc 780
ctgggtgtgg ggatgaggca gagattgggg gcaccttgca gggtcatagc aggtggctgt 840
ggtgagatgg aggaagacac ctgggggtact gctctaggct gtcagacata cagaagctgg 900
cccagccaag cccagggggt gcaagggaca tccttttgtg tccccagtga tctgcagctc 960
tcagacaccc tcaagcacag tgcctcttgc ccagcccagc actctcagtg gggagccagg 1020
tgggagaaca ggctcggaag gggacctagg cttatgcagc gagccgggca aagctggaac 1080
tgagagccag gccctggat gcccctggc ttgtggagt ctgggatact gaggggagg 1140
gacagggcag gggagtgcgg tgctctcacc ttgacttga actcattccc caggggacag 1200
gggaaagcct ctcaggatcc acagatgccc agtctcccaa gaggggcctg gtcccatgg 1260
aggaaaactc catctactcc tcctggcagg aaggtaagtt ggaggacgtg caagggcagc 1320
ctcagcccc caccaccagg gctgggtctt ttgggactg acggagctgt cctggccacc 1380
tgccacagtg ggcgagtttc ccgtggtggt gcagaggact gaggcgcga cccgctgcca 1440
gctgaagggg ccggccctgc tgggtgctggg ccagacgcc atccagctga gggaggccaa 1500
ggcaccagc ccctctacag ctggccctac cacttcctgc gcaagttcgg ctccgacaag 1560
gtgaggtgca ggggtgggaa agggtgagg gctgacagcc tggaccctcc tgtaatccc 1620
caccctgtgt ccctgtgccc agggcgtgtt ctcttttag gccggccgtc gctgccactc 1680
gggtgagggc ctctttgcct tcagcaccct ctgtgcccct gacctgtgca gggctgtggc 1740
cggggccatc gccgccagcg ggagcggctg ccagagctga ccaggcccca gccctgcccc 1800
ctgccacggg ccacctctct gccctccctg gacaccccg gagagcttcg ggagatgcca 1860
ccaggacctg agccacccac gtccaggaaa atgcacctgg ccgagcccg accccagagc 1920
ctgccgtac tgctaggccc ggagcccaac gatctggcgt ccgggctcta cgcttcagt 1980
tgcaagcgtg ccagtgggccc ccaggccaat gacacctct atgagaacct gtgtgtgctg 2040
gagccagccc ccacgctgca cggtggggaa cctgagccgc acgagggccc cggcagccc 2100
agccccacaa ccagtcccat ctaccacaac ggccaggact tgagctggcc cggcccgccc 2160
aacgacagta ccctggaggc ccagtaccgg cggctgctgg agctggatca ggtggagggc 2220
acaggccgcc ctgacctca ggcaggtttc aaggccaagc tggtgacct gctgagtcgt 2280
gagcggagga agggcccagc ccctgtgac cggccctgaa cggccagcag agtggtggcc 2340
agaggggaga ggtgctcccc ctgggacagg agggtgggct ggtgggcaaa cattgggccc 2400
atgcagacac acgctgtgt ccacctggc ctgcaggaa aaggcaggcc gctgtggag 2460
gacctcagcc ctgcccctgc ctctcatga atagtgtgca gactcacaga taataaagct 2520
cagagcagct cccggcaggg gactcacgg cacacgcccc tgcccacgtt cattgcccgc 2580
aacacaagca ccctgtgccg gttccagggg cacaggtagc ctgggcctta cctgccaccc 2640
gtgggctcaa acccactgca gcagacagac gggatggaaa tcattaggac tccatgttgc 2700
tctgcacggc cgagtgcac gaagaggcag gcggaggag ctgtgaggct tacttgtcag 2760
actcaggaag gagcaacatg agggcccaac tggagaccg gagggccgag ctgggaggag 2820
gcagtggggg cggggtgcag gtggaaggga ttccagagac accctcgtcc aaaacacttg 2880
ttccctgctg aaactccaac aatttgaga tacttctggg aacccaggc gtcagtctcc 2940
tcatctgtaa aggagagaga accgatgacg tatcaggcat aatccttgat gagagtttgc 3000
tgctgcctta ctcagtgcc aagcgtgggg gacacagccg tgttcaggac agccttggtc 3060
ctgttctccg ggagccgaca ttccagggg agagaagttt cctgaagact tccatgctgc 3120
gttccctct ctgctcctgc tcctggcgcc atcctaggag ccagccatgc acgcaagcgt 3180
catgcctcca gggctctgac tgcccagccc ctaccgcaa ctccacctca gctgcacaca 3240
cccttggcac atcctgaacc tcattttcat gacggacaca caatttttgc tctctcctgt 3300
ccaagcctca tcctctggcc gccacctct tccagctcac ttcctttagt gcggccagta 3360
ccgcccctgc ctaggcatgt cgacctgcag ggacctttt ctggtcttc gaggcctctg 3420
cccaccatcc cctctttgtt ctccatagtc ccttccccct gttctctctc gtttcatctt 3480
actggtctgg caaagtcccc ggccttgggc gagccagacc tcctcagtgc ctgcacacag 3540
ctgcccacag ccagagaaat ccatttaagc agactgcctg catccttctt aacagtgcaa 3600

```

```

ggcaggcact cctgccaca agagaccctg ttcctagta gggcagcttt tctcctcccc 3660
agaacctcct gtctatcccc acccaatgtc tctccacagg catattgggg aaacagggtca 3720
ggctctcccc ccgtatctgc aagtgtactg gcatccatct gtcttcttcc tacccttaca 3780
gtagaaacag tgtctgtccc cagctgtgct ctgatcccg ctcctttcac ctcagagctt 3840
ggaaaattga gctgtcccca ctctctcctg cgccattca tctaccage agcttttcca 3900
gccacacgca aacatgtctc gtaatttcac attttaaacc ttccttgac ctcacattcc 3960
tcttcggcca cctctgtttc tctgttctc ttcacagcaa aaactgttca aaagagtgtg 4020
tgattacttt catttccact ttctcaccct cattctctcc tcaattaact ctccttcac 4080
cccatgatgc cattatgtgg cttttattag agtcaccaac cttattctcc aaaacaaaag 4140
caacaaggac tttgacttct cagcagcact cagctctggg tcttgaaaca ccccgttac 4200
ttgctattcc tcctacctca taacaatctc cttcccagcc tctactgctg ctttctctga 4260
gttcttcccc gggctcctagg ctcagatgta gtgtagctca accctgctac acaaagaatc 4320
tcttgaaagc ctgtaaaaaat gtccatgcat gttctgtgag tgatctacca agaaaataaa 4380
aaattttaaa aatcaaatgc ccatgcctgg gccacacgc aggggctctg atttcatcag 4440
tctggtaggt ggggttctggg catccacgct cactggattt ccggatgatt gtagtatgca 4500
gcctaggctg ggaaccactg gctcagcaa gccagtcatt ctccagggtg cacagacct 4560
ctagggtgcta atgaccccgga aggtctgtct cagtgcaca cctccccctg agtccagat 4620
ttaggaatcc cactgcacac gagacatctg gatgtggaaa agacatctcc agatcccatg 4680
ggtgaaaggg ggttggggga atggagactc gtgttcttcc aggatgtgtg tggacacaga 4740
atgcaaagcc tggagggatg ctagagccat agggaggaag atttcggctc acttattcat 4800
gcaagcactt cctgatgggt aaggctctag agcaagctga ggccaagagg cgggcagtcg 4860
aggtgctgct gcaggcacc cactcccta cagtggcaag cccaagccca gcccttggca 4920
gctcaaatcc caggacacgc tgaaggtcac ccagagagtc aggggcatgg ctagaaccag 4980
aaccaggac tctggggacc cagcatggca tcctttcctt cattacaaat ctgagctgct 5040
ttgtttccta gggatttctg tgatattcca aggggactgt gggaaagaaa gtccttggaa 5100
accaccagga cgctagaggc ctggcctgga gcctcaggag tctcgccac cagagggcgc 5160
tggttctctg tccaggctca gttgctacgc aggggctgcc tgtgctggga ggctccccag 5220
gggacacaga ccagagcctt gcaccagccc aaggaatggg agcctggggg cctctctgct 5280
ggaggactgc caggaccccc aggctgcgc ctcttcttct gctcatttgc tgtttcactt 5340
tgtcaatcct tccttcttct gtgtgttcat tcacatccac tgtgtgctgg ccctggggaa 5400
atgttagata agacacatta gctgtgtgtc ttcattgtcc taacaaagaa cacaccctgg 5460
aaagagcacc gcagagagtc cccattcccc catctccctc cacacatgga atctggagat 5520
gccttttcca catccagatg tctctggtgc tgtgggattc ttaaataaac aaacatttca 5580
tacagaatgt gagatgatgg agatgctatg gggaaaagta aagcagaggg agggcctagt 5640
gtgtgatgcy ggtgaggcat ccagggattg ctgtttcagc tgtgatcagg aaaggccctg 5700
ggaggaggcc acatctgagc agagacctaa ataaagtgg aaacctgttg ctgagatctc 5760
tggaagagtg tttcaagggc cgggcaccgg gcatggtggc tcacgcctgt aatcccagca 5820
ctttgggagg ccaaggcagg tggatcgctg gaggtcagga gtttgagagc agcctgacca 5880
acatggagaa acccatctc tactaaacat ataaaaatta tccgggcatg gtggttcatg 5940
cctgtagtcc cagctactcg ggaggttag gcaggagaat cacttgaacg tgggaggcag 6000
aggttgcagc aagccgagat cacaccactg cactccagcc tggatgacag agcgagactc 6060
cgtctcaaaa aaaaaaaga aaagaaaaaa gaaaaaaaag gaaaagtgtt tcaagcaggg 6120
gaactggcaa gtggagaggc cctgaggcag aaatatgctt ggctgctgg aggaaatgtg 6180
agtgaggagg tcagggtggc tggagtggag ggagcgagt gtaggagtca gaccagttt 6240
attcatattc tgtaggtctt aaggacttca gttttatttt gagtgaata tgagccact 6300
ggaatgctaa aagctgagag tgacatggtg ctgtgattct ggcttataaa atatcacttt 6360
ggctgcttcg tgaagactct ggaaggggca agggtgaaag cagggatgcc cgttaggaga 6420
ccgttacagg ggcgcaggca caaatggca gtggctggga caatggtggc agcagcgggt 6480
agatgtgaac atgttgaagg tggaaatttgc agaactcggg ggaggacaga agagaaagga 6540
taacttcacg gtttctgctg aaccagtgg ataaatgttg gtggcacttc ttgaagttag 6600
gaaggagtta ggaaggtggg aaaggcacia gtttgaattg ggccatgatg gtctgagata 6660
cctagtacag tggttcccca accttttttg cagaagggac cgctttcatg gaagacaatt 6720
ttccacaga ctgggggtgg ggtggggatg gtttcagggt gggtcgagt cagtacattt 6780
atcattagac tctttttttt tttttttttt tgagatagag tctcgctctg tcaccacac 6840
tgagtgtagc tggagccatc ttggctcact acaacctctg ctgccagggt tcaagtcat 6900
ctcctgcctc agcctctcaa gtagctggga ttataggcat atgcgccacc acgccagct 6960

```



```

aattttttagta ttttttagtag agacgggggtt tcaccatatt ggccaggatg gtctcgaact 7020
cctgacctca agtgatcctc ccccgectca acctcccaaa gtgctgggggt tacaggcgtg 7080
aaccactgca cccggcccat ttatcattag attctcataa ggaatgagca acctagatcc 7140
ctcgcatgca cagttcacaa tagggttcac gtcctatgg gagtctaag ctgccgtgc 7200
actcagcttc tctggcttgc cgctgctcac cttctgctgt gcagcccagt tccaacagg 7260
ccacaaacgg ggagttgggg acccctgac tagtaaaca ctaggcaggg ttttgataa 7320
tggagttaga gttcctgggg agaggtcagg ctggccatga aacatgggat gcctttgcat 7380
ataggtggtg ttgaaagcca caggacagta cggggtctca gggggtgagc ataaagagag 7440
gcgacatcag atggccaagg ccagaggcag aggaggatgg gaaggagggg ccagtggggc 7500
aggggggaagc tgtgaagcca gggaaaaagg gtgtttcgcg gaaaaggatc aacctggacc 7560
agtgtgccc ctaggcaggg caggatgaaa cttaaccacc acggattcca tggcccatg 7620
gcctccaggc cacaggggac cttgagaaga gagatctcag gggacgggtg cggacaagag 7680
cccgctggc atggcttcaa gagataactg aaggaaagca agtgagacg cgataaacag 7740
acaactccct ggaggaattt tactctcag aggagaatta aagggtagta gctggagagg 7800
gatgtgggt caagagaagg tctttaacga cgagaactct cacggcgggt tgtgcagaac 7860
agggtgggtg tgatgactgt ggatggagag gggagaactg cagcgactct gtcctaggag 7920
gaggtgatgg gccgggacca ccaagcgagt ggagggtgga cggcccttcc ctcacccga 7980
caccgcagtg tgcctagtgt ccgtgcgcgc gccctagtgt cctgggctga acgcggggccc 8040
gggactctga ggacgcctcc caggcgcgca gtccgtctgg ccaagtgga gcgggacggc 8100
ngcttccgac ggtgcgcggg tgggctcggg gttgcaggga catccggcgt ccgctcctgc 8160
cctgttttcc tgccttcgca gagcgttgcg caactctagc tttaaacgcc cctgtcccc 8220
tcaacttgct tccccagcc cctctgattt acagattctg cagtccccga gggttgcgcc 8280
tacgataccg aactcgcg cagcctgcga ggcgagtatg atcgtcccat ttttcggagt 8340
agcaaaactaa ggttcagaga ctactatgtc ccaggtcggt ctggtttgaa ggtccgcttt 8400
cctctccctc cgccagcggg cgggtgcgag gactgggcga ggacgcgtt ccctaaggag 8460
gcgacccgca gccccggccc cctcccgact ccgccccgtt gcagggcccg ggtcggcgag 8520
gcctctcagc tctaagcccg acgggacttg gtgattgggc aggacggaag agctgggtgg 8580
ggctttccac cagcggagaa agtctagtgg gcgtggtcgc gacgagggcg tggcctggtg 8640
ccccgcccc gcgcgcgcg tcaaagtga ggggtggtgt gggggcgggg tcagaacact 8700
ggcgcccgat cccaacgagg ctccctggag cccgacgcag agcagcggcc tggccgggccc 8760
aagcaggtat cgacgaccgc gcggggcgctc ttgggctgga ccaggcgggc gcccggggccc 8820
tgctgaggac cacaaagggc actgggggtc gtggtccagg ctgtgcttcc tcccgctggc 8880
cctggccctt gcctccgccc ccgccccgc cttcctgcg ctaagccggc tgcggcgggg 8940
ccgattggcg cctgcgggct tcttgcgcg gggccagtct aatgcatggg gcccgggcgg 9000
gggactaagg ggaactgag tcacgtcgg gtgggagcag ttctgtgtgg gaggcaccac 9060
ccccactgg gtcgggggaa ggatccccct ccaagctatg cttaggggtc ccagcccca 9120
tctgtctcca caggggccgc acccactcc cgccttcccc ttcttcagca ccagggggtc 9180
ccgccctggc tcccagcagc ctcgactggt cccggaatgg ctagggagat ccgctgcagc 9240
cgctccctc cctccctc cctccctc cctccctc cctccctc cctccctc 9300
cccctcgct cccaagcccc cgtgtgctc ctcgctggc tctccgcaca gtgtcagctt 9360
acacgcctta tatagtccga gcaggctcca gccgcggcct gctgccggga cctgggggag 9420
ggggagagga gagccggccc ctgactcacc cggaccgccc gaggtccag gctggcttgg 9480
ggggaggccg cgccagttaa gtccctcggc ccacccctgg ttgcaaagaa cctcaagcct 9540
ggattcaggc acccctcacc gttccagtcc caaggggagg ggggctgctc ctgtcttcc 9600
aaagtgaggt ccgccagcca gcagcccagg ccagcctgac aaaatacctg cctcctatgg 9660
cttgggctg ctcaggggct gccgctgctt gcctggcccc tgtccaaggc tggatcctg 9720
agctggcccc gcctgcctgc ctgcccggcc accatgctgg ccaactacct tctcttctct 9780
cctctcagga gccgcatca tggattcctt caaagtatg ctggaggggc cagcaccttg 9840
gggcttccgg ctgcaagggg gcaaggactt caatgtgccc ctctccattt cccgggtgag 9900
cctaggtttg gggagggggc tccccagcg gtctttcggt gcttaggtct ccagaggggtg 9960
atggggggag tccaaacagg agctggtcag gggccagcag gccaggagat gtctagggtc 10020
ggagatgtag tggtaacctg ctgccacaag gactcccaat gaggtggata ctgggagggg 10080
gcacccaggc ttctccagcc ctgactgta ccgatgctg ttctcccaag ctctgtggc 10140
cacctctgag ggtggaggg aggtcattg tgcaggatgg gagcctaaca tttcaggagg 10200
tatctaaact tgaggtggca atgcttgag ccaggcccca ggcaggacac tgtgactata 10260
ggatttcact tcagcctcac tgccgcccag ggaatagcaa tctcatccc gtttttccag 10320

```

```

atgagagaag aactcatgga gaggtggcgg ggctcgctca tcgagtccat ggtgaagcag 10380
ggattggaat tgaggcacag catggcgtag attttttgtg ggtagaaggg gtctctcccc 10440
agcctatgta aggaccaca tccactgttc ccattcagga tgtggtggcc tttgacccca 10500
agcagaagtg taggacaggg ctccattcta ggggcttaac ttcagcttcc aagagcctgc 10560
cctggtgtgg gtggagctgg aggctggctc ctccctgtag cagggggatt gccttataag 10620
cccaagaatg cagccccacg ctgggatggc caacagtggc tgcggtctgc agagctgaaa 10680
agggctggcc taggcctggc cccctgaacc ccactggtgg gcctctcagc tggtcaccag 10740
gctgcagctc cagctgtatg gtccagtgtg gagacacaac aaattgcctg cccagagtgg 10800
gtgaggccag cctgtcggct ggcatctctg actggcctgg gggtcaggag ggggtgggga 10860
cttcctgccc ctatatccgc ctgccccgag agaccacccc aggcgcggg tgggcaggca 10920
gctgttgtca ggaagcccaa ggcaagccca gcctggaggg gccagaggg tcgtggcctg 10980
aggaggggct caagctggag tctgtctgta ggagctgggc gtgggggtta ggggtggcag 11040
gccagcagtg ctcttctcag gggctccttg atggcattct cctggaacct gccccgccag 11100
cagggtagtg aggcagtggg tgcctatga cacagctccc actacatagc cctcacacag 11160
ccctgaaacc tacctgacgt cctgctccct gggaaagtgc tggcccagtg tgtctgggga 11220
gcctgaacct cagtttcttc cctgatggag atgactttca gatatggcct gttgggggca 11280
ctccgggctc cagctccctg gtcagcatcc ctggcatgtg ggccggggcca ctagctgac 11340
ccagccctgg agttggacct gggccacat ggggtgggtga ggtgggctt tctgagttag 11400
gccagcccc tccccctccc ctgaccccag aatggaggga ggtgggaggg gcaagggctg 11460
gctgtgggcc caggcctggg agatgaggta acgtctggga ctggggggct gggctgctca 11520
ggctgactca cccccacct atgcagggtc cagccccctg gctttttccc tcttggttc 11580
ctctggcctt accctgcccc tggcttgagc cctccctgc ctctctccag ccaccgccc 11640
agcgtgtct tctgctctcc tgcctgccc cccacgctct gaacaccct catcctctgt 11700
gcttcctgcc ctctcactc tgggaaggga agcgtcccc gccccccacc cctctccag 11760
gagccagcta gctgcacccc aagaccccca cctcgggctc agcccacagc tcccaggagc 11820
cagccctgtg ggcagggagt ggctgggcca ggtttccctt ctactgactc accatgacct 11880
tgagtaagtc acttccctc tggggtgtca cttcccata cacagtataa ggggttgatt 11940
tagttggatt gaactaaagg tgagggagtg gctcagggtg tctccaggtg ggtgacccc 12000
tcagttgggc ccccatgctc agcagagggt gccacagtg gtggagcctt agggtcagag 12060
acacttcctg gctctgcctc ttactagctg ggtgacttga ggcaagtgt ttaacctctc 12120
tgtgtacatt tgcaagtgca aaatgggtaa aatcccagat tactccacaa ggttggtgga 12180
agattcagtg tcaatatgta gcatagttgg tgctcaataa actgaagcaa gtcttcttat 12240
ttagcgagtg aggaaggggc cgccagctc tcttagcct ctgacctct acgcaagcaa 12300
gaggtcatgt tgagcccagc tgcctttct tttcccagtg ctgtcaagct ctgtgcctgg 12360
ctgccctgcc ctctgacatc tctctgaaac ctcttgctc ccctctccct gcctcagctc 12420
agtctgtgca ctgacccacc tgaggagcct cctggggcca ctggcagcct ggaccccccc 12480
agatccccc caccagtgga aattgtcttc cagcactgcc tcacaaaagc ctacttgatg 12540
cagtgccagg cctcttgcca gatggctggg tggctccctta ggcttgagc cagtcaagct 12600
gccctgctg tgttgctggg gctgggctag aggcctggaa ggggtttatc agggtcaccc 12660
tctcagggcc tgggagatac ccaatcccag acattaaaac tgccagtagc ccctctacct 12720
tcaaagccaa gtcttggtcc ctccccctgg cattcaaagc catcgtaagt gaactctcac 12780
ccgctaggga gcacagcca ttctccttta ccgagggcca ccgcttctc aaagtcattc 12840
ctgatggctc cagctcatgc tgggtggcagc catttctccc agcctactgt ctctactcat 12900
tgccacagga accagggact cccagctcaa gagcctgaag gattggggtc aggggaaatt 12960
ggcagtcgag ggcttgggag tgacagccat gtatggccta cgaagtccca gctgtcaact 13020
taggtcccat tcaggcagtg ttcacaggga accgggagat aacagggcct gttcctggct 13080
ctcaaagggc cccagcagac ccctatagat ggcccccgac aggggtgctg ggggtgagag 13140
gtccataaga gccccggtg gtttcgggga ggaagctgcc ccctgcatgg gccagagggc 13200
atatctggta ggtggagtgg cctgggcagg aggcagcag gagcctcaa aggcaatggt 13260
cctctgaaa cacttgggct ttagcctgag cgtggctgtt tgtggacatc atagcaattt 13320
ctggactgtg ggggagggtg gtggcggtga atagataagc atcgtgactg gggaagctca 13380
ggtgagcacc acctgagggg gaggggtctg cagtgaataa ataagcagtg tgactgggaa 13440
attgtgaagc tcaggtgagc gccaccacct cctgggttgc tttagtgtcc agcagctgcc 13500
tagaactatg ttgaatgaag agctctctgg gttctggaag tgggacagct ttgggtgggg 13560
cagtgttacc accgtcagcc tggcttgggt ctgcagggtc cagggcctcg gtcactttgc 13620
ttctctctcc acagctcact cctgggggca aagcggcgca ggcggagtg gccgtgggtg 13680

```

actgggtgct	gagcatcgat	ggcgagaatg	cgggtagcct	cacacacatc	gaagctcaga	13740
acaagatccg	ggcctgcggg	gagcgccctca	gcctgggcct	cagcaggat	gcgggtggac	13800
atggatgggt	gcgcccgcgc	tggcagtggg	gatccctgcg	ccccggcccg	ctgtcacgct	13860
ttccttctcc	tccagggtccc	agccggttca	gagcaaaccg	cagaaggtag	gaggctggcc	13920
gggacatccg	ggcgggtggg	ggtgtgggct	tggacggcca	ggcctgctcg	ccctcctggc	13980
acattctcgg	taccccaatc	cctggccggg	agtggagggc	agaaaccgga	gctaaggcgg	14040
gtctaggggc	ctggagtga	gccaggggct	gctgcacggc	cctggcacca	cgcatgtccg	14100
cctgtctgtc	cgctgtctg	tccgcctgct	gcctcccgc	gccggcgctg	cgtgctcgcc	14160
cgcactcggg	cagccctcgg	tccgtcgtgg	actgagatcg	ccactcccaa	atggggccct	14220
tgaaacctga	gtcgtcctct	ccccgtagcc	tccaaataga	tgtagggggg	gggggtgggg	14280
tgggggggctg	gagctgccgc	tgtcctctgc	tgcaggcgcc	ccacttccac	ccaggccccc	14340
accttaccct	gcccgcggc	cctgcccggc	tgtgtctctg	cccaggcctc	cgcccccgcc	14400
gcggaccctc	cgcggtacac	ctttgcaccc	agcgtctccc	tcaacaagac	ggcccggcct	14460
ttgggcgccc	cgcccgctg	acagcgcccc	gcagcagaat	gggtacgtcg	gcccctgccc	14520
gcccgcgccc	acgccatcag	gcccactgtg	gccccacgcc	cgctgcccgc	tgtgtctcag	14580
tctgtgctgc	gccccagccc	ggcggaaccg	tgcggcacgc	cccctggcgg	ccgggtgggg	14640
gctgcaggca	cagggtccct	cccgaggctg	tggcgccctg	cagggtcacc	cctggggagg	14700
ggtctctgaa	tgacgcgcg	ccccctgctg	gcggctgggg	gttgggttgt	ggtgtcgggc	14760
cagctgagcc	ccagacactc	agtgcgcgct	tgtccccggc	tgttctgacc	cctccccgtc	14820
tttcttctcc	tccgtgtgtc	gtccctttgt	ccctttatct	gtctgtctgt	cttatttctc	14880
tcacagggtg	agaccctga	caagtcagt	agccccctc	tgctgtgccc	tttcttcttc	14940
cttttggcac	tctgggtggc	ggccccctcc	caccctggct	gccctcctct	ccacttcgcc	15000
ctcctgtcct	ctcacctacc	cgcccagcag	ggctcctggc	ctcaccctta	cccactccct	15060
cccactactg	taaccctaac	ccacatgcac	caaatcctgg	gaggggctgc	ccccaccgcc	15120
cacccccagt	gtgggttct	gagccacacc	ctccccacag	acagccgctc	cgaccgctgg	15180
tcccagatgc	cagcaagcag	cggtgatgg	agaacacaga	ggactggcgg	ccgcggccgg	15240
ggacaggcca	gtcgcgttcc	tccgcaccc	ttgcccacct	cacaggcacc	gagttcagta	15300
agtgcagccc	cagggcaggg	ggtactttcc	tgcccccag	cccaggcgtg	atccctgacc	15360
ctgtgtcttt	tttggtcaat	gcctgctctc	gctctctcag	tgcaagaccc	ggatgaggag	15420
cacctgaaga	aatcaaggta	cagggacggg	caccagcccc	tctccacct	ctgcctctt	15480
ccattccagc	tactgccctg	tgtctactcc	tgaggctccc	agctggggct	ctcaattctc	15540
ccttccttcc	ttccttccct	ccttccttcc	ttccttccct	ccttccttcc	ttccttccct	15600
cccttcctcc	ttccttccct	cttccatttc	ttccctccct	ccttccttcc	ctcctccctc	15660
cctgcctccc	ttccatctct	ccttccttcc	acttcttctc	ccctctctct	ctgcccctca	15720
gggaaaagta	tgtcctggag	ctgcagagcc	cacgctacac	ccgctccgg	gactggcacc	15780
accagcgtc	tgcccacgtg	ctcaacgtgc	agtctgtagc	cgccctctc	cagccggctg	15840
ccctctctgc	ctccctcttt	ctgttccctc	tgcccagggc	accccttag	tgctccagc	15900
ttctgcctac	ctcacccccc	ctttcgtgcc	cctggcctga	gcctcctgct	ggcctggccc	15960
tggccgcccc	cctgggttca	tctgacactg	ccttccctct	ttgcctgtg	gtactgctgt	16020
ctgccagggtc	tgtgctgcct	tgggcatgga	ataaacattc	tcagccctgc	ttgctctgcc	16080
tgtcttctat	ctttgtggac	ctggtttgca	tttgggtgt	gggggtgttt	cgtggttcgg	16140
actgtttggg	ccctgcccgc	cttgttttca	gtgggagggg	gtacctggca	aaggggcct	16200
gccctgccat	cacagatggc	ttcctggcat	gaggggagcc	ccaggagctg	cctcagaagc	16260
gggagccctg	cctcgtctcc	cagctagaga	ccgcacacca	gctaactgga	cattgctagg	16320
agaagctgcc	cttcccatcc	ctacccaggt	gggacctgga	atccaactcg	gcagtttcca	16380
cgccccaggt	catctcccg	ggggccagca	ggacccagg	tgggggggtg	ggccatgtca	16440
ggaagctcag	ccatgcaggg	ccttgaatgg	cagatcttgc	agccagggtg	ccaggacaga	16500
agccccagcc	ccagcctcat	ctacacccca	ggagccctgg	cctggtgaga	gggagtgggc	16560
tcgggcctgg	gcaagggtgg	gcagcctcca	ggggcatggg	ggtggtgggc	ttctctcagc	16620
tgctggggc	tcacccccg	tcctttgggg	tccctgggca	cccctttaga	gtcactttcc	16680
ccggcaggcc	ctaccgcccc	cagccctacc	agccgcccgc	cctgggctgt	ggaccctgcy	16740
tttgccgagc	gctatgcccc	ggacaaaacg	agcacagtgc	tgaccgggca	cagccagccg	16800
gccacgcccc	cgccgctgca	gagccgcacc	tccattgtgc	aggcagctgc	cggaggggtg	16860
ccaggagggg	gcagcaacaa	cggcaagact	cccgtgtgtc	accagtgcc	caaggtcatc	16920
cgggtgggtg	cctgttctctg	tccgacctg	gctttcccat	cctgcagccc	agccccacct	16980
gtctgcccac	ctgtcttgcc	tcagctgcga	ctggggggaa	taaggattca	gttctcagct	17040

```

ggagtaggag tagggacctg ggctgggtcc tcccattctt aatcccacgc tacctacccc 17100
agcccaacca caacaactgc tagcagcatc tgccgtggcg aaatagccga agggccaacc 17160
ataggctgaa gctgcacccc tacctttgct gctctctggg caaagagggg cctgccccct 17220
cccagcgctg ctgccccctc ctctgtctct ctgtctccct ctgctctcag agcatacagg 17280
cctggagcca ctccctctgt gcactgcccc gtggggccaa gcagcatcaa acacccccca 17340
gcatacagct gccggattct agagccttcc taattcgag gcctggcctg ctctcatctc 17400
tgtcagctct tttttttttt tttttgaaac agagtctcac tgtgttgccc acgttggcgt 17460
gcagtggcgc gatctcggct cactgcaacc tctgctcct gggttcaaga gattctcctg 17520
cctcagcctc ctgagtagct gggattacag gcacccgcca ccatgcctgg ctaattttgt 17580
atTTTTtagta gagacggggt tttaccatgt tggccaggct ggtctcaaac tctcaccctc 17640
aggtgatctc aggcctgcct tggcctccca aagtgtctggg actacagggtg tgagccactg 17700
tgcccagccg actctatcag ctcttgccag gtagaacagg caggccagca ggacagggca 17760
gctccagggt ttgccagggt gcggctcagc ttttatgagg ctccagtcgt cagcccttcc 17820
tcccggggct ctccctgctc taaagctgcc tctcctgtca ccagcagttc agtgtggcgg 17880
actggctctg taagcttcat ggctgccacg gtcacttccc aagcctgtct tctatcctat 17940
gtggaaaaat gggagaatga actgtccctc ccaaggcctc ctggtgggtg gtcagtcac 18000
ctgaaggggg ccaagacccc cactctctg cgtgtgctcc ctctgaccgc tctgcctccc 18060
ctgagggggc cgctacctgg tggcgctggg ccacgcgtac caccggagg agtttgtgtg 18120
tagccagtgt gggaggtcc tggagagggt tggcttcttt gaggagaagg gcgccatctt 18180
ctgccacca tgctatgacg tgcgtatgc accagctgt gccaagtgc agaagaagat 18240
tacaggcgtg agtagggctg gctggcgggg aggtggctcc aagcctgtca gtgggaacga 18300
gggctgctgg gaaaccaca gtccaggtct ctccccagt gacctccgg gtccttacca 18360
gcgtaataaa tgggctgctg tactggcctc accctgcatt agtcaggatg ctcttaacaa 18420
atgaccatgt tctgtctcag aaaccgcca aggtgcaaa gagcaggagg accaagccag 18480
gagaagccct gggccctcct gactccact ttgggtctc cctgccctgg tgaaatgaca 18540
gaacggccaa cttgacacgc tgaagctgct ctgtctcatg cgtcctcctc atttctggat 18600
ccagagccag ggctgccagg agtagccaga gagctctgtg tggatgatgt catattagt 18660
aggtttacct tgaccacgag cagtgggaaa ctcaaaataa tggatggctt tttctcatct 18720
aaaaacatcc cggggtgggt ggtctgggac tgatctgggt gaccagggt ccgccttgtt 18780
gcttgactgt tggcagcacc tgcttactta ccactcatgg tgcaagatga cacttcagcc 18840
tccgccaaaa tgtcacctt ccagccagca ggaagtcgga aggagaagaa agggacaga 18900
gccccatggc gtccatcctt agaggatgct gccacctgaa cctctgcttt catcctgtt 18960
gtcagaaccc agtcacatga ccacaccag tggcaacgga ggctgggaaa tatagtcttt 19020
atTTTgggca cccatgtgtc cagcaaaact ggggggtcca tcagtcggca agaacgggag 19080
agtggccgat gcagtggctg atgcttgtat ccagcactt tgggaggctg aggtgggcag 19140
atcacctgag gtcaggagt caagaccagc ctggccaata tggtgaaacc ctgtctctac 19200
taaaaaataa aaaattagct ggggtgtgct ggcacactgt agtcccagct acttgggagg 19260
ctgaggcagg agaatcgct gatcttgaga ggtggagggt gcagtgagcc aagattgtgc 19320
cactgccttc cagcctggga gacagcaaaa aaaaaaaaaa aaaaaaaaaa aaaaagggcc 19380
aggcacgggt gctcacacct gtaatcccag cactttggga ggccgagatg ggccgatcac 19440
gaggtcagga gattgagacc atcctggcta acacggtgaa accccatctc tactaaaaat 19500
acaaaaaaat tggccgggca tggatggagta gtcccagcta ctggggaggc tgaggcagga 19560
gaatggcgtg aacctgggag gcagagcttg cagtgagccg agatcgccgc actgcactcc 19620
agcctgggca acagagcgag actcttgtct caaaaagaaa aaaagaaaga gaaatctgcc 19680
tcccagcctt gggctcctgc cctaccagcc cacaccctg gtagagcctc ctctcccacc 19740
agctcaaagc ccaagttcct tcaactgtgac cttgtctgct cctctaaaac aggcaacacc 19800
agacagttag aagagccagc cagacatggg cagaaaacct atttctgtga tctactggct 19860
gtgtgagcag gggctagtgt ctctctctgg gcctcactga agagaagggt ggcactatgc 19920
tagggccggc acggttgcaa ggtagatgta agatggggta cagggtgtgt ggagggcaga 19980
aatgcacat ccgaaggcta catgtcccc acacttatgt cttgcttggc ccacactgtt 20040
tcattttaaa atcagtagca aacaatttaa aaaatcagaa gatttgctg catgatgcag 20100
tggctcatgc ctgtaatccc agcactttgg gaggccaagg tgggaggatt gcttgagccc 20160
aggagttaa gaccagcatg ggcacatag caagaccct gtttctacaa aaaaaaaaaa 20220
attagaaaat tagccaagt tggatggcat cacctgtggt ccagctact tgggaggcag 20280
agggaaagt agatctcct ctttttatt ctttatgtat aatgatagg tcttgtctg 20340
ttgccaggc tggagtgcag tggcatgat actgctcact gcagccttga tctcctgggc 20400

```

tcagaggatc	ctccccacctc	agcctcccaa	atagctagga	ctagagggtgc	ccaccagcat	20460
gctcagcaga	tttttaaatc	ttttttaga	gatgaggttt	tgctatgttg	cccaggctgg	20520
tctcgaactc	ctggcctcga	gcgatcctcc	caccttggcc	tcccaaagca	ctgggattac	20580
agacgtgagc	cactgcgccc	agcagatttc	tctttaacac	ctagatttca	gcctgagcca	20640
ggcaggcatt	cctgaatgaa	ccagtagtac	tgctcccaga	agaagaggtc	ctcctccgtg	20700
tgacacagtc	cccacttggc	ccttgcaggg	attggatctg	ggatccctgg	atttaaactc	20760
agggccatcc	tcataacagc	ctcacaaggc	tgggattagc	ttcccagttc	acaagggag	20820
aaaccaagac	ttgagaaggt	caaggtctgg	ccagaccac	acatcttgga	ccctcatacc	20880
gcctcgaggc	cccatgctgc	cctctgcctg	ctccagatgt	gaatactgct	ggccctggct	20940
ggccccggct	ggccccgagg	gtcctagggg	tgaacagccc	agcccaggga	gagctcagcc	21000
ccttgtgcct	ctgccccctc	ccacctcctg	cggaggccag	tcgactcacc	cacaaagggc	21060
caggcactgt	ggggatagat	cagctaacaa	aacagttgat	gcttcctgcc	cttctggggc	21120
ttacattttg	gctggaagaa	gaggggagag	gcagactgta	agcaataagc	gcaataagta	21180
ggttgcctgg	aagtaatggt	agatcacgtt	acggaaaaca	ggaaagagca	gagcgacaag	21240
tgctgggggtg	cgtggtgcag	ggaaggcagc	tggtgtgctg	tggtgtgggtc	agagtggggc	21300
ctcatggaga	agactgcatt	cgagcagaaa	cttgaagggg	gtgaggggtg	agcctagaga	21360
tatctggggc	agagcagtc	aggcagagg	gacagccgtg	gtcaagccca	ggacaggagt	21420
gtgcctgggtg	tgccagtttc	aggcaagagg	ccagtgtgca	gaggcaagg	gagaacgcaa	21480
gggagagcag	tgccggagac	gggtgggaac	gaggtcagac	ctgctggcct	ccagcctctg	21540
catggggcct	ggctcttgct	gggagcaatg	ggaagcagta	cacagtttca	tgcaagggga	21600
gaaggcctgt	cttgggttgc	aggggcacgc	tgtggcagct	gggatcagag	agaggagctt	21660
gtaggccagt	tggtatgtgg	tcccacgggc	cagatggcca	tggtttacct	cacttcaggg	21720
aggctgtgag	aagcactcag	aatctggatg	tgccttgggg	gtgggcccga	ctggatttcc	21780
tggtggacct	ggtgtggggg	gtgagaggag	ggtgtgtttg	gctgcagcag	acaggagaat	21840
ggagttgcc	tccgcgtgat	ggggatggct	gtgggaggag	aggtttgggg	tgagggaatc	21900
aggaactgag	tgctggacat	ggcaagtctg	aaggcgcagt	ggtcgtccac	tcagagacct	21960
tgaggttga	gatggagggt	tgggagtcct	gaacagttag	atgtagtggt	taccgcgaga	22020
aggaacaggg	cttgccggcca	gccctcctgt	gttcccgtga	cccagggcag	ggcaggaggg	22080
gcctgagcct	gccgagtgac	tgggacctcc	ttccaggaga	tcatgcacgc	cctgaagatg	22140
acctggcacg	tgactgcctt	tacctgtgct	gcctgcaaga	cgcccatccg	gaacaggggc	22200
ttctacatgg	aggagggcgt	gccctattgc	gagcgaggta	cccactggcc	agtgaggggtg	22260
aggaggtatg	gtgcatgggg	caggcatgaa	tccaggtcct	ctttctctct	gccccattc	22320
tcagactatg	agaagatggt	tggcacgaaa	tgccatggct	gtgacttcaa	gatcgacgct	22380
ggggaccgct	tcctggaggc	cctgggcttc	agctggcatg	acacctgctt	cgtctgtgcg	22440
gtgagagccc	cgccccctga	actgagcccc	aagcccaccg	gccctctggt	cattccccag	22500
gagatgcagg	agaagtggg	aaggggcctc	tcctgtgtcc	cccaacccca	tgtagctggg	22560
cctttgctgt	ccttagatat	gtcagatcaa	cctggaagga	aagaccttct	actccaagaa	22620
ggacaggcct	ctctgcaaga	gccatgcctt	ctctcatgtg	tgagccccct	ctgcccacag	22680
ctgccgcggt	ggccccctagc	ctgagggggc	tggagtctgt	gccctgcatt	tctgggtagg	22740
gctggcaatg	gttgccctaa	ccctggctcc	tggcccagag	ctggggctcc	ctgggcccctg	22800
ccccaccac	cttatcctcc	caccccactc	cctccaccac	cacagcacac	cgatgctggc	22860
cacaccagcc	ccctttcacc	tccagtgcc	caataaacct	gtaccagct	gtgtcttctg	22920
tgcccttccc	ctgtgcaccc	ggaggggcag	aatttgaggc	acgtggcagg	gtggagagta	22980
agatggtttt	cttgggctgg	ccatctgggt	ggctctcgtg	atgcagacat	ggcgggctca	23040
tggttagtgg	aggaggtaca	ggcgagacc	catgtgccag	gcccgggtgc	cacagacatg	23100
aggggagcca	ctggtctggc	ctggccttga	ggtagagaa	gggtagttag	gaagggtagt	23160
tagcatgggt	gctcatgcct	gtgatccag	cactttggaa	ggccaagggt	ggcagatcgc	23220
ttgaggtcag	gagttcgaga	cctcatggcc	aacacggtga	aacagcgtct	ctagtaaaaa	23280
tacaaaaatt	agccgagtgt	ggtggggcat	gcctgtaatc	ccagccactc	aggaggctga	23340
ggcgggaaaa	tcacttgaac	ctgggaagtg	gaggttgag	tgagctgaga	tcacaccact	23400
gcgcgcgagc	ctgggtggca	gatggcagag	cgagaccctg	cttcaaaaaa	aaaaaaaaaa	23460
aaaaaaaaaa	gaagggtagt	tgtagtggg	ggtggatctg	cagagatatg	gtgtggaaaa	23520
cagcaatggc	cacagcaaag	tctggagggg	gccagctgcc	gtccaaacag	aagaaggcag	23580
ggctggagag	ggtagccctt	aggtcctggg	aagccacgag	tgccaggcag	tagagctggg	23640
gctgtctctt	gaggttaggg	cagggcaagg	cacagcagag	tttgaaatag	gtttgtgttg	23700
tattgcagaa	aagaggcccc	agaacactga	gggagtgcag	gagggaggct	gggaggagga	23760

```
gttgccagcag ggcctagggg cggggggccag gcaagggagg ggcagagagt aatatggcag 23820
agatgggacc cagtggcagg tccgggggat gagggatgga gagaaggaca ggagcgttgc 23880
caggcatctg gcctatacca gacatgctca cgctgtctcc cgcgaaacctc ctagcaacct 23940
tgcgccgttg tctgcaatca cttatttcat tttttctttt ttaactttaa ttttttttgt 24000
ttttaagaga caggatctcc ctaggttgcc cgggctgggt tcaaactcct gggctcaagc 24060
aattcttctt ccttagcccc aaagtgtctg cattacaggt gtgagccacc atgcttgcc 24120
cacttatttt ctagatgagg cacagaaaga ttgggagact tgaccaaggt cacgctgtca 24180
ttgagccatg agccagacta gaatccaggc ctgaagctgg gtgcgctgtc ccaggactgg 24240
ctggcactga gtaccatttg ccagcgagca tctctctggg aagctgactt ctgcccggta 24300
cctggaggac tgtagacctt ggtggtggcg ccgtcactct ggggcttctt gcctcccact 24360
gatgcccgcg ccaccctaga gggactgtca tctctcctgt cccaagcctg gactggaaag 24420
actgaagaga agccttaagt aggccaggac agctcagtgt gccatggctg ccgctccttc 24480
agtgggtccct ggcattgagga cctgcaacac atctgttagt cttctcaaca ggcccttggc 24540
ccggtccccct ttaagagacg agaagggtg ggcacggtga ctcacacctc taatcccagc 24600
actttggaag gctgaggctg gagaagggtt ccagcttagg agttcaggac cagcctgggc 24660
aacatggtga gacctgttt tgttttgttt tttgtttttt tgagatggag tcttgctctg 24720
tcgcccaggc tggagtgcag 24740
```

<210> 42

<211> 25

<212> DNA

<213> Rattus norvegicus

<400> 42

gcactacctt gaaggaatcc atggt

25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/11664

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.

US CL : 435/320.1, 325; 530/350, 388.1; 536/23.5; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 325; 530/350, 388.1; 536/23.5; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BODEN et al. LMP-1, a LIM-domain protein, mediates BMP-6 effects on bone formation. Endocrinology. 1998. Vol. 139, No. 12, pages 5125-5134, entire document.	1-37
A	HOGAN et al. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes and Development. 1996. Vol. 10, pages 1580-1594, entire document.	1-37
A	KINGSLEY, DM What do BMPs do in mammals? Clues from the mouse short-ear mutation. Trends Genet. January 1994. Vol. 10, No. 1, pages 16-21, entire document.	1-37

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 JULY 2000

Date of mailing of the international search report

29 AUG 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ANNE-MARIE BAKER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/11664

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

A61K 48/00; C07H 21/04; C07K 14/00, 16/00; C12N 15/63, 15/85, 15/86

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST

Dialog (file: medicine)

search terms: gene(w)transfer, LMP, bone, LIM, mineral?, human, osteogen?

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 November 2000 (09.11.2000)

PCT

(10) International Publication Number
WO 00/66178 A1

(51) International Patent Classification⁷: A61K 48/00,
C07H 21/04, C07K 14/00, 16/00, C12N 15/63, 15/85,
15/86

(21) International Application Number: PCT/US00/11664

(22) International Filing Date: 28 April 2000 (28.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/132,021 30 April 1999 (30.04.1999) US

(71) Applicant (for all designated States except US): EMORY
UNIVERSITY [US/US]; 1380 South Oxford Road, At-
lanta, GA 30322 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BODEN, Scott, D.
[US/US]; 2842 Cravey Drive, N.E., Atlanta, GA 30345
(US). HAIR, Gregory, A. [US/US]; 1887 Chrysler Drive,
N.E., Atlanta, GA 30345 (US).

(74) Agents: GARRETT, Arthur, S. et al.; Finnegan, Hen-
derson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street,
N.W., Washington, DC 20005-3315 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- With (an) indication(s) in relation to deposited biological
material furnished under Rule 13bis separately from the
description.

(48) Date of publication of this corrected version:

15 March 2001

(15) Information about Correction:

see PCT Gazette No. 11/2001 of 15 March 2001, Section
II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 00/66178 A1

(54) Title: LIM MINERALIZATION PROTEIN SPLICE VARIANTS

(57) Abstract: The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising splice variants of nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation by transfecting osteogenic precursor cells with an isolated nucleic acid molecule comprising a nucleotide sequence encoding splice variants of LIM mineralization protein. The transfection may occur *ex vivo* or *in vivo* by direct injection of virus or naked plasmid DNA. In a particular embodiment, the invention provides a method of fusing a spine by transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected osteogenic precursor cells with a matrix and contacting the matrix with the spine. Finally, the invention relates to methods for inducing systemic bone formation by stable transfection of host cells with the vectors of the invention.

LIM Mineralization Protein Splice Variants

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

The field of the invention relates generally to osteogenic cells and the formation of bone and boney tissue in mammalian species. Specifically, the invention concerns a novel family of proteins, and nucleic acids encoding those proteins, that enhances the efficacy of bone mineralization *in vitro* and *in vivo*.

10 The invention provides methods for treating a variety of pathological conditions associated with bone and boney tissue, such as, for example, spine fusion, fracture repair and osteoporosis.

2. Description of the Related Art

15 Osteoblasts are thought to differentiate from pluripotent mesenchymal stem cells. The maturation of an osteoblast results in the secretion of an extracellular matrix which can mineralize and form bone. The regulation of this complex process is not well understood but is thought to involve a group of signaling glycoproteins known as bone morphogenetic proteins (BMPs). These
20 proteins have been shown to be involved with embryonic dorsal-ventral patterning, limb bud development, and fracture repair in adult animals. B. L. Hogan, Genes & Develop., 10:1580 (1996). This group of transforming growth factor-beta superfamily secreted proteins has a spectrum of activities in a variety of cell types at different stages of differentiation; differences in
25 physiological activity between these closely related molecules have not been clarified. D. M. Kingsley, Trends Genet., 10:16 (1994).

To better discern the unique physiological role of different BMP signaling proteins, we recently compared the potency of BMP-6 with that of BMP-2 and BMP-4, for inducing rat calvarial osteoblast differentiation. Boden *et al.*,
30 Endocrinology, 137:3401 (1996). We studied this process in first passage (secondary) cultures of fetal rat calvaria that require BMP or glucocorticoid for

initiation of differentiation. In this model of membranous bone formation, glucocorticoid (GC) or a BMP will initiate differentiation to mineralized bone nodules capable of secreting osteocalcin, the osteoblast-specific protein. This secondary culture system is distinct from primary rat osteoblast cultures which
5 undergo spontaneous differentiation. In this secondary system, glucocorticoid resulted in a ten-fold induction of BMP-6 mRNA and protein expression which was responsible for the enhancement of osteoblast differentiation. Boden *et al.*, Endocrinology, 138:2920 (1997).

In addition to extracellular signals, such as the BMPs, intracellular
10 signals or regulatory molecules may also play a role in the cascade of events leading to formation of new bone. One broad class of intracellular regulatory molecules are the LIM proteins, which are so named because they possess a characteristic structural motif known as the LIM domain. The LIM domain is a cysteine-rich structural motif composed of two special zinc fingers that are
15 joined by a 2-amino acid spacer. Some proteins have only LIM domains, while others contain a variety of additional functional domains. LIM proteins form a diverse group, which includes transcription factors and cytoskeletal proteins. The primary role of LIM domains appears to be in mediating protein-protein interactions, through the formation of dimers with identical or different LIM
20 domains, or by binding distinct proteins.

In LIM homeodomain proteins, that is, proteins having both LIM domains and a homeodomain sequence, the LIM domains function as negative regulatory elements. LIM homeodomain proteins are involved in the control of cell lineage determination and the regulation of differentiation, although LIM-
25 only proteins may have similar roles. LIM-only proteins are also implicated in the control of cell proliferation since several genes encoding such proteins are associated with oncogenic chromosome translocations.

Humans and other mammalian species are prone to diseases or injuries that require the processes of bone repair and/or regeneration. For example,
30 treatment of fractures would be improved by new treatment regimens that could stimulate the natural bone repair mechanisms, thereby reducing the time

required for the fractured bone to heal. In another example, individuals afflicted with systemic bone disorders, such as osteoporosis, would benefit from treatment regimens that would results in systemic formation of new bone.

Such treatment regimens would reduce the incidence of fractures arising from
5 the loss of bone mass that is a characteristic of this disease.

For at least these reasons, extracellular factors, such as the BMPs, have been investigated for the purpose of using them to stimulate formation of new bone *in vivo*. Despite the early successes achieved with BMPs and other extracellular signalling molecules, their use entails a number of disadvantages.
10 For example, relatively large doses of purified BMPs are required to enhance the production of new bone, thereby increasing the expense of such treatment methods. Furthermore, extracellular proteins are susceptible to degradation following their introduction into a host animal. In addition, because they are typically immunogenic, the possibility of stimulating an immune response to the
15 administered proteins is ever present.

Due to such concerns, it would be desirable to have available treatment regimens that use an intracellular signalling molecule to induce new bone formation. Advances in the field of gene therapy now make it possible to introduce into osteogenic precursor cells, that is, cells involved in bone
20 formation, or peripheral blood leukocytes, nucleotide fragments encoding intracellular signals that form part of the bone formation process. Gene therapy for bone formation offers a number of potential advantages: (1) lower production costs; (2) greater efficacy, compared to extracellular treatment regiments, due to the ability to achieve prolonged expression of the
25 intracellular signal; (3) it would by-pass the possibility that treatment with extracellular signals might be hampered due to the presence of limiting numbers of receptors for those signals; (4) it permits the delivery of transfected potential osteoprogenitor cells directly to the site where localized bone formation is required; and (5) it would permit systemic bone formation, thereby
30 providing a treatment regimen for osteoporosis and other metabolic bone diseases.

SUMMARY OF THE INVENTION

The present invention seeks to overcome the drawbacks in the prior art by providing novel compositions and methods for inducing bone formation using an intracellular signalling molecule that participates early in the cascade of events that leads to bone formation. Applicants have discovered 10-4/RLMP (SEQ ID NO: 1, SEQ ID NO: 2), a novel LIM gene with a sequence originally isolated from stimulated rat calvarial osteoblast cultures. The gene has been cloned, sequenced and assayed for its ability to enhance the efficacy of bone mineralization *in vitro*. The protein RLMP affects mineralization of bone matrix as well as differentiation of cells into the osteoblast lineage. Unlike other known cytokines, for example, BMPs, RLMP is not a secreted protein, but is instead an intracellular signaling molecule. This feature has the advantage of providing intracellular signaling amplification as well as easier assessment of transfected cells. It is also suitable for more efficient and specific *in vivo* applications. Suitable clinical applications include enhancement of bone repair in fractures, bone defects, bone grafting, and normal homeostasis in patients presenting with osteoporosis.

Applicants have also cloned, sequenced and deduced the amino acid sequence of a corresponding human protein, named human LMP-1. The human protein demonstrates enhanced efficacy of bone mineralization *in vitro* and *in vivo*.

In addition, the applicants have characterized a truncated (short) version of LMP-1, termed HLMP-1s. This short version resulted from a point mutation in one source of a cDNA clone, providing a stop codon which truncated the protein. The short version (LMP-1s) is fully functional when expressed in cell culture and *in vivo*.

Using PCR analysis of human heart cDNA library, Applicants have identified two alternative splice variants (referred to as HLMP-2 and HLMP-3) that differ from HLMP-1 in a region between base pairs 325 and 444 in the

nucleotide sequence encoding HLMP-1. The HLMP-2 sequence has a 119 base pair deletion and an insertion of 17 base pairs in this region. Compared to HLMP-1, the nucleotide sequence encoding HLMP-3 has no deletions, but it does have the same 17 base pairs as HLMP-2, which are inserted at position
5 444 in the HLMP-1 sequence.

Additional features and advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by practice of the invention. The objectives and other advantages of the invention will be realized and attained by the methods and
10 compositions of matter particularly pointed out in the written description and claims hereof.

In one broad aspect, the invention relates to an isolated nucleic acid molecule comprising a nucleic acid sequence encoding any LIM mineralization protein, wherein the nucleic acid molecule hybridizes under standard
15 conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 25, and wherein the molecule hybridizes under highly stringent conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 26. In a specific aspect, the isolated nucleic acid molecule encodes HLMP-1, HLMP-1s, RLMP, HLMP-2, or HLMP-3. In addition, the invention is
20 directed to vectors comprising these nucleic acid molecules, as well as host cells comprising the vectors. In another specific aspect, the invention relates to the proteins themselves.

In a second broad aspect, the invention relates to antibody that is specific for LIM mineralization protein, including HLMP-1, HLMP-1s, RLMP,
25 HLMP-2, and HLMP-3. In one specific aspect, the antibody is a polyclonal antibody. In another specific aspect, the antibody is a monoclonal antibody.

In a third broad aspect, the invention relates to method of inducing bone formation wherein osteogenic precursor cells are transfected with an isolated nucleic acid molecule comprising a nucleotide sequence encoding LIM
30 mineralization protein. In one specific aspect, the isolated nucleic acid molecule is in a vector, which may be a plasmid or a virus, such as adenovirus

or retrovirus. The transfection may occur *ex vivo* or *in vivo* by direct injection of the isolated nucleic acid molecule. The transfected isolated nucleic acid molecule may encode HLMP-1, HLMP-1s, RLMP, HLMP-2, or HLMP-3.

In a further aspect, the invention relates to methods of fusing a spine by
 5 transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected osteogenic precursor cells with a matrix and contacting the matrix with the spine.

In yet another aspect, the invention relates to methods for inducing
 10 systemic bone formation by stable transfection of host cells with the vectors of the invention.

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed.

15

ABBREVIATIONS AND DEFINITIONS

	BMP	Bone Morphogenetic Protein
	HLMP-1	Human LMP-1, also
20		designated as Human LIM
		Protein or HLMP
	HLMP-1s	Human LMP-1 Short
		(truncated) protein
	HLMPU	Human LIM Protein Unique
25		Region
	LMP	LIM mineralization protein
	MEM	Minimal essential medium
	Trm	Triamcinolone
	-GlyP	Beta-glycerolphosphate
30	RACE	Rapid Amplification of cDNA
		Ends

	RLMP	Rat LIM mineralization protein, also designated as RLMP-1
	RLMPU	Rat LIM Protein Unique Region
5	RNAse	RNAse inhibitor
	ROB	Rat Osteoblast
	10-4	Clone containing cDNA sequence for RLMP (SEQ ID NO: 2)
10	UTR	Untranslated Region
	HLMP-2	Human LMP Splice Variant 2
	HLMP-3	Human LMP Splice Variant 3
15		

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to novel mammalian LIM proteins, herein
 20 designated LIM mineralization proteins, or LMP. The invention relates more
 particularly to human LMP, known as HLMP or HLMP-1, or alternative splice
 variants of human LMP, which are known as HLMP-2 or HLMP-3. The
 applicants have discovered that these proteins enhance bone mineralization in
 mammalian cells grown *in vitro*. When produced in mammals, LMP also
 25 induces bone formation *in vivo*.

Ex vivo transfection of bone marrow cells, osteogenic precursor cells,
 peripheral blood leukocytes, or mesenchymal stem cells with nucleic acid that
 encodes LMP or HLMP, followed by reimplantation of the transfected cells in
 the donor, is suitable for treating a variety of bone-related disorders or injuries.
 30 For example, one can use this method to: augment long bone fracture repair;
 generate bone in segmental defects; provide a bone graft substitute for

fractures; facilitate tumor reconstruction or spine fusion; and provide a local treatment (by injection) for weak or osteoporotic bone, such as in osteoporosis of the hip, vertebrae, or wrist. Transfection with LMP or HLMP-encoding nucleic acid is also useful in: the percutaneous injection of transfected marrow
5 cells to accelerate the repair of fractured long bones; treatment of delayed union or non-unions of long bone fractures or pseudoarthrosis of spine fusions; and for inducing new bone formation in avascular necrosis of the hip or knee.

In addition to *ex vivo*-based methods of gene therapy, transfection of a recombinant DNA vector comprising a nucleic acid sequence that encodes
10 LMP or HLMP can be accomplished *in vivo*. When a DNA fragment that encodes LMP or HLMP is inserted into an appropriate viral vector, for example, an adenovirus vector, the viral construct can be injected directly into a body site where endochondral bone formation is desired. By using a direct, percutaneous injection to introduce the LMP or HLMP sequence stimulation of
15 bone formation can be accomplished without the need for surgical intervention either to obtain bone marrow cells (to transfect *ex vivo*) or to reimplant them into the patient at the site where new bone is required. Alden *et al.*, Neurosurgical Focus (1998), have demonstrated the utility of a direct injection method of gene therapy using a cDNA that encodes BMP-2, which was cloned
20 into an adenovirus vector.

It is also possible to carry out *in vivo* gene therapy by directly injecting into an appropriate body site, a naked, that is, unencapsulated, recombinant plasmid comprising a nucleic acid sequence that encodes HLMP. In this embodiment of the invention, transfection occurs when the naked plasmid DNA
25 is taken up, or internalized, by the appropriate target cells, which have been described. As in the case of *in vivo* gene therapy using a viral construct, direct injection of naked plasmid DNA offers the advantage that little or no surgical intervention is required. Direct gene therapy, using naked plasmid DNA that encodes the endothelial cell mitogen VEGF (vascular endothelial growth
30 factor), has been successfully demonstrated in human patients. Baumgartner *et al.*, Circulation, 97(12):1114-23 (1998).

By using an adenovirus vector to deliver LMP into osteogenic cells, transient expression of LMP is achieved. This occurs because adenovirus does not incorporate into the genome of target cells that are transfected. Transient expression of LMP, that is, expression that occurs during the lifetime
5 of the transfected target cells, is sufficient to achieve the objects of the invention. Stable expression of LMP, however, can occur when a vector that incorporates into the genome of the target cell is used as a delivery vehicle. Retrovirus-based vectors, for example, are suitable for this purpose.

Stable expression of LMP is particularly useful for treating various
10 systemic bone-related disorders, such as osteoporosis and osteogenesis imperfecta. For this embodiment of the invention, in addition to using a vector that integrates into the genome of the target cell to deliver an LMP-encoding nucleotide sequence into target cells, LMP expression is placed under the control of a regulatable promoter. For example, a promoter that is turned on by
15 exposure to an exogenous inducing agent, such as tetracycline, is suitable. Using this approach, one can stimulate formation of new bone on a systemic basis by administering an effective amount of the exogenous inducing agent. Once a sufficient quantity of bone mass is achieved, administration of the exogenous inducing agent is discontinued. This process may be repeated as
20 needed to replace bone mass lost, for example, as a consequence of osteoporosis.

Antibodies specific for HLMP are particularly suitable for use in methods for assaying the osteoinductive, that is, bone-forming, potential of patient cells. In this way one can identify patients at risk for slow or poor healing of bone
25 repair. Also, HLMP-specific antibodies are suitable for use in marker assays to identify risk factors in bone degenerative diseases, such as, for example, osteoporosis.

Following well known and conventional methods, the genes of the present invention are prepared by ligation of nucleic acid segments that
30 encode LMP to other nucleic acid sequences, such as cloning and/or expression vectors. Methods needed to construct and analyze these

recombinant vectors, for example, restriction endonuclease digests, cloning protocols, mutagenesis, organic synthesis of oligonucleotides and DNA sequencing, have been described. For DNA sequencing DNA, the dideoxyterminator method is the preferred.

5 Many treatises on recombinant DNA methods have been published, including Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, 2nd edition (1988), Davis *et al.*, Basic Methods in Molecular Biology, Elsevier (1986), and Ausubel *et al.*, Current Protocols in Molecular Biology, Wiley Interscience (1988). These reference manuals are
10 specifically incorporated by reference herein.

Primer-directed amplification of DNA or cDNA is a common step in the expression of the genes of this invention. It is typically performed by the polymerase chain reaction (PCR). PCR is described in U.S. Patent No. 4,800,159 to Mullis *et al.* and other published sources. The basic principle of
15 PCR is the exponential replication of a DNA sequence by successive cycles of primer extension. The extension products of one primer, when hybridized to another primer, becomes a template for the synthesis of another nucleic acid molecule. The primer-template complexes act as substrate for DNA polymerase, which in performing its replication function, extends the primers.
20 The conventional enzyme for PCR applications is the thermostable DNA polymerase isolated from *Thermus aquaticus*, or Taq DNA polymerase.

Numerous variations of the basic PCR method exist, and a particular procedure of choice in any given step needed to construct the recombinant vectors of this invention is readily performed by a skilled artisan. For example,
25 to measure cellular expression of 10-4/RLMP, RNA is extracted and reverse transcribed under standard and well known procedures. The resulting cDNA is then analyzed for the appropriate mRNA sequence by PCR.

The gene encoding the LIM mineralization protein is expressed in an expression vector in a recombinant expression system. Of course, the
30 constructed sequence need not be the same as the original, or its complimentary sequence, but instead may be any sequence determined by the

degeneracy of the DNA code that nonetheless expresses an LMP having bone forming activity. Conservative amino acid substitutions, or other modifications, such as the occurrence of an amino-terminal methionine residue, may also be employed.

5 A ribosome binding site active in the host expression system of choice is ligated to the 5' end of the chimeric LMP coding sequence, forming a synthetic gene. The synthetic gene can be inserted into any one of a large variety of vectors for expression by ligating to an appropriately linearized plasmid. A regulatable promoter, for example, the *E. coli* lac promoter, is also suitable for
10 the expression of the chimeric coding sequences. Other suitable regulatable promoters include trp, tac, recA, T7 and lambda promoters.

DNA encoding LMP is transfected into recipient cells by one of several standard published procedures, for example, calcium phosphate precipitation, DEAE-Dextran, electroporation or protoplast fusion, to form stable
15 transformants. Calcium phosphate precipitation is preferred, particularly when performed as follows.

DNAs are coprecipitated with calcium phosphate according to the method of Graham and Van Der, Virology, 52:456 (1973), before transfer into cells. An aliquot of 40-50 μ g of DNA, with salmon sperm or calf thymus DNA as
20 a carrier, is used for 0.5×10^6 cells plated on a 100 mm dish. The DNA is mixed with 0.5 ml of 2X Hepes solution (280 mM NaCl, 50 mM Hepes and 1.5 mM Na_2HPO_4 , pH 7.0), to which an equal volume of 2x CaCl_2 (250 mM CaCl_2 and 10 mM Hepes, pH 7.0) is added. A white granular precipitate, appearing after 30-40 minutes, is evenly distributed dropwise on the cells, which are allowed to
25 incubate for 4-16 hours at 37°C. The medium is removed and the cells shocked with 15% glycerol in PBS for 3 minutes. After removing the glycerol, the cells are fed with Dulbecco's Minimal Essential Medium (DMEM) containing 10% fetal bovine serum.

DNA can also be transfected using: the DEAE-Dextran methods of
30 Kimura *et al.*, Virology, 49:394 (1972) and Sompayrac *et al.*, Proc. Natl. Acad. Sci. USA, 78:7575 (1981); the electroporation method of Potter, Proc. Natl.

Acad. Sci. USA, 81:7161 (1984); and the protoplast fusion method of Sandri-Goddin *et al.*, Molec. Cell. Biol., 1:743 (1981).

Phosphoramidite chemistry in solid phase is the preferred method for the organic synthesis of oligodeoxynucleotides and polydeoxynucleotides. In addition, many other organic synthesis methods are available. Those methods are readily adapted by those skilled in the art to the particular sequences of the invention.

The present invention also includes nucleic acid molecules that hybridize under standard conditions to any of the nucleic acid sequences encoding the LIM mineralization proteins of the invention. "Standard hybridization conditions" will vary with the size of the probe, the background and the concentration of the nucleic acid reagents, as well as the type of hybridization, for example, *in situ*, Southern blot, or hybridization of DNA-RNA hybrids (Northern blot). The determination of "standard hybridization conditions" is within the level of skill in the art. For example, see U.S. Patent 5,580,775 to Freneau *et al.*, herein incorporated by reference for this purpose. See also, Southern, E. M., J. Mol. Biol., 98:503 (1975), Alwine *et al.*, Meth. Enzymol., 68:220 (1979), and Sambrook *et al.*, Molecular Cloning: A laboratory Manual, 2nd edition, pp. 7.19-7.50, Cold Spring Harbor Press (1989).

One preferred set of standard hybridization conditions involves a blot that is prehybridized at 42°C for 2 hours in 50% formamide, 5X SSPE (150 mM NaCl, 10 mM Na H₂PO₄ [pH 7.4], 1 mM EDTA [pH 8.0]), 5X Denhardt's solution (20 mg Ficoll, 20 mg polyvinylpyrrolidone and 20 mg BSA per 100 ml water), 10% dextran sulphate, 1% SDS and 100 g/ml salmon sperm DNA. A ³²P-labelled cDNA probe is added, and hybridization is continued for 14 hours. Afterward, the blot is washed twice with 2X SSPE, 0.1% SDS for 20 minutes at 22°C, followed by a 1 hour wash at 65°C in 0.1X SSPE, 0.1 %SDS. The blot is then dried and exposed to x-ray film for 5 days in the presence of an intensifying screen.

Under "highly stringent conditions," a probe will hybridize to its target sequence if those two sequences are substantially identical. As in the case of standard hybridization conditions, one of skill in the art can, given the level of skill in the art and the nature of the particular experiment, determine the conditions under which only substantially identical sequences will hybridize.

Another aspect of the invention includes the proteins encoded by the nucleic acid sequences. In still another embodiment, the invention relates to the identification of such proteins based on anti-LMP antibodies. In this embodiment, protein samples are prepared for Western blot analysis by lysing cells and separating the proteins by SDS-PAGE. The proteins are transferred to nitrocellulose by electroblotting as described by Ausubel *et al.*, Current Protocols in Molecular Biology, John Wiley and Sons (1987). After blocking the filter with instant nonfat dry milk (1 gm in 100 ml PBS), anti-LMP antibody is added to the filter and incubated for 1 hour at room temperature. The filter is washed thoroughly with phosphate buffered saline (PBS) and incubated with horseradish peroxidase (HRPO)-antibody conjugate for 1 hour at room temperature. The filter is again washed thoroughly with PBS and the antigen bands are identified by adding diaminobenzidine (DAB).

Monospecific antibodies are the reagent of choice in the present invention, and are specifically used to analyze patient cells for specific characteristics associated with the expression of LMP. "Monospecific antibody" as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for LMP. "Homogeneous binding" as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with LMP, as described above. Monospecific antibodies to LMP are purified from mammalian antisera containing antibodies reactive against LMP or are prepared as monoclonal antibodies reactive with LMP using the technique of Kohler and Milstein, Nature, 256:495-97 (1975). The LMP specific antibodies are raised by immunizing animals such as, for example, mice, rats, guinea

pigs, rabbits, goats or horses, with an appropriate concentration of LMP either with or without an immune adjuvant.

In this process, preimmune serum is collected prior to the first immunization. Each animal receives between about 0.1 mg and about 1000 mg of LMP associated with an acceptable immune adjuvant, if desired. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing *Corynebacterium parvum* and tRNA adjuvants. The initial immunization consists of LMP in, preferably, Freund's complete adjuvant injected at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. Those animals receiving booster injections are generally given an equal amount of the antigen in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20° C.

Monoclonal antibodies (mAb) reactive with LMP are prepared by immunizing inbred mice, preferably Balb/c mice, with LMP. The mice are immunized by the IP or SC route with about 0.1 mg to about 10 mg, preferably about 1 mg, of LMP in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3-30 weeks. Immunized mice are given one or more booster immunizations of about 0.1 to about 10 mg of LMP in a buffer solution such as phosphate buffered saline by the intravenous (IV) route. Lymphocytes from antibody-positive mice, preferably splenic lymphocytes, are obtained by removing the spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions

which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NS1/Ag 4-1; MPC-11; S-194 and Sp 2/0, with Sp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin in supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21, and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using LMP as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, "Soft Agar Techniques", in Tissue Culture Methods and Applications, Kruse and Paterson (eds.), Academic Press (1973). See, also, Harlow *et al.*, Antibodies: A Laboratory Manual, Cold Spring Laboratory (1988).

Monoclonal antibodies may also be produced *in vivo* by injection of pristane- primed Balb/c mice, approximately 0.5 ml per mouse, with about 2×10^6 to about 6×10^6 hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.

In vitro production in anti-LMP mAb is carried out by growing the hybridoma cell line in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.

Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays, which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays

are used to detect the presence of the LMP in body fluids or tissue and cell extracts.

It is readily apparent to those skilled in the art that the above described methods for producing monospecific antibodies may be utilized to produce
5 antibodies specific for polypeptide fragments of LMP, full-length nascent LMP polypeptide, or variants or alleles thereof.

In another embodiment, the invention is directed to alternative splice variants of HLMP-1. PCR analysis of human heart cDNA revealed mRNA for two HLMP alternative splice variants, named HLMP-2 and HLMP-3, that differ
10 from HLMP-1 in a region between base pairs 325 and 444 in the hLMP-1 sequence. The HLMP-2 sequence has a 119 base pair deletion and an insertion of 17 base pairs in this region. These changes preserve the reading frame, resulting in a 423 amino acid protein, which compared to HLMP-1, has a
15 net loss of 34 amino acids (40 amino acids deleted plus 6 inserted amino acids). HLMP-2 contains the c-terminal LIM domains that are present in HLMP-1.

Compared to HLMP-1, HLMP-3 has no deletions, but it does have the same 17 base pair insertion at position 444. This insertion shifts the reading frame, causing a stop codon at base pairs 459-461. As a result, HLMP-3
20 encodes a protein of 153 amino acids. This protein lacks the c-terminal LIM domains that are present in HLMP-1 and HLMP-2. The predicted size of the proteins encoded by HLMP-2 and HLMP-3 was confirmed by western blot analysis.

PCR analysis of the tissue distribution of the three splice variants
25 revealed that they are differentially expressed, with specific isoforms predominating in different tissues. HLMP-1 is apparently the predominant form expressed in leukocytes, spleen, lung, placenta, and fetal liver. HLMP-2 appears to be the predominant isoform in skeletal muscle, bone marrow, and heart tissue. HLMP-3, however, was not the predominant isoform in any tissue
30 examined.

Overexpression of HLMP-3 in secondary rat osteoblast cultures induced bone nodule formation (287 ± 56) similar to the effect seen for glucicorticoid (272 ± 7) and HLMP-1 (232 ± 200). Since HLMP-3 lacks the C-terminal LIM domains, these regions are not required for osteoinductive activity.

5 Overexpression of HLMP-2, however, did not induce nodule formation (11 ± 3). These data suggest that the amino acids encoded by the deleted 119 base pairs are necessary for osteoinduction. The data also suggest that the distribution of HLMP splice variants may be important for tissue-specific function. Surprisingly, we have shown that HLMP-2 inhibits steroid-induced
10 osteoblast formation in secondary rat osteoblast cultures. Therefore, HLMP-2 will have therapeutic utility in clinical situations where bone formation is not desirable.

On July 22, 1997, a sample of 10-4/RLMP in a vector designated pCMV2/RLMP (which is vector pRc/CMV2 with insert 10-4 clone/RLMP) was
15 deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852. The culture accession number for that deposit is 209153. On March 19, 1998, a sample of the vector pHis-A with insert HLPM-1s was deposited at the American Type Culture Collection ("ATCC"). The culture accession number for that deposit is 209698. On April 14, 2000,
20 samples of plasmids pHAhLMP-2 (vector pHisA with cDNA insert derived from human heart muscle cDNA with HLMP-2) and pHAhLMP-3 (vector pHisA with cDNA insert derived from human heart muscle cDNA with HLMP-3) were deposited with the ATCC, 10801 University Blvd., Manassas, VA, 20110-2209, USA, under the conditions of the Budapest treaty. The accession numbers for
25 these deposits are _____ and _____, respectively. These deposits, as required by the Budapest Treaty, will be maintained in the ATCC for at least 30 years and will be made available to the public upon the grant of a patent disclosing them. It should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent
30 rights granted by government action.

In assessing the nucleic acids, proteins, or antibodies of the invention, enzyme assays, protein purification, and other conventional biochemical methods are employed. DNA and RNA are analyzed by Southern blotting and Northern blotting techniques, respectively. Typically, the samples analyzed are size fractionated by gel electrophoresis. The DNA or RNA in the gels are then transferred to nitrocellulose or nylon membranes. The blots, which are replicas of sample patterns in the gels, were then hybridized with probes. Typically, the probes are radiolabelled, preferably with ^{32}P , although one could label the probes with other signal-generating molecules known to those in the art. Specific bands of interest can then be visualized by detection systems, such as autoradiography.

For purposes of illustrating preferred embodiments of the present invention, the following, non-limiting examples are included. These results demonstrate the feasibility of inducing or enhancing the formation of bone using the LIM mineralization proteins of the invention, and the isolated nucleic acid molecules encoding those proteins.

Example 1: Calvarial Cell Culture

Rat calvarial cells, also known as rat osteoblasts ("ROB"), were obtained from 20-day pre-parturition rats as previously described. Boden *et al.*, Endocrinology, 137(8):3401-07 (1996). Primary cultures were grown to confluence (7 days), trypsinized, and passed into 6-well plates (1×10^5 cells/35 mm well) as first subculture cells. The subculture cells, which were confluent at day 0, were grown for an additional 7 days. Beginning on day 0, media were changed and treatments (Tm and/or BMPs) were applied, under a laminar flow hood, every 3 or 4 days. The standard culture protocol was as follows: days 1-7, MEM, 10% FBS, 50 g/ml ascorbic acid, \pm stimulus; days 8-14, BGJb medium, 10% FBS, 5mM -GlyP (as a source of inorganic phosphate to permit mineralization). Endpoint analysis of bone nodule formation and osteocalcin secretion was performed at day 14. The dose of BMP was chosen as 50 ng/ml

based on pilot experiments in this system that demonstrated a mid-range effect on the dose-response curve for all BMPs studied.

EXAMPLE 2: Antisense Treatment and Cell Culture

5

To explore the potential functional role of LMP-1 during membranous bone formation, we synthesized an antisense oligonucleotide to block LMP-1 mRNA translation and treated secondary osteoblast cultures that were undergoing differentiation initiated by glucocorticoid. Inhibition of RLMP
10 expression was accomplished with a highly specific antisense oligonucleotide (having no significant homologies to known rat sequences) corresponding to a 25 bp sequence spanning the putative translational start site (SEQ ID NO: 42). Control cultures either did not receive oligonucleotide or they received sense oligonucleotide. Experiments were performed in the presence (preincubation)
15 and absence of lipofectamine. Briefly, 22 g of sense or antisense RLMP oligonucleotide was incubated in MEM for 45 minutes at room temperature. Following that incubation, either more MEM or pre-incubated lipofectamine/MEM (7% v/v; incubated 45 minutes at room temperature) was added to achieve an oligonucleotide concentration of 0.2 M. The resulting
20 mixture was incubated for 15 minutes at room temperature. Oligonucleotide mixtures were then mixed with the appropriate medium, that is, MEM/Ascorbate/ \pm Trm, to achieve a final oligonucleotide concentration of 0.1 M.

Cells were incubated with the appropriate medium (\pm stimulus) in the
25 presence or absence of the appropriate oligonucleotides. Cultures originally incubated with lipofectamine were re-fed after 4 hours of incubation (37°C; 5% CO₂) with media containing neither lipofectamine nor oligonucleotide. All cultures, especially cultures receiving oligonucleotide, were re-fed every 24 hours to maintain oligonucleotide levels.

30 LMP-1 antisense oligonucleotide inhibited mineralized nodule formation and osteocalcin secretion in a dose-dependent manner, similar to the effect of

BMP-6 oligonucleotide. The LMP-1 antisense block in osteoblast differentiation could not be rescued by addition of exogenous BMP-6, while the BMP-6 antisense oligonucleotide inhibition was reversed with addition of BMP-6. This experiment further confirmed the upstream position of LMP-1 relative to BMP-6 in the osteoblast differentiation pathway. LMP-1 antisense oligonucleotide also inhibited spontaneous osteoblast differentiation in primary rat osteoblast cultures.

EXAMPLE 3: Quantitation of Mineralized Bone Nodule Formation

10

Cultures of ROBs prepared according to Examples 1 and 2 were fixed overnight in 70% ethanol and stained with von Kossa silver stain. A semi-automated computerized video image analysis system was used to quantitate nodule count and nodule area in each well. Boden *et al.*, Endocrinology, 137(8):3401-07 (1996). These values were then divided to calculate the area per nodule values. This automated process was validated against a manual counting technique and demonstrated a correlation coefficient of 0.92 ($p < 0.000001$). All data are expressed as the mean \pm standard error of the mean (S.E.M.) calculated from 5 or 6 wells at each condition. Each experiment was confirmed at least twice using cells from different calvarial preparations.

EXAMPLE 4: Quantitation of Osteocalcin Secretion

Osteocalcin levels in the culture media were measured using a competitive radioimmunoassay with a monospecific polyclonal antibody (Pab) raised in our laboratory against the C-terminal nonapeptide of rat osteocalcin as described in Nanes *et al.*, Endocrinology, 127:588 (1990). Briefly, 1 g of nonapeptide was iodinated with 1 mCi ^{125}I -Na by the lactoperoxidase method. Tubes containing 200 l of assay buffer (0.02 M sodium phosphate, 1 mM EDTA, 0.001% thimerosal, 0.025% BSA) received media taken from cell cultures or osteocalcin standards (0 - 12,000 fmole) at 100 l/tube in assay

buffer. The Pab (1:40,000; 100 l) was then added, followed by the iodinated peptide (12,000 cpm; 100 l). Samples tested for non-specific binding were prepared similarly but contained no antibody.

Bound and free PABs were separated by the addition of 700 l goat anti-rabbit IgG, followed by incubation for 18 hours at 4°C. After samples were centrifuged at 1200 rpm for 45 minutes, the supernatants were decanted and the precipitates counted in a gamma counter. Osteocalcin values were reported in fmole/100 l, which was then converted to pmole/ml medium (3-day production) by dividing those values by 100. Values were expressed as the mean \pm S.E.M. of triplicate determinations for 5-6 wells for each condition. Each experiment was confirmed at least two times using cells from different calvarial preparations.

EXAMPLE 5: Effect of Trm and RLMP on Mineralization *In Vitro*

15

There was little apparent effect of either the sense or antisense oligonucleotides on the overall production of bone nodules in the non-stimulated cell culture system. When ROB's were stimulated with Trm, however, the antisense oligonucleotide to RLMP inhibited mineralization of nodules by > 95%. The addition of exogenous BMP-6 to the oligonucleotide-treated cultures did not rescue the mineralization of RLMP-antisense-treated nodules.

Osteocalcin has long been synonymous with bone mineralization, and osteocalcin levels have been correlated with nodule production and mineralization. The RLMP-antisense oligonucleotide significantly decreases osteocalcin production, but the nodule count in antisense-treated cultures does not change significantly. In this case, the addition of exogenous BMP-6 only rescued the production of osteocalcin in RLMP-antisense-treated cultures by 10-15%. This suggests that the action of RLMP is downstream of, and more specific than, BMP-6.

EXAMPLE 6: Harvest and Purification of RNA

Cellular RNA from duplicate wells of ROBs (prepared according to
5 Examples 1 and 2 in 6-well culture dishes) was harvested using 4M guanidine
isothiocyanate (GIT) solution to yield statistical triplicates. Briefly, culture
supernatant was aspirated from the wells, which were then overlaid with 0.6
ml of GIT solution per duplicate well harvest. After adding the GIT solution, the
plates were swirled for 5-10 seconds (being as consistent as possible).
10 Samples were saved at -70°C for up to 7 days before further processing.

RNA was purified by a slight modification of standard methods
according to Sambrook *et al.*, Molecular Cloning: a Laboratory Manual, 2nd
Ed., chapter 7.19, Cold Spring Harbor Press (1989). Briefly, thawed samples
received 60 l 2.0 M sodium acetate (pH 4.0), 550 l phenol (water saturated)
15 and 150 l chloroform:isoamyl alcohol (49:1). After vortexing, the samples were
centrifuged (10000 x g; 20 minutes; 4°C), the aqueous phase transferred to a
fresh tube, 600 l isopropanol was added and the RNA precipitated overnight at
-20°C.

Following the overnight incubation, the samples were centrifuged
20 (10000 x g; 20 minutes) and the supernatant was aspirated gently. The pellets
were resuspended in 400 l DEPC-treated water, extracted once with
phenol:chloroform (1:1), extracted with chloroform:isoamyl alcohol (24:1) and
precipitated overnight at -20°C after addition of 40 l sodium acetate (3.0 M; pH
5.2) and 1.0 ml absolute ethanol. To recover the cellular RNA, the samples
25 were centrifuged (10000 x g; 20 min), washed once with 70% ethanol, air dried
for 5-10 minutes and resuspended in 20 l of DEPC-treated water. RNA
concentrations were calculated from optical densities that were determined
with a spectrophotometer.

EXAMPLE 7: Reverse Transcription-Polymerase Chain Reaction

Heated total RNA (5 g in 10.5 l total volume DEPC-H₂O at 65°C for 5 minutes) was added to tubes containing 4 l 5X MMLV-RT buffer, 2 l dNTPs, 2 l
5 dT17 primer (10 pmol/ml), 0.5 l RNAsin (40U/ml) and 1 l MMLV-RT (200 units/l). The samples were incubated at 37°C for 1 hour, then at 95°C for 5 minutes to inactivate the MMLV-RT. The samples were diluted by addition of 80 l of water.

Reverse-transcribed samples (5 l) were subjected to polymerase-chain
10 reaction using standard methodologies (50 l total volume). Briefly, samples were added to tubes containing water and appropriate amounts of PCR buffer, 25 mM MgCl₂, dNTPs, forward and reverse primers for glyceraldehyde 3-phosphate dehydrogenase (GAP, a housekeeping gene) and/or BMP-6), ³²P-dCTP, and Taq polymerase. Unless otherwise noted, primers were
15 standardized to run consistently at 22 cycles (94°C, 30"; 58°C, 30"; 72°C, 20").

EXAMPLE 8: Quantitation of RT-PCR Products by Polyacrylamide Gel Electrophoresis (PAGE) and PhosphorImager Analysis

20 RT-PCR products received 5 l/tube loading dye, were mixed, heated at 65°C for 10 min and centrifuged. Ten l of each reaction was subjected to PAGE (12% polyacrylamide:bis; 15 V/well; constant current) under standard conditions. Gels were then incubated in gel preserving buffer (10% v/v
25 glycerol, 7% v/v acetic acid, 40% v/v methanol, 43% deionized water) for 30 minutes, dried (80°C) *in vacuo* for 1-2 hours and developed with an electronically-enhanced phosphorescence imaging system for 6-24 hours. Visualized bands were analyzed. Counts per band were plotted graphically.

30

EXAMPLE 9: Differential Display PCR

RNA was extracted from cells stimulated with glucocorticoid (Trm, 1 nM). Heated, DNase-treated total RNA (5 g in 10.5 l total volume in DEPC-H₂O at 65°C for 5 minutes) was reverse transcribed as described in Example 7, but H-T₁₁M (SEQ ID. NO: 4) was used as the MMLV-RT primer. The resulting cDNAs were PCR-amplified as described above, but with various commercial primer sets (for example, H-T₁₁G (SEQ ID NO: 4) and H-AP-10 (SEQ ID. NO: 5); GenHunter Corp, Nashville, TN). Radiolabelled PCR products were fractionated by gel electrophoresis on a DNA sequencing gel. After electrophoresis, the resulting gels were dried *in vacuo* and autoradiographs were exposed overnight. Bands representing differentially-expressed cDNAs were excised from the gel and reamplified by PCR using the method of Conner *et al.*, Proc. Natl. Acad. Sci. USA, 88:278 (1983). The products of PCR reamplification were cloned into the vector PCR-II (TA cloning kit; InVitrogen, Carlsbad, CA).

EXAMPLE 10: Screening of a UMR 106 Rat Osteosarcoma Cell cDNA Library

A UMR 106 library (2.5×10^{10} pfu/ml) was plated at 5×10^4 pfu/ml onto agar plates (LB bottom agar) and the plates were incubated overnight at 37°C. Filter membranes were overlaid onto plates for two minutes. Once removed, the filters were denatured, rinsed, dried and UV cross-linked. The filters were then incubated in pre-hybridization buffer (2X PIPES [pH 6.5], 5% formamide, 1% SDS and 100 g/ml denatured salmon sperm DNA) for 2 h at 42°C. A 260 base-pair radiolabelled probe (SEQ ID NO: 3; ³²P labelled by random priming) was added to the entire hybridization mix/filters, followed by hybridization for 18 hours at 42°C. The membranes were washed once at room temperature (10 min, 1 x SSC, 0.1% SDS) and three times at 55°C (15 min, 0.1 x SSC, 0.1% SDS).

After they were washed, the membranes were analyzed by autoradiography as described above. Positive clones were plaque purified. The procedure was repeated with a second filter for four minutes to minimize spurious positives. Plaque-purified clones were rescued as lambda SK(-) phagemids. Cloned cDNAs were sequenced as described below.

EXAMPLE 11: Sequencing of Clones

Cloned cDNA inserts were sequenced by standard methods. Ausubel *et al.*, Current Protocols in Molecular Biology, Wiley Interscience (1988). Briefly, appropriate concentrations of termination mixture, template and reaction mixture were subjected to an appropriate cycling protocol (95°C,30s; 68°C,30s; 72°C,60s; x 25). Stop mixture was added to terminate the sequencing reactions. After heating at 92°C for 3 minutes, the samples were loaded onto a denaturing 6% polyacrylamide sequencing gel (29:1 acrylamide:bis-acrylamide). Samples were electrophoresed for about 4 hours at 60 volts, constant current. After electrophoresis, the gels were dried *in vacuo* and autoradiographed.

The autoradiographs were analyzed manually. The resulting sequences were screened against the databases maintained by the National Center for Biotechnology Information (NIH, Bethesda, MD; <http://www.ncbi.nlm.nih.gov/>) using the BLASTn program set with default parameters. Based on the sequence data, new sequencing primers were prepared and the process was repeated until the entire gene had been sequenced. All sequences were confirmed a minimum of three times in both orientations.

Nucleotide and amino acid sequences were also analyzed using the PCGENE software package (version 16.0). Per cent homology values for nucleotide sequences were calculated by the program NALIGN, using the following parameters: weight of non-matching nucleotides, 10; weight of non-matching gaps, 10; maximum number of nucleotides considered, 50; and minimum number of nucleotides considered, 50.

For amino acid sequences, per cent homology values were calculated using PALIGN. A value of 10 was selected for both the open gap cost and the unit gap cost.

5 EXAMPLE 12: Cloning of RLMP cDNA

The differential display PCR amplification products described in Example 9 contained a major band of approximately 260 base pairs. This sequence was used to screen a rat osteosarcoma (UMR 106) cDNA library.

- 10 Positive clones were subjected to nested primer analysis to obtain the primer sequences necessary for amplifying the full length cDNA. (SEQ. ID NOs: 11, 12, 29, 30 and 31) One of those positive clones selected for further study was designated clone 10-4.

- Sequence analysis of the full-length cDNA in clone 10-4, determined by
15 nested primer analysis, showed that clone 10-4 contained the original 260 base-pair fragment identified by differential display PCR. Clone 10-4 (1696 base pairs; SEQ ID NO: 2) contains an open reading frame of 1371 base pairs encoding a protein having 457 amino acids (SEQ ID NO: 1). The termination codon, TGA, occurs at nucleotides 1444-1446. The polyadenylation signal at
20 nucleotides 1675-1680, and adjacent poly(A)⁺ tail, was present in the 3' noncoding region. There were two potential N-glycosylation sites, Asn-Lys-Thr and Asn-Arg-Thr, at amino acid positions 113-116 and 257-259 in SEQ ID NO: 1, respectively. Two potential cAMP- and cGMP-dependent protein kinase phosphorylation sites, Ser and Thr, were found at amino acid positions 191
25 and 349, respectively. There were five potential protein kinase C phosphorylation sites, Ser or Thr, at amino acid positions 3, 115, 166, 219, 442. One potential ATP/GTP binding site motif A (P-loop), Gly-Gly-Ser-Asn-Asn-Gly-Lys-Thr, was determined at amino acid positions 272-279.

- In addition, two highly conserved putative LIM domains were found at
30 amino acid positions 341-391 and 400-451. The putative LIM domains in this newly identified rat cDNA clone showed considerable homology with the LIM

domains of other known LIM proteins. However, the overall homology with other rat LIM proteins was less than 25%. RLMP (also designated 10-4) has 78.5% amino acid homology to the human enigma protein (see U.S. Patent No. 5,504,192), but only 24.5% and 22.7% amino acid homology to its closest rat homologs, CLP-36 and RIT-18, respectively.

EXAMPLE 13: Northern Blot Analysis of RLMP Expression

Thirty μ g of total RNA from ROB cells, prepared according to Examples 1 and 2, was size fractionated by formaldehyde gel electrophoresis in 1% agarose flatbed gels and osmotically transblotted to nylon membranes. The blot was probed with a 600 base pair EcoR1 fragment of full-length 10-4 cDNA labeled with 32 P-dCTP by random priming.

Northern blot analysis showed a 1.7 kb mRNA species that hybridized with the RLMP probe. RLMP mRNA was up-regulated approximately 3.7-fold in ROB cells after 24 hours exposure to BMP-6. No up-regulation of RLMP expression was seen in BMP-2 or BMP-4-stimulated ROB cells at 24 hours.

EXAMPLE 14: Statistical Methods

For each reported nodule/osteocalcin result, data from 5-6 wells from a representative experiment were used to calculate the mean \pm S.E.M. Graphs may be shown with data normalized to the maximum value for each parameter to allow simultaneous graphing of nodule counts, mineralized areas and osteocalcin.

For each reported RT-PCR, RNase protection assay or Western blot analysis, data from triplicate samples of representative experiments, were used to determine the mean \pm S.E.M. Graphs may be shown normalized to either day 0 or negative controls and expressed as fold-increase above control values.

Statistical significance was evaluated using a one-way analysis of variance with post-hoc multiple comparison corrections of Bonferroni as appropriate. D. V. Huntsberger, "The Analysis of Variance," in Elements of Statistical Variance, P. Billingsley (ed.), pp. 298-330, Allyn & Bacon Inc.,
5 Boston, MA (1977) and Sigmastat, Jandel Scientific, Corte Madera, CA. Alpha levels for significance were defined as $p < 0.05$.

EXAMPLE 15: Detection of Rat LIM Mineralization Protein by Western Blot Analysis

10

Polyclonal antibodies were prepared according to the methods of England *et al.*, Biochim.Biophys. Acta, 623:171 (1980) and Timmer *et al.*, J. Biol. Chem., 268:24863 (1993).

HeLa cells were transfected with pCMV2/RLMP. Protein was harvested
15 from the transfected cells according to the method of Hair *et al.*, Leukemia Research, 20:1 (1996). Western Blot Analysis of native RLMP was performed as described by Towbin *et al.*, Proc. Natl. Acad. Sci. USA, 76:4350 (1979).

EXAMPLE 16: Synthesis of the Rat LMP-Unique (RLMPU) derived Human
20 PCR product

Based on the sequence of the rat LMP-1 cDNA, forward and reverse PCR primers (SEQ ID NOs: 15 and 16) were synthesized and a unique 223 base-pair sequence was PCR amplified from the rat LMP-1 cDNA. A similar
25 PCR product was isolated from human MG63 osteosarcoma cell cDNA with the same PCR primers.

RNA was harvested from MG63 osteosarcoma cells grown in T-75 flasks. Culture supernatant was removed by aspiration and the flasks were overlaid with 3.0 ml of GIT solution per duplicate, swirled for 5-10 seconds,
30 and the resulting solution was transferred to 1.5 ml eppendorf tubes (5 tubes with 0.6 ml/tube). RNA was purified by a slight modification of standard

methods, for example, see Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, chapter 7, page 19, Cold Spring Harbor Laboratory Press (1989) and Boden *et al.*, *Endocrinology*, 138:2820-28 (1997). Briefly, the 0.6 ml samples received 60 μ l 2.0 M sodium acetate (pH 4.0), 550 μ l water saturated phenol and 5 150 μ l chloroform:isoamyl alcohol (49:1). After addition of those reagents, the samples were vortexed, centrifuged (10000 x g; 20 min; 4°C) and the aqueous phase transferred to a fresh tube. Isopropanol (600 μ l) was added and the RNA was precipitated overnight at -20°C. The samples were centrifuged (10000 x g; 20 minutes) and the supernatant was aspirated gently. The pellets were 10 resuspended in 400 μ l of DEPC-treated water, extracted once with phenol:chloroform (1:1), extracted with chloroform:isoamyl alcohol (24:1) and precipitated overnight at -20°C in 40 μ l sodium acetate (3.0 M; pH 5.2) and 1.0 ml absolute ethanol. After precipitation, the samples were centrifuged (10000 x g; 20 min), washed once with 70% ethanol, air dried for 5-10 minutes and 15 resuspended in 20 μ l of DEPC-treated water. RNA concentrations were derived from optical densities.

Total RNA (5 μ g in 10.5 μ l total volume in DEPC-H₂O) was heated at 65°C for 5 minutes, and then added to tubes containing 4 μ l 5X MMLV-RT buffer, 2 μ l dNTPs, 2 μ l dT17 primer (10 pmol/ml), 0.5 μ l RNAsin (40 U/ml) and 1 μ l MMLV-RT 20 (200 units/ μ l). The reactions were incubated at 37°C for 1 hour. Afterward, the MMLV-RT was inactivated by heating at 95°C for 5 minutes. The samples were diluted by addition of 80 μ l water.

Transcribed samples (5 μ l) were subjected to polymerase-chain reaction using standard methodologies (50 μ l total volume). Boden *et al.*, *Endocrinology*, 25 138:2820-28 (1997); Ausubel *et al.*, "Quantitation of rare DNAs by the polymerase chain reaction", in *Current Protocols in Molecular Biology*, chapter 15.31-1, Wiley & Sons, Trenton, NJ (1990). Briefly, samples were added to tubes containing water and appropriate amounts of PCR buffer (25 mM MgCl₂, dNTPs, forward and reverse primers (for RLMPU; SEQ ID NOs: 15 and 16), 30 ³²P-dCTP, and DNA polymerase. Primers were designed to run consistently at

22 cycles for radioactive band detection and 33 cycles for amplification of PCR product for use as a screening probe (94°C, 30 sec, 58°C, 30 sec; 72°C, 20 sec).

- Sequencing of the agarose gel-purified MG63 osteosarcoma-derived
5 PCR product gave a sequence more than 95% homologous to the RLMPU PCR product. That sequence is designated HLMP unique region (HLMPU; SEQ ID NO: 6).

EXAMPLE 17: Screening of reverse-transcriptase-derived MG63 cDNA

10

- Screening was performed with PCR using specific primers (SEQ ID NOs: 16 and 17) as described in Example 7. A 717 base-pair MG63 PCR product was agarose gel purified and sequenced with the given primers (SEQ. ID NOs: 12, 15, 16, 17, 18, 27 and 28). Sequences were confirmed a
15 minimum of two times in both directions. The MG63 sequences were aligned against each other and then against the full-length rat LMP cDNA sequence to obtain a partial human LMP cDNA sequence (SEQ ID NO: 7).

EXAMPLE 18: Screening of a Human Heart cDNA Library

20

- Based on Northern blot experiments, it was determined that LMP-1 is expressed at different levels by several different tissues, including human heart muscle. A human heart cDNA library was therefore examined. The library was plated at 5×10^4 pfu/ml onto agar plates (LB bottom agar) and plates were
25 grown overnight at 37° C. Filter membranes were overlaid onto the plates for two minutes. Afterward, the filters denatured, rinsed, dried, UV cross-linked and incubated in pre-hybridization buffer (2X PIPES [pH 6.5]; 5% formamide, 1% SDS, 100 g/ml denatured salmon sperm DNA) for 2 h at 42°C. A radiolabelled, LMP-unique, 223 base-pair probe (^{32}P , random primer labelling;
30 SEQ ID NO: 6) was added and hybridized for 18 h at 42°C. Following hybridization, the membranes were washed once at room temperature (10 min,

1 x SSC, 0.1% SDS) and three times at 55°C (15 min, 0.1 x SSC, 0.1% SDS). Double-positive plaque-purified heart library clones, identified by autoradiography, were rescued as lambda phagemids according to the manufacturers' protocols (Stratagene, La Jolla, CA).

5 Restriction digests of positive clones yielded cDNA inserts of varying sizes. Inserts greater than 600 base-pairs in length were selected for initial screening by sequencing. Those inserts were sequenced by standard methods as described in Example 11.

 One clone, number 7, was also subjected to automated sequence
10 analysis using primers corresponding to SEQ ID NOs: 11-14, 16 and 27. The sequences obtained by these methods were routinely 97-100% homologous. Clone 7 (Partial Human LMP-1 cDNA from a heart library; SEQ. ID NO: 8) contained sequence that was more than 87% homologous to the rat LMP cDNA sequence in the translated region.

15

EXAMPLE 19: Determination of Full-Length Human LMP-1 cDNA

 Overlapping regions of the MG63 human osteosarcoma cell cDNA sequence and the human heart cDNA clone 7 sequence were used to align
20 those two sequences and derive a complete human cDNA sequence of 1644 base-pairs. NALIGN, a program in the PCGENE software package, was used to align the two sequences. The overlapping regions of the two sequences constituted approximately 360 base-pairs having complete homology except for a single nucleotide substitution at nucleotide 672 in the MG63 cDNA (SEQ ID
25 NO: 7) with clone 7 having an "A" instead of a "G" at the corresponding nucleotide 516 (SEQ ID NO: 8).

 The two aligned sequences were joined using SEQIN, another subprogram of PCGENE, using the "G" substitution of the MG63 osteosarcoma cDNA clone. The resulting sequence is shown in SEQ ID NO: 9. Alignment of
30 the novel human-derived sequence with the rat LMP-1 cDNA was accomplished with NALIGN. The full-length human LMP-1 cDNA sequence

(SEQ. ID NO: 9) is 87.3% homologous to the translated portion of rat LMP-1 cDNA sequence.

EXAMPLE 20: Determination of Amino Acid Sequence of Human LMP-1

5

The putative amino acid sequence of human LMP-1 was determined with the PCGENE subprogram TRANSL. The open reading frame in SEQ ID NO: 9 encodes a protein comprising 457 amino acids (SEQ. ID NO: 10). Using the PCGENE subprogram Align, the human LMP-1 amino acid sequence was
10 found to be 94.1% homologous to the rat LMP-1 amino acid sequence.

EXAMPLE 21: Determination of the 5 Prime Untranslated Region of the Human LMP cDNA

15 MG63 5' cDNA was amplified by nested RT-PCR of MG63 total RNA using a 5' rapid amplification of cDNA ends (5' RACE) protocol. This method included first strand cDNA synthesis using a lock-docking oligo (dT) primer with two degenerate nucleotide positions at the 3' end (Chenchik *et al.*,
CLONTECHniques, X:5 (1995); Borson *et al.*, PC Methods Applic., 2:144
20 (1993)). Second-strand synthesis is performed according to the method of Gubler *et al.*, Gene, 25:263 (1983), with a cocktail of *Escherichia coli* DNA polymerase I, RNase H, and *E. coli* DNA ligase. After creation of blunt ends with T4 DNA polymerase, double-stranded cDNA was ligated to the fragment
(5' -CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCCGGGCAGGT- 3')
25 (SEQ.ID NO: 19). Prior to RACE, the adaptor-ligated cDNA was diluted to a concentration suitable for Marathon RACE reactions (1:50). Adaptor-ligated double-stranded cDNA was then ready to be specifically cloned.

First-round PCR was performed with the adaptor-specific oligonucleotide, 5'-CCATCCTAATACGACTCACTATAGGGC- 3' (AP1) (SEQ.ID
30 NO: 20) as sense primer and a Gene Specific Primer (GSP) from the unique region described in Example 16 (HLMPU). The second round of PCR was

performed using a nested primers GSP1-HLMPU (antisense/reverse primer) (SEQ. ID NO: 23) and GSP2-HLMPUF (SEQ. ID NO: 24) (see Example 16; sense/forward primer). PCR was performed using a commercial kit (Advantage cDNA PCR core kit; CloneTech Laboratories Inc., Palo Alto, CA) that utilizes
5 an antibody-mediated, but otherwise standard, hot-start protocol. PCR conditions for MG63 cDNA included an initial hot-start denaturation (94°C, 60 sec) followed by: 94°C, 30 sec; 60°C, 30 sec; 68°C, 4 min; 30 cycles. The first-round PCR product was approximately 750 base-pairs in length whereas the nested PCR product was approximately 230 base-pairs. The first-round PCR
10 product was cloned into linearized pCR 2.1 vector (3.9 Kb). The inserts were sequenced in both directions using M13 Forward and Reverse primers (SEQ. ID NO: 11; SEQ. ID NO: 12)

EXAMPLE 22: Determination of Full-length Human LMP-1 cDNA with 5 Prime
15 UTR

Overlapping MG63 human osteosarcoma cell cDNA 5'-UTR sequence (SEQ ID NO: 21), MG63 717 base-pair sequence (Example 17; SEQ ID NO: 8) and human heart cDNA clone 7 sequence (Example 18) were aligned to derive
20 a novel human cDNA sequence of 1704 base-pairs (SEQ.ID NO: 22). The alignment was accomplished with NALIGN, (both PCGENE and Omiga 1.0; Intelligenetics). Over-lapping sequences constituted nearly the entire 717 base-pair region (Example 17) with 100% homology. Joining of the aligned sequences was accomplished with SEQIN.

25

EXAMPLE 23: Construction of LIM Protein Expression Vector

The construction of pHIS-5ATG LMP-1s expression vector was carried out with the sequences described in Examples 17 and 18. The 717 base-pair
30 clone (Example 17; SEQ ID NO: 7) was digested with ClaI and EcoRV. A small fragment (~250 base-pairs) was gel purified. Clone 7 (Example 18; SEQ

ID NO: 8) was digested with Clal and Xbal and a 1400 base-pair fragment was gel purified. The isolated 250 base-pair and 1400 base-pair restriction fragments were ligated to form a fragment of ~1650 base-pairs.

Due to the single nucleotide substitution in Clone 7 (relative to the 717
5 base-pair PCR sequence and the original rat sequence) a stop codon at translated base-pair 672 resulted. Because of this stop codon, a truncated (short) protein was encoded, hence the name LMP-1s. This was the construct used in the expression vector (SEQ ID NO: 32). The full length cDNA
10 sequence with 5' UTR (SEQ ID NO: 33) was created by alignment of SEQ ID NO: 32 with the 5' RACE sequence (SEQ ID NO: 21). The amino acid sequence of LMP-1s (SEQ ID NO: 34) was then deduced as a 223 amino acid protein and confirmed by Western blot (as in Example 15) to run at the predicted molecular weight of ~ 23.7 kD.

The pHis-ATG vector (InVitrogen, Carlsbad, CA) was digested with
15 EcoRV and Xbal. The vector was recovered and the 1650 base-pair restriction fragment was then ligated into the linearized pHis-ATG. The ligated product was cloned and amplified. The pHis-ATG-LMP-1s Expression vector, also designated pHis-A with insert HLMP-1s, was purified by standard methods.

20 EXAMPLE 24: Induction of Bone Nodule Formation and Mineralization *In vitro* with LMP Expression Vector

Rat Calvarial cells were isolated and grown in secondary culture according to Example 1. Cultures were either unstimulated or stimulated with
25 glucocorticoid (GC) as described in Example 1. A modification of the Superfect Reagent (Qiagen, Valencia, CA) transfection protocol was used to transfect 3 g/well of each vector into secondary rat calvarial osteoblast cultures according to Example 25.

Mineralized nodules were visualized by Von Kossa staining, as described in
30 Example 3. Human LMP-1s gene product overexpression alone induced bone nodule formation (~203 nodules/well) *in vitro*. Levels of nodules were

approximately 50% of those induced by the GC positive control (~412 nodules/well). Other positive controls included the pHisA-LMP-Rat expression vector (~152 nodules/well) and the pCMV2/LMP-Rat-Fwd Expression vector (~206 nodules/well), whereas the negative controls included the pCMV2/LMP-Rat-Rev. Expression vector (~2 nodules/well) and untreated (NT) plates (~4 nodules/well). These data demonstrate that the human cDNA was at least as osteoinductive as the rat cDNA. The effect was less than that observed with GC stimulation, most likely due to suboptimal doses of Expression vector.

10

EXAMPLE 25: LMP-Induced Cell Differentiation *In Vitro* and *In Vivo*

The rat LMP cDNA in clone 10-4 (see Example 12) was excised from the vector by double-digesting the clone with NotI and ApaI overnight at 37°C. Vector pCMV2 MCS (InVitrogen, Carlsbad, CA) was digested with the same restriction enzymes. Both the linear cDNA fragment from clone 10-4 and pCMV2 were gel purified, extracted and ligated with T4 ligase. The ligated DNA was gel purified, extracted and used to transform *E. coli* JM109 cells for amplification. Positive agar colonies were picked, digested with NotI and ApaI and the restriction digests were examined by gel electrophoresis. Stock cultures were prepared of positive clones.

A reverse vector was prepared in analogous fashion except that the restriction enzymes used were XbaI and HindIII. Because these restriction enzymes were used, the LMP cDNA fragment from clone 10-4 was inserted into pRc/CMV2 in the reverse (that is, non-translatable) orientation. The recombinant vector produced is designated pCMV2/RLMP.

An appropriate volume of pCMV10-4 (60 nM final concentration is optimal [3 g]; for this experiment a range of 0-600 nM/well [0-30 g/well] final concentration is preferred) was resuspended in Minimal Eagle Media (MEM) to 450 l final volume and vortexed for 10 seconds. Superfect was added (7.5 l/ml final solution), the solution was vortexed for 10 seconds and then incubated at

room temperature for 10 minutes. Following this incubation, MEM supplemented with 10% FBS (1 ml/well; 6 ml/plate) was added and mixed by pipetting.

5 The resulting solution was then promptly pipetted (1 ml/well) onto washed ROB cultures. The cultures were incubated for 2 hours at 37°C in a humidified atmosphere containing 5% CO₂. Afterward, the cells were gently washed once with sterile PBS and the appropriate normal incubation medium was added.

Results demonstrated significant bone nodule formation in all rat cell
10 cultures which were induced with pCMV10-4. For example, pCMV10-4 transfected cells produced 429 nodules/well. Positive control cultures, which were exposed to Trm, produced 460 nodules/well. In contrast, negative controls, which received no treatment, produced 1 nodule/well. Similarly, when
15 cultures were transfected with pCMV10-4 (reverse), no nodules were observed.

For demonstrating *de novo* bone formation *in vivo*, marrow was aspirated from the hindlimbs of 4-5 week old normal rats (rnu/+; heterozygous for recessive athymic condition). The aspirated marrow cells were washed in alpha MEM, centrifuged, and RBCs were lysed by resuspending the pellet in
20 0.83% NH₄Cl in 10 mM Tris (pH 7.4). The remaining marrow cells were washed 3x with MEM and transfected for 2 hours with 9 µg of pCMV-LMP-1s (forward or reverse orientation) per 3 x 10⁶ cells. The transfected cells were then washed 2X with MEM and resuspended at a concentration of 3 x 10⁷ cells/ml.

25 The cell suspension (100 µl) was applied via sterile pipette to a sterile 2 x 5 mm type I bovine collagen disc (Sulzer Orthopaedics, Wheat Ridge, CO). The discs were surgically implanted subcutaneously on the skull, chest, abdomen or dorsal spine of 4-5 week old athymic rats (rnu/rnu). The animals were scarified at 3-4 weeks, at which time the discs or surgical areas were
30 excised and fixed in 70% ethanol. The fixed specimens were analyzed by radiography and undecalcified histologic examination was performed on 5 m

thick sections stained with Goldner Trichrome. Experiments were also performed using devitalized (guanidine extracted) demineralized bone matrix (Osteotech, Shrewsbury, NJ) in place of collagen discs.

Radiography revealed a high level of mineralized bone formation that conformed to the form of the original collagen disc containing LMP-1s transfected marrow cells. No mineralized bone formation was observed in the negative control (cells transfected with a reverse-oriented version of the LMP-1s cDNA that did not code for a translated protein), and absorption of the carrier appeared to be well underway.

Histology revealed new bone trabeculae lined with osteoblasts in the LMP-1s transfected implants. No bone was seen along with partial resorption of the carrier in the negative controls.

Radiography of a further experiment in which 18-sets (9 negative control pCMV-LMP-REV & 9 experimental pCMV-LMP-1s) of implants were added to sites alternating between lumbar and thoracic spine in athymic rats demonstrated 0/9 negative control implants exhibiting bone formation (spine fusion) between vertebrae. All nine of the pCMV-LMP-1s treated implants exhibited solid bone fusions between vertebrae.

EXAMPLE 26: The Synthesis of pHIS-5' ATG LMP-1s Expression Vector from the sequences Demonstrated in Examples 2 and 3.

The 717 base-pair clone (Example 17) was digested with Clal and EcoRV (New England Biologicals, city, MA). A small fragment (~250 base-pairs) was gel purified. Clone No. 7 (Example 18) was digested with Clal and XbaI. A 1400 base-pair fragment was gel purified from that digest. The isolated 250 base-pair and 1400 base-pair cDNA fragments were ligated by standard methods to form a fragment of ~1650 bp. The pHIS-A vector (InVitrogen) was digested with EcoRV and XbaI. The linearized vector was recovered and ligated to the chimeric 1650 base-pair cDNA fragment. The ligated product was cloned and amplified by standard methods, and the pHIS-

A-5' ATG LMP-1s expression vector, also denominated as the vector pHis-A with insert HLMP-1s, was deposited at the ATCC as previously described.

EXAMPLE 27: The Induction of Bone Nodule Formation and Mineralization *In*

5 *Vitro* With pHis-5' ATG LMP-1s Expression Vector

Rat calvarial cells were isolated and grown in secondary culture according to Example 1. Cultures were either unstimulated or stimulated with glucocorticoid (GC) according to Example 1. The cultures were transfected
10 with 3 g of recombinant pHis-A vector DNA/well as described in Example 25. Mineralized nodules were visualized by Von Kossa staining according to Example 3.

Human LMP-1s gene product overexpression alone (*i.e.*, without GC stimulation) induced significant bone nodule formation (~203 nodules/well) *in*
15 *vitro*. This is approximately 50% of the amount of nodules produced by cells exposed to the GC positive control (~412 nodules/well). Similar results were obtained with cultures transfected with pHisA-LMP-Rat Expression vector (~152 nodules/well) and pCMV2/LMP-Rat-Fwd (~206 nodules/well). In contrast, the negative control pCMV2/LMP-Rat-Rev yielded (~2 nodules/well),
20 while approximately 4 nodules/well were seen in the untreated plates. These data demonstrate that the human LMP-1 cDNA was at least as osteoinductive as the rat LMP-1 cDNA in this model system. The effect in this experiment was less than that observed with GC stimulation; but in some the effect was comparable.

25

EXAMPLE 28: LMP Induces Secretion of a Soluble Osteoinductive Factor

Overexpression of RLMP-1 or HLMP-1s in rat calvarial osteoblast cultures as described in Example 24 resulted in significantly greater nodule
30 formation than was observed in the negative control. To study the mechanism of action of LIM mineralization protein conditioned medium was harvested at

different time points, concentrated to 10 X, sterile filtered, diluted to its original concentration in medium containing fresh serum, and applied for four days to untransfected cells.

Conditioned media harvested from cells transfected with RLMP-1 or
5 HLMP-1s at day 4 was approximately as effective in inducing nodule formation as direct overexpression of RLMP-1 in transfected cells. Conditioned media from cells transfected with RLMP-1 or HLMP-1 in the reverse orientation had no apparent effect on nodule formation. Nor did conditioned media harvested from LMP-1 transfected cultures before day 4 induce nodule formation. These
10 data suggest that expression of LMP-1 caused the synthesis and/or secretion of a soluble factor, which did not appear in culture medium in effective amounts until 4 days post transfection.

Since overexpression of rLMP-1 resulted in the secretion of an osteoinductive factor into the medium, Western blot analysis was used to
15 determine if LMP-1 protein was present in the medium. The presence of rLMP-1 protein was assessed using antibody specific for LMP-1 (QDPDEE) and detected by conventional means. LMP-1 protein was found only in the cell layer of the culture and not detected in the medium.

Partial purification of the osteoinductive soluble factor was accomplished
20 by standard 25% and 100% ammonium sulfate cuts followed by DE-52 anion exchange batch chromatography (100 mM or 500 mM NaCl). All activity was observed in the high ammonium sulfate, high NaCl fractions. Such localization is consistent with the possibility of a single factor being responsible for conditioning the medium.

25

EXAMPLE 29: Gene Therapy In Lumbar Spine Fusion Mediated by Low Dose Adenovirus

This study determined the optimal dose of adenoviral delivery of the
30 LMP-1 cDNA (SEQ ID NO: 2) to promote spine fusion in normal, that is, immune competent, rabbits.

A replication-deficient human recombinant adenovirus was constructed with the LMP-1 cDNA (SEQ ID NO: 2) driven by a CMV promoter using the Adeno-Quest™ Kit (Quantum Biotechnologies, Inc., Montreal). A commercially available (Quantum Biotechnologies, Inc., Montreal) recombinant adenovirus containing the beta-galactosidase gene was used as a control.

Initially, an *in vitro* dose response experiment was performed to determine the optimal concentration of adenovirus-delivered LMP-1 ("AdV-LMP-1") to induce bone differentiation in rat calvarial osteoblast cultures using a 60-minute transduction with a multiplicity of infection ("MOI") of 0.025, 0.25, 2.5, or 25 plaque-forming units (pfu) of virus per cell. Positive control cultures were differentiated by a 7-day exposure to 10^{-9} M glucocorticoid ("GC"). Negative control cultures were left untreated. On day 14, the number of mineralized bone nodules was counted after von Kossa staining of the cultures, and the level of osteocalcin secreted into the medium (pmol/mL) was measured by radioimmunoassay (mean \pm SEM).

The results of this experiment are shown in Table I. Essentially no spontaneous nodules formed in the untreated negative control cultures. The data show that a MOI equal to 0.25 pfu/cell is most effective for osteoinducing bone nodules, achieving a level comparable to the positive control (GC). Lower and higher doses of adenovirus were less effective.

TABLE I

Outcome	AdV-LMP-1 Dose (MOI)					
	Neg. Ctrl.	GC	0.025	0.25	2.5	25
Bone Nodules	0.5 \pm 0.2	188 \pm 35	79.8 \pm 13	145.1 \pm 13	26.4 \pm 15	87.6 \pm 2
Osteocalcin	1.0 \pm 0.1	57.8 \pm 9	28.6 \pm 11	22.8 \pm 1	18.3 \pm 3	26.0 \pm 2

In vivo experiments were then performed to determine if the optimal *in vitro* dose was capable of promoting intertransverse process spine fusions in skeletally mature New Zealand white rabbits. Nine rabbits were anesthetized and 3 cc of bone marrow was aspirated from the distal femur through the intercondylar notch using an 18 gauge needle. The buffy coat was then isolated, a 10-minute transduction with AdV-LMP-1 was performed, and the cells were returned to the operating room for implantation. Single level posterolateral lumbar spine arthrodesis was performed with decortication of transverse processes and insertion of carrier (either rabbit devitalized bone matrix or a collagen sponge) containing 8-15 million autologous nucleated buffy coat cells transduced with either AdV-LMP-1 (MOI = 0.4) or AdV-BGal (MOI = 0.4). Rabbits were euthanized after 5 weeks and spine fusions were assessed by manual palpation, plain x-rays, CT scans, and undecalcified histology.

The spine fusion sites that received AdV-LMP-1 induced solid, continuous spine fusion masses in all nine rabbits. In contrast, the sites receiving AdV-BGal, or a lower dose of AdV-LMP-1 (MOI = 0.04) made little or no bone and resulted in spine fusion at a rate comparable to the carrier alone (< 40%). These results were consistent as evaluated by manual palpation, CT scan, and histology. Plain radiographs, however, sometimes overestimated the amount of bone that was present, especially in the control sites. LMP-1 cDNA delivery and bone induction was successful with both of the carrier materials tested. There was no evidence of systemic or local immune response to the adenovirus vector.

These data demonstrate consistent bone induction in a previously validated rabbit spine fusion model which is quite challenging. Furthermore, the protocol of using autogenous bone marrow cells with intraoperative *ex vivo* gene transduction (10 minutes) is a more clinically feasible procedure than other methods that call for overnight transduction or cell expansion for weeks in culture. In addition, the most effective dose of recombinant adenovirus (MOI=0.25) was substantially lower than doses reported in other gene therapy

applications (MOI-40-500). We believe this is due to the fact that LMP-1 is an intracellular signaling molecule and may have powerful signal amplification cascades. Moreover, the observation that the same concentration of AdV-LMP-1 that induced bone in cell culture was effective *in vivo* was also surprising given the usual required increase in dose of other growth factors when translating from cell culture to animal experiments. Taken together, these observations indicate that local gene therapy using adenovirus to deliver the LMP-1 cDNA is possible and the low dose required will likely minimize the negative effects of immune response to the adenovirus vector.

EXAMPLE 30: Use of Peripheral Venous Blood Nucleated Cells (Buffy Coat) for Gene Therapy With LMP-1 cDNA To Make Bone

In four rabbits we performed spine fusion surgery as above (Example 29) except the transduced cells were the buffy coat from venous blood rather than bone marrow. These cells were transfected with Adeno-LMP or pHIS-LMP plasmid and had equivalent successful results as when bone marrow cells were used. This discovery of using ordinary venous blood cells for gene delivery makes gene therapy more feasible clinically since it avoids painful marrow harvest under general anesthesia and yields two times more cells per mL of starting material.

EXAMPLE 31: Isolation of Human LMP-1 Splice Variants

Intron/Exon mRNA transcript splice variants are a relatively common regulatory mechanism in signal transduction and cellular/tissue development. Splice variants of various genes have been shown to alter protein-protein, protein-DNA, protein-RNA, and protein-substrate interactions. Splice variants may also control tissue specificity for gene expression allowing different forms (and therefore functions) to be expressed in various tissues. Splice variants are a common regulatory phenomenon in cells. It is possible that the LMP

splice variants may result in effects in other tissues such as nerve regeneration, muscle regeneration, or development of other tissues.

To screen a human heart cDNA library for splice variants of the HLMP-1 sequence, a pair of PCR primer corresponding to sections of SEQ ID NO: 22 was prepared. The forward PCR primer, which was synthesized using standard techniques, corresponds to nucleotides 35-54 of SEQ ID NO: 22. It has the following sequence:

5' GAGCCGGCATCATGGATTCC 3' (SEQ ID NO: 35)

10

The reverse PCR primer, which is the reverse complement of nucleotides 820-839 in SEQ ID NO: 22, has the following sequence:

5' GCTGCCTGCACAATGGAGGT 3' (SEQ ID NO: 36)

15

The forward and reverse PCR primers were used to screen human heart cDNA (ClonTech, Cat No. 7404-1) for sequences similar to HLMP-1 by standard techniques, using a cycling protocol of 94°C for 30 seconds, 64°C for 30 seconds, and 72°C for 1 minute, repeated 30 times and followed by a 10 minute incubation at 72°C. The amplification cDNA sequences were gel-purified and submitted to the Emory DNA Sequence Core Facility for sequencing. The clones were sequenced using standard techniques and the sequences were examined with PCGENE (Intelligenetics; Programs SEQUIN and NALIGN) to determine homology to SEQ ID NO: 22. Two homologous nucleotide sequences with putative alternative splice sites compared to SEQ ID NO: 22 were then translated to their respective protein products with Intelligenetic's program TRANSL.

25

One of these two novel human cDNA sequences (SEQ ID NO: 37) comprises 1456 bp:

30

10 20 30 40 50 60

CGACGCAGAG CAGCGCCCTG GCCGGGCCAA GCAGGAGCCG GCATCATGGA TTCCTTCAAG
 70 80 90 100 110 120
 GTAGTGCTGG AGGGGCCAGC ACCTTGGGGC TTCCGGCTGC AAGGGGGCAA GGAATTCAAT
 130 140 150 160 170 180
 5 GTGCCCCCTCT CCATTTCCCG GCTCACTCCT GGGGGCAAAG CGGCGCAGGC CGGAGTGGCC
 190 200 210 220 230 240
 GTGGGTGACT GGGTGCTGAG CATCGATGGC GAGAATGCGG GTAGCCTCAC ACACATCGAA
 250 260 270 280 290 300
 GCTCAGAACA AGATCCGGGC CTGCGGGGAG CGCCTCAGCC TGGGCCTCAG CAGGGCCCAG
 10 310 320 * 330 340 * 350 360
 CCGGTTTCAGA GCAAACCGCA GAAGGTGCAG ACCCCTGACA AACAGCCGCT CCGACCGCTG
 370 380 390 400 410 420
 GTCCCAGATG CCAGCAAGCA GCGGCTGATG GAGAACACAG AGGACTGGCG GCCGCGGCCG
 430 440 450 460 470 480
 15 GGGACAGGCC AGTCGCGTTC CTTCCGCATC CTTGCCCACC TCACAGGCAC CGAGTTCATG
 490 500 510 520 530 540
 CAAGACCCGG ATGAGGAGCA CCTGAAGAAA TCAAGCCAGG TGCCAGGAC AGAAGCCCCA
 550 560 570 580 590 600
 GCCCCAGCCT CATCTACACC CCAGGAGCCC TGGCCTGGCC CTACCGCCCC CAGCCCTACC
 20 610 620 630 640 650 660
 AGCCGCCCCG CCTGGGCTGT GGACCCTGCG TTTGCCGAGC GCTATGCCCC GGACAAAACG
 670 680 690 700 710 720
 AGCACAGTGC TGACCCGGCA CAGCCAGCCG GCCACGCCCA CGCCGCTGCA GAGCCGCACC
 730 740 750 760 770 780
 25 TCCATTGTGC AGGCAGCTGC CGGAGGGGTG CCAGGAGGGG GCAGCAACAA CGGCAAGACT
 790 800 810 820 830 840
 CCCGTGTGTC ACCAGTGCCA CAAGGTCATC CGGGGCCGCT ACCTGGTGGC GTTGGGCCAC
 850 860 870 880 890 900

```

      GCGTACCACC CGGAGGAGTT TGTGTGTAGC CAGTGTGGGA AGGTCCTGGA AGAGGGTGGC
          910          920          930          940          950          960
      TTCTTTGAGG AGAAGGGCGC CATCTTCTGC CCACCATGCT ATGACGTGCG CTATGCACCC
          970          980          990         1000         1010         1020
5      AGCTGTGCCA AGTGCAAGAA GAAGATTACA GGCGAGATCA TGCACGCCCT GAAGATGACC
          1030         1040         1050         1060         1070         1080
      TGGCACGTGC ACTGCTTTAC CTGTGCTGCC TGCAAGACGC CCATCCGGAA CAGGGCCTTC
          1090         1100         1110         1120         1130         1140
      TACATGGAGG AGGGCGTGCC CTATTGCGAG CGAGACTATG AGAAGATGTT TGGCACGAAA
10          1150         1160         1170         1180         1190         1200
      TGCCATGGCT GTGACTTCAA GATCGACGCT GGGGACCGCT TCCTGGAGGC CCTGGGCTTC
          1210         1220         1230         1240         1250         1260
      AGCTGGCATG ACACCTGCTT CGTCTGTGCG ATATGTCAGA TCAACCTGGA AGGAAAGACC
          1270         1280         1290         1300         1310         1320
15      TTCTACTCCA AGAAGGACAG GCCTCTCTGC AAGAGCCATG CCTTCTCTCA TGTGTGAGCC
          1330         1340         1350         1360         1370         1380
      CCTTCTGCCC ACAGCTGCCG CGGTGGCCCC TAGCCTGAGG GGCCTGGAGT CGTGGCCCTG
          1390         1400         1410         1420         1430         1440
      CATTTCTGGG TAGGGCTGGC AATGGTTGCC TTAACCCTGG CTCCTGGCCC GAGCCTGGGC
20          1450
      TCCCGGGCCC TGCCCA

```

Reading frame shifts caused by the deletion of a 119 bp fragment
 (between *) and the addition of a 17 bp fragment (underlined) results in a
 25 truncated gene product having the following derived amino acid sequence
 (SEQ ID NO: 38):

```

      10          20          30          40          50          60

```

MDSFKVVLEG PAPWGFRLQG GKDFNVPLSI SRLTPGGKAA QAGVAVGDWV LSIDGENAGS
 70 80 90 100 110 120
 LTHIEAQNKI RACGERLSLG LSRAQPVQNK POKVQTPDKQ PLRPLVPDAS KQRLMENTED
 130 140 150 160 170 180
 5 WRPRPGTGQS RSFRILAHLT GTEFMQDPDE EHLKSSQVP RTEAPAPASS TPQEPWPGPT
 190 200 210 220 230 240
 APSPTSRPPW AVDPFAERY APDKTSTVLT RHSQPATPTP LQSRTSIVQA AAGGVPGGGS
 250 260 270 280 290 300
 NNGKTPVCHQ CHQVIRARYL VALGHAYHPE EFVCSQCGKV LEEGGFFEEK GAIFCPPCYD
 10 310 320 330 340 350 360
 VRYAPSCAKC KKKITGEIMH ALKMTWHVLC FTCAACKTPI RNRAFYMEEG VPYCERDYEK
 370 380 390 400 410 420
 MFGTKCQWCD FKIDAGDRFL EALGFSWHD TCFVCAICQIN LEGKTFYSKK DRPLCKSHAF
 SHV

15 This 423 amino acid protein demonstrates 100% homology to the
 protein shown in Sequence ID No. 10, except for the sequence in the
 highlighted area (amino acids 94-99), which are due to the nucleotide changes
 depicted above.

The second novel human heart cDNA sequence (SEQ ID NO: 39)
 20 comprises 1575 bp:

10 20 30 40 50 60
 CGACGCAGAG CAGCGCCCTG GCCGGGCCAA GCAGGAGCCG GCATCATGGA TTCCTTCAAG
 70 80 90 100 110 120
 25 GTAGTGCTGG AGGGGCCAGC ACCTTGGGGC TTCCGGCTGC AAGGGGGCAA GGA CTTC AAT
 130 140 150 160 170 180
 GTGCCCTCT CCATTTCCCG GCTCACTCCT GGGGGCAAAG CGGCGCAGGC CGGAGTGGCC
 190 200 210 220 230 240

GTGGGTGACT GGGTGCTGAG CATCGATGGC GAGAATGCGG GTAGCCTCAC ACACATCGAA
250 260 270 280 290 300
GCTCAGAACAA AGATCCGGGC CTGCGGGGAG CGCCTCAGCC TGGGCCTCAG CAGGGCCAG
310 320 330 340 350 360
5 CCGGTTTCTCAGA GCAAACCGCA GAAGGCCTCC GCGGACCTCC GCGGTACACC
370 380 390 400 410 420
TTTGACCCCA GCGTCTCCCT CAACAAGACG GCGGCGCCCT TTGGGGCGCC CCCGCCCGCT
430 440 450 460 470 480
GACAGCGCCC CGCAACAGAA TGGGTGAGAG CCCCTGACAA ACAGCCGCTC CGACCGCTGG
10 490 500 510 520 530 540
TCCCAGATGC CAGCAAGCAG CGGCTGATGG AGAACACAGA GGACTGGCGG CCGCGGCCGG
550 560 570 580 590 600
GGACAGGCCA GTCGCGTTCC TTCCGCATCC TTGCCCACCT CACAGGCACC GAGTTCATGC
610 620 630 640 650 660
15 AAGACCCGGA TGAGGAGCAC CTGAAGAAAT CAAGCCAGGT GCCCAGGACA GAAGCCCCAG
670 680 690 700 710 720
CCCCAGCCTC ATCTACACCC CAGGAGCCCT GGCCTGGCCC TACCGCCCCC AGCCCTACCA
730 740 750 760 770 780
GCCGCCCCGCC CTGGGCTGTG GACCCTGCGT TTGCCGAGCG CTATGCCCCG GACAAAACGA
20 790 800 810 820 830 840
GCACAGTGCT GACCCGGCAC AGCCAGCCGG CCACGCCCAC GCCGCTGCAG AGCCGCACCT
850 860 870 880 890 900
CCATTGTGCA GGCAGCTGCC GGAGGGGTGC CAGGAGGGGG CAGCAACAAC GGCAAGACTC
910 920 930 940 950 960
25 CCGTGTGTCA CCAGTGCCAC AAGGTCATCC GGGGCCGCTA CCTGGTGGCG TTGGGCCACG
970 980 990 1000 1010 1020
CGTACCACCC GGAGGAGTTT GTGTGTAGCC AGTGTGGGAA GGTCTTGGA GAGGGTGGCT
1030 1040 1050 1060 1070 1080

TCTTTGAGGA GAAGGGCGCC ATCTTCTGCC CACCATGCTA TGACGTGCGC TATGCACCCA
 1090 1100 1110 1120 1130 1140
 GCTGTGCCAA GTGCAAGAAG AAGATTACAG GCGAGATCAT GCACGCCCTG AAGATGACCT
 1150 1160 1170 1180 1190 1200
 5 GGCACGTGCA CTGCTTTACC TGTGCTGCCT GCAAGACGCC CATCCGGAAC AGGGCCTTCT
 1210 1220 1230 1240 1250 1260
 ACATGGAGGA GGGCGTGCCC TATTGCGAGC GAGACTATGA GAAGATGTTT GGCACGAAAT
 1270 1280 1290 1300 1310 1320
 GCCATGGCTG TGA~~CTT~~CAAG ATCGACGCTG GGGACCGCTT CCTGGAGGCC CTGGGCTTCA
 10 1330 1340 1350 1360 1370 1380
 GCTGGCATGA CACCTGCTTC GTCTGTGCGA TATGTCAGAT CAACCTGGAA GGAAAGACCT
 1390 1400 1410 1420 1430 1440
 TCTACTCCAA GAAGGACAGG CCTCTCTGCA AGAGCCATGC CTTCTCTCAT GTGTGAGCCC
 1450 1460 1470 1480 1490 1500
 15 CTTCTGCCCCA CAGCTGCCGC GGTGGCCCCCT AGCCTGAGGG GCCTGGAGTC GTGGCCCTGC
 1510 1520 1530 1540 1550 1560
 ATTTCTGGGT AGGGCTGGCA ATGGTTGCCT TAACCCTGGC TCCTGGCCCG AGCCTGGGCT
 1570
 CCCGGGCCCT GCCCA

20 Reading frame shifts caused by the addition of a 17 bp fragment
 (bolded, italicized and underlined) results in an early translation stop codon at
 position 565-567 (underlined).

The derived amino acid sequence (SEQ ID NO: 40) consists of 153
 amino acids:

25

10 20 30 40 50 60
 MDSFKVVLEG PAPWGFRLQG GKDFNVPLSI SRLTPGGKAA QAGVAVGDWV LSIDGENAGS
 70 80 90 100 110 120

LTHIEAQNKI RACGERLSLG LSRAQPVQSK POKASAPAA PPRYTFAPSV SLNKTARFPG

130

140

150

APPPADSAPO ONGCRPLTNS RSDRWSOMPA SSG

- 5 This protein demonstrates 100% homology to SEQ ID NO: 10 until amino acid 94, where the addition of the 17 bp fragment depicted in the nucleotide sequence results in a frame shift. Over amino acids 94-153, the protein is not homologous to SEQ ID NO: 10. Amino acids 154-457 in SEQ ID NO: 10 are not present due to the early stop codon depicted in nucleotide sequence.

EXAMPLE 32: Genomic HLMP-1 Nucleotide Sequence

Applicants have identified the genomic DNA sequence encoding HLMP-1, including putative regulatory elements associated with HLMP-1 expression.

- 5 The entire genomic sequence is shown in SEQ ID. NO: 41. This sequence was derived from AC023788 (clone RP11-564G9), Genome Sequencing Center, Washington University School of Medicine, St. Louis, MO.

- The putative promoter region for HLMP-1 spans nucleotides 2,660-8,733 in SEQ ID NO: 41. This region comprises, among other things, at least
 10 ten potential glucocorticoid response elements ("GREs") (nucleotides 6148-6153, 6226-6231, 6247-6252, 6336-6341, 6510-6515, 6552-6557, 6727-6732, 6752-6757, 7738-7743, and 8255-8260), twelve potential Sma-2 homologues to Mothers against Drosophilla decapentaplegic ("SMAD") binding element sites (nucleotides 3569-3575, 4552-4558, 4582-4588, 5226-5232, 6228-6234,
 15 6649-6655, 6725-6731, 6930-6936, 7379-7384, 7738-7742, 8073-8079, and 8378-8384), and three TATA boxes (nucleotides 5910-5913, 6932-6935, and 7380-7383). The three TATA boxes, all of the GREs, and eight of the SMAD binding elements ("SBEs") are grouped in the region spanning nucleotides 5,841-8,733 in SEQ ID NO: 41. These regulatory elements can be used, for
 20 example, to regulate expression of exogenous nucleotide sequences encoding proteins involved in the process of bone formation. This would permit systemic administration of therapeutic factors or genes relating to bone formation and repair, as well as factors or genes associated with tissue differentiation and development.

- 25 In addition to the putative regulatory elements, 13 exons corresponding to the nucleotide sequence encoding HLMP-1 have been identified. These exons span the following nucleotides in SEQ ID NO: 41:

30	Exon 1	8733-8767
	Exon 2	9790-9895
	Exon 3	13635-13787

	Exon 4	13877-13907
	Exon 5	14387-14502
	Exon 6	15161-15297
	Exon 7	15401-15437
5	Exon 8	16483-16545
	Exon 9	16689-16923
	Exon 10	18068-18248
	Exon 11	22117-22240
	Exon 12	22323-22440
10	Exon 13	22575-22911

In HLMP-2 there is another exon (Exon 5A), which spans nucleotides 14887-14904.

All cited publications and patents are hereby incorporated by reference in their entirety.


15 While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be appreciated by one skilled in the art from reading this disclosure that various changes in form and detail can be made without departing from the true scope of the invention.

Applicant's or agent's file reference number 6148.. 2-304	International application PCT/US00/11664
--	---

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>17</u> , line <u>20</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, VA 20110-2209	
Date of deposit 14 April 2000	Accession Number PTA-1698
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input type="checkbox"/> For receiving Office use only This sheet was received with the international application	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: 17 JUL 2000
Authorized officer	Authorized officer 


Applicant's or agent's file reference number 6148...2-304	International application PCT/US00/11664
--	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>17</u> , line <u>21</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, VA 20110-2209	
Date of deposit 14 April 2000	Accession Number PTA-1699
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only
<input type="checkbox"/> This sheet was received with the international application
Authorized officer

For International Bureau use only
<input type="checkbox"/> This sheet was received by the International Bureau on: 17 JUL 2000
Authorized officer 

We claim:

1. An isolated nucleic acid molecule comprising a SEQ ID NO: 37 or
SEQ ID NO: 39.
2. An isolated human LMP protein encoded by SEQ ID NO: 37 or SEQ
5 ID NO: 39.
3. A vector comprising the isolated nucleic acid molecule of claims 1.
4. A host cell comprising the vector of claim 3.
5. The host cell of claim 4, wherein the host cell is selected from the
group consisting of prokaryotic cells, yeast cells and mammalian
10 cells
6. The isolated nucleic acid molecule of claim 1, further comprising a
label.
7. A human LIM mineralization protein comprising an amino acid
sequence selected from the group consisting of SEQ ID NO: 38 and SEQ ID
15 NO: 40.
8. A monoclonal antibody specific for a HLMP-2 (SEQ ID NO: 38) or
HLMP-3 (SEQ ID NO: 40).
9. A method of inducing bone formation comprising transfecting
osteogenic precursor cells or peripheral blood leukocytes with an isolated
20 nucleic acid molecule comprising SEQ ID NO: 39.
10. The method of claim 9, wherein the isolated nucleic acid molecule is
in a vector.
11. The method of claim 10, wherein the vector is an expression vector.
12. The method of claim 11, wherein the vector is a plasmid.
- 25 13. The method of claim 11, wherein the vector is a virus.
14. The method of claim 13, wherein the virus is an adenovirus
15. The method of claim 13, wherein the virus is a retrovirus.
16. The method of claim 9, wherein the osteogenic precursor cells or
peripheral blood leukocytes are transfected *ex vivo*.
- 30 17. The method of claim 9, wherein the osteogenic precursor cells are
transfected *in vivo* by direct injection of the isolated nucleic acid molecule.

18. The method of claim 9, wherein the LIM mineralization protein is HLMP-3 (SEQ ID NO: 40).

19. A method of fusing a spine, comprising:

- (a) transfecting osteogenic precursor cells or peripheral blood leukocytes with an isolated nucleic acid molecule comprising SEQ ID NO: 39;
- (b) admixing the transfected osteogenic precursor cells or peripheral blood leukocytes with a matrix; and
- (c) contacting the matrix with the spine;

wherein expression of the nucleotide sequence causes mineralized bone formation in the matrix.

20. The method of claim 19, wherein the osteogenic precursor cells or peripheral blood cells are transfected *ex vivo*.

21. A method of inducing systemic bone formation in a mammalian host in need thereof, comprising:

- a) transfecting osteogenic precursor cells or peripheral blood leukocytes with a vector that is stably maintained in the osteogenic precursor cells or peripheral blood leukocytes, the vector comprising SEQ ID NO: 39 operably linked to a regulatable promoter, wherein the regulatable promoter responds to an exogenous control compound; and
- (b) administering to the host, as needed, an amount of the exogenous control substance effective to cause expression of SEQ ID NO: 39.

22. A method of stimulating production of an osteogenic soluble factor by an osteogenic cell, comprising:

(a) transfecting the osteogenic cell or peripheral blood leukocyte with an isolated nucleic acid molecule comprising SEQ ID NO: 39; and

5 (b) overexpressing the isolated nucleic acid molecule.

23. An osteogenic soluble factor produced by the method of claim 22.

24. The osteogenic soluble factor of claim 23, wherein the osteogenic factor is a protein.

25. A method of inhibiting the expression of HLMP-2 or HLMP-3
10 comprising transfecting a cell wherein HLMP-2 or HLMP-3 is expressed with an antisense oligonucleotide.

26. The method of claim of claim 17, wherein the isolated nucleic acid molecule is in a vector selected from the group consisting of a plasmid and a virus.

15 27. The method of claim 26, wherein the vector is a plasmid, which plasmid is directly injected into muscle tissue.

28. A method of inhibiting bone formation comprising transfecting osteogenic precursor cells or peripheral blood leukocytes with an isolated nucleic acid molecule comprising SEQ ID NO: 37.

20 29. The method of claim 28, wherein the isolated nucleic acid molecule is in a vector.

30. The method of claim 29, wherein the vector is an expression vector.

31. The method of claim 30, wherein the vector is a plasmid.

32. The method of claim 30, wherein the vector is a virus.

25 33. The method of claim 32, wherein the virus is an adenovirus

34. The method of claim 32, wherein the virus is a retrovirus.

35. The method of claim 28, wherein the osteogenic precursor cells or peripheral blood leukocytes are transfected *ex vivo*.

30 36. The method of claim 28, wherein the osteogenic precursor cells are transfected *in vivo* by direct injection of the isolated nucleic acid molecule.

37. The method of claim 28, wherein the LIM mineralization protein is HLMP-2 (SEQ ID NO: 38).

SEQUENCE LISTING

<110> Boden M.D., Scott D
Hair Ph.D., Gregory A

<120> LIM Mineralization Protein Splice Variants

<130> splice variant LMP

<140> 6148.0222-00304

<141> 2000-04-28

<150> 60/132,021

<151> 1999-04-30

<160> 42

<170> PatentIn Ver. 2.1

<210> 1

<211> 457

<212> PRT

<213> Rattus norvegicus

<400> 1

Met	Asp	Ser	Phe	Lys	Val	Val	Leu	Glu	Gly	Pro	Ala	Pro	Trp	Gly	Phe
1				5					10					15	

Arg	Leu	Gln	Gly	Gly	Lys	Asp	Phe	Asn	Val	Pro	Leu	Ser	Ile	Ser	Arg
		20						25					30		

Leu	Thr	Pro	Gly	Gly	Lys	Ala	Ala	Gln	Ala	Gly	Val	Ala	Val	Gly	Asp
		35					40					45			

Trp	Val	Leu	Ser	Ile	Asp	Gly	Glu	Asn	Ala	Gly	Ser	Leu	Thr	His	Ile
	50					55					60				

Glu	Ala	Gln	Asn	Lys	Ile	Arg	Ala	Cys	Gly	Glu	Arg	Leu	Ser	Leu	Gly
65					70					75				80	

Leu	Ser	Arg	Ala	Gln	Pro	Ala	Gln	Ser	Lys	Pro	Gln	Lys	Ala	Leu	Thr
			85						90					95	

Pro	Pro	Ala	Asp	Pro	Pro	Arg	Tyr	Thr	Phe	Ala	Pro	Ser	Ala	Ser	Leu
			100					105					110		

Asn	Lys	Thr	Ala	Arg	Pro	Phe	Gly	Ala	Pro	Pro	Pro	Thr	Asp	Ser	Ala
		115					120						125		

Leu	Ser	Gln	Asn	Gly	Gln	Leu	Leu	Arg	Gln	Leu	Val	Pro	Asp	Ala	Ser
	130					135					140				

Lys	Gln	Arg	Leu	Met	Glu	Asn	Thr	Glu	Asp	Trp	Arg	Pro	Arg	Pro	Gly
145					150					155					160

Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
 165 170 175
 Glu Phe Met Gln Asp Pro Asp Glu Glu Phe Met Lys Lys Ser Ser Gln
 180 185 190
 Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Thr Ile Pro Gln Glu
 195 200 205
 Ser Trp Pro Gly Pro Thr Thr Pro Ser Pro Thr Ser Arg Pro Pro Trp
 210 215 220
 Ala Val Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser
 225 230 235 240
 Thr Val Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln
 245 250 255
 Asn Arg Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Gly Thr Gly Gly
 260 265 270
 Gly Ser Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Lys Ile
 275 280 285
 Ile Arg Gly Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu
 290 295 300
 Glu Phe Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe
 305 310 315 320
 Phe Glu Glu Lys Gly Ala Ile Phe Cys Pro Ser Cys Tyr Asp Val Arg
 325 330 335
 Tyr Ala Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile
 340 345 350
 Met His Ala Leu Lys Met Thr Trp His Val Pro Cys Phe Thr Cys Ala
 355 360 365
 Ala Cys Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly
 370 375 380
 Ala Pro Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys
 385 390 395 400
 Arg Gly Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala
 405 410 415
 Leu Gly Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln
 420 425 430
 Ile Asn Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Lys Pro Leu
 435 440 445
 Cys Lys Ser His Ala Phe Ser His Val
 450 455

<210> 2
 <211> 1696
 <212> DNA
 <213> *Rattus norvegicus*

<400> 2
 gcacgaggat cccagcgcggt ctccctggagg ccgcccaggca gccgcccagc cgggcatctca 60
 ggagcaggta ccatggattc cttcaaggta gtgctggagg gacctgcccc ttggggcttc 120
 cgtctgcaag ggggcaagga cttcaacgtg cccctctcca tctctcggt cactcctgga 180
 ggcaaggccg cacaggccgg tgtggccgtg ggagactggg tactgagtat cgacgggtgag 240
 aacgccggaa gcctcacaca cattgaagcc cagaacaaga tccgtgcctg tggggagcgc 300
 ctacgcctgg gtcttagcag agcccagcct gctcagagca aaccacagaa ggccctgacc 360
 cctcccgccg acccccagag gtacactttt gcaccaagcg cctccctcaa caagacggcc 420
 cggcccttcg gggcaccccc acctactgac agcgccctgt cgcagaatgg acagctgctc 480
 agacagctgg tccctgatgc cagcaagcag cggctgatgg agaatactga agactggcgc 540
 ccgcgccag ggacaggcca gtcccgttcc ttccgcatcc ttgctcacct caccgggcaca 600
 gagttcatgc aagaccggga tgaggaattc atgaagaagt caagccagggt gccaggaca 660
 gaagccccag cccagcctc aaccataccc caggaatcct ggctggccc caccaccccc 720
 agccccacca gccgcccacc ctgggeegta gatcctgcat ttgctgagcg ctatgcccc 780
 gacaaaacca gcacagtgtc gaccgcagac agccagccag ccacacctac gcctctgcag 840
 aaccgcacct ccatagtcca ggctgcagct ggagggggca caggaggagg cagcaacaat 900
 ggcaagacgc ctgtatgcca ccagtgccac aagatcatcc gccgcccata cctggtagca 960
 ctggggccag cgtaccatcc tgaggaatct gtgtgcagcc agtgtgggaa ggtcctggaa 1020
 gaggggtggt tcttcgagga gaaggagct atcttttgcc cctcctgcta tgatgtgcgc 1080
 tatgcaccca gctgtgcca atgcaagaag aagatcactg gagagatcat gcatgcgctg 1140
 aagatgacct ggcatgttcc ctgcttcacc tgtgcagcct gcaaaacccc tatccgcaac 1200
 agggctttct acatggagga gggggctccc tactgcgagc gagattacga gaagatgttt 1260
 ggcacaaagt gtcgcggtg tgacttcaag atcgatgccg gggaccgttt cctggaagcc 1320
 ctgggtttca gctggcatga tacgtgtttt gtttgcgcaa tatgtcaaat caacttgga 1380
 ggaaagacct tctactccaa gaaggacaag cccctgtgca agagccatgc cttttccac 1440
 gtatgagcac ctccctcacac tactgccacc ctactctgcc agaagggtga taaaatgaga 1500
 gagctctctc tcctcgacc tttctgggtg gggtggcag ccattgtcct agccttggt 1560
 cctggccaga tectggggct cctcctcac agtccccctt cccacacttc ctccaccacc 1620
 accaccgtca ctcacaggtg ctagcctcct agccccagtt cactctggtg tcacaataaa 1680
 cctgtatgta gctgtg 1696

<210> 3
 <211> 260
 <212> DNA
 <213> *Rattus norvegicus*

<400> 3
 ttctacatgg aggagggggc tccctactgc gagcgagatt acgagaagat gtttggcaca 60
 aagtgtcgcg gctgtgactt caagatcgat gccggggacc gtttcctgga agcctgggt 120
 ttcagctggc atgatacgtg ttttgtttgc gcaatatgtc aaatcaactt ggaaggaaag 180
 accttctact ccaagaagga caagccctg tgcaagagcc atgccttttc ccacgtatga 240
 gcacctctc acactactgc 260

<210> 4
 <211> 16
 <212> DNA
 <213> MMLV

<400> 4

aagctttttt tttttg

16

<210> 5

<211> 13

<212> DNA

<213> MMLV

<400> 5

aagcttggct atg

13

<210> 6

<211> 223

<212> DNA

<213> Homo sapiens

<400> 6

atccttgctc	acctcacggg	caccgagttc	atgcaagacc	eggatgagga	gcacctgaag	60
aaatcaagcc	aggtgcccag	gacagaagcc	ccagccccag	cctcatctac	accccaggag	120
ccctggcctg	gccctaccgc	ccccagccct	accagccgct	cgccctgggc	tgtggaccct	180
gcgtttgccg	agcgtatgc	cccagacaaa	accagcacag	tgc		223

<210> 7

<211> 717

<212> DNA

<213> Homo sapiens

<400> 7

atggattcct	tcaaggtagt	gctggagggg	ccagcacctt	ggggcttccg	gctgcaaggg	60
ggcaaggact	tcaatgtgcc	cctctccatt	tcccggctca	ctcctggggg	caaagcggcg	120
caggccggag	tggccgtggg	tgactgggtg	ctgagcatcg	atggcgagaa	tgccggtagc	180
ctcacacaca	tgaagctca	gaacaagatc	cgggcctgcg	gggagcgctt	cagcctgggc	240
ctcagcaggg	cccagccggt	tcagagcaaa	ccgcagaagg	cctccgcccc	cgcgcgggac	300
cctccgcggt	acacctttgc	acccagcgtc	tccctcaaca	agacggcccc	gccctttggg	360
gcgccccccg	ccgctgacag	cgccccgcaa	cagaatggac	agccgctccg	accgctggtc	420
ccagatgcca	gcaagcagcg	gctgatggag	aacacagagg	actggcggcc	gcggccgggg	480
acaggccagt	cgcgttcctt	ccgcatacct	gcccacctca	caggcaccga	gttcatgcaa	540
gacccggatg	aggagcacct	gaagaaatca	agccagggtg	ccaggacaga	agccccagcc	600
ccagcctcat	ctacacccca	ggagccctgg	cctggcccta	ccgccccag	ccctaccagc	660
cgcccgccct	gggctgtgga	ccctgcgttt	gccgagcgct	atgccccgga	caaaacg	717

<210> 8

<211> 1488

<212> DNA

<213> Homo sapiens

<400> 8

atcgatggcg	agaatgcggg	tagcctcaca	cacatcgaag	ctcagaacaa	gatccggggc	60
tgccggggag	gcctcagcct	gggcctcagc	agggcccagc	cggttcagag	caaaccgcag	120
aaggcctccg	ccccgcgcgc	ggacctccg	cggtagacct	ttgcacccag	cgtctccctc	180
aacaagacgg	cccgccctt	tggggcgccc	ccgcccgtg	acagcgcccc	gcaacagaat	240
ggacagccgc	tccgaccgct	ggtcccagat	gccagcaagc	agcggctgat	ggagaacaca	300

```

gaggactggc ggccgcggcc ggggacaggc cagtcgcgtt ccttccgcat ccttgccac 360
ctcacaggca ccgagttcat gcaagaccgc gatgaggagc acctgaagaa atcaagccag 420
gtgccaggga cagaagcccc agccccagcc tcatctacac cccaggagcc ctggcctggc 480
cctaccgccc ccagccctac cagccgcgcg ccctgagctg tggaccctgc gtttgccgag 540
cgctatgccc cggacaaaac gagcacagtg ctgaccgcgc acagccagcc ggccacgccc 600
acgccgctgc agagccgcac ctccattgtg caggcagctg ccggaggggg gccaggaggg 660
ggcagcaaca acggcaagac tcccgtgtgt caccagtgc acaagggtcat ccggggccgc 720
tacctggtgg cgttgggcca cgcgtaccac ccggaggagt ttgtgtgtag ccagtgtggg 780
aagggtcctgg aagagggtgg cttctttgag gagaaggggc ccatcttctg ccaccatgc 840
tatgacgtgc gctatgcacc cagctgtgcc aagtgcaga agaagattac aggcgagatc 900
atgcacgccc tgaagatgac ctggcacgtg cactgcttta cctgtgctgc ctgcaagacg 960
cccatccgga acagggcctt ctacatggag gagggcgtgc cctattgcga gcgagactat 1020
gagaagatgt ttggcacgaa atgccatggc tgtgacttca agatcgacgc tggggaccgc 1080
ttcctggagg ccctgggctt cagctggcat gacacctgct tcgtctgtgc gatatgtcag 1140
atcaacctgg aaggaaagac cttctactcc aagaaggaca ggctctctg caagagccat 1200
gccttctctc atgtgtgagc cccttctgcc cacagctgcc gcggtggccc ctagcctgag 1260
gggcctggag tcgtggccct gcatttctgg gtagggctgg caatggttgc cttaacctg 1320
gtcctgggcc cgagcctggg ctcccgggcc cctgcccacc caccttatcc tcccaccca 1380
ctccctccac caccacagca caccggtgct ggccacacca gcccccttcc acctccagt 1440
ccacaataaa cctgtaccca gctgaattcc aaaaaatcca aaaaaaaa 1488

```

<210> 9

<211> 1644

<212> DNA

<213> Homo sapiens

<400> 9

```

atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaaggg 60
ggcaaggact tcaatgtgcc cctctccatt tcccggctca ctccctggggg caaagcgggc 120
caggccggag tggccgtggg tgactgggtg ctgagcatcg atggcgagaa tgcgggtagc 180
ctcacacaca tcgaagctca gaacaagatc cgggcctgcg gggagcgccct cagcctgggc 240
ctcagcaggg cccagccggt tcagagcaaa ccgcagaagg cctccgcccc cgcccgggac 300
cctccgcggg acacctttgc acccagcgct tccctcaaca agacggcccc gccctttggg 360
gcgccccgcg ccgctgacag cgcgccgcaa cagaatggac agccgctccg accgctggtc 420
ccagatgccca gcaagcagcg gctgatggag aacacagagg actggcgggc gcggccgggg 480
acaggccagt cgcgttcctt ccgcatcctt gccacctca caggcaccga gttcatgcaa 540
gaccgggatg aggagcacct gaagaaatca agccaggtgc ccaggacaga agccccagcc 600
ccagcctcat ctacacccca ggagccctgg cctggcccta ccgccccag ccctaccagc 660
cgccccccct gggtgtgga ccttgcgttt gccgagcgct atgccccgga caaaacgagc 720
acagtgtgga cccggcacag ccagccggcc acgcccacgc cgctgcagag ccgcacctcc 780
attgtgcagg cagctgccgg aggggtgcca ggagggggca gcaacaacgg caagactccc 840
gtgtgtcacc agtgccacaa ggtcatccgg gccgctacc tgggtggcgtt gggccacgcg 900
taccacccgg aggagtttgt gtgtagccag tgtgggaagg tcctggaaga ggggtggctt 960
tttgaggaga agggcgccat cttctgcccc ccatgctatg acgtgcgcta tgcaccagc 1020
tgtgccaagt gcaagaagaa gattacaggc gagatcatgc acgccctgaa gatgacctg 1080
cacgtgcact gctttacctg tgctgcctgc aagacgcccc tccggaacag ggccttctac 1140
atggaggagg gcgtgcccta ttgcgagcga gactatgaga agatgtttgg cacgaaatgc 1200
catggctgtg acttcaagat cgacgctggg gaccgcttcc tggaggccct gggttccagc 1260
tggcatgaca cctgcttcgt ctgtgcgata tgtcagatca acctggaagg aaagaccttc 1320
tactccaaga aggacaggcc tctctgcaag agccatgcct tctctcatgt gtgagccct 1380
tctgcccaca gctgcgcggg tggcccttag cctgaagggc ctggagtcgt ggcctgtcat 1440
ttctgggtag ggctggcaat ggttgcccta accctggctc ctggcccgag cctgggctcc 1500
cgggcccttg cccaccacc ttatccctcc accccactcc ctccaccacc acagcacacc 1560
ggtgctggcc acaccagccc cctttcacct ccagtgcac aataaacctg taccagctg 1620
aattccaaaa aatccaaaa aaaa 1644

```

<210> 10

<211> 457

<212> PRT

<213> Homo sapiens

<400> 10

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
 1 5 10 15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
 20 25 30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
 35 40 45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
 50 55 60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
 65 70 75 80

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
 85 90 95

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
 100 105 110

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
 115 120 125

Pro Gln Gln Asn Gly Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser
 130 135 140

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
 145 150 155 160

Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
 165 170 175

Glu Phe Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln
 180 185 190

Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu
 195 200 205

Pro Trp Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro Trp
 210 215 220

Ala Val Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser
 225 230 235 240

Thr Val Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln
 245 250 255

Ser Arg Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Val Pro Gly Gly

260	265	270
Gly Ser Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Lys Val 275 280 285		
Ile Arg Gly Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu 290 295 300		
Glu Phe Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe 305 310 315 320		
Phe Glu Glu Lys Gly Ala Ile Phe Cys Pro Pro Cys Tyr Asp Val Arg 325 330 335		
Tyr Ala Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile 340 345 350		
Met His Ala Leu Lys Met Thr Trp His Val His Cys Phe Thr Cys Ala 355 360 365		
Ala Cys Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly 370 375 380		
Val Pro Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys 385 390 395 400		
His Gly Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala 405 410 415		
Leu Gly Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln 420 425 430		
Ile Asn Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Arg Pro Leu 435 440 445		
Cys Lys Ser His Ala Phe Ser His Val 450 455		

<210> 11

<211> 22

<212> DNA

<213> Rattus norvegicus

<400> 11

gccagggttt tcccagtcac ga

22

<210> 12

<211> 22

<212> DNA

<213> Rattus norvegicus

<400> 12

gccagggttt tcccagtcac ga

22

<210> 13
<211> 22
<212> DNA
<213> Homo sapiens

<400> 13
tcttagcaga gccagcctg ct

22

<210> 14
<211> 22
<212> DNA
<213> Homo sapiens

<400> 14
gcatgaactc tgtgcccgtg ag

22

<210> 15
<211> 20
<212> DNA
<213> Rattus norvegicus

<400> 15
atccttgctc acctcacggg

20

<210> 16
<211> 22
<212> DNA
<213> Rattus norvegicus

<400> 16
gcactgtgct ggttttgtct gg

22

<210> 17
<211> 23
<212> DNA
<213> Homo sapiens

<400> 17
catggattcc ttcaaggtag tgc

23

<210> 18
<211> 20
<212> DNA
<213> Homo sapiens

<400> 18
gttttgtctg gggcagagcg

20

<210> 19
<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: adaptor for
Marathon RACE reactions

<400> 19

ctaatacgac tcactatagg gctcgagcgg ccgcccgggc aggt

44

<210> 20

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer
specific for Marathon RACE adaptor

<400> 20

ccatccta acgactcact atagggc

27

<210> 21

<211> 765

<212> DNA

<213> Homo sapiens

<400> 21

```

ccgttggttg taaaacgacg cagagcagcg ccctggccgg gccaaagcagg agccggcattc 60
atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaagg 120
ggcaaggact tcaatgtgcc ctctccatt tcccggtca cctctggggg caaggccgtg 180
caggccggag tggccgtaag tgactgggtg ctgagcatcg atggcgagaa tgcgggtagc 240
ctcacacaca tcgaagctca gaacaagatc cgggcctgcg gggagcgcct cagcctgggc 300
ctcaacaggg cccagccggt tcagaacaaa ccgcaaaagg cctccgcccc cgccgcggac 360
cctccgcggt acacctttgc accaagcgte tccctcaaca agacggcccc gcccttgggg 420
gccccccgc ccgctgacag cgcgccgcag cagaatggac agccgctccg accgctggtc 480
ccagatgcc aagcagcag gctgatggag aacacagagg actggcgggc gcggccgggg 540
acaggccagt gccgttcctt tcgcatcctt gctcacctta caggcaccga gttcatgcaa 600
gaccgggatg aggagcacct gaagaaatca agccaggtgc ccaggacaga agccccagcc 660
ccagcctcat ctacaccca ggagccctgg cctggcccta ccgccccag ccctaccagc 720
cgccccctt gggctgtgga cctgcggtt gccgagcgct atgcc 765

```

<210> 22

<211> 1689

<212> DNA

<213> Homo sapiens

<400> 22

```

cgacgcagag cagcgccctg gccgggcca aagcagagccg gcatcatgga ttccttcaag 60
gtagtgtctg aggggcccag accttggggc tccggctgc aagggggcaa ggacttcaat 120
gtgcccctct ccatttccc gctcactcct gggggcaaa cggcgaggc cggagtggcc 180
gtgggtgact ggggtgctgag catcgatggc gagaatgcgg gtagcctcac acacatcgaa 240
gtcagaaca agatccgggc ctgcggggag cgcctcagcc tgggcctcag cagggccag 300

```

```

cgggttcaga gcaaaccgca gaaggcctcc gccccgcgcg cggaccctcc gcggtacacc 360
tttgcaccca gcgtctccct caacaagacg gcccggccct ttggggcgcc cccgcccgt 420
gacagcgccc cgcaacagaa tggacagccg ctccgaccgc tgggtcccaga tgccagcaag 480
cagcggtga tggagaacac agaggactgg cggccgcggc cggggacagg ccagtgcgt 540
tccttccgca tccttgccca cctcacaggc accgagttca tgcaagaccc ggatgaggag 600
cacctgaaga aatcaagcca ggtgcccagg acagaagccc cagccccagc ctcatctaca 660
cccaggagc cctggcctgg ccctaccgcc ccagcccta ccagccgcc gccctgggct 720
gtggaccctg cgtttgccga gcgtatgcc ccggacaaaa cgagcacagt gctgaccgg 780
cacagccagc cggccacgcc cagcccgctg cagagccgca cctccattgt gcaggcagct 840
gccggagggg tgccaggagg gggcagcaac aacggcaaga ctcccgtgtg tcaccagtgc 900
cacaagggtca tccggggccg ctacctggtg gcgttgggccc acgcgtacca cccggaggag 960
tttgtgtgta gccagtgtgg gaaggctcctg gaagagggtg gcttctttga ggagaagggc 1020
gccatcttct gccaccatg ctatgacgtg cgctatgcac ccagtgtgc caagtgcagg 1080
aagaagatta caggcgagat catgcacgcc ctgaagatga cctggcacgt gcactgcttt 1140
acctgtgctg cctgcaagac gcccatccgg aacagggcct tctacatgga ggagggcggtg 1200
ccctattgct agcgagacta tgagaagatg tttggcacga aatgccatgg ctgtgacttc 1260
aagatcgacg ctggggaccg ctccctggag gccctgggct tcagctggca tgacacctgc 1320
ttcgtctgtg cgatatgtca gatcaacctg gaaggaaaga ccttctactc caagaaggac 1380
aggcctctct gcaagagcca tgccttctct catgtgtgag ccccttctgc ccacagctgc 1440
cgcggtggcc cctagcctga ggggcctgga gtgctggccc tgcatttctg ggtagggctg 1500
gcaatgggtg ccttaacct ggctcctggc ccgagcctgg gctcccgggc ccctgcccac 1560
ccaccttacc tccccacccc actccctcca ccaccacagc acaccgggtg tggccacacc 1620
agcccccttt cacctccagt gccacaataa acctgtacct agctgaattc caaaaaatcc 1680
aaaaaaaaa

```

<210> 23
 <211> 22
 <212> DNA
 <213> Homo sapiens

<400> 23
 gcactgtgct cgttttgtcc gg 22

<210> 24
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 24
 tccttgctca cctcacgggc a 21

<210> 25
 <211> 30
 <212> DNA
 <213> Homo sapiens

<400> 25
 tcctcatccg ggtcttgcac gaactcgggtg 30

<210> 26
 <211> 28
 <212> DNA

<213> Homo sapiens

<400> 26

gcccccgccc gctgacagcg ccccgcaa

28

<210> 27

<211> 24

<212> DNA

<213> Homo sapiens

<400> 27

tccttgctca cctcacgggc accg

24

<210> 28

<211> 22

<212> DNA

<213> Homo sapiens

<400> 28

gtaatacgac tcactatagg gc

22

<210> 29

<211> 23

<212> DNA

<213> Rattus norvegicus

<400> 29

gcggctgatg gagaatactg aag

23

<210> 30

<211> 23

<212> DNA

<213> Rattus norvegicus

<400> 30

atcttggtggc actggtggca tac

23

<210> 31

<211> 22

<212> DNA

<213> Rattus norvegicus

<400> 31

tgtgtcgggt cagcactgtg ct

22

<210> 32

<211> 1620

<212> DNA

<213> Homo sapiens

<400> 32

```

atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaaggg 60
ggcaaggact tcaatgtgcc cctctccatt tcccggctca ctctggggg caaagcggcg 120
caggccggag tggccgtggg tgactgggtg ctgagcatcg atggcgagaa tgcgggtagc 180
ctcacacaca tcgaagctca gaacaagatc cgggcctgcg gggagcgctt cagcctgggc 240
ctcagcaggg ccagccgggt tcagagcaaa ccgcagaagg cctccgcccc cgccgctggg 300
cctccgcggt acacctttgc acccagcgtc tccctcaaca agacggcccc gccctttggg 360
gcgcccccg cgcgtgacag cgcgccgcaa cagaatggac agccgctccg accgctggtc 420
ccagatgccg gcaagcagcg gctgatggag aacacagagg actggcgggc gcggccgggg 480
acaggccagt cgcgttctct cgcctcctt gccacctca caggcaccca gttcatgcaa 540
gacccggatg aggagcacct gaagaaatca agccaggtgc ccaggacaga agccccagcc 600
ccagcctcat ctacacccca ggagccctgg cctggcccta ccgccccag ccctaccagc 660
cgccccccct gagctgtgga ccctgcgttt gccgagcgct atgccccgga caaacgagc 720
acagtgtgta ccggcacag ccagccggcc acgcccacgc cgtgcagag ccgcacctcc 780
attgtgcagg cagctgccgg aggggtgcca ggagggggca gcaacaacgg caagactccc 840
gtgtgtcacc agtgcacaaa ggtcatccgg ggcgctacc tgggtggcgtt gggccacgcg 900
taccacccgg aggagtttgt gtgtagccag tgtgggaagg tcctggaaga ggggtgcttc 960
tttgaggaga agggcgccat cttctgcca ccatgctatg acgtgcgcta tgcaccagc 1020
tgtgccaagt gcaagaagaa gattacaggc gagatcatgc acgccctgaa gatgacctgg 1080
cacgtgcact gctttacctg tgctgcctgc aagacgcccc tccggaacag gcccttctac 1140
atggaggagg gcgtgcccta ttgcgagcga gactatgaga agatgtttgg cacgaaatgc 1200
catggctgtg acttcaagat cgacgctggg gaccgcttcc tggaggccct gggcttcagc 1260
tgccatgaca cctgcttcgt ctgtgcgata tgtcagatca acctggaagg aaagaccttc 1320
tactccaaga aggacaggcc tctctgcaag agccatgcct tctctcatgt gtgagccct 1380
tctgccaca gctgcgcggg tggcccttag cctgaggggc ctggagtcgt ggcctgcat 1440
ttctgggtag ggctggcaat ggttgcccta acctggctc ctggccgag cctgggctcc 1500
cgggcccttg cccacccacc ttatcctccc acccactcc ctccaccacc acagcacacc 1560
ggtgctggcc acaccagccc cctttcacct ccagtgccac aataaacctg taccagctg 1620

```

<210> 33

<211> 1665

<212> DNA

<213> Homo sapiens

<400> 33

```

cgacgcagag cagcgccctg gccgggcca a gcaggagccg gcatcatgga ttccttcaag 60
gtagtgtggt agggggccagc accttggggc tccggctgc aagggggcaa ggacttcaat 120
gtgcccctct ccatttcccg gctcactcct gggggcaaag cggcgaggc cggagtggcc 180
gtgggtgact ggggtgtgag catcgatggc gagaatgcgg gtagcctcac acacatcgaa 240
gctcagaaca agatccgggc ctgcggggag cgcctcagcc tgggcctcag cagggccag 300
ccggttcaga gcaaacgcga gaaggcctcc gccccgcgg cggaccctcc gcgtacacc 360
tttgacccca gcgtctccct caacaagacg gcccgccct tggggcgcc cccgccgct 420
gacagcgccc cgcaacagaa tggacagccg ctccgaccgc tgggtccaga tgcagcaag 480
cagcggtgta tggagaacac agaggactgg cggccgcggc cggggacagg ccagtgcgct 540
tccttccgca tccttgccca cctcacaggc accgagttca tgcaagacct ggatgaggag 600
cacctgaaga aatcaagcca ggtgcccagg acagaagccc cagccccagc ctcatctaca 660
ccccaggagc cctggcctgg cctaccgcc cccagcccta ccagccgcc gccctgagct 720
gtggaccctg cgtttgccga gcgctatgcc ccggacaaaa cgagcacagt gctgaccgg 780
cacagccagc cggccacgcc cagccgctg cagagccgca cctccattgt gcaggcagt 840
gccggagggg tgccaggagg gggcagcaac aacggcaaga ctcccggtg tcaccagtgc 900
cacaaggtca tccggggcgg ctacctggtg gcgttggggc acgcgtacca cccggaggag 960
tttgtgtgta gccagtgtgg gaaggtcctg gaagaggggt gcttctttga ggagaagggc 1020
gccatcttct gccccacctg ctatgacgtg cgctatgcac ccagctgtgc caagtgcag 1080
aagaagatta caggcgagat catgcacgcc ctgaagatga cctggcacgt gcactgcttt 1140
acctgtgctg cctgcaagac gcccatccgg aacagggcct tctacatgga ggagggcggt 1200

```

```

ccctattgcg agcgagacta tgagaagatg tttggcacga aatgccatgg ctgtgacttc 1260
aagatcgacg ctggggaccg cttcctggag gccctgggct tcagctggca tgacacctgc 1320
ttcgtctgtg cgatatgtca gatcaacctg gaaggaaaga ctttctactc caagaaggac 1380
aggcctctct gcaagagcca tgccttctct catgtgtgag ccccttctgc ccacagctgc 1440
cgcggtggcc cctagcctga ggggcctgga gtcgtggccc tgcatttctg ggtagggctg 1500
gcaatgggtg ccttaaccct ggctcctggc ccgagcctgg gctcccgggc ccctgcccac 1560
ccaccttatc ctcccacccc actccctcca ccaccacagc acaccggtgc tggccacacc 1620
agcccccttt cacctccagt gccacaataa acctgtaccc agctg 1665

```

<210> 34

<211> 223

<212> PRT

<213> Homo sapiens

<400> 34

```

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
  1             5             10             15

```

```

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Scr Arg
          20             25             30

```

```

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
      35             40             45

```

```

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
      50             55             60

```

```

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
      65             70             75             80

```

```

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
          85             90             95

```

```

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
      100             105             110

```

```

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
      115             120             125

```

```

Pro Gln Gln Asn Gly Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser
      130             135             140

```

```

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
      145             150             155             160

```

```

Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
          165             170             175

```

```

Glu Phe Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln
          180             185             190

```

```

Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu
          195             200             205

```

```

Pro Trp Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro

```

210

215

220

<210> 35
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 35
 gagccggcat catggattcc

20

<210> 36
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 36
 gctgcctgca caatggaggt

20

<210> 37
 <211> 1456
 <212> DNA
 <213> Homo sapiens

<400> 37
 cgacgcagag cagcgccctg gccggggccaa gcaggagccg gcatcatgga ttccttcaag 60
 gtagtgctgg agggggccagc accttggggc ttccggctgc aagggggcaa ggacttcaat 120
 gtgcccctct ccatttcccg gctcactcct gggggcaaaag cggcgaggc cggagtggcc 180
 gtgggtgact ggggtgctgag catcgatggc gagaatgcgg gtagcctcac acacatcgaa 240
 gctcagaaca agatccgggc ctgcggggag cgcctcagcc tgggcctcag cagggcccag 300
 ccggttcaga gcaaaccgca gaaggtgcag acccctgaca aacagccgct ccgaccgctg 360
 gtcccagatg ccagcaagca gccgctgatg gagaacacag aggactggcg gccgcggccg 420
 gggacaggcc agtcgcgttc cttccgcctc cttgcccacc tcacaggcac cgagttcatg 480
 caagaccggg atgaggagca cctgaagaaa tcaagccagg tgcccaggac agaagcccca 540
 gccccagcct catctacacc ccaggagccc tggcctggcc ctaccgcccc cagccctacc 600
 agccgcccgc cctgggctgt ggaccctgcg tttgccgagc gctatgcccc ggacaaaacg 660
 agcacagtgc tgaccggca cagccagccg gccacgcccc cggcgtgca gagccgcacc 720
 tccattgtgc aggcagctgc cggaggggtg ccaggagggg gcagcaacaa cggcaagact 780
 cccgtgtgtc accagtgccca caaggtcatc cggggccgct acctggtggc gttggggccac 840
 gcgtaccacc cggaggagtt tgtgtgtagc cagtgtggga aggtcctgga agaggggtggc 900
 ttctttgagg agaagggcgc catcttctgc ccaccatgct atgacgtgcg ctatgcaccc 960
 agctgtgccca agtgcaagaa gaagattaca ggcgagatca tgcacgccct gaagatgacc 1020
 tggcacgtgc actgctttac ctgtgctgcc tgcaagacgc ccatccggaa cagggccttc 1080
 tacatggagg agggcgtgcc ctattgcgag cgagactatg agaagatgtt tggcacgaaa 1140
 tgccatggct gtgacttcaa gatcgacgct ggggaccgct tcctggaggc cctgggcttc 1200
 agctggcatg acacctgctt cgtctgtgcg atatgtcaga tcaacctgga aggaaagacc 1260
 ttctactcca agaaggacag gcctctctgc aagagccatg cttctctca tgtgtgagcc 1320
 ccttctgccc acagctgccg cgggtggccc tagcctgagg ggccctggagt cgtggccctg 1380
 catttctggg tagggctggc aatggttgcc ttaacctggc ctccctggccc gagcctgggc 1440
 tcccgggccc tgcca 1456

<210> 38
 <211> 423

<212> PRT

<213> Homo sapiens

<400> 38

```

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
  1             5             10             15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
          20             25             30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
          35             40             45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
          50             55             60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
          65             70             75             80

Leu Ser Arg Ala Gln Pro Val Gln Asn Lys Pro Gln Lys Val Gln Thr
          85             90             95

Pro Asp Lys Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser Lys Gln
          100            105            110

Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly Thr Gly
          115            120            125

Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr Glu Phe
          130            135            140

Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln Val Pro
          145            150            155            160

Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu Pro Trp
          165            170            175

Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro Trp Ala Val
          180            185            190

Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser Thr Val
          195            200            205

Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln Ser Arg
          210            215            220

Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Val Pro Gly Gly Gly Ser
          225            230            235            240

Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Gln Val Ile Arg
          245            250            255

Ala Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu Glu Phe
          260            265            270

Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe Phe Glu

```

275	280	285
Glu Lys Gly Ala Ile Phe Cys Pro Pro Cys Tyr Asp Val Arg Tyr Ala		
290	295	300
Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile Met His		
305	310	315 320
Ala Leu Lys Met Thr Trp His Val Leu Cys Phe Thr Cys Ala Ala Cys		
	325	330 335
Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly Val Pro		
	340	345 350
Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys Gln Trp		
	355	360 365
Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala Leu Gly		
	370	375 380
Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln Ile Asn		
385	390	395 400
Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Arg Pro Leu Cys Lys		
	405	410 415
Ser His Ala Phe Ser His Val		
	420	

<210> 39

<211> 1575

<212> DNA

<213> Homo sapiens

<400> 39

```

cgacgcagag cagcgcacctg gccggggccaa gcaggagccg gcatcatgga ttccttcaag 60
gtagtgtctgg agggggccagc accttggggc ttccggctgc aagggggcaa ggacttcaat 120
gtgcccctct ccatattcccg gctcactcct gggggccaaag cggcgcaggc cggagtggcc 180
gtgggtgact ggggtgtgag catcgatggc gagaatgcgg gtagcctcac acacatcgaa 240
gctcagaaca agatccgggc ctgcggggag cgcctcagcc tgggcctcag cagggccag 300
ccggttcaga gcaaaccgca gaaggcctcc gccccgcgg cggaccctcc gcgttacacc 360
tttgcaccca gcgtctccct caacaagacg gcccggccct ttggggcgcc cccgcccgct 420
gacagcgccc cgcaacagaa tgggtgcaga cccctgacaa acagccgctc cgaccgctgg 480
tcccagatgc cagcaagcag cggctgatgg agaacacaga ggactggcgg ccgcggccgg 540
ggacaggcca gtcgcgttcc ttccgcatcc ttgcccacct cacaggcacc gagttcatgc 600
aagaccgga tgaggagcac ctgaagaaat caagccaggt gccaggaca gaagccccag 660
ccccagctc atctacaccc caggagccct ggcctggccc taccgcccc agcctacca 720
gccgcccggc ctgggctgtg gaccctgcgt ttgccgagcg ctatgcccc gacaaaacga 780
gcacagtgtg gaccggcac agccagccgg ccacgcccac gccgctgcag agccgcacct 840
ccattgtgca ggcagctgcc ggaggggtgc caggaggggg cagcaacaac ggcaagactc 900
ccgtgtgtca ccagtgcac aaggtcatcc ggggcccgtc cctgggtggc ttgggccacg 960
cgtaccaccc ggaggagttt gtgtgtagcc agtgtgggaa ggtcctggaa gaggggtggc 1020
tctttgagga gaagggcgcc atcttctgcc caccatgcta tgacgtgcgc tatgcacca 1080
gctgtgccaa gtgcaagaag aagattacag gcgagatcat gcacgccctg aagatgacct 1140
ggcacgtgca ctgctttacc tgtgctgcct gcaagacgcc catccggaac agggccttct 1200

```

```

acatggagga gggcgtgccc tattgcgagc gagactatga gaagatgttt ggcacgaaat 1260
gccatggctg tgacttcaag atcgacgctg gggaccgctt cctggaggcc ctgggcttca 1320
gctggcatga cacctgcttc gtctgtgcga tatgtcagat caacctggaa ggaaagacct 1380
tctactccaa gaaggacagg cctctctgca agagccatgc cttctctcat gtgtgagccc 1440
cttctgcccc cagctgccgc ggtggccctt agcctgaggg gcctggagtc gtggccctgc 1500
atttctgggt agggctggca atggttgect taacctggc tcctggcccg agcctgggct 1560
cccgggccct gcca                                     1575

```

<210> 40

<211> 153

<212> PRT

<213> Homo sapiens

<400> 40

```

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
  1              5              10              15

```

```

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
          20              25              30

```

```

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
  35              40              45

```

```

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
  50              55              60

```

```

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
  65              70              75              80

```

```

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
          85              90              95

```

```

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
  100              105              110

```

```

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
  115              120              125

```

```

Pro Gln Gln Asn Gly Cys Arg Pro Leu Thr Asn Ser Arg Ser Asp Arg
  130              135              140

```

```

Trp Ser Gln Met Pro Ala Ser Ser Gly
  145              150

```

<210> 41

<211> 24740

<212> DNA

<213> Homo sapiens

<400> 41

```

nnnnnntgta ttttatcata ttttaaaaat caaaaaacaa aaggcagttg aggttaggca 60
tggaggttcg tgctgtaat cccagcactt tgggaagccg aagcacgtgg atcacctgag 120
gtcaggagtt cgagaccagc ctgcccaata tggtaaaacc ctgtctctac taaaaatata 180
aaaaattagc caggcatggt ggtgggcacc tgtaatccca gctacttggg agactgaggc 240

```

```

aggagaatca cttaaacccg ggaggcgggc tgggcgcggg ggctcatgcc tgtaatccca 300
gcactttggg agggcgagac agggcgatca tgaggtcagg agatcgagat catcctggct 360
aacatggtga aaccccatct ctactaaaaa tacaaaaaaa attagccagg cctgggtggcg 420
ggcacctgta gtcccagcta cttgggaggg tgaggcagga gaatggcgtg aacctgggag 480
gcggcgttgc agtgagccaa gatcgcgcca ctgcactcca gcctgggcga caagagttag 540
actccatctt aaagaaaaaa aacaaacccg ggaggcggaa attgcagtca gccgagatct 600
cgccattgca ctcaagtatg ggtgacagag caagactcca tgtcaaaaaa aaaggcagtt 660
gacaggagca aggagcctgg tgaggaagct gtggcatttg acccggtgtg gttgctatgg 720
gccaggggtg tgctagttaga ggagctgagt gggaaagagc acaggggaca tgctgaaggc 780
ctgggtgtgg ggatgaggca gagattgggg gcaccttgca gggtcatagc aggtggctgt 840
ggtgagatgg aggaagacac ctgggggtact gctctaggct gtcagacata cagaagctgg 900
cccagccaag cccaggggct gcaagggaca tccttttgtg tccccagtga tctgcagctc 960
tcagacaccc tcaagcacag tgccctctgc ccagcccagc actctcagtg gggagccagg 1020
tgggagaaca ggctcggaag gggacctagg cttatgcagc gagccgggca aagctggaac 1080
tggagcccag gcccctggat gccccctggc ttgtggagtt ctgggatact gaggggaggg 1140
gacagggcat gggagtgcgg tgcctctacc tttgacttga actcattccc caggggacag 1200
gggaggcctc ctcaggatcc acagatgccc agtctcccaa gaggggcctg gtccccatgg 1260
aggaaaactc catctactcc tcctggcagg aaggtaaagt ggaggacgtg caagggcagc 1320
ctcagccccc cacaccaggg gctgggtctt tttgggactg acggagctgt cctggccacc 1380
tgccacagtg ggcgagtttc ccgtgggtgg gtagggactg gagggcgcca cccgtgcca 1440
gtggaagggg ccggccctgc tgggtgctgg ccagacgcc atccagctga gggaggccaa 1500
ggcaccaggg ccctctacag ctggccctac cacttctgc gcaagtctgg ctccgacaag 1560
gtgaggtgca ggggtgggaa agggtgaggg gctgacagcc tggaccctcc tgctaattcc 1620
caccctgtgt ccctgtgccc agggcgtgtt ctcctttgag gccggccgtc gctgccactc 1680
gggtgagggc ctctttgcct tcagcaccct ctgtgcccct gacctgtgca gggctgtggc 1740
cggggccatc gccgccagcg ggagcggctg ccagagctga ccaggcccca gccctgcccc 1800
ctgccacggg ccacctctct gccctccctg gacacccccc gagagcttcg ggagatgcca 1860
ccaggacctg agccaccac gtccaggaaa atgcacctgg ccgagcccgg accccagagc 1920
ctgccgctac tgctaggccc ggagcccaac gatctggcgt ccgggctcta cgttctagt 1980
tgcaagcgtg ccagtgggcc cccaggcaat gagcacctct atgagaacct gtgtgtgctg 2040
gaggccagcc ccacgtgca cgggtgggaa cctgagccgc acgagggccc cggcagccgc 2100
agccccacaa ccagtcccat ctaccacaac ggccaggact tgagctggcc cggccccggc 2160
aacgacagta ccctggaggc ccagtaccgg cggctgctgg agctggatca ggtggagggc 2220
acagggccgc ctgacctca ggcaggtttc aaggccaaagc tggtagccct gctgagtcgt 2280
gagcggagga agggccagc cccttgtgac cgccctgaa cggccagcag agtggtgccc 2340
agaggggaga ggtgctcccc ctgggacagg aggggtgggt ggtgggcaaa cattggcccc 2400
atgcagacac acgcctgtgt ccacctggc ctgcaggaa aaggcaggcc gcctgtggag 2460
gacctcagcc ctgccctgcc ctctcatga atagtgtgca gactcacaga taataaagct 2520
cagagcagct cccggcaggg gcactcacgg cacacgcccc tgcccacgtt cattgcccgc 2580
aacacaagca ccctgtgccg gttccagggg cacaggtgac ctgggcctta cctgccaccc 2640
gtgggctcaa acccactgca gcagacagac gggatggaaa tcattaggac tccatgttgc 2700
tctgcacggc cgagtgcac gaagaggcag gcggagggag ctgtgaggct tacttgtcag 2760
actcaggaag gagcaacatg agggcccaac tggagacccg gagggccgag ctgggaggag 2820
gcagtggggg cgggtgtag gtggaaggga tttcagagac accctcgtcc aaaacacttg 2880
ttccctgctg aaactccaac aatttgtaga tacttctggg aaccccaggc gtcagtctcc 2940
tcactgttaa aggagagaga accgatgacg tatcaggcat aatccttgat gagagtttgc 3000
tgctgtccta ctcagtgcga ggcgtgggg gacacagccg tgttcaggac agccttggtc 3060
ctgttctccg ggagccgaca ttccagggg agagaagttt cctgaagact tccatgctgc 3120
gttccctcct ctgctcctgc tctggcgcc atcctaggag ccagccatgc acgtaagcgt 3180
catgcctcca gggctctgac tgcccagccc ctacccgcaa ctccacctca gctgcacaca 3240
cccttggcac atcctgaacc tcattttcat gacggacaca caatttttgc tctctcctgt 3300
ccaagcctca tcctctggcc gccacctcct tccagctcac ttcctttagt gcgccagta 3360
ccgccccctg ctaggcatgt cgacctgcag ggacctttt ctggctcttc gaggcctctg 3420
cccaccatcc cctctttgtt ctccatagtc ccttccccct gttctctctc gtttcatctt 3480
actggtctgg caaagtcccc ggccttgggc gagccagacc tcctcagtgc ctgcacacag 3540
ctgcccacag ccagagaaat ccatttaagc agactgcctg catccttctt aacagtgcaa 3600

```

```

ggcaggcact ccctgccaca agagaccctg ttccctagta gggcagcttt tctcctcccc 3660
agaacctcct gtctatcccc acccaatgtc tcctcacagg catattgggg aaacagggtca 3720
ggctctccca cgtatctctg aagtgtactg gcatccatct gtcttcttcc tacccttaca 3780
gtagaaacag tgtctgtccc cagctgtgct ctgatcccgg ctcttttcac ctgagagctt 3840
ggaaaattga gctgtcccca ctctctcctg cgccattca tcctaccagc agcttttcca 3900
gccacacgca aacatgtctt gtaatttcac attttaaacc ttcccttgac ctacatttcc 3960
tcttcggcca cctctgtttc tctgttcttc ttcacagcaa aaactgttca aaagagttgt 4020
tgattacttt catttccact ttctcacccc cattctctcc tcaattaaact ctcttctatc 4080
cccagatgac cattatgtgg cttttattag agtcaccaac cttattctcc aaaacaaaag 4140
caacaaggac tttgacttct cagcagcact cagctctggg tcttgaaaca cccccgttac 4200
ttgctattcc tcctacctca taacaatctc ctccagcc tctactgctg ctttctctga 4260
gttcttccca gggctcctagg ctgagatgta gtgtagctca accctgctac acaaagaatc 4320
tcctgaaagc ctgtaaaaat gtccatgcat gttctgtgag tgatctacca agaaaataaa 4380
aaattttaaa aatcaaatgc ccagtcctgg gccacacgc aggggctctg atttcatcag 4440
tctggtaggt ggggttctggg catccacgct cactggattt ccggatgatt gtagtatgca 4500
gcctaggctg ggaaccactg gcctcagcaa gccagtcatt ctccagggtg cacagaccct 4560
ctagggtgcta atgaccccgga aggtctgtct tcagtgcaca cctccccctg agctccagat 4620
ttaggaattcc cactgcacac gagacatctg gatgtggaag agacatctcc agatcccatg 4680
ggtgaaaggg ggttgaggga atggagactc gtgttcttcc aggatgtgtg tggacacaga 4740
atgcaaagcc tggagggatg ctgagcccat agggaggaag atttcggctc acttattcat 4800
gcaagcactt cctgatgggt aaggcttag agcaagctga ggccaagagg cgggcagtcg 4860
aggtgctgct gcaggcacc ccactcccta cagtggcaag cccaagccca gcccttgga 4920
gctcaaatcc caggacacgc tgaagggtcac ccagagagtc aggggcatgg ctgaaccag 4980
aaccaggac tctggggacc cagcatggca tcctttcctt cattacaaat ctgagctgct 5040
ttgtttccta gggatttctg tgatattcca aggggactgt gggaaagaaa gtccttgga 5100
accaccagga cgctagaggc ctggcctgga gcctcaggag tctcggccac cagagggcg 5160
tggttccttg tccagggtcca gttgctacgc aggggctgcc tgtgctggga ggctcccag 5220
gggacacaga ccagagcctt gcaccagccc aaggaatggg agcctggggg cctctctgct 5280
ggaggactgc caggaccccc aggtgcccgc ctcttcttct gctcatttgc tgtttcactt 5340
tgtcaatcct tcctttcttc gtgtgttcat tcacatccac tgtgtgctgg ccctggggaa 5400
atgttagata agacacatta gctgtgtgtc ttcatgttcc taacaaagaa cacaccctgg 5460
aaagtagcacc gcagagagtc cccattcccc cactccctc cacacatgga atctggagat 5520
gccttttcca catccagatg tctctggtgc tgtgggattc ttaaataaac aaacatttca 5580
tacagaatgt gagatgatgg agatgctatg gggaaaagta aagcagaggg agggcctagt 5640
gtgtgatgcg ggtgaggcat ccagggttgc ctgtttcagc tgtgatcagg aaaggccctg 5700
ggaggaggcc acatctgagc agagacctaa ataaagtgtg aaacctgttg ctgagatatt 5760
tggaagaagt tttcaagggc cgggcaccgg gcatggtggc tcacgcctgt aatcccagca 5820
ctttgggagg ccaaggcagg tggatcgctg gaggtcagga gtttgagagc agcctgacca 5880
acatggagaa accccatctc tactaaacat ataaaaatta tccgggcatg gtggttcatg 5940
cctgtagtcc cagctactcg ggaggttgag gcaggagaat cacttgaacg tgggaggcag 6000
aggttgacgc aagccgagat cacaccactg cactccagcc tggatgacag agcgagactc 6060
cgtctcaaaa aaaaaaaga aaagaaaaaa gaaaaaaaag gaaaagtgtt tcaagcaggg 6120
gaactggcaa gtggagaggc cctgaggcag aaatatgctt ggctgctgg aggaatgtg 6180
agtgaggagg tcagggtggc tggagtggag ggagcgagtg gtaggagtca gaccagttt 6240
attcatattc ttaggtctt aaggacttca gttttatttt gagtgaata tgagccact 6300
ggaatgctaa aagctgagag tgacatgggt cgtgtattct ggctttaaaa atactacttt 6360
ggctgcttcg tgaagactct ggaaggggca agggtgaaag cagggatgcc cgtaggaga 6420
ccgttacagg ggcgcaggca caaaatggca gtggctggga caatggtggc agcagcggtt 6480
agatgtgaac atgttgagg tggatttgc agaactctgg ggaggacaga agagaaagga 6540
taacttcatc gtttctgctg aaccagttgg ataaatgttg gtggcacttc ttgaagttag 6600
gaaggagtta ggaaggtggg aaaggcacia gtttgatttg ggccatgatg gtctgagata 6660
cctagtacag tggttcccca acctttttgg cagaagggac cgctttcatg gaagacaatt 6720
ttccacaga ctgggggtgg ggtggggatg gtttcagggt ggctcgagtg cagtacattt 6780
atcattagac tctttttttt tttttttttt tgagatagag tctcgctctg tcaccacac 6840
tggagtgcag tggagccatc ttggctcact acaacctctg ctgcccagg tcaagtcat 6900
ctcctgcctc agcctctcaa gtagctggga ttataggcat atgcgccacc acgcccagct 6960

```

```

aattttttagta ttttttagtag agacgggggtt tcaccatatt ggccaggatg gtctcgaact 7020
cctgacctca agtgatcctc ccccgccctca acctcccaaa gtgctgggggt tacaggcgtg 7080
aaccactgca cccggcccat ttatcattag attctcataa ggaatgagca acctagatcc 7140
ctcgcatgca cagttcacaa tagggttcac gctcctatgg gagtctaata ctgccgctgc 7200
actcagcttc tctggcttgc cgctgctcac cttctgctgt gcagcccagt tcctaacagg 7260
ccacaaacgg ggagttgggg acccctgac tagtaaacaat ctaggcaggg ttttgataa 7320
tggagttaga gttcctgggg agaggtcagg ctggccatga aacatgggat gcctttgcat 7380
ataggtggtg ttgaaagcca caggacagta cggggtctca gggggtgagc ataaagagag 7440
gcgacatcag atggccaagg ccagaggcag agggaggatgg gaaggagggg ccagtggggc 7500
agggggaagc tgtgaagcca gggaaaaagg gtgtttcgcg gaaaaggatc aacctggacc 7560
agtgtgccc ctaggcaggg caggatgaaa cttaaccacc acggattcca tggccccatg 7620
gcctccaggc cacaggggac cttgagaaga gagatctcag gggacgggtg cggacaagag 7680
cccgccctggc atggcttcaa gagataactg aaggaaagca agtgagagc cgataaacag 7740
acaactccct ggaggaattt tactctcgag aggagaatta aagggtagta gctggagagg 7800
gatgtgggg caagagaagg tctttaacga cgagaactct cacggcggtt tgtgcagaac 7860
aggggtgggtg tgatgactgt ggatggagag gggagaactg cagcgactct gtccataggag 7920
gaggtgatgg gccgggacca ccaagcgagt ggaggggtga cgcccttcc ctcacccgca 7980
caccgcgatg tgctcagtg cctgcccgc cgtgggctga acgcggggccc 8040
gggactctga ggacgcctcc caggcgcgca gtccgtctgg ccaagggtga gcgggacggc 8100
ngcttccgac ggtgcgcggg tgggctcggg gttgcaggga catccggcgt ccgctcctgc 8160
cctgttttcc tgcttccgca gagcgttgcg caactctagc tttaaacgcc cctgtcccc 8220
tcaacttgct tccccagcc cctctgattt acagattctg cagtccccga ggggtgcgcc 8280
tacgataccg aactcgcgg cagcctgcga ggcgagtatg atcgteccat ttttcggagt 8340
agcaaaactaa ggttcagaga ctactatgtc ccaggtcggg ctggtttgaa ggtccgcttt 8400
cctctccctc cgccagcggg cggtcgaggg gactgggcga ggcagcgctt ccctaaggag 8460
gcgacccgca gccccggccc cctcccgact ccgccccgtt gcagggcccg ggtcggcgag 8520
gcctctcagc tctaagcccg acgggacttg gtgattgggc aggacggaag agctgggtgg 8580
ggctttccac cagcggagaa agtctagtgg gctggtcgc gacgagggcg tggcctggtg 8640
ccccgcccc gtccgcgcgc tcaaagtga ggggtgctgt gggggcgggg tcagaacact 8700
ggcgccgat cccaacgagg ctccctggag ccgacgcag agcagcgccc tggccggggc 8760
aagcaggtat cgacgaccgc gcggggcgctc ttgggctgga ccaggcgggc gcccgggggc 8820
tgctgaggac cacaaaggc actgggggtc gtggtccagg ctgtgcttcc tcccgctggc 8880
cctggccctc gcctccgccc ccgccccgc cttcctgccg ctaagccggc tgcggcgggg 8940
ccgattggcg cctgccggct tctgcgccg gggccagtct aatgcatggg gcccgggcg 9000
gggactaagg ggaaactgag tcacgtcggg gtgggagcag ttctgtgtgg gaggcaccac 9060
ccccactgg gctcggggaa ggatccccct ccaagctatg cttgagggtc ccagccccc 9120
tctgtctcca caggggcgc accccactcc cgccttcccc ttcttcagca cccaggggtc 9180
ccgcccgtgc tccagcagc ctcgactggt ccggaatgg ctaggaggat ccgctgcagc 9240
cgctccctc cctccctc cctccctc cctccctc cctccctc cctccctc 9300
cccctcgct cccaagcccc cgtgtgctcc ctcgctggc tctccgcaca gtgtcagctt 9360
acacgcctta tatagtcga gcaggctcca gccgcggcct gctgccggga cctggggggc 9420
ggggagagga gagccggccc ctgactcacc cggaccgccc gaggtccag gctggcttgg 9480
ggggagggcg cgccagttta gtccctcggc ccaccttg ttgcaaagaa cctcaagcct 9540
ggattcaggc acccctcacc gttccagtc caaggggagg ggggctgctc ctgtcttcc 9600
aaagtgaggt ccgcccagca gcagcccagg ccagcctgac aaaatacctg cctcctatgg 9660
cttgggcgtg ctcaggggct gcccgctgct gctggcccc tgtccaaggc tggatccctg 9720
agctggcccg gcctgcctgc ctgcccgc accatgctgg ccaactacct tctctctct 9780
cctctcagga gccggcatca tggattcctt caaagtatg ctggaggggc cagcaccttg 9840
gggcttccg ctgcaaggg gcaaggactt caatgtgccc ctctccattt cccgggtgag 9900
cctaggtttg gggaggggg tccccagcg gtctttcggg gcttaggtct ccagaggtg 9960
atggggggag tctaacagg agctggtcag gggccagcag gccaggagat gtctaggtcc 10020
ggagatgtag tggtaacctg ctgccacaag gactcccaat gaggtggata ctgggaggg 10080
gcacccaggc ttctccagcc ctgcaactgta cccgatgctg ttctcccaag ctctgtggc 10140
cacctctgag ggctggagg aggtcattg tgcaggatgg gagcctaaca tttcaggagg 10200
tatctaaact tgaggtggca atgcttggag ccaggcccca ggcaggacac tgtgactata 10260
ggatttcact tcagcctcac tgccgcccag ggaatagcaa tcctcatccc gtttttccag 10320

```

```

atgagagaag aactcatgga gaggtggcgg ggctcgctca tcgagtcctat ggtgaagcag 10380
ggattggaat tgaggcacag catggcgtag attttttgtg ggtagaaggg gtctctcccc 10440
agcctatgta aggacccaca tccactgttc ccattcagga tgtggtggcc tttgacccca 10500
agcagaagtg taggacaggg tccattcta ggggcttaac ttcagcttcc aagagcctgc 10560
cctggtgtgg gtggagctgg aggctggctc ctccctgtag cagggggatt gccttataag 10620
cccaagaatg cagccccacg ctgggatggc caacagtggc tgcggtctgc agagctgaaa 10680
agggctggcc taggcctggc cccctgaacc ccactggtgg gcctctcagc tggtcaccag 10740
gctgcagctc cagctgtatg gtccagtgtg gagacacaac aaattgcctg cccagagtgg 10800
gtgaggccag cctgtcggct ggcatctctg actggcctgg gggtcaggag ggggtgggga 10860
cttctgccc ctatatccgc ctgccccgag agaccacccc aggcgcccgg tgggcaggca 10920
gctgttgta ggaagcccaa ggcaagccca gcctggaggg gccagaggg tcgtggcctg 10980
aggaggggct caagctggag tctgtctgta ggagctgggc gtgggggtta ggggtggcag 11040
gccagcagtg ctcttctcag gggctcctttg atggcattct cctggaacct gccccgccag 11100
cagggtagtg aggcagtggg tgcctatga cacacgtccc actacatagc cctcacacag 11160
ccctgaaacc tacctgacgt cctgtccctt gggaaagtgc tggcccagtg tgtctgggga 11220
gcctgaacct cagtttcttc cctgatggag atgactttca gatatggcct gttgggggca 11280
ctccgggctc cagctccctg gtcagcatcc ctggcatgtg ggcggggcca ctagctgac 11340
ccagccctgg agttggacct gggcccacat ggggtgggtga ggtgggcttt tctgagttag 11400
gccagcccc tccccctccc ctgaccccc agatgagggg ggtgggaggg gcaagggtg 11460
gctgtggggc cagggcctgg agatgaggta acgtctggga ctggggggct gggctgctca 11520
ggctgactca cccccacctc atgcagggtc cagccccctg gctttttccc tcttgggttc 11580
ctctggcctt accctgcccc tggttgagc cctccctgc ctctctccag ccaccgccc 11640
agcgtgtct tctgtctctc tgctgcccc cccacgtctt gaacaccctt cactctctgt 11700
gcttctgcc ctctcactc tgggaaggga agcgtcccc gccccccacc cctctccag 11760
gagccagcta gctgcacccc aagaccccca cctcgggctc agcccacagc tcccaggagc 11820
cagccctgtg ggcagggagt ggctgggcca ggtttccctt ctactgactc accatgacct 11880
tgagttaagt acttccccctc tggggtgtca ctccccata cacagtataa ggggttgatt 11940
tagttggatt gaactaaagg tgagggagtg gctcagggtg tctccaggtg gggtgacccc 12000
tcagtggggc ccccatgctc agcagaggtg gccacagtg gtggagcctt agggtcagag 12060
acacttcctg gctctgctc ttactagctg ggtgacttga ggcaagtgtt ttaacctctc 12120
tgtgtacatt tgcaagtga aaatgggtaa aatcccagat tactccacaa ggttggtgga 12180
agattcagtg tcaatatgta gcatagttgg tgctcaataa actgaagcaa gtcttcttat 12240
ttagcgagtg aggaaggggc cgccgagctc tcttagcctt ctgacctcct acgcaagcaa 12300
gagtcagtgt tgagcccagc tcgcctttct tttcccagtg ctgtcaagct ctgtgcctgg 12360
ctgccctgcc ctctgacatc tctctgaaac ctcttgctc cctctcctt gcctcagctc 12420
agtctgtgca ctgacccacc tgaggagcct cctggggcca ctggcagcct ggaccccccc 12480
agatcccccc caccagtgta aattgtcttc cagcactgcc tcacaaaagc ctacttgatg 12540
cagtggcaag cctcttgcca gatggctggg ttgtccctta ggcttgagc cagtcaagct 12600
gccctgctg tgttgctggg gctgggctag aggcctggaa ggggtttatc agggtcaccc 12660
tctcagggcc tgggagatac ccaatcccag acattaaaac tgccagtagc cctctacct 12720
tcaaagccaa gtccctggctc ctccccctgg cattcaaagc catcgtaagt gaactctcac 12780
ccgctaggca gcacacgcca ttctccttta ccgaggccca ccgcttctc aaagtcattc 12840
ctgatggctt cagctcatgc tgggtggcagc catttctccc agcctactgt ctctactcat 12900
tgccacagga accagggaact cccagctcaa gagcctgaag gattggggtc aggggaaatt 12960
ggcagtcgag ggcttgggag tgacagccat gtatggccta cgaagtccca gctgtcaact 13020
taggtcccat tcaggcagtg ttcacaggga accgggagat aacagggcct gttcctggct 13080
ctcaaagggt cccagcagac ccctatagat ggcccccgac aggggtgctg ggggtgagag 13140
gtccataaga gcccccggtg gtttcgggga ggaagctgcc cctgcatgg gccagagggc 13200
atatctggta ggtggagtgg cctgggcagg aggccagcag gagcctcaaa aggcaatggt 13260
cctcctgaaa cacttgggct ttagcctgag cgtggctgtt tgtggacatc atagcaattt 13320
ctggactgtg ggggaggggt gtggcggtga atagataagc atcgtgactg gggaagctca 13380
ggtgagcacc acctgaggga gagggtctgg cagtgaataa ataagcagtg tgactgggaa 13440
attgtgaagc tcaggtgagc gccaccacct cctgggttgc ttagtgtcc agcagctgcc 13500
tagaactatg ttgaatgaag agctctctgg gttctggaag tgggacagct ttgggtgggg 13560
cagtgttacc accgtcagcc tggcttgggt ctgcagggtc cagggcctcg gtcactttgc 13620
ttctctctcc acagctcact cctgggggca aagcggcgca ggccggagtg gccgtgggtg 13680

```

actgggtgct gagcatcgat ggcgagaatg cgggtagcct cacacacatc gaagctcaga 13740
 acaagatccg ggcctgcggg gagcgccctca gcctgggcct cagcaggatc gcgggtggac 13800
 atggatgggt gcgcccgcgc tggcagtggg gatccctgcg gcccggccg ctgtcacgct 13860
 ttccttctcc tccagggccc agccggttca gagcaaaccc cagaaggtag gaggtctggc 13920
 gggacatccg ggcgggtggg ggtgtgggct tggacggcca ggcctgctcg cctcctggc 13980
 acattctcgg taccccaatc cctggccggg agtggagggc agaaaccgga gctaaggcgg 14040
 gtctagggcc ctggagttga gccaggggct gctgcacggt cctggcacca cgcatgtcgg 14100
 cctgtctgtc cgctgtctg tccgctgct gcctcccgcc gccggcgctg cgtgctcgcc 14160
 cgcactcggg cagccctcgg tccctgctgg actgagatcg ccaactccaa atggggccct 14220
 tgaacactga gtcgtcctct ccccgtagcc tccaaataga ttaggggggt ggggtggggg 14280
 tggggggctg gagctgcgcg tgtcctctgc tgcaggcgcc ccaactccac ccaggccccc 14340
 accttacctt gcccgcccgc cctgcccggc tgtgtctctg cccaggcctc cggccccgcc 14400
 gcggaccctc cgcggtacac ctttgcaccc agcgtctccc tcaacaagac ggcccgccct 14460
 ttgggcgccc ccgcccgcctg acagcgcccc gcagcagaat gggtagctcg gccctgccc 14520
 gcccgcccgc acgccatcag gccactgtg gccccacgcc cgctgccgcg tgetgctcag 14580
 tctgtgctgc gcccagccc ggcggaaccg tgcggcacgc cccctggcgg ccgggggtggg 14640
 gctgcaggca cagggccctt cccgaggtg tggcgcttg cagggcaccc cctggggagg 14700
 ggtctctgaa tgacgcgcg cccctgctg gcggtgggg gttgggttgt ggtgtcgggc 14760
 cagctgagcc ccagacactc agtgcgcct tctccccggc tgttctgacc cctccccgct 14820
 tttctcctc tctgtgtct gtccctttgt ccttttatct gtctgtctgt cttatttctt 14880
 tcacaggtgc agaccctga caagtacgtg agccccctc tgctgtgccc tttcttcttc 14940
 cttttggcac tctgggtggc ggccctccc caccctggct gccctcctt ccaactcgcc 15000
 ctctgtcct ctcacctacc cgccagcag ggtcctggc ctcacctta ccaactccct 15060
 cccatcactg taacccaaac ccacatgcac caaatcctg gaggggctgc cccaccgcc 15120
 cacccccagt gtgggttct gagccacacc ctccccacag acagccgctc cgaccgctgg 15180
 tcccagatgc cagcaagcag cggctgatgg agaacacaga ggactggcgg ccgcgccggg 15240
 ggacaggcca gtcgcgttcc ttccgcaccc ttgcccacct cacaggcacc gagttcagta 15300
 agtgccagcc cagggcaggg ggtactttcc tcgccccag cccaggcgtg atccctgacc 15360
 ctgtgtcttt tttggtcaat gcctgcctct gctctctcag tgcaagaccc ggatgaggag 15420
 cacctgaaga aatcaaggta cagggacggg caccagcccc tctccacct cctgcctctt 15480
 ccattccagc tactgcctg tgtctactcc tgaggtccc agctggggct ctcaattctc 15540
 ccttccttcc ttccttctt ccttccttcc ttccttctt ccttccttcc ttccttctt 15600
 ccttccttcc ttccttctt ccttccttcc ttccttctt ccttccttcc ttccttctt 15660
 cctgcctccc ttccttctt ccttccttcc ttccttctt ccttccttcc ttccttctt 15720
 gggaaaagta tgcctggag ctgcagagcc cagcctacac ccgctccgg gactggcacc 15780
 accagcgctc tgcccacgtg ctcaacgtgc agtcgtagcc cggccctctc cagccggctg 15840
 cctctctgct ctcctcttct ctgttcttcc tgcccagggc acccccttag tgctccagc 15900
 ttctgcctac ctcacccccc ctttctgtgc cctggcctga gcctcctgt ggctggccc 15960
 tggccgcca cctgggttca tctgacactg ccttccctct ttgcccgtg gtactgctgt 16020
 ctgccaggte tgtgctgcct tgggcatgga ataaacattc tcagccctgc ttgctctgcc 16080
 tgtcttctat ctttgtggac ctggtttgca ttgggggtgt ggggtgttt cgtggttcgg 16140
 actgtttggg cctgcccgtc cttgttttca gtgggagggg gtacctggca aaggggccct 16200
 gccctgccat cacagatggc ttccctggcat gaggggagcc ccaggagctg cctcagaagc 16260
 gggagccctg cctcgtctcc cagctagaga ccgcacacca gctaactgga cattgctagg 16320
 agaagctgcc cttcccaccc ctaccccagt gggacctgga atccaactcg gcagtttcca 16380
 cgccccagc catctcccgt ggggcccagca ggacccaggt tgggggggtg ggccatgtca 16440
 ggaagctcag ccattgaggg ccttgaatgg cagatcctgc agccagggtg ccaggacaga 16500
 agccccagc ccagcctcat ctacacccca ggagccctgg cctgggtgaga gggagtgggc 16560
 tggggcctgg gcaagggtgg gcagcctcca ggggcatggg ggtggtgggc tctctcagc 16620
 tgctgggggc tccacccccg tcccttgggg tccctgggca cccctttaga gtcacttctc 16680
 ccggcaggcc ctaccgcccc cagccctacc agccgcccgc cctgggctgt ggaccctgcg 16740
 tttgcccagc gctatgcccc ggacaaaacg agcacagtgc tgaccgggca cagccagccg 16800
 gccacgcca cgcgctgca gagccgcacc tccattgtgc aggcagctgc cggaggggtg 16860
 ccaggagggg gcagcaacaa cggcaagact cccgtgtgtc accagtgcca caaggtcatc 16920
 cgtgggtgg cctgttccctg tccgacctg gcttcccat cctgcagccc agccccacct 16980
 gtctgcccac ctgtcctggc tcagctgcga ctggggggaa taaggattca gttctcagct 17040


```

ggagtaggag tagggacctg ggctgggtcc tccattctt aatcccacgc tacctacccc 17100
agcccaccca caacaactgc tagcagcatc tgccgtggcg aaatagccga agggccaacc 17160
ataggctgaa gctgcacccc tacctttgct gctctctggg caaagagggg cctgccccct 17220
cccagcgcgt ctgccccctc ctctgtctct ctgtctccct ctgctctcag agcatacagg 17280
cctggagcca ctccctctgt gcactgcccc gtggggccaa gcagcatcaa acacccccca 17340
gcacagcgt gccggattct agagccttcc taattcgcag gcctggcctg ctctcatctc 17400
tgtcagctct tttttttttt tttttgaaac agagtctcac tgtgttgccc acgttggcgt 17460
gcagtggcgc gatctcggct cactgcaacc tctgcctcct gggttcaaga gattctcctg 17520
cctcagcctc ctgagtagct gggattacag gcacccgcca ccatgcctgg ctaattttgt 17580
atttttagta gagacggggt tttaccatgt tggccaggct ggtctcaaac tctcacctc 17640
aggtgatctc aggcctgcct tggcctccca aagtgtctggg actacagggtg tgagccactg 17700
tgcccagccg actctatcag ctcttgccag gtagaacagg caggccagca ggacagggca 17760
gctccagggt ttgcccaggg gcggctcagc ttttatgagg ctccagtcgt cagcccttcc 17820
tcccggggtc ctccctgtct taaagctgcc tctcctgtca ccagcagttc agtgtggcgg 17880
actggctctg taagcttcat ggctgccacg gtcacttccc aagcctgtct tctatcctat 17940
gtgaaaaatg gggagaatga actgtccctc ccaaggcctc ctggtgggtg gtcagtcac 18000
ctgaaggggg ccaagacccc cactctctg cgtgtgtctc ctctgaccgc tctgcctcc 18060
ctgcaggggc cgctacctgg tggcgctggg ccacgcgtac caccggagg agtttgtgtg 18120
tagccagtgt ggaaggtcc tgggaagagg tggcttcttt gaggaagaagg gcgccatctt 18180
ctgcccacca tgctatgacg tgcgctatgc acccagctgt gccaaagtga agaagaagat 18240
tacaggcgtg agtagggctg gctggcgggg aggtgggtccc aagcctgtca gtgggaacga 18300
gggctgctgg gaaaccacac gtccaggtct ctccccaggt gagcctccgg gtccttacca 18360
gcgtaataaa tgggctgctg tactggcctc accctgcatt agtcaggatg ctcttaacaa 18420
atgaccatgt tctgtctcag aaaccgccc aggtgcacaa gagcaggagg accaagccag 18480
gagaagccct gggccctcct gactccact ttgggtctct cctgccctgg tgaaatgaca 18540
gaacggccaa cttgacacgc tgaagctgct ctgtctcatg cgtcctcctc atttctggat 18600
ccagagccag ggctgccagg agtagccaga gagctctgtg tggatgatgt catattagt 18660
aggtttacct tgaccacgag cagtgggaaa ctcaaaataa tgggtggctta tttctcatct 18720
aaaaacatcc cggggtgggt ggtctgggac tgatctggtg gaccagggt ccgccttgtt 18780
gcttgactgt tggcagcacc tgettactta ccaactcatg tgcaagatga cacttcagcc 18840
tccgcaaaaa gtctacctt ccagccagca ggaagtcgga aggagaagaa aggggacaga 18900
gccccatggc gtccatcctt agaggatgct gccacctgaa cctctgcttt catcctgtt 18960
gtcagaaccc agtcacatga ccacaccag tggcaacgga ggctgggaaa tatagtcttt 19020
attttgggca cccatgtgtc cagcaaaact ggggggtcca tcagtcggca agaaccgggag 19080
agtgcccgat gcagtggctg atgcttgat cccagcactt tgggaggctg aggtgggcag 19140
atcacctgag gtcaggagt caagaccagc ctggccaata tggtgaaacc ctgtctctac 19200
taaaaaataa aaaattagct ggggtgtgct ggcacactgt agtcccagct acttgggagg 19260
ctgaggcagg agaatcgctt gatcttgaga ggtggagggt gcagtgagcc aagattgtgc 19320
cactgccttc cagcctggga gacagcaaaa aaaaaaaaaa aaaaaaaa aaaaagggcc 19380
aggcacggtg gctcacacct gtaatcccag cactttggga ggccgagatg ggcgatcac 19440
gaggtcagga gattgagacc atcctggcta acacggtgaa acccatctc tactaaaaat 19500
acaaaaaaat tggccgggca tgggtggagta gtcccagcta ctggggaggc tgaggcagga 19560
gaatggcgtg aacctgggag gcagagcttg cagtgagccg agatcgcgcc actgcactcc 19620
agcctgggca acagagcgag actcttgtct caaaaagaaa aaaagaaaga gaaatctgcc 19680
tcccagcctt gggctcctgc cctaccagcc cacaccctg gtagagcctc ctctcccacc 19740
agctcaaagc ccaagttcct tcaactgtgac cttgtctgct cctctaaaac aggcaacacc 19800
agacagttag aagagccagc cagacatggg cagaaaaacct atttctgtga tctactggct 19860
gtgtgagcag gggctagtgt ctctctctgg gcctcactga agagaagggt ggactatgc 19920
tagggccggc acggttgcaa ggtagatgta agatggggta cagggtgtgt ggagggcaga 19980
aatgcacat ccgaaggcta catgtcccc acacttatgt cttgcttggc ccacactgtt 20040
tcattttaaa atcagtagca aacaatttaa aaaatcagaa gatttgctg catgatgcag 20100
tggctcatgc ctgtaatccc agcactttgg gaggccaagg tgggaggatt gcttgagccc 20160
aggagttcaa gaccagcatg ggcacatag caagaccct gtttctacaa aaaaaaaa 20220
attagaaaat tagccaagt tgggtggcatg cacctgtggt cccagctact tgggaggcag 20280
agggaaagt agatctcctg ctttttatt ctttatgtat aatgatagg tcttgcctg 20340
ttgcccaggc tggagtgcag tggcatgatc actgctcact gcagccttga tctcctgggc 20400

```

tcagaggatc	ctcccacctc	agcctcccaa	atagctagga	ctagagggtgc	ccaccagcat	20460
gctcagcaga	tttttaaatc	tttttgtaga	gatgagggtt	tgctatgttg	cccaggctgg	20520
tctcgaactc	ctggcctcga	gcgatcctcc	caccttgggc	tcccaaagca	ctgggattac	20580
agacgtgagc	cactgcgcc	agcagatttc	tctttaacac	ctagatttca	gcctgagcca	20640
ggcaggcatt	cctgaatgaa	ccagtagtac	tgctcccaga	agaagaggtc	ctcctccgtg	20700
tgacacagtc	cccacttggc	ccttgccagg	attggatctg	ggatccctgg	atttaaaactc	20760
agggccatcc	tcataacagc	ctcacaaggc	tgggattagc	ttcccagttc	acaagggaag	20820
aaaccaagac	ttgagaaggt	caaggtctgg	ccagaccac	acatcttgga	ccctcatacc	20880
gcctcgaggc	cccatgctgc	cctctgcctg	ctccagatgt	gaatactgct	ggccctggct	20940
ggccccggct	ggccccgagg	gtcctaggga	tgaacagccc	agcccaggga	gagctcagcc	21000
ccttgtgcct	ctgccccctc	ccacctcctg	cggaggccag	tcgactcacc	cacaaagggc	21060
caggcactgt	ggggatagat	cagctaacaa	aacagttgat	gcttcctgcc	cttctggggc	21120
ttacattttg	gctggaagaa	gaggggagag	gcagactgta	agcaataagc	gcaataagta	21180
ggttgccctg	aagtaatgtt	agatcacgtt	acggaaaaca	ggaaagagca	gagcgacaag	21240
tgctgggggtg	cgtggtgcag	ggaaggcagc	tggtgctgct	tggtgtggtc	agagtggggc	21300
ctcatggaga	agactgcatt	cgagcagaaa	cttgaagggg	gtgaggggtg	agcctagaga	21360
tatctggggc	agagcagtc	aggcagaggg	gacagccggg	gtcaagcccc	ggacagcagt	21420
gtgcctgggtg	tgccagtctc	aggcaagagg	ccagtgtgca	gaggcaaggt	gagaacgcaa	21480
gggagagcag	tggcgagac	gggtgggaac	gaggtcagac	ctgctggcct	ccagcctctg	21540
catgggggctt	ggctcttgct	gggagcaatg	ggaagcagta	cacagtttca	tgagggggga	21600
gaaggcctgt	cttgggttgc	aggggcacgc	tgtggcagct	gggatcagag	agaggagctt	21660
gtaggccagt	tggtatgtgg	tcccacgggc	cagatggcca	tggttacct	cacttcaggg	21720
aggctgtgag	aagcactcag	aatctggatg	tgcttggggg	gtgggcccc	ctggatttcc	21780
tggtggacct	ggtgtggggg	gtgagaggag	ggtgtgtttg	gctgcagcag	acaggagaat	21840
ggagttgcca	tccgcgtgat	ggggatggct	gtgggaggag	aggtttgggg	tgagggaatc	21900
aggaactgag	tgctggacat	ggcaagtctg	aaggcgagct	ggtcgtccac	tcagagacct	21960
tggagttgga	gatggagggtg	tgggagtcct	gaacagttag	atgtagtggt	taccgcgaga	22020
aggaacaggg	cttgcggcca	gcccctcctgt	gttcccgtga	cccagggcag	ggcaggaggg	22080
gcctgagcct	gccgagtgc	tgggacctcc	ttccaggaga	tcatgcacgc	cctgaagatg	22140
acctggcacg	tgactgctt	tacctgtgct	gcctgcaaga	cgcccatccg	gaacaggggc	22200
ttctacatgg	aggagggcgt	gcccatttgc	gagcgaggta	cccactggcc	agtgagggtg	22260
aggagggatg	gtgcattggg	caggcatgaa	tccaggtcct	ctttctctct	gccccattc	22320
tcagactatg	agaagatggt	tggcacgaaa	tggcatggct	gtgacttcaa	gatcgacgct	22380
ggggaccgct	tcctggaggc	cctgggcttc	agctggcatg	acacctgctt	cgtctgtgcg	22440
gtgagagccc	cgccctcga	actgagcccc	aagcccaccg	gccctctggt	cattccccag	22500
gagatgcagg	agaagtggg	aaggggcctc	tcctgctgcc	cccaaccca	tgtgactggg	22560
cctttgctgt	ccttagatat	gtcagatcaa	cctggaagga	aagaccttct	actccaagaa	22620
ggacaggcct	ctctgcaaga	gccatgcctt	ctctcatgtg	tgagccccct	ctgcccacag	22680
ctgccgcggg	ggcccctagc	ctgagggggc	tggagtcgtg	gcctgcatt	tctgggtagg	22740
gctggcaatg	gttgccctaa	ccctggctcc	tggcccagac	ctggggctcc	ctggggcctg	22800
ccccacccac	cttatcctcc	cacccactc	cctccaccac	cacagcacac	cgatgctggc	22860
cacaccagcc	ccctttcacc	tccagtgcga	caataaacct	gtacccagct	gtgtcttgtg	22920
tgcccttccc	ctgtgcatcc	ggaggggcag	aatttgaggc	acgtggcagg	gtggagagta	22980
agatggtttt	cttgggctgg	ccatctgggt	ggtcctcgtg	atgcagacat	ggcgggctca	23040
tggttagtggt	aggaggtaca	ggcgagacct	catgtgccag	gcccggtgcc	cacagacatg	23100
aggggagcca	ctggtctggc	ctggcttgga	ggttagagaa	gggtagttag	gaagggtagt	23160
tagcatgggtg	gctcatgcct	gtgatcccag	cactttggaa	ggccaagggtg	ggcagatcgc	23220
ttgaggtcag	gagttcgaga	cctcatggcc	aacacgggtga	aacagcgtct	ctagtaaaaa	23280
tacaaaaatt	agccgagtg	ggtggggcat	gcctgtaatc	ccagccactc	aggaggctga	23340
ggcgggaaaa	tactttgaac	ctgggaagtg	gaggttgtag	tgagctgaga	tcacaccact	23400
gcgcgcgagc	ctgggtggca	gatggcagag	cgagacctg	cttcaaaaaa	aaaaaaaaaa	23460
aaaaaaaaaa	gaagggtagt	tgtagtggg	ggtggatctg	cagagatatg	gtgtggaaaa	23520
cagcaatggc	cacagcaaag	tcctggaggg	gccagctgcc	gtccaaacag	aagaaggcag	23580
ggctggagag	ggtagccctt	aggtcctggg	aagccacgag	tgccaggcag	tagagctggg	23640
gctgtctctt	gaggttaggg	cagggcaagg	cacagcagag	tttgaatatg	gtttgtgttg	23700
tattgcagaa	aagaggcccc	agaacactga	gggagtgtag	gagggagggt	gggaggagga	23760

```

gttgccagcag ggcctagggg cggggggccag gcaagggagg ggcagagagt aatatggcag 23820
agatgggacc cagtggcagg tccgggggat gagggatgga gagaaggaca ggagcgttgc 23880
caggcatctg gcctatacca gacatgctca cgctgtctcc cgcgaaacct ctagcaacct 23940
tgcgccgttg tctgcaatca cttatttcat tttttctttt ttaactttaa ttttttttgt 24000
ttttaagaga caggatctcc ctaggttgcc cgggctgggt tcaaactcct gggctcaagc 24060
aattcttcct ccttagcccc aaagtgctgg cattacaggt gtgagccacc atgcctggcc 24120
cacttatttt ctagatgagg cacagaaaga ttgggagact tgaccaaggt cacgctgtca 24180
ttgagccatg agccagacta gaatccaggc ctgaagctgg gtgcgctgtc ccaggactgg 24240
ctggcactga gtaccatttg ccagcgagca tctctctggg aagctgactt ctgcccggta 24300
cctggaggac tgtagacctt ggtggtggcg ccgtcactct ggggcttcct gcctccact 24360
gatgcccga ccaccctaga gggactgtca tctctcctgt cccaagcctg gactggaaag 24420
actgaagaga agccttaagt aggccaggac agctcagtgt gccatggctg cccgtecttc 24480
agtgggccct ggcattgagga cctgcaacac atctgttagt cttctcaaca ggcccttggc 24540
ccggccccct ttaagagacg agaagggtg ggcacggtga ctcacacctc taatcccagc 24600
actttggaag gctgaggctg gagaagggtc ccagcttagg agttcaggac cagcctgggc 24660
aacatggtga gaccctgttt tgttttgttt tttgtttttt tgagatggag tcttgcctctg 24720
tcgcccaggc tggagtgcag 24740

```

<210> 42

<211> 25

<212> DNA

<213> *Rattus norvegicus*

<400> 42

gcactacctt gaaggaatcc atggt

25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/11664

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.

US CL : 435/320.1, 325; 530/350, 388.1; 536/23.5; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 325; 530/350, 388.1; 536/23.5; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BODEN et al. LMP-1, a LIM-domain protein, mediates BMP-6 effects on bone formation. Endocrinology. 1998. Vol. 139, No. 12, pages 5125-5134, entire document.	1-37
A	HOGAN et al. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes and Development. 1996. Vol. 10, pages 1580-1594, entire document.	1-37
A	KINGSLEY, DM What do BMPs do in mammals? Clues from the mouse short-ear mutation. Trends Genet. January 1994. Vol. 10, No. 1, pages 16-21, entire document.	1-37



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 JULY 2000

Date of mailing of the international search report

29 AUG 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ANNE-MARIE BAKER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/11664

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

A61K 48/00; C07H 21/04; C07K 14/00, 16/00; C12N 15/63, 15/85, 15/86

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST

Dialog (file: medicine)

search terms: gene(w)transfer, LMP, bone, LIM, mineral?, human, osteogen?

SEQUENCE LISTING

<110> Bodan M.D., Scott D
Hair Ph.D., Gregory A

<120> LIM Mineralization Protein Splice Variants

<130> splice variant LMP

<140> 6148.0222-00304

<141> 2000-04-29

<150> 60/132,021

<151> 1999-04-30

<160> 42

<170> PatentIn Ver. 2.1

<210> 1

<211> 457

<212> PRT

<213> Rattus norvegicus

<400> 1

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
1 5 10 15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
20 25 30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
35 40 45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
50 55 60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
65 70 75 80

Leu Ser Arg Ala Gln Pro Ala Gln Ser Lys Pro Gln Lys Ala Leu Thr
85 90 95

Pro Pro Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Ala Ser Leu
100 105 110

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Thr Asp Ser Ala
115 120 125

Leu Ser Gln Asn Gly Gln Leu Leu Arg Gln Leu Val Pro Asp Ala Ser
130 135 140

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
145 150 155 160

Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
 165 170 175
 Glu Phe Met Gln Asp Pro Asp Glu Glu Phe Met Lys Lys Ser Ser Gln
 180 185 190
 Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Thr Ile Pro Gln Glu
 195 200 205
 Ser Trp Pro Gly Pro Thr Thr Pro Ser Pro Thr Ser Arg Pro Pro Trp
 210 215 220
 Ala Val Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser
 225 230 235 240
 Thr Val Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln
 245 250 255
 Asn Arg Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Gly Thr Gly Gly
 260 265 270
 Gly Ser Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Lys Ile
 275 280 285
 Ile Arg Gly Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu
 290 295 300
 Glu Phe Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe
 305 310 315 320
 Phe Glu Glu Lys Gly Ala Ile Phe Cys Pro Ser Cys Tyr Asp Val Arg
 325 330 335
 Tyr Ala Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile
 340 345 350
 Met His Ala Leu Lys Met Thr Trp His Val Pro Cys Phe Thr Cys Ala
 355 360 365
 Ala Cys Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly
 370 375 380
 Ala Pro Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys
 385 390 395 400
 Arg Gly Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala
 405 410 415
 Leu Gly Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln
 420 425 430
 Ile Asn Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Lys Pro Leu
 435 440 445
 Cys Lys Ser His Ala Phe Ser His Val
 450 455

<210> 3
 <211> 1696
 <212> DNA
 <213> Rattus norvegicus

<400> 2
 gcacgaggat cccagcgagg ctccctggagg ccgcccaggca gccgcccagg cgggcattca 60
 ggagcaggta ccattggattc cttcaaggta gtgctggagg gacctgcccc ttggggcttc 120
 ogtctgcaag ggggcaaggc cttcaacgtg cccctctcca tctctegget cactcctgga 180
 ggcaaggccg caccaggccg tgtggccgtg ggagactggg tactgagtat cgacggtgag 240
 aacgcgggaa gcttcacaca cattgaagcc cagaacaaga tccgtgcctg tgggggagcg 300
 ctacgcttgg gtcttagcag agcccagcct gctcagagca aaccacagaa ggccctgacc 360
 cctccgcccg accccccgag gtacactttt gcaccaagcg cctccctcaa caagacggcc 420
 eggcccttgg gggcaccccc acctactgac agcgcctgtt cgcagaatgg acagctgctc 480
 agacagctgg tccctgatgc cagcaagcag cggctgatgg agaatactga agactggcgc 540
 ccgcgccag ggacaggcca gtcccgttcc ttccgcctcc ttgctcacct caccggcaca 600
 gaggttcctg aagaccggga tgagggaattc atgaagaagt caagccagggt gccacggaca 660
 gaagccccag ccccagcctc aaccataccc caggaatcct ggccctggccc caccaccccc 720
 agccccacca gcggccccc cttgggcccga gatcctgcct ttgctgagcg ctatgcccc 780
 gacaaaacca gcacagtgtt gaccgcacac agccagccag ccacacctac gctcctgcag 840
 aacgcacact ccatagttca ggctgcagct ggagggggca caggaggagg cagcaacaa 900
 ggcagacgcg ctgtacgcca ccagtgcac aagatcctcc gccggcgata cctggtagca 960
 ctgggccaag cgtaccatcc tgagggaattt gtgtgcagcc agtggtggga ggtcctggaa 1020
 gagggtggct tcttcaggga gaaggagctt attttttgcc cctcctgcta tgatgtgcgc 1080
 tatgcacca gctgtgcaca atgcagaag aagatcactg gagagatcat gcatgcgctg 1140
 aagatgacct ggcctgttcc ctgcttccc tgtgcagcct gcaaaaaccc tatccgcaac 1200
 agggctttct acatggagga gggggctccc tactgcyagc gagattacga gaagatgttt 1260
 ggacacaaagt gtgcgggctg tgacttcaag atcgatgcgg gggacggttt cctgggaagc 1320
 ctgggtttca gctggcatga taagtgtttt gtttgcgcaa tatgtcaaat caacttggaa 1380
 ggaagacact tctactccaa gaaggacaa cccctgtgca agagccatgc cttttccac 1440
 gtatgagcac ctccctcacac tactgcaccc ctactctgoc agaaggggtga taaaatgaga 1500
 gagctctctc tccctcgacc tttctgggtg gggctggcag ccattgtctc agccttggct 1560
 cctggccaga tcttggggct cctcctccac agtccccctt cccacacttc ctccacccac 1620
 accacogtca ctcaacagtg ctagcctcct agcccagtt cactctggtg tcacaataaa 1680
 cctgtatgta gctgtg 1696

<210> 3
 <211> 260
 <212> DNA
 <213> Rattus norvegicus

<400> 3
 ttctacatgg aggagggggc tccctactgc gagcgagatt acgagaagat gtttggcaca 60
 aagtgtggcg gctgtgactt caagatcgat gccggggacc gtttctcaga agccctgggt 120
 ttacagctggc atgatacgtg ttttgtttgc gcaatagtc aaatcaactt ggaaggaaag 180
 acctttctact ccaagaagga caagccctgt tgcaagagcc atgccttttc ccacgtatga 240
 gcaactcttc acactactgc 260

<210> 4
 <211> 16
 <212> DNA
 <213> MNLV

<400> 4
aaagctatcttt tttttg

16

<210> 5
<211> 13
<212> DNA
<213> MMLV

<400> 5
aaagcttgggt atg

13

<210> 6
<211> 223
<212> DNA
<213> Homo sapiens

<400> 6
atccttgctc acctcaaggc caccagagtc atgcagagcc cggatgagga gcaactgaag 60
aaatcaagcc aggtgcccag gacagaagcc ccagcccccag cctcatctac accccaggag 120
ccctggcctg gccctaccgc cccagaccct accagccgcc cgccttgggc tgtggacct 180
gggtttgcgc agcgttatgc cccagacaaa accagcacag tgc 223

<210> 7
<211> 717
<212> DNA
<213> Homo sapiens

<400> 7
atggattctc tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaaggg 60
ggcaaggact tcaatgtgcc cctctccatt tccgggtcct ctcctggggg caaagcggcg 120
caggccggag tggccgtggg tgactgggtg ctgagcatcg atggcgagaa tgcgggtagc 180
ctcaacacaa tcgaagctca gacaaagatc cgggcttgcg ggtagcgcct cagcctgggc 240
ctcagcaggg ccagcctggg tcagagcaaa ccgcagaaag cctccgcccc cgcgcgggac 300
cctccggcgt acacctttgc acccagctc tccctcaaca agacggcccg gcccttggg 360
gcgcctccgc ccgtgacag cgcctccgca cagaatggac agcgcctccg accgctggtc 420
ccagatgcct gcaagcagcg gctgctggg aacacagagg actggcgccc gcggccgggg 480
acaggccagt cgccttctct cgcctcctt gccacctca caggcaccca gttcattgca 540
gacccggatg aggagcacct gaaagaaatc agccaggtgc ccaggacaga agccccagcc 600
ccagcctcat ctacacccca ggagccctgg cctggcctta ccgccccag cctaccagc 660
cgcccgccct gggctgtgga cctgngtlt gccgagcgt atgcccggga caaaacg 717

<210> 8
<211> 1488
<212> DNA
<213> Homo sapiens

<400> 8
atcgatggcg aagatgcggg tagcctcaca cactcgaag ctccagacaa gatccgggcc 60
tgccggggagc gctcagcct gggcctcagc agggccccag cggttcagag caaacccgag 120
aaggcctccg ccccgccgc ggacccctcg cggtaacact ttgcacccag cgtctccctc 180
aacaagaagg ccgggcccct tggggcgccc ccgcccgtg acagcgccc gcaacagaat 240
ggacagccgc tccgaccgct ggtcccagat gccagcagc agcggctgat ggagaacaca 300

```

gaggactggc ggcgcggccc ggggacaggc cagtgcggtt ccttcggcat ccttgcccac 360
ctcacaggca ccgagttcat gcaagaccgc gatgaggagc acctgaagaa atcaagccag 420
gtgcccagga cagaagcccc agccccagcc tcactctacac cccaggagcc ctggccctggc 480
cctacccccc ccagccctac cagccgcgcc ccatgagctg tggacccctgc gtttgccgag 540
cgctatgcgc cggacsaaac gagcacagtg ctgacccggc acagccagcc ggcacccccc 600
acgcgcgtgc agagccgcac ctccattgtg caggcagctg ccggaggggt gccaggaggg 660
ggcagcaca acggcagagc tcccggtgtg caccagtgcc acaaggtcct ccggggccgc 720
tacctggtgg cgttgggcca cgggtaccac cgggaggagt ttgtgtgtag ccagtgtggg 780
aaggctcctg aagagggctg cttcttttgg gagaagggcg ccactctctg cccaccatgc 840
tatgacgtgc gctatgcacc cagctgtgac aagtgcagga agaagattac aggcagagac 900
atgcacgccc tgaagatgac ctggcaccgt cactgcttta cctgtgctgc ctgcaagacg 960
cccatccgga acagggcctt ctacatggag gagggcgctc cctattggca gcgagactat 1020
gagaagatgt tgggcaagaa atgccatggc tgtgacttca agatcgacgc tggggaccgc 1080
ttcctggagg cctgggcctt cagctggcat gacacctgct tcgtctgtgc gctatgtcag 1140
atcaacctgg aaggaagac cttctactcc aagaaggaca ggccctctctg caagagccat 1200
gccttctctc abgtgtgagc ccttctgccc caccgctgcc gcggtggccc ctgacctgag 1260
gggcttgagg tctggccctt gcatttctgg gtagggtggg caatgggtgc cttaaccttg 1320
gctcctggcc cagacctggg ctcccgggcc cctggccacc cacttatctc tccccccca 1380
ctccctccac caccacagca caccggtgct ggccacacca gccccccttc acctccagtg 1440
ccacaatana cctgtacca gctgaattcc aaaaaatca aaaaaaaa 1488

```

<210> 9

<211> 1644

<212> DNA

<213> Homo sapiens

<400> 9

```

atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcagggg 60
ggcaaggact tcaatgtgcc cctctccatt tccgggtcca ctccggggg caaagcgggg 120
caggccggag tggcctgtgg tgaactgggt ctgagcatcg atggcgagaa tgcgggttagc 180
ctcacacaca tcgaagctca gacaaagatc cgggcctgag gggagcgcc cagcctgggc 240
ctcagcaggg cccagccggt tcagagcaaa ccgcagaag cctccgccc cgcgcgggac 300
cctccgpggt acacctttgc acccagcgtc tccctcaaca agacggcccg gccctttggg 360
ggcgcgcgcg ccgctgacag cgcgcgcgar cagaatggac agccgctccg accgctgggc 420
ccagatgcca gcaagcagcg gctgatggag aacacagagg actggcgccc ggcgcggggg 480
acaggccagc cggcttccct ccgcctccct gccacccca caggccacca gttcatgcaa 540
gacccggatg aggagcact gaagaaatca agccaggtgc ccaggacaga agccccagcc 600
cagacctcat ctacacccca ggaagcctgg cctggcccta ccgccccag cctacccagc 660
cgcccgccct gggctgtgga cctgctgtt gccagcgct atgcccggg caaaacggagc 720
acagtgtgga cccggcacag ccagcgggac ccgcccagcc cgtgcagag ccgcacctcc 780
attgtgcagg cagctgcggg aggggtgcca ggaaggggca gcaaccacgg caaagactccc 840
gtgtgtcacc agtgccacaa ggttactccg ggcgcgtacc tgggtgggtt gggccacggg 900
taccaccccg aggagtttgt ggttagccag tgtgggaagg tcttggaaag ggggtggcttc 960
tttgaggaga agggcgccat cttctgcccc ccctgctctg acgtgcgcta tgcacccagc 1020
tgtccaaat gcaagaagaa gattacagga gagatcatgc acccctgaa gatgacctgg 1080
cagctgcact gctttacctg tgetgctgc aagacgccc tcaggacag gccctctac 1140
atggaggagg gcgtgcccct ttgcagagca gactatgaga agatgtttgg caccgaattgc 1200
catggctgtg acttcaagat cgaagctggg gacccgttcc tggaggccct gggcttcagc 1260
tggcatgaca cctgcttcgt ctgtggata tgtcagatca acctggaagg aaagaccttc 1320
tactccaaga aggacaggcc tcttgcagag agccctgccc tctctcatgt gtgagcccc 1380
tctgcccaca gctgcgcggg tggcccttag cctgaggggc ctggagctgt ggccttgcat 1440
ttctgggtag gctggcaat ggttgcctta accctggctc ctggcccgag cctgggtccc 1500
cgggccccct cccacccacc ttatccctcc accccactcc ctccaccacc acagracacc 1560
ggtgctggcc acaccagccc cctttcacct ccagtgcacc aataaacctg taccagctg 1620
aattccaaaa aatccaaaa aaaa 1644

```

<210> 10

<211> 457

<212> PRT

<213> Homo sapiens

<400> 10

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
 1 5 10 15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
 20 25 30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
 35 40 45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
 50 55 60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
 65 70 75 80

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
 85 90 95

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
 100 105 110

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
 115 120 125

Pro Gln Gln Asn Gly Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser
 130 135 140

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
 145 150 155 160

Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
 165 170 175

Glu Phe Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln
 180 185 190

Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu
 195 200 205

Pro Trp Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro Trp
 210 215 220

Ala Val Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser
 225 230 235 240

Thr Val Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln
 245 250 255

Ser Arg Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Val Pro Gly Gly

260	265	270
Gly Ser Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Lys Val		
275	280	285
Ile Arg Gly Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu		
290	295	300
Glu Phe Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe		
305	310	315
Phe Glu Glu Lys Gly Ala Ile Phe Cys Pro Pro Cys Tyr Asp Val Arg		
325	330	335
Tyr Ala Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile		
340	345	350
Met His Ala Leu Lys Met Thr Trp His Val His Cys Phe Thr Cys Ala		
355	360	365
Ala Cys Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly		
370	375	380
Val Pro Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys		
385	390	395
His Gly Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala		
405	410	415
Leu Gly Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln		
420	425	430
Ile Asn Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Arg Pro Leu		
435	440	445
Cys Lys Ser His Ala Phe Ser His Val		
450	455	

<210> 11

<211> 22

<212> DNA

<213> Rattus norvegicus

<400> 11

gccagggttt tccagtcac ga

22

<210> 12

<211> 22

<212> DNA

<213> Rattus norvegicus

<400> 12

gccagggttt tccagtcac ga

22

<210> 13
<211> 22
<212> DNA
<213> Homo sapiens

<400> 13
tcttagcaga gccagcctg ct

22

<210> 14
<211> 22
<212> DNA
<213> Homo sapiens

<400> 14
gcctgaactc tgtgccctg ag

22

<210> 15
<211> 20
<212> DNA
<213> Rattus norvegicus

<400> 15
atccttgcgc acctcaggg

20

<210> 16
<211> 22
<212> DNA
<213> Rattus norvegicus

<400> 16
gcactgtgct ggttttgtct gg

22

<210> 17
<211> 23
<212> DNA
<213> Homo sapiens

<400> 17
catggattcc ttcaaggtag tgc

23

<210> 18
<211> 20
<212> DNA
<213> Homo sapiens

<400> 18
gttttgcctg gggcagagcg

20

<210> 19
<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: adaptor for
Marathon RACE reactions

<400> 19

ctaatacagac tcaactatagg gctcgagcgg ccgcccgggc aggt

40

<210> 20

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer
specific for Marathon RACE adaptor

<400> 20

ccatcctaatt acgactcaact atagggc

27

<210> 21

<211> 765

<212> DNA

<213> Homo sapiens

<400> 21

```

ccgttggttg taaaaagacg cagagcagcg cctcgcccg gccagcagg agccggcacc 60
atggattcct tcaaggtagt gctggagggg ccagcaactt ggggcttcg gctgcaagg 120
ggcaaggact tcaatgtgc ctcctccatt tcccggtca cctctgggg caaggccgtg 180
caggccggag tggcgtaag tgactgggtg ctgagcatcg atggcgagaa tggggtagc 240
ctcaacacac tcaagctca gaacaagatc cgggcctgcg gggagcgct cagcctgggc 300
ctcaacaggg ccagccgggt tcagaaacaa ccgcaaaagg cctccggccc cgcgcgggac 360
cctccggggt acacctttgc accaagcgtc tccctcaaca agaogggccg gcccttgggg 420
ggccccccgc ccgtgacag cgcctccgag cagaatggac agccgtccg accgctggtc 480
ccagatgcca gcaagcagcg gctgatggag aacacagagg actggcggcc ggggcccggg 540
acaggccagt gccgttcctt togcatacct gctacacctt caggcaccga gtteatgcaa 600
gaacccggatg aggagcacct gaagaaatca agccagggtc ccaggacaga agccccagcc 660
ccagcctcat ctacacccca ggaacccctg cctggcctta cggccccag cctaccagc 720
cgccccccct gggctgtgga cctgcgttt gcgagcgct atgac 765

```

<210> 22

<211> 1689

<212> DNA

<213> Homo sapiens

<400> 22

```

cgacgcagg cagcgcctg gcggggccaa gcaggagccg gcatcatgga ttccctcaag 60
gtagtgtcgg agggggccagc accttggggc ttccggtgc aagggggcaa ggacttcaat 120
gtgcctctct ccatttccc gctcactcct gggggcaaa cggcgaggc cggagtggcc 180
gtgggtgact ggggtgtgag catcgatggc gagaatgcgg gtacctcac acacatcgaa 240
gtcagaaca agatccgggc ctgcggggag cgctcagcc tgggcctcag caggggccag 300

```

```

ocgggttcaga gcaaacccgca gaaggcctcc gcccccgcgc oggaacntcc ggggtacacc 360
tttgacccca ggcctctccct caacaagacg gcccgggccct ttggggcgcc ccggcccgct 420
gacagcgccc cgcacacgaa tggacagccg ctccgaccgc tggccccaga tgcacgcaag 480
cagcgggtga tggagaaac agaggactgg cggccgcggc cggggacagg ccagtgcgt 540
tccttcgcga tccttgccca cctcacaggc accgagttca tgcaagacc ccgatgaggag 600
caccctgaaga aatcaagcca ggtgcccagg acagaaagcc cggcccagc ctcatctaca 660
ccccaggagc cctggcctgg ccctaccgcc ccagcccta ccagccgcc gccctgggct 720
gtggaccctg cgtttgcga ggcctatgcc ccggacaaa cagcacagc gctgacccg 780
cacagccagc eggcacagcc cagcccgctg cagagccgca cctccattgt gcaggcagct 840
gcgggagggg tgcaggagg gggcagcaac aacggcaaga ctcccgctgt taccagtg 900
cacaaggctc tcggggcgcc ctacctggtg gcggtggg ccgcgtacca ccggaggag 960
tttgtgtgta gccagtgtgg gaaggtctct gaagagggtg gcttctttga ggagaagg 1020
gccatctctt gccaccatg ctatgaagt cgtatgcac ccagctgtgc caagtgcag 1080
aagaagatta caggcgagat catgcacgcc ctgaagatga cctggcacgt gcactgctt 1140
acctgtgctg cctgcaagac gccatcccg aacaggccct tctacatgga ggaggcgctg 1200
ccctattgcg agcgagacta tgagaagatg tttggcacga aatgccatgg ctgtgactt 1260
aagategacg ctggggaccc ctctctggag gccctgggct tccgtggca tgacacctg 1320
ttcgtctgtg cgtatgtct gatcaacct gaaggaaaga ccttctact caagaaggac 1380
agggctctct gcaagagcca tgcttctct catgtgtg ccccttctgc ccacagctg 1440
cgcggtggcc cctagcctga ggggcctgga gtcgtggccc tgcattctg ggtagggtg 1500
gcaatggttg ccttaacct ggcctcctgg ccgagcctgg gctcccggg ccctgcccac 1560
ccaccttate ctccacccc actccctcca ccaccacag acaccggtg tggccacac 1620
agcccccttt cacctccagt gccacacata acctgtacc agctgaattt caaaaatcc 1680
aaaaaanaa

```

<210> 33

<211> 22

<212> DNA

<213> Homo sapiens

<400> 23

gcactgtgct cgttttgtcc gg

22

<210> 34

<211> 21

<212> DNA

<213> Homo sapiens

<400> 24

tccttgcaca cctcagggc a

21

<210> 25

<211> 30

<212> DNA

<213> Homo sapiens

<400> 25

tcctcatccg ggtcttgcat gaactcgggtg

30

<210> 26

<211> 28

<212> DNA

<213> Homo sapiens

<400> 26

gcctccggccc gctgacagcg ccccgcaa

25

<210> 27

<211> 24

<212> DNA

<213> Homo sapiens

<400> 27

tccttgcctca cctcacgggc aacg

24

<210> 28

<211> 32

<212> DNA

<213> Homo sapiens

<400> 28

gtatatacgac taactatagg gc

22

<210> 29

<211> 33

<212> DNA

<213> Rattus norvegicus

<400> 29

gggctgatg gagaatactg aag

23

<210> 30

<211> 23

<212> DNA

<213> Rattus norvegicus

<400> 30

atcttgtggc actggtggca tac

23

<210> 31

<211> 22

<212> DNA

<213> Rattus norvegicus

<400> 31

tgtgtcgggt cagcactgtg ct

22

<210> 32

<211> 1620

<212> DNA

<213> Homo sapiens

<400> 32

```

atggattccct tcaaggtagt gctggaggggg ccagcaccctt ggggcttccg gctgcaagg 60
ggcaaggagct tcaatgtgcc cctctccatt tcccggtcca ctctggggg caaagcggcg 120
caggccggag tggccgtggg tgaactgggtg ctgagcatcg atggcgagaa tgggggtagc 180
ctcacacaca tcgaagctca gaacaagatc cgggctgtcg gggagcgcc cagcctgggc 240
ctcagcaggg cccagccggg tcaagagcaaa ccgcagaaag cctccgcccc cgcgcgggac 300
cctccggggt acaccttttg acccagcgtc tccctcaaca agacggcccc gccctttggg 360
ggccccccgc ccgctgacag cgcgccgcaa cagatggac agccgctccg accgctggtc 420
ccagatgcca gcagcagcg gctgatggag aacacagagg actggcgcc gccggccggg 480
acaggccagt cgggttccct ccgcctcctt gccacctca caggcaaccg gttcatgcaa 540
gacccggatg aggagcacc gaagaaatca agccagggtg ccaggacaga agccccagc 600
ccagcctcat ctacaccccc ggggcctgg cctggcccta ccgccccag cctaccagc 660
cgccccccct gagctgtgga cctgctgttt gccgagcgct atgccccgga caaaccgagc 720
acagtgtctg cccggcacag ccgcggggcc acgcaccgc cgtgacagag ccgacctcc 780
attgtgcagg cagctgcggg aggggtgcca ggggggggca gcaacaacgg caagactccc 840
gtgtgtcacc agtgccscas ggtcatccgg ggcggctacc tgggtggcgtt gggccacggc 900
taccacccgg aggggtttgt gtgtagccag tgtgggaagg tccctggaaga ggggtggctt 960
tttgaggaga agggcgccat cttctgcaca ccatgctatg acgtgcgcta tgaaccaga 1020
tgtgccagt gcaagaagaa gattacaggc gagatcatgc acgcccga gaatgacctg 1080
cagctgcact cctttacctg tgcctgcctg aagacggcca tccgggaacg ggccttctac 1140
atggaggagg gcgtgcctta ttgcagaga gactatgaga agatgtttgg caagaaatgc 1200
catggctgtg acttcaagat cgcgcgtggg gaccgcttc tggaggccct gggcttcaga 1260
tggcatgaca cctgcttctg ctgtgcgata tgtcagatca acctggaagg aaagaccttc 1320
tactccaaga aggacaggcc tctctgcaag agccatgct tctctcatgt gtgagccct 1380
tctgccaca gctgcgcggg tggccctag cctgagggg ctaggagtgt ggccttgc 1440
ttctgggtag ggctggcaat ggttgcccta accctggct ctaggcccag cctgggctcc 1500
cgggccccct cccacccacc ttatctctcc accccactcc ctacaccacc acagcacacc 1560
ggtgctggcc acaccagccc cctttcacct ccagtgcacc aataaacctg taccagctg 1620

```

<210> 33

<211> 1665

<212> DNA

<213> Homo sapiens

<400> 33

```

cgacgcagag caggccctg gccgggcca gacggagccg gcatcatgga ttcttcaag 60
gtagtgtgg aggggcccgc accttggggc ttccggctgc aagggggcaa ggaactcaat 120
gtgcctctct ccaatttccg gtcactcct gggggcaaa cggcgaggc cggagtggcc 180
gtgggtgact ggggtgtgag catcgatggc gagaatggcg gtgacctac acacatcgaa 240
gctcagaaac agatccgggc ctgcccggag cgcctcagcc tgggcctcag cagggccag 300
ccggttcaga gcaaacccga gaaggcctcc gcccgcggc cggaccctcc gccgtacacc 360
tttgaccca gcgtctccct caacaagag gcccgccct ttggggcgcc ccgcccgt 420
gacagcgccc cgcacagaa tggacagcgg ctccgacggc tggctccaga tgcagcaag 480
caggcgctga tggagaacac agaggactgg cggccggggc cggggacagg ccagtccgt 540
tccctccgca tccctgccc cctcacaggg acgagttca tgcagacc cggatgaggag 600
cactgaaga aatcaagcca ggtgcccagg acagaagccc cagccccag ctcactaca 660
cccaggagc cctggcctgg cctacccgc ccagacctc ccagccggcc gccctgagct 720
gtggacctcg cgtttgcga gcgtatgccc cgggacaaa cagacacagt gctgacccgg 780
cacagccagc cggccacgac cagcccgctg cagagccgca cctccattgt gcaggcagct 840
gcccgggggg tgcaggagg gggcagcaac aacggcaaga ctcccggtg tccaccgtg 900
cacagggtca tccggggccg ctacctgggt gogttgggccc acggtacca cccggaggag 960
tttgtgtgta gccagtgtgg gaaggtccct gaagagggtg gcttctttga ggagagggg 1020
gccatcttct gccaccatg ctatgaogtg cgtatgcac ccagtgtg ccaagtgaag 1080
aagaagatta caggcgagat catgcacgac ctgaagatga cctggcagct gcaactgctt 1140
acctgtgctg cctgcaagac gcccatccgg aacaggccct tctacatgga ggaaggcggt 1200

```

```

ccctattgcg agcgagacta tgagaagatg tttggcacga aatgccatgg ctgtgacttc 1260
aagatcgacg ctggggacgg ctctctggag gccctgggct ttagctggca tgacacctgc 1320
ttcgtctgtg cgatacgtca gatcaacctg gaaggaaaga ccttctactc caagaaggac 1380
aggcctctct gcaagagcca tgccttctct catgtgtgag ccccttctgc ccacagctgc 1440
cgcggtggcc cctagcctga ggggcttggg gtctgtggcc tgcatttctg ggtagggtctg 1500
gcastggttg ccttaacctt ggtcctctgg ccgagcctgg gctcccgggc cctbgcccac 1560
ccaccttacc ctcccacccc actcctctca ccaaccacgc acaccggctg tggccacacc 1620
agcccccttt caactccagt gccacaataa acctgtaccc agctg 1665

```

<210> 34

<211> 223

<212> PRT

<213> Homo sapiens

<400> 34

```

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
  1             5             10             15

```

```

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
          20             25             30

```

```

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
          35             40             45

```

```

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
          50             55             60

```

```

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
          65             70             75             80

```

```

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Glu Lys Ala Ser Ala
          85             90             95

```

```

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
          100            105            110

```

```

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
          115            120            125

```

```

Pro Gln Gln Asn Gly Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser
          130            135            140

```

```

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
          145            150            155            160

```

```

Thr Gly Cln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
          165            170            175

```

```

Glu Phe Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln
          180            185            190

```

```

Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu
          195            200            205

```

```

Pro Trp Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro

```

210

215

220

<210> 35
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 35
 gagccggcct catggattcc

20

<210> 36
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 36
 gctgcctgca caatggaggt

20

<210> 37
 <211> 1456
 <212> DNA
 <213> Homo sapiens

<400> 37
 cagccgcagag cagccgcctg gccggggccaa gcaggagccg gcattcatgga ttccttccag 60
 gtatgtcttg agggggccagc accttggggc ttcggctgc aggggggcaa ggacttcaat 120
 gtgcctctct ccatcttccg gctcactcct gggggcaaag cggcgccagg cggagtggcc 180
 gtgggtgact ggggtctgag catcgatggg gagaatgcgg gtatgcctcac acacatcgaa 240
 gctcagaaca agatccgggc ctgcggggag cgcctcagac tgggcctcag caggggccag 300
 ccgggttcaga gcaaacccga gaaggtgcag accctgaca aacagccgct ccgacgctg 360
 gtcccagatg ccagcaagca ggggtctgat gaggacag aggactggcg gccgcggccg 420
 gggacaggcc agtcgcttc ctccgcctc ctgcccacc tccagggcag cgagtccatg 480
 caagaccggg atgaggagca cctgaagaaa tcagccagg tgcccaggac agaagcccca 540
 gccccagcct catctacac ccaggagccc tggcctggcc ctacggcccc cagccctacc 600
 agccgccccg cctgggctgt ggaacctgag ttctgcgagc gctatgcccc ggacaaaacy 660
 agccacagtgc tgaccggga cagccagccg gccacgcccc cgcgctgca gagccgcacc 720
 tccattgtgc aggcagctgc cggaggggtg ccaggagggg gcagcaacaa cggcaagact 780
 cccgtgtgtc accagtgcac caaggtcatc cggggccgct acctggtggc gttggggcac 840
 ggtaccacac cggaggagtt tgtgtgtagc cagtgtggga aggtcctgga agagggtgac 900
 ttctttgagg agaggggggc catcttctgc ccaccatgct atgacgtgag ctatgcaccc 960
 agctgtgcca agtgcaagaa gaagattaca ggcgagatca tgcacgacct gaagatgac 1020
 tggcaagtgc actgctttac ctgtgctgcc tgcagacgc ccatccggaa cagggccttc 1080
 taactggagg agggcgtgcc ctattggag cggagctatg agaagatgtc tggcaccgaa 1140
 tgccatggct tgacttcaa gctcgacgt ggggaccgct tctggaggc cctgggcttc 1200
 agctggcatg acacctgct cgtctgtgag atatgtcaga tcaacctgga aggaagagc 1260
 ttctactcca agagggacag gcctctctgc aagagccatg ccttctctca tgtgtgagcc 1320
 ccttctgccc acagctgcgg cggtagcccc tagcctgagg ggccctggag cgtggccctg 1380
 catttctggg tagggctggc aatgggtgac ttaacctgag ctctggcccc gagcctgggc 1440
 tccggggccc tgcccc 1456

<210> 38
 <211> 423

<212> PRT

<213> Homo sapiens

<400> 35

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
 1 5 10 15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
 20 25 30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
 35 40 45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
 50 55 60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
 65 70 75 80

Leu Ser Arg Ala Gln Pro Val Gln Asn Lys Pro Gln Lys Val Gln Thr
 85 90 95

Pro Asp Lys Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser Lys Gln
 100 105 110

Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly Thr Gly
 115 120 125

Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr Glu Phe
 130 135 140

Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln Val Pro
 145 150 155 160

Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu Pro Trp
 165 170 175

Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro Trp Ala Val
 180 185 190

Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser Thr Val
 195 200 205

Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln Ser Arg
 210 215 220

Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Val Pro Gly Gly Gly Ser
 225 230 235 240

Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Gln Val Ile Arg
 245 250 255

Ala Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu Glu Phe
 260 265 270

Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe Phe Glu

275	280	285
Glu Lys Gly Ala Ile Phe Cys Pro Pro Cys Tyr Asp Val Arg Tyr Ala		
290	295	300
Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile Met His		
305	310	315 320
Ala Leu Lys Met Thr Trp His Val Leu Cys Phe Thr Cys Ala Ala Cys		
	325	330 335
Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly Val Pro		
	340	345 350
Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys Gln Trp		
	355	360 365
Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala Leu Gly		
	370	375 380
Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln Ile Asn		
	385	390 395 400
Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Arg Pro Leu Cys Lys		
	405	410 415
Ser His Ala Phe Ser His Val		
	420	

<210> 39

<211> 1575

<212> DNA

<213> Homo sapiens

<400> 39

```

cgacgcagag cagcgcctg gccgggcaa gcaggagcog gcacatgga ttccctcaag 60
gtagtgcctg agggggcagc accttggggc ttccggtgc aggggggcaa ggacttcaat 120
gtgcccctct ccatttcccg gctcactcct gggggcaaa cggcgcaggc cggagtggcc 180
gtgggtgact ggggtgctgag catcgatggc gagaatgcgg gtacccctac acacatcgaa 240
gctcagaaca agatccgggc ctgcggggag cgcctcagcc tgggcctcag caggggccag 300
ccggttcaga gcaaacgcga gaaggcctcc gccccggcgg cggaccctcc gcggtacacc 360
tttgacccca gcgtctccct caacaagacg gccgggccc ttggggcgcc cccgcccgt 420
gacagcgccc cgcaacagaa tgggtgcaga cccctgacaa acagcgcctc cgacogctgg 480
tcccagatgc cagcaagcag cggctgatgg agaacaaga ggactggcgg ccgcgggcgg 540
ggacaggcca gtgcggttcc ttccgcctcc ttgcccacct cacaggcacc gacttcctgc 600
aagaccggga tgaggagcac ctgaagaaat caagccaggt gcccgaggca gaagccccag 660
ccccagctcc atctacccc caggagccct ggcctggccc taaccgcccc agccctacca 720
gcgcggcgcc ctggggtgctg gaccctgcgt ttgcggagcg ctatgcccgg gacaaaacga 780
gcacagtgtc gaccgggca cccagccgg ccacgcccac gccgctgcag agcgcacot 840
ccattgtgca ggcagctgcc ggagggtgc caggaggggg cagcaacaac ggcaagactc 900
ccgtgtgtca ccagtgcac aaggctcatc ggggcojcta cctggtggcg ttgggcccag 960
cgtaccaccc ggaggagtct gtgtgtagcc agtgtgggaa ggtcctggaa gagggtggct 1020
cttttgaggga gaagggcgcc stcttctgcc caccatgcta tgacgtggc tatgaccca 1080
gctgtgccaa gtgcaagaag aagattacag gcgagatcat gcacgcccgt aagatgacct 1140
ggcacgtgca ctgcttacc tgtgtgctc gccagacgc catccgggac agggccttct 1200

```

```

acatggagga gggcgtgcc tattgcgagc gagactatga gaagatgttt ggcacgaaat 1260
gccatggctg tgacttcaag atcgacgctg gggaccgctt cctggaggcc ctgggcttca 1320
gctggcatga cactgcttc gtctgtgca tatgtcagat caacctggaa ggaaagacct 1380
tctaactcaa gaaggacagg cctctctgca agagccatgc ctctctcat gtgtgagccc 1440
cttctgccc cagctgcgc ggtggccct agcctgaggg gcctggagtc gtggccctgc 1500
attctgggt agggtggca atggttgct tascctggc tctggccc agcctgggt 1560
cccgggccct gccc 1575

```

<210> 40

<211> 153

<212> PRT

<213> Homo sapiens

<400> 40

```

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
  1             5             10             15

```

```

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
      20             25             30

```

```

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
      35             40             45

```

```

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
      50             55             60

```

```

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
      65             70             75             80

```

```

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
      85             90             95

```

```

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
      100            105            110

```

```

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
      115            120            125

```

```

Pro Gln Gln Asn Gly Cys Arg Pro Leu Thr Asn Ser Arg Ser Asp Arg
      130            135            140

```

```

Trp Ser Gln Met Pro Ala Ser Ser Gly
      145            150

```

<210> 41

<211> 24740

<212> DNA

<213> Homo sapiens

<400> 41

```

nnnnmtgta ttttatcata ttttaaaat caaaaaacaa aaggcagttg aggttaggca 60
tggaggttgg tggctgtaat cccagacact tgggaagccg aagcacgtgg atcacctgag 120
gtcaggagtt ccagaccagc ctgcacaata tggtaaaacc ctgtctctac taaaaataca 180
aaaaattagc caggcatggg ggtgggcacc tgtastccca gctacttggg agactgagge 240

```

```

aggagaatca cttanaaccy ggaggcggggc tggggcgggt ggatcatgcc tghtaatcca 300
gcactttggg aggcogagac agggcgatca tgaggteagg agatcgagat catcctggct 360
aacatgggtga aaccccatct ctactaaaaa tacaaaaaaa attagccagg cctgggtggg 420
ggcacctgtga gtccocagcta cttggggggc tgaggccagg gaaatggcgtg aacctggggg 480
goggcgttgc agtgagccca gatcgccca ctgcactcca gccctgggcca caagagtga 540
actccatctt aaagaaaaaa aacaaacccg ggaggcggaa attgcagtca gccgagatct 600
cgccattgca ctcaagtatg ggtgacagag caagactcca tgtcaaaaaa aaaggcagtt 660
gacaggagca agggagcctgg tgaggaaagct gtggcatttg acccggtctg gttgctatgg 720
gocagggttg tctagttaga ggagctgagt gggaaagagc acaggggaca tgcgtgaagg 780
ctgggtgttg ggatgaggca gagatcgggg gcaccttgca gggtcatagc aggtggctgt 840
ggtagagatg aggaagacac ctgggggtact gctctaggct gtcagacata cagaagctgg 900
cccagccaag cccaggggct gcaagggaca tccctttgtg tcccagtgat tctgcagctc 960
tcagacaccc tcaagccacg tgccctcttg ccagcccagc actctcagtg gggagccagg 1020
tgggagaaac ggctcgggag gggacctaag ctatgcagc gagccgggca aagctgggaa 1080
tgaggccca gcccctggat gccccttggt ttgtggagt ctgggatact gaggggaggg 1140
gacagggcat gggagtgcgg tgetctcacc ttgtacttga actcattccc caggggacag 1200
gggaggcttc ctcaggatcc acagatgccc agtctccca gaggggcctg gtcccctagg 1260
aggaabaatc catctactcc tccctggcagg aaggtaaagt ggaggacgtg caagggcagc 1320
ctcagccccc caacccaggg gctgggtctt ttctgggact acggagctgt cctggccacc 1380
tgcacagtg ggagagtctt ccgtgggtgt ttcaggagct gaggccgcca cccgtgccc 1440
gctgaaggg ccggccctgc tgggtgctgg ccagagccgc atccagctga gggaggccaa 1500
ggcaccacgg cctctacac ctggccctac cacttccctg gcaagttcgg ctccgacaa 1560
gtgaggtgca ggggtgggaa aggttgagg gctgacagcc tggaccctcc tghtaatccc 1620
caccogtgtg cctgtgccc agggcgtgtt ctcctttgag gcgggcctg cctgcccacc 1680
gggtgagggc ctctttgccc tcagcaccct ctgtgcccct gacctgtgca gggctgtggc 1740
cggggccatc gcccgcagcg ggagcggctg ccagagctga ccaggcccca gccctgcccc 1800
ctgcacaggg ccacccctct gcccctcctg gacacccccc gagagctctg ggagatgcca 1860
ccaggacctg agccacccac gtccaggaaa atgacactgg ccgagcccg gacccagagc 1920
ctgcgcctac tgcagggccc ggagcccaac gatctgggt ccgggctcta cgttccagt 1980
tgcaagcgtg ccagtgggcc ccaggccaat gagcaactct atgagaacct gtgtgtgtg 2040
gaggccagcc ccacgctgca cgttggggaa cctgagccgc acgagggccc cggcagccgc 2100
agcccccaca ccagtcccat ctaccacac ggccaggact tgagctggcc cggccgggcc 2160
aacgacagta cctggaggc ccagtaccgg cggctgctgg agctggatca ggtggaggg 2220
acaggccgca ctgacccca ggcaggttcc aaggccaaag tgggtgacct gctgagctgt 2280
gagcggagga agggcccgcc ccttctgtgc cggccctgaa cggccagcag agtggtggcc 2340
agaggggaga ggtgctcccc ctgggacagg aggttgggct ggtgggcaaa cattgggccc 2400
atgcagacac acgctgtgtt ccaacctggc ctgcagggaa aaggcaggcc gctgtgggag 2460
gacctcagcc ctgcccctgc ctcctcatga atagtgtgca gactcacaga taataaagct 2520
cagagcagct cccggcaggg gcactcaagg cacaagcccc tgcccacgtt cattgaggcc 2580
aacacaagca cctgtgccc gttccagggg cacaggtgac ctgggcctta cctgcccacc 2640
gtgggtctca acccaactga gcagacagac gggatggaaa tcaataggac tccatgttgc 2700
tctgcacggc ctagtgacac gaagaggcag gcgaggggag ctgtgaggct tacttgtcag 2760
actcaggag aggcacacat agggcccaac tggagacccg gaggcccgag ctgggaggag 2820
gcagtggggc cgggtgagag gtggagggga tttagagac accctcgtcc aaaaacatt 2880
ttccctgtg aaactccaa aatttgagga tacttctggg aacccagggc gtcagtctcc 2940
tcactgttaa aggagagaga accgagtagy tatcaggcat aatccttgat gaggtttgc 3000
tgoxtgcta ctacgtgcca ggcctgggg gacacggccg tgttcaggac agccttggtc 3060
ctgttctccg ggagccgaca ttccaggggg agagaagttt cctgaagact tccatgctgc 3120
gttccctcct ctgctcctgc tccctggccc ctccaggag ctccacctca gctgcacaca 3180
catgcccaca gggctctgac tgcacagccc ctacccgca caatttttgc tctctcctgt 3240
cccttggcac atcctgaacc tcattttcct gacggacaca caatttttgc tctctcctgt 3300
ccaagcctca tccctbggcc gcccctcct tcagctcac ttcccttagt ggggcagta 3360
cggccctgc ctaggcatgt cgaactgag ctggctcttc gaggcctctg 3420
cccaccatcc cctctttgtt ctccatagtc ccttccccc gttctctctc gtttcatctt 3480
actggtctgg caaagtcacc ggcttgggg gagccagacc tccctagtgcc ctgcacacag 3540
ctgcccacag ccaggagaa ctatttaagc agactgctgt catccttctt aacagtgcac 3600

```

```

ggcagggaact cccggaacaa agagaccctg ttccctagta gggcagcttt tctctcccc 3660
agaacotcct gtctatcccc acccaatgtc toctcacagg catattgggg aaacagggtca 3720
ggctctccca ccgtatctgc aagtgtactg gcacccatct gtcttcttcc taccctaca 3780
gtagaacacag tgtctgtccc cagctgtgtc ctgtaccogg ctcttttcc ctcagagctt 3840
ggaaaattga gctgtcccca ctctctctct gcccattca tectaccagc agcttttcca 3900
gcccacagca aacatgtctc gtaatttcc attttaaac ttcccttgac ctacatctcc 3960
tcttgggcca cctctgttcc tctgtctctc ttccagcaa aaactgttca aaagagtgt 4020
tgattacttt catttccact ttctccccc cattctctcc tcaattaaact ctcttctac 4080
cccattgtgc cattatgtgg cttttattag agtcacacac cttattctcc aaacacaaag 4140
caacaaggac ttgtacttct cagcagcact cagctctggg tcttgaacaa ccccggttac 4200
ttgtatttcc tctacctcca caacaatctc ctctccagcc tctactgtct ccttctctga 4260
gttcttccca ggttcttagg ctcatgtgta gtgtagctca accctgtctc acaaaagatc 4320
tcttgaaagc ctgtaaaaat gtccatgcat gttctgtgag tgatctacca agaaaaataa 4380
aaatttttaa aatcaaatgc ccatgcttgg gcccacagc aggggtctct atttcatcag 4440
tctggttagt ggggttctgg catccacgct cactggattt ccggtatgatt gtagtatgca 4500
gootaggctg ggaaccactg gcttcagcaa ggcagtcatt ctccagggtgt caccagacct 4560
ctagggtgcta atgaccccca aggtctgtct tcaagtgcac cctccccctg agctccagat 4620
ttagggaatcc cactgcacac gagacatctg gatgtggaaa agacatctcc agatcccatg 4680
ggtgaaaggg ggttggggga atggagactc gtgttcttcc aggtatgtgt tggacacaga 4740
atgcaagccc tggaggggtg cttagagcat agggagggag atttctgctc ctctattcat 4800
gcagcactt cctgatgggt aaggctctag aagcaagctga gggcaagagg cgggagctcg 4860
aggtgtctct gcaaggcaacc cactcccta cagtggcaag cccaagcca ggccttggca 4920
gtctaaatcc caggacacgn tgaaggtcac ccagagagtc aggggcatgg ctagaacccag 4980
aaaccaggac tctggggacc cagcctggca tcttctctct cattacaaat ctgagctgct 5040
ttgttttcta gggatttctg tgatattcca aggggactgt gggaaagaaa gtcttggaa 5100
accaccagga cgttagaggc ctggcctgga gcttcaggag tctogggcac cagaggggoc 5160
tggttctctg tccaggtcca gttgctacgc aagggtctgc tgtgtctgga ggtctccccc 5220
gggacacaga ccagagcctc gcaccagccc aaggaatggg agcctggggg gtctctctgt 5280
ggaggaactg caggaccccc aggtctgccc ctcttctct gtctatttgc tgtttcactt 5340
tgtcaatcct tctttcttcc gttgttctat tccatctcac tgbtgtctg ccttggggaa 5400
atgttagata agacacatta gctgtgtgtc ttcatgttcc taacaaagaa caccacctgg 5460
aaagagcacc gcagagagtc cccattcccc catctccctc caccatgga atctggagat 5520
gccttttcca catccagatg tctctgtgtc tgttgggttc taaataaac aaacatttca 5580
tacagaatgt gagatgatg agatgtatg gggaaaaagta aagcagaggg agggcctagt 5640
gtgtgatgct ggtgagggcat ccagggatgt ctgtttcagc tgtgatcagg aaaggccctg 5700
ggagggagcc acatctgagc agagacctaa ataaagtgtg aaactctgtt ctgagatatc 5760
tggagaagtg ttccaagggc cgggcacccg gcatgtgtgc tccgacctgt aatcccagca 5820
ctttgggagg ccagggcagg tggatcgtct gaggtcagga gtttgagagc agctgacca 5880
acatggagaa accccatctc tactaaact ataaaaatta tccgggcatg gtgttcatg 5940
cctgtagtcc cagctactct ggaggttgag gcaggagaat cacttgaacg tgggaggcag 6000
aggttgacgc aagccgagat caccacctg cactccagcc tggatgacag agcagagctc 6060
cgtctcaaaa aaaaaaaaga aaagaaaaaa gaaaaaaaaa gaaaagtgtt tcaagcaggg 6120
gaactggcaa gtggagaggc cctgaggcag aaatatgctt ggcctgtctg aggaatgtg 6180
agtggagggg tcagggtggc tggagtggag ggagcaggtg gtaggagtea gaccagttt 6240
attcatattc tgtaggctct aaggacttca gttttatttt gagtgcata tgaagccact 6300
ggaatgctaa aagctgagag tgacatgggt ctgtgtattt ggttttaaaa atatcacttt 6360
ggctgtctcg tgaagactct ggaaggggca aggttgaag cagggatgcc cgttaggaga 6420
cgtttacagc ggcgagggca caaatggca gttgctggga caatgggtggc agcagcgggt 6480
agatgtgaac atgttgaagg tggaaatttg agaactctgg ggaggacaga agagaaagg 6540
taacttctac gtttctgtct aaccagtgtg ataatgttg gtggcacttc ttgaagtga 6600
gaaggagtta ggaagggtgg aaaggcaca gtttgaattg ggcctatgat gtctgagata 6660
cctagtacag tggttcccca acctttttgg cagaagggac cgtttctatg gaagacaatt 6720
tttccacaga ctgggggtgg ggtggggatg gtttcaagg gtctcaggtg cagtacattt 6780
atcattagac tctttttttt ttttttttt tgagatagag tctcgtctct taccacacac 6840
tggagtgacg tggagccatc ttggtcact acnacctct ctgcccagggt tcaagtcatt 6900
ctcctgcctc agcctctcaa gtgtctggga ttataggcat atgcgccacc acgcccagct 6960

```


aattttttgtat ttttttagtag agacgggggtt tcacratatt ggccaggatg gtctcgaact 7020
oatgacctca agtgatccctc ccccgccctca acctcccaaa gtgctgggggt tacaggcgtg 7080
aaccaactgca cccggcccat ttatcattag attctcataa ggaatgagca acctagatcc 7140
ctcgcatgca cagttcacaa tagggttcac gctcctatgg gagtctaatg ctgcccgtgc 7200
actcagcttc tctggcttgc cgtcgtcac cttctgctgt gcagcccagt tctaacagg 7260
ccacaaacgg ggagttgggg acccctgac tagtaaacat ctaggcaggg tttcggataa 7320
tgaggttaga gttccctgggg agaggtcagg ctggccatga aacatgggat gcccttgcct 7380
ataggtgggtg ttgaagcca caggacagta cggggtctca gggggtgagc ataaagagag 7440
gcyacatcag atggccaagg ccagagggcag aggaggtatg gaaggagggg ccagtgggggc 7500
aggggggaagc tgtgaagcca gggaaaaagg gtgttccgg gaaaaggatc aacctggacc 7560
agtgtctgcc ctaggcaggg caggatgaaa cttaaccacc accgattcca cggcccatg 7620
gctccaggc cacaggggac cttgagaaga gagatctcag gggacgggtg cggacaagag 7680
ccgcctggc atggcttcaa gagatbaact aggaaaaa agtgagagc cgataaacag 7740
acaaacctctt ggaggaattt tactctcgag agyagaatta agggtagta gctggagagg 7800
gatgtgggg caagagaagg ggttttaacga cagaaactct caggcgggtt tgtgcagaac 7860
aggggtgggtg tgatgactgt ggtatggagag gggagaactg cagcgaactc gtcctaggag 7920
gaggtgatgg gcggggacca ccaagcagtc cgaagggtga cgcctcttc ctcacccaga 7980
caccgcctat tgcctcagtg cctgcccgc cgttccctgg ggcctatg cctgggctga accgggggc 8040
gggactctga ggaagcctcc caggcgcga gtccgtctgg ccaaggtgga gcgggacggc 8100
ngcttccgac ggtgcggggg tggctcggg gttgcaggga catccgggt ccgctcctgc 8160
cctgttttcc tgccttcgca gaggcttgg caactctagc ttaaaagcc cctgtccccc 8220
tcnaactgtc tcccacagc cctctgattt acagattctg cagtccccga gggttgcgcc 8280
tacgataccg aactcgcgg cagcctgcga ggcagtatg atcgtcccat ttttcggagt 8340
agcaaacctaa ggttcagaga ctactatgtc ccaggtcgg ctggtttgaa ggtccgctct 8400
cctctccctc cgcagcggg cgttcgagg gactgggcga ggcagcgtc cctaaaggag 8460
gcgacccgca gccccggccc cctccgact cgcctccgtt gcagggcccg ggtcggcgag 8520
gctctcagc tctaaagccg aggggacttg gtgattgggc aggacgggaag agctgggttg 8580
ggctttccac cagcggagaa agtctagtg gctgggtcgc gacgaggggc tggcctgggt 8640
cccgcgcgc gtcgcgcgc tcaaaagtga ggttgctgt gggggcgggg tcagaacact 8700
ggcggccgat ccaacaggg cctccctggag ccgcagcag agcagcgcgc tggcgggggc 8760
agcagggctat cgaagacgc gggggcgtga ttgggctgga ccaggcgggc gcccggggc 8820
tgctgaggac cacaaaggg cactgggggtc gtgtccagg ctgtgcttcc tcccgtggtc 8880
cctggccctt gctccgcgc cggcccccgc cttcctgccc cttaagccggc tggcggggg 8940
cagattggcg cctgcccgtt cctgcccgc gggccagtct aatgcctggg gcccggggcg 9000
gggactaagg ggaactgag tcaagtctgt gtaggagcag ttctgtgtgg gaggcaccac 9060
ccccactgg gctcggggaa ggtccccct ccaagctatg cttgagggtc ccagccccc 9120
ttgtctcca caggggcgc ccccaactcc cgccttccc ttcttcagca ccaggggtc 9180
ccgcccgtgc tcccagcgc cctcactgg cccgggaatg ctaggaggat ccgctgcagc 9240
cgcctccctc cctccctc cctccctc cctccctc cctccctc cctccctc 9300
ccccctggct cccaaagccc cgtgtgctcc ctcogctggc tctccgcaca gtgtcagctt 9360
acacgcctta tatagtcga gcaggctcca gccgcggcct gctgcccggg cctggggggg 9420
ggggagagga gaggcggccc ctgactcacc cggacccccc gaggtccag gctggccttg 9480
ggggagggcg cgcagttta gtcctcggc ccaacccctg ttgcaaaaga cctcaagcct 9540
ggattcaggg acccctcacc gttccagtc caaggggagg ggggctgctc ctgtcttcc 9600
aaagttaggt ccgcagcca gcagccaggg ccagcctgac aaataacctg cctcctatg 9660
cttggcggtg ctcaagggt ccccgctgct ggcctggccc ccaatgctgg ccactcactt tctctctct 9720
agctggcccg gccctgctg ctgcagccc caaatgctg caatgtgccc ctctccattt cccgggtgag 9780
cctctcagga gccggcatca tggattcctt caatgtgccc ctctccattt cccgggtgag 9840
gggcttccgg ctgcaaggg gcaaggactt caatgtgccc ctctccattt cccgggtgag 9900
cctaggtttg gggaggggg tccccagcg gctcttctgg gcttaggtct ccagagggtg 9960
atggggggag tccaaacagg agctggtcag gggccagcag gccaggagat gtctaggtcc 10020
ggagatgtag tggtaacctg ctgcacaaag gactcccaat cccgatgctg gaggctaca 10080
gcaacccagge ttctccagcc ctgcaactga aggtcattg tgcaggatgg ggcaggaac 10140
cacctctgag ggtgaggg atgcttggag ccaggcccca ggcaggaac 10200
tatctaaact tgaggtggca atgcttggag ggaatagcaa tctcctccc 10260
ggatttcaact tcagcctcac tgcgcgccag ggaatagcaa tctcctccc 10320

atgagagaa	aaatcatgga	gaggtggcgg	ggctogctca	togagtcac	ggtagagcag	10380
ggattggaat	tgaggacacag	catggcgtac	atctttttgtg	ggtagaagg	gtctctcccc	10440
agcctatgta	aggacccaca	tccactgttc	ccattccagga	tgtaggtggc	tttgaoooo	10500
agcagaagt	taggacaggg	ctccattcta	ggggcttaac	ttcagcttcc	aaagagcctgc	10560
cctggtgtgg	gtggagcctgg	aggctggctc	ctccctgtag	cagggggatt	gccttataag	10620
cccaagaatg	cagccccacy	ctgggatggc	caacagtggc	tgagggtctgc	agagctgaaa	10680
agggtctggc	taggcctggc	ccctgaacc	ccactgggtgg	gcctctcagc	tggtcaccag	10740
gctgcagctc	cagctgtatg	gtccagtgtg	gagacacaa	aaattgcctg	ccagaggtgg	10800
gtgaggccag	cctgtcggct	ggcatctctg	actggcctgg	gggtcaggag	gggtggggga	10860
cttctctccc	ctatctccgc	ctgccccggg	agacccccc	aggcggcggg	tggtcaggca	10920
gctgttgtca	ggaagcccaa	ggcaagccca	gcctggagg	gcccagagg	togtggcctg	10980
aggaggggct	caagctggag	tctgtctgta	ggagctgggc	gtgggggtta	gggtgggcag	11040
gccagcagtg	ctctctcag	gggtcctttg	atggcattct	cctggaaacct	gcccogccag	11100
cagggtagtg	aggeagtggt	tgccctatga	cacaogtccc	actacatagc	ctccacacag	11160
ccctgaacc	tacctgacgt	cctgctccct	gggaagtgc	tgcccagtg	tgtctgggga	11220
gcctgaacct	cagtttcttc	cctgabtggag	atgactttca	gatattggcct	gttgggggca	11280
ctccgggctc	cagctccctg	gtcagcatcc	ctggcatgtg	ggcggggcca	ctagctgcat	11340
ccagccctgg	agttggacct	gggcccacat	gggtgggtga	gggtgggcttt	tctgagttag	11400
gccagccccc	tcccccctcc	ctgaccccag	aattggaggga	ggtagggagg	gcaaggctcg	11460
gctgtggtcc	caggcctggg	agatgaggtta	acgtctggga	ctggggggct	gggctgctca	11520
ggctgactca	ccccacctc	atgcagggtc	cagccccctg	gctttttccc	tacttggttc	11580
ctctggcctt	accctgcccc	tggtctgagc	ccctccctgc	ctctctccag	ccacccgccc	11640
agcgtgtct	tctgtctctc	tgctgcctc	cccacgtctc	gaacacccct	cactctctgt	11700
gcttctgtcc	ctcctcactc	tggaaggga	agcgtcccc	gccccccacc	ccctctccag	11760
gagccagcta	gctgcacccc	aagaccccca	cctcgggtc	agccacagc	tcccaggagc	11820
cagccctgtg	ggcaggggag	ggctgggcca	ggtttccctt	ctactgactc	acctgacct	11880
tgagtaagtc	acttccccct	tggtgtgtca	cttccccata	cacagtataa	gggttgatt	11940
tagttggatt	gaactaaagg	tgaggagtg	gctcagggtg	tctccagggt	ggctgacccc	12000
tcagttgggc	ccccatgctc	agcagaggtg	gcccacagtg	gtggagcctt	aggtcagag	12060
acacttctcg	gctctgctc	ttactagctg	ggtagcttga	ggcaagtgtg	ttacacctctc	12120
tggtgtacatt	tgcaagtga	aatgggtga	aatccagat	tactccacaa	ggttgtttgga	12180
agattcagtg	tcaatatgta	gcatagttgg	tgctcaataa	actgaagcaa	gtcttcttat	12240
ttagcagtg	agggaagggg	cgcagagctc	tcttagcctt	ctgacctcct	acgcaagcaa	12300
gaggtcagtg	tgagccagc	tgcctttct	tttcccagtg	ctgtcaagct	ctgtgcctgg	12360
ctgcccctgc	ctctgacatc	tctctgaaac	ctcttgctc	ccctctccct	gcctcagctc	12420
agtctgtgca	ctgaacccac	tgaggagcct	cctggggcca	ctggcagcct	ggaccccccc	12480
agatccccc	caccagtgga	aatgtcttc	cagcactgcc	tcacaaaagc	ctacttgatg	12540
cagtgccagg	cctcttgcca	gatggctggg	tggtccctta	ggcttggaac	cagtcagct	12600
gccctgctg	tggtgtggg	gctgggttag	aggcctggaa	gggtttatc	aggtcacc	12660
tctcaggggc	tggtgagatac	ccaatcccag	acattaaaac	tgccagtagc	ccctctacct	12720
tcaagcccaa	gtcctggtcc	cttcccctgg	cattcaaaagc	cctogtaagt	gaactctcac	12780
ccgtataggca	gcacacgcca	ttctccttta	ccgaggccca	ccgtctctc	aaagtcattc	12840
ctgatggtct	cagctcatgc	tggtggcagg	cattctctcc	agcctactgt	ctctactcat	12900
tgccacagga	acccgggact	cccagctcaa	gagcctgaag	gattggggtc	aggggaaatt	12960
ggcagtcag	ggcttgggag	tgacagccct	gtatggccta	ggaagtccca	gctgtcaact	13020
taggtcccat	tcaggcagtg	ttcacaggga	accgggagat	aacagggcct	gttccctggct	13080
ctcaataagg	cccagcagac	ccctatagat	ggcccccgac	aggttgctgg	gggttgagag	13140
gtccataaga	gcccccggtg	gtttcgggga	ggaaagctgcc	ccctgcctgg	gccagagggc	13200
atatctggta	gggtggagtg	cctgggcagg	aggccagcag	gagcctcaaa	aggcaatggc	13260
cctcctgaaa	caettgggct	ttagcctgag	cgtggctgtt	tgtagacatc	atagcaattt	13320
ctggactgtg	ggggagggtg	gtggcgtga	atagataagc	atcgtgactg	gggaagctca	13380
gggtgagccc	acctgaggga	gaggtctgg	cagtgataaa	ataagcagtg	tgactgggaa	13440
attgtgaagc	tcagggtgagc	gccacccact	cctgggttgc	tttagtgtcc	agcagctgccc	13500
tagaactatg	ttgaatgag	agctctctgg	gttctgggag	tggtgacagct	tggttgggg	13560
cagtggttcc	acagtcagcc	tggtctgggt	ctgcagggtc	cagggcctcg	gtcactttgc	13620
ttctctctcc	acagctcact	cctgggggca	aaggggcgca	ggccggagtg	gcctgggtg	13680

actgggtgct gagcatogac ggcgagaatg cgggttagcct cacacacacac gaagctcaga 13740
 acaagatccg ggcctgcggg gagcgccctca gcctgggcct cagcaggtat ggggtggac 13800
 atggatgggt ggcgcgcgcg tggcagtggt gatccctgcg gcccgcccg etgtcacgct 13860
 ttccctctcc tccagggccc agccggttca gagcaaaccc cagaaggtag gaggctggcc 13920
 gggacatccg ggcggtgggc ggtgtgggtc tggacggcca ggctgtctcg cctccctggc 13980
 acattctcgg taccaccaac cctggccggg agtggagggc agaaaccgga gctaaggcgg 14040
 gtctaggggc ctggagtga gccaggggct gctgcacggc cctggcacc cgcattgtccg 14100
 cctgtctgtc cgcctgtctg tccgctgct gcctcccgcc gccggcgtg cgtgtctgcc 14160
 cgcactcggc cagccctcgg tccgtgctgg actgagatcg cactcccaa atgggocct 14220
 tgaacctga gtcgtcctct cccggtagcc tccaaataga tctagggggt ggggtggggg 14280
 tggggggctg gagctgcgcg tgtcctctgc tgcagggcgc cacttccac ccaggccccc 14340
 acctacccc gccgcgcgcg cctggccggc cgtgtctctg cccaggcctc cgcgcccgcc 14400
 gcggacccctc cgcggtacac ctttgcaccc agcgtctccc tcaacaagac ggcccgccct 14460
 ttgggcgcgc ccgcgcgctg acagcgcccc gcagcagaat gggtaogtcg gccctgcgc 14520
 gcccggcgcgc agcccatcag gcccaactgt gccccaagcc cgtgcgcgc tctgtctcag 14580
 tctgtgctgc gcccaagccc gggggaaccc tgcggcaogc cccctggcgg cgggggtggg 14640
 gctgcaggca caggccccc cccagggtct tgggccttg cagggcacog cctggggagg 14700
 ggtctctgaa tgcgcgcgcg cccctgctg ggggtgggg gttgggttgt ggtgtcgggc 14760
 cagctgagcc ccagacactc agtgcgcgct tgtcccgcc tgttctgacc cctcccgctc 14820
 ttctctctct cctgtgtct gtccctttgt ccccttatct gctgtctgt cttatttctc 14880
 tcacaggtgc agacccctga caagtacgt agcccccctc tgcctgtgc tttctctctc 14940
 cttttggcac tctgggtggc ggcgccctcc caccctggct gccctctct cactctgc 15000
 ctccctgtct ctacactac agccagcag ggtccctggc ctacccctta cccactccct 15060
 cccactcact taaccacaa ccacatgcac caaatcctgg gaggggctgc cccacccgc 15120
 cccccccagt gtgggggtct gagccacac cccccacag acagccgctc cgcagcctg 15180
 tccacagatgc cagcaagcag cggctgatgg agaacacaga ggactggcgg ccggggcccg 15240
 ggacaggcca gtcgcgttc tccgcctcc ttgcccacct caagggcacc gagtacagta 15300
 agtgcagacc cagggcagg ggtactttcc tgcgccccag cccaggcgtg atccctgac 15360
 ctgtgtcttt tttggtaaat ggcctgcctc gctctctcag tgcagaccc ggtgaggg 15420
 cactgaaga aatcaaggta cagggaaggg caaccagccc tctccacct cctgctctct 15480
 ccattccagc tactgcctg tgtctactcc tggaggtccc agctggggct ctcaattctc 15540
 ccttccctcc ttcctctct ccttctctcc ttcctctct ccttctctcc ttcctctct 15600
 ccttctctcc ttcctctct ctttctctcc ttcctctct ccttctctcc ccttctctct 15660
 cctgctctcc ttcctctct ccttctctcc ccttctctct ccttctctct ccttctctct 15720
 gggaaaagta tgcctggag ctgcagagcc caagctacac cgcctccgg gactggcacc 15780
 accagcgctc tgcacagtg ctcaagctgc agtctagacc cggccctctc cagccggctg 15840
 cctctctctc cctctctct ctgttctctc tgcacagggc accccttag tgcctccagc 15900
 ttctgctac ctacccccc ctttctctcc cctggcctga gctcctgct ggcctggccc 15960
 tggcgcgcac cctgggttca tctgacactg ccttctctct tgcctctgt gtagctgt 16020
 ctgcccaggtc tgtgtgctc tgggcctgga ataaacatc tcagccctgc ttgctctgc 16080
 tgtctctctc ctttctggac ctggttctga tttgggggtg ggggtgtctt cgtggtctcg 16140
 actgtttggg cctggtctc cttgttttca gtggggaggg gtactctgga aaggggccct 16200
 gccctgccat cacagatggc ttccctggct gaggggagcc ccaggagctg cctcagaagc 16260
 gggagccctc cctgctctc cagctagaga ccgcacacca gctaactgga cattgctagg 16320
 agaagctgcc cttcccatcc ctaccccagc gggacctgga atccactcg gcagtttcca 16380
 cgcgccagct catctccgt ggggcagca ggacccaggt tgggggggtg ggcctgtca 16440
 ggaagctcag ccatgcagg ccttgatgg cagactctg agccaggtgc ccaggacaga 16500
 agccccagcc ccagcctcat ctacacccca ggagccctgg cctggtgaga gggagtgggc 16560
 tggggcctgg gcaagggtg gcagcctcca ggggcctgg ggtggtgggc ttctctcagc 16620
 tgcctggggc tccacccccc cctttgggg tccctgggca cccctttaga gtagcttcc 16680
 ccggcaggcc ctaccgcctc cagccctacc agccgcgcg cctgggctgt ggacccctgc 16740
 tttgcgcagc gctatgccc ggacaaaac agcacagtc tgcacggca cagccagccg 16800
 gccacgccc cgcgctgca gagccgcacc tccattgtgc aggcagctgc cggagggtg 16860
 ccaggagggg gcagcaacaa ccggcaagac cctgtgtgtc accagtcca caaggctac 16920
 cgtgggtgg cctgttctc tccgacctg gcttcccat cctgcagccc agccccacct 16980
 gtctgcccac ctgtcttgc ccagctgcga ctggggggaa taaggattca gttctcagct 17040

```

ggagtaggag tagggacctg ggctgggtcc tcccattctt aatcccacgc taactacccc 17100
agcccaccca caaacaactgc tagcagcctc tgcctgggag aaatagccga agggccaacc 17160
ataggctgaa gctgcacccc taactttgct gctctctggg caasgagggg cctgccccct 17220
cccagcgctg ctgcacctcc ctctgctct ctgtctccct ctgtctctag agcatcacgg 17280
cctggagcca cccctctgtg gcactgcccc tgggggcca gacgcatcaa acacccccca 17340
gcacagcgct gccggattct agagccttcc taattcgag gectggcctg ctctcatctc 17400
tgtcagctct tttttttttt tttttgaaac agagtctcac tgtgttgccc acgttggcgt 17460
gcagtggcgc gatctcggct cactgcaacc tetgctctt gggttcaaga gattctcctg 17520
cctcagcctc ctgagtagct gggattacag gcacccgcca ccatgcctgg ctaattttgt 17580
attttttagta gagacggggg tttaccatgt tggccaggct ggtctcaca cctcaccctc 17640
aggtgatctc aggcctgctt tggcctccca aagtgtggg actacaggtg tgagccactg 17700
tgcccagcgg actctatcag ctcttgccag gtagaacagg caggccagca ggacagggca 17760
gctccagggt ttgcccaggg gggctcagc ttttatgagg ctccagtcgt cagcccttcc 17820
tcccgggggt ctccctgctc taaagctgct tctctgtca ccagcagttc agtgbtgggg 17880
actggctctg taagcttcat ggtgcacag gtcacttccc aagcctgtct tctatcctat 17940
gtggaaaaat gggagaatga actgtccctc ccaaggcctc ctggbtgggtg gtcagtcaac 18000
ctgaaggggg ccaagacccc cactctctg cgtgtgctcc ctctgacccg tctcgctctc 18060
ctgcaggggg cgtacctggg tggcgctggg ccaagcgtac caccggagg agtttgtgtg 18120
tagccagtgct gggaggttcc tggasagagg tggctcttct gaggagaagg gcgcacatt 18180
ctgcccacca ttctatgacg tggctatgct cccagctgtt gccagtgca agaagaagt 18240
tacaggcgtg agtagggctg gctggggggg aggtgttccc aagcctgtca gtgggaagga 18300
gggtgtgtgg gaaccccaca gtccaggctc ctcccagggt gacccctcgg gtccctacca 18360
gggtaataaa tgggtgtgtg taetggctc accctgcatt agtcaggatg ctcttaacaa 18420
atgacctgtt tctgtctcag aaacccgcca agcctgcaca gacaggagg accaagccag 18480
gagaagccct gggccctcct gactccact ttgggctctc cctgcccctg tgaatgaca 18540
gaacggccaa cttgacacgc tgaagctgct ctgtctcatg cgtctctctc atttctggat 18600
ccagagccag ggctgcagg agtagccaga gacgtctgtg tgggtgatgt catattagt 18660
aggtttacct tgacccagag cagtgggaaa ctcaaaaata tgggtggctta tttctcatct 18720
aaaaacatcc cgggtgggtt ggtctgggac tgatctgggt gacccaggct ccgccttgtt 18780
gcttgactgt tggcagcacc tgettactta ccactcatgg tgcaagatga cacttcagcc 18840
tccgccaana tgcacacct ccagccagca ggaagtcgga agpagaaga aggggacaga 18900
gcccacatgg gtccatctct agaggatgt gccacctgaa cctctgctt catctgttg 18960
gtcagaaccc agtcacatga ccacacccag tggcaacgga ggctgggaaa tatagtctt 19020
attttgggca cccatgtgtc cagcaaaact ggggggttcca tcagtccgca agaaccggag 19080
agtggccgat gcagtggctg atgttgttat cccagcactt tgggaggtcg aggtgggcag 19140
atcacctgag gtccaggagt caagaccagc ctggccaata tgggtgaacc ctgtctctac 19200
taaaaaataa aaaattagct ggggtgtgtg ggcacactgt agtcccagct acttggggag 19260
ctgagggcgg agaactgctt gatcttgaga ggtggagggt gcagttagcc aagatttgtc 19320
cactgcttcc cagcctggga gacagcaaaa aaaaaaaana aaaaaaaana aaaaagggcc 19380
agggcaggtg gctcacacct gtaatcccag cactttggga ggccgagatg ggcggatcac 19440
gaggtcagga gattgagacc atcctggctc acacggtgaa accccatctc tactaaaaat 19500
acaaaaaaat tggccgggca tgggtggagta gtcccagcta ctggggaggc tgaggcagga 19560
gaatggcgtg aacctgggag gcagagcttg cagttagccg agatcgcgcc actgcactcc 19620
agcctgggca acagagcgag actcttgtct caaaaagaaa aaagaaaga gaactctgcc 19680
tcccagcctt gggctcctgc cctaccagcc cacacccctg gtagagcctc ctctccccc 19740
agctcaagc ccaagttcct tcactgtgac ctgtctgtct cctctaaaac aggcacacc 19800
agacagtga agagccagc cagacatggg cagaaaacct attctgtga tctactggct 19860
gtgtgagcag gggctagtgt ctctctctgg gctcactga agagaagggt ggcactatgc 19920
tagggccggc acggttgcaa ggtagatgta agatgggtga cagggtgtgt ggagggcaga 19980
aatgcacct ccgaaggcta catgtcccc acacttatgt cttgottggc ccacactgtt 20040
tcatttttaa atcagtagca aacaatttaa aaaatcagaa gatttgctg catgatgcag 20100
tggctcatgc ctgtaatccc agcactttgg gaggccaagg tgggaggatt gcttgagccc 20160
agggattcaa gaccagcatg ggcacatag caagacccct gtttctacaa aaaaaaaa 20220
attagaaaat tagccaaagt tgggtggcatg cactgtgtt cccagctact tgggaggcag 20280
agggaaagt agatctcctg ctttttattt ctttatgtat aatgataggg tcttgctctg 20340
tggccaggc tggagtgag tggcatgat actgtcact gcagcctga tctctgggc 20400

```

tcagaggatc	ctcccaacctc	agcctcccaa	atagctagga	ctagagggtgc	ccaccagcat	20460
gctcagcaga	tttttaaatc	ttttttaga	gatgagggtt	tgtatgttg	ccagggctgg	20520
tctcgaaetc	ctggcctcga	gogatccctc	caccttggtc	tcccaaagca	ctgggattac	20580
agacgtgagc	cactgcccgc	agcagatttc	tctttaacac	ctagatttca	gcctgagcca	20640
ggcaggcatt	cctgaatgaa	ccagtgtac	tgtccccaga	agaagaggtc	ctcctccgtg	20700
tgacacagtc	cccacttggt	ccttgccagg	attggatctg	ggatccctgg	atttaasctc	20760
agggccatcc	tcataacagc	ctcacaaggc	tgggatttag	ttccagtttc	acaagggaag	20820
aaaccaagac	ttgagaaggt	caaggtctgg	ccagaccac	acatcttgga	ccctcatacc	20880
gcctcgaggc	cccatgctgc	cctctgcctg	ctccagatgt	gaatactgct	ggccctggct	20940
ggcccccggc	ggcccccagg	gtcctaggga	tgaacagccc	agcccsaggga	gagctcagcc	21000
ccttgtgctc	ctgccccctc	ccacctctct	cggaggccag	togactcacc	cacaaagggc	21060
caggcactgt	ggggatagat	cagctaacaa	aaccgttgat	gcttccctgc	cttctggggc	21120
ttacattttg	gctggagaa	gaggggagag	gcagactgta	agcaantaag	gcataaagta	21180
ggttgccctg	aagtaatggt	agatcacgtt	acggaaaaca	ggaaagagca	gagcgacaag	21240
tgcctgggtg	ogtggtgcag	ggaaggcagc	tggctgctgc	tgggtgkgtc	agagtgggct	21300
ctcatggaga	agactgcatt	cgagcagaaa	cctgaagggg	gtgaggggtg	agcctagaga	21360
tatctggggc	agagcagtc	aggcagaggg	gacagccggt	gtcagcccca	ggacaggagt	21420
gtgcttggtg	tgcaggttcc	aggcaagagg	ccagtgtgca	gaggaagggt	gagaaagcaa	21480
gggagagcag	tggcggagac	gggtgggaac	gaggtcagac	ctgctggcct	ccagcctctg	21540
catggggctt	ggctcttgct	gggagcaatg	ggagcagta	cacagtttca	tgcaggggga	21600
gaaggccctg	cttgggttgc	aggggcacgc	tgtggcagct	gggatcagag	agaggagcct	21660
gtaggccagt	tgttatgtgg	tccacggggc	cagatggcca	tggcttaact	cacttcaggg	21720
aggctgtgag	aagcactcag	actctggatg	tgccttgggg	gtgggcccc	ctggatttcc	21780
tgggtgacct	ggtgtggggk	gtgagaggag	ggtgtgtttg	gctgcagccg	acaggagaaat	21840
ggagttgcca	tccgctgat	ggggatggct	gtgggaggag	aggcttgggg	tgagggaatc	21900
aggaactgag	tgttgacac	ggcaagtctg	aaggcgcagt	ggtcgtccac	tcagagacct	21960
tggagttgga	gatggaggtg	tggaggtcct	gacaggttag	atgtagtgtt	taccgcgaga	22020
aggaacaggg	cttgccgcac	gccttctctg	gttccctgta	cccagggcag	ggcaggaggg	22080
gcctgagcct	gccgagtgac	tgggaacctc	ttccaggaga	tcatgcacgc	cctgaagatg	22140
acctggcacg	tgcactgctt	tacctgtgct	gcctgcaaga	cgcacatccg	gaacagggct	22200
ttctacatgg	aggaggggct	gccttattgc	gagcgaggta	cccactggcc	agtgaagggtg	22260
aggagggtatg	gtgcattggg	caggcatgaa	tccaggtcct	ctttctctct	gcccccatg	22320
tcagactatg	agaagatggt	tggcagagaa	tgcactggct	gtgaotccac	gatcagcgtc	22380
ggggaccgct	tccctggggc	cctgggcttc	agctggcctg	acacctgott	cgtctgtgct	22440
gtgagagccc	cgcccccaga	actgagcccc	aagccacccg	gcctctgttt	cattcccccag	22500
gagatgcagg	agaagttggg	aaggggcctc	tccgtgtgct	cccaaccccc	tgtgactggg	22560
actttgtctg	ccttagatat	gtcagatcaa	cctggaaggga	aagaccttct	actccagaaa	22620
ggacaggcct	ctctgcaaga	gccatgcctt	cttccatgtg	tgagccctct	ctgcccacag	22680
ctgcccgggt	ggcccccagc	ctgaggggct	tggagtctgt	gcctctgact	tctgggtagg	22740
gctggcaatg	gttgccctaa	ccctggctcc	tggcccgagc	ctggggctcc	ctgggcccctg	22800
ccccaccac	cttatcctcc	cacccactcc	cctccaccac	cacagcacac	cgatgctggc	22860
cacacacagc	ccctttccac	tccagtgcac	caataaacct	gtacccagct	gtgtcttgtg	22920
tgccttcccc	ctgtgcaccc	ggaggggcag	aatttgaggc	acgtggcagg	gtggagagta	22980
agatgggttt	cttgggctgg	ccctctgggt	ggtcctcgtg	atgcagacat	ggcgggctca	23040
tgggtagtgg	aggagggtaca	ggcgagaccc	catgtgccag	gcccggtgct	cacagacatg	23100
aggggagcca	ctggctctggc	ctggcttgga	ggttagagaa	gggtagttag	gaagggtagt	23160
tagcatgtg	gtcatgctct	gtgatccag	cactttggaa	ggccaaagggtg	ggcagatcgc	23220
ttgaggtcag	gagttcagaa	cctcatggcc	aacacgggtga	aacagcgtct	ctagtataaa	23280
tacaaaaatt	agccgagtg	ggtggggcat	gcctgtatcc	ccagccactc	aggaggctga	23340
ggcgggaaaa	tcaactgaac	ctgggaagtg	gaggttgacg	tgaactgaga	tcacaccact	23400
gogcgcgagc	ctgggtggca	gatggcagag	cgagacccctg	cttcbaaaaa	aaaaaaaaaa	23460
aaaaaataaa	gaagggtagt	tgtagtgggg	ggtggatctg	cagagatctg	gtgtggaaaa	23520
cagcaatggc	cacagcaag	tccctggagg	gccaagctgct	gtccaaacag	aagaaggcag	23580
ggctggagag	ggtagccctt	aggtcctggg	aagccacgag	tgcacggcag	tagagctggg	23640
gctgtctctt	gaggttaggg	cagggcaggg	cacagcagag	tttgaaatag	gttctgtgtg	23700
tattgcagaa	aagaggcccc	agaacactga	gggagtgcag	gagggaggct	gggagggaga	23760

```

gttgacgacg ggccatagggg cgggggcccag gcaagggagg ggcagagagt aatatggcag 23820
agatgggacc cagtggcagg tccgggggat gagggatgga gagaaggaca ggagcgttgc 23890
caggcatctg ggcataacca gacatgctca cgtgtctcc cgcgaacctc ctagcaacct 23940
tgogcogttg tctgcaatca cttatttcat tttttcttt ttaactttaa ttttttttct 24000
ttttaagaga caggatctcc ctaggttgac cgggctggtt tcaaaactct gggctcaagc 24060
aattcttctt ccttagcccc aaagtgtctg cattacagg gtgagccacc atgcttgccc 24120
caettatttt ctatgtaggg cacagaaaga ttgggagact tgaaccaagg cactgtgtca 24180
ttgagccatg agccagacta gaatccaggc ctgaagctgg gtgogctgtc ccaggactgg 24240
ctggcactga gtaccatttg ccaggcgagc tctctctggg aagctgactt ctgcccggta 24300
cctggaggac tctagacctt ggtggtggcg cgtcactct ggggttctt gctccact 24360
gatgcccga ccacctaga gggactgtca tctctctgt cccaagctg gactggaaag 24420
actgaagaga agccttaagt aggcaggac agctcagtgt gccatggctg ccgtctctc 24480
agtggctcct ggcattgagg cctgcaaac acctgtttag cttctcaaca ggcccttggc 24540
ccggtccctt ttaagagacg agaagggtcg ggcacggtga ctacacctc taatccagc 24600
actttggaag gctgaggctg gagaagggtt ccagcttagg agttcaggac cagcctgggc 24660
aacatggtga gacctgttt tgttttgtt tttgttttt tgagatggag cttgtctctg 24720
tcgccaggc tggagtgcag 24740

```

<210> 42

<211> 25

<212> DNA

<213> Rattus norvegicus

<400> 42

gcactacctt gaaggaaacc atggc

25